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Abbreviations 
1.1. Analytics 
13
C-NMR Carbon 13 Nuclear Magnetic Resonance 
1
H-NMR Proton Nuclear Magnetic Resonance 
Calcd Calculated 
COSY Correlation Spectroscopy 
DEPT Distortionless Enhancement by Polarization Transfer 
ESI Electrospray Ionization 
FP Fluorescence Polarization 
G HPLC gradient 
HPLC High Pressure Liquid Chromatography 
HR High Resolution 
HSQC Heteronuclear Single Quantum Coherence 
MALDI-TOF Matrix Assisted Lased Desorption Ionization Time Of Flight 
MS Mass Spectroscopy 
Pe Effective permeability 
Rf Retention factor 
RP Reverse Phase 
TLC Thin Layer Chromatography 
tR Retention time 
z Charge 
1.2. Solvents 
ACN Acetonitrile 
AcOEt Ethyl acetate 
DCM Dichloromethane 
DMF N,N-Dimethylformamide 
DMSO Dimethyl sulfoxide 
iPrOH Isopropanol 
MeOH Methanol 
PE Petroleum ether 
TEA Triethylamine 
TFA Trifluoroacetic acid 
THF Tetrahydrofuran 
TBME tert-Butyl methyl ether 
1.3. Chemicals and reagents 
Ac2O Acetic anhydride 
Ac Acetyl 
Ala L-Alanine 
Alloc Allyloxycarbonyl 
Arg L-Arginine 
Asp L-Aspartic acid 
  
II 
Bn Benzyl 
Boc tert-Butyloxycarbonyl 
Bzl Benzyl 
Cbz Carboxybenzyl 
CPP Cell-Penetrating Peptide 
Cf 5(6)-Carboxyfluorescein 
CF3 4,4,4-Trifluoro-3-(trifluoromethyl)butanoic acid 
2Cl-Z 2-Chlorobenzyloxy-carbonyl 
CNS Central Nervous System 
Cl-Trt 2-Chlorotrityl resin 
Cys L-Cysteine 
Dap 2,3-Diaminopropionic acid 
DBU 1,8-Diazabicyclo[5.4.0]undec-7-ene 
DIBAL Diisobutylaluminum hydride 
DIC N,N’-Diisopropylcarbodiimide 
DIPEA N,N-Diisopropylethylamine 
DKP Diketopiperazine 
DMAP 4-Dimethylaminopyridine 
DPPA Diphenylphosphoryl azide 
DTT Dithiothreitol 
EDC•HCl 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
hydrochloride 
EDT 1,2-Ethanedithiol 
Fm Fluorenylmethyl 
Fmoc Fluorenylmethyloxycarbonyl 
Fmoc-O2O Fmoc-8-amino-3,6-dioxaoctanoic acid  
Gln L-Glutamine 
Glu L-Glutamic acid 
HATU O-(7-Azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium 
hexafluorophosphate 
HBTU O-Benzotriazole-N,N,N',N'-tetramethyl-uronium-
hexafluorophosphate 
His L-Histidine 
HOAc Acetic acid 
HOAt 1-Hydroxy-7-azabenzotriazole 
HOBt 1-Hydroxybenzotriazole 
Leu L-Leucine 
Lys L-Lysine 
NHS N-Hydroxysuccinimide 
NTCP N-Tetrachlorophthaloyl  
Pbf 2,2,4,6,7-Pentamethyl-dihydrobenzofurane-5-sulfonyl 
Phe L-Phenylalanine 
Phe(4-NH2) 4-Amino-L-phenylalanine 
PPAA Propane phosphonic acid anhydride 
Pro L-Proline 
  
III 
PS-DCC Polymer supported cyclohexylcarbodiimide 
Py Pyridine 
PyBOP 1H-Benzotriazol-1-yloxytris(pyrrolidino)phosphonium 
hexafluorophosphate 
SAA Sugar Amino Acid 
Ser L-Serine 
TBTU O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyl-uronium 
tetrafluoroborate 
tBu tert-Butyl 
TFA Trifluoroacetic acid 
TIS Triisopropylsilane 
Trp L-Tryptophan 
Trt Trityl 
Tyr L-Tyrosine 
Val L-Valine 
Z Carboxybenzyl 
1.4. Symbols and other abbreviations 
1D One-dimensional 
2D Two-dimensional 
abs Absorbance 
BBB Blood-Brain Barrier 
c Concentration 
eq Equivalent 
h Hours 
J Coupling constant 
KD Dissociation constant 
M Molar concentration 
mM Millimolar concentration 
MW Microwave 
nm Nanometer 
PAMPA Parallel Artificial Membrane Permeability Assay 
PPI Protein-Protein Interaction 
SPPS Solid-Phase Peptide Synthesis 
min Minutes 
s Seconds 
r.t. Room temperature 
 Difference 
 Chemical shift 
 Wavelength 
m Micrometer 
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* Amino acids abbreviations follow the rules of the Comission on Biochemical Nomenclature of the IUPAC-IUB as specified in Eur. J. 
Biochem. 1984; 138, 9-37 and Eur. J. Biochem. 1993; 213, 2. 
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Annex IV: resins and linkers 
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Nomenclature 
The nomenclature used in this work to define the cyclic peptides was based on an 
innovative system propose by Spengler et al.
1
 in which the head-to-tail cyclopeptides are 
represented in one-line text formulae using a three-letter symbols. According to this 
nomenclature system the ’&’ represents the start or the end of a chemical bond, thus the 
two ‘&’ symbols placed at the beginning and end of the peptide sequence represent the 
amide bond between the N- and C-terminal amino acids. Indeed, otherwise than is 
required by this nomenclature, the amino acids were placed in the same order of the 
correspondent linear peptide. 
The peptides with the same amino acids sequences were identify with the same product 
number. An alphabetic letter or a symbol (’) were added to indicate a differentiation 
among the structures with the same amino acid residues but with a different 
stereochemistry, bearing or not protecting groups or synthesized using different 
methodology. Roman numerals were used to define the intermediates of the linear 
peptide synthesis in solution. 
The cyclopeptides (except those conjugated with the glycosidic carrier) are identified 
with the same number of the corresponding linear peptide preceded by the prefix cyclo. 
(1) Spengler, J.; Jimenez, J. C.; Burger, K.; Giralt, E.; Albericio, F. Abbreviated nomenclature for cyclic and branched homo- and 
hetero-detic peptides. The journal of peptide research: official journal of the American Peptide Society 2005, 65, 550-555. 
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Perspectives and objectives 
 
Perspectives 
Protein–protein interactions (PPIs) control the functions of living cells, such as signal 
transduction, cell cycle, proliferation and metabolism, representing a promising new class 
of attractive therapeutic targets for the development of future drugs. 
The advancement in drug discovery efforts towards PPIs has been recently referred as ‘the 
unmined biology gold reserve’.1 Worldwide research efforts have driven recent 
pharmaceutical successes, and consequently, the emerging role of PPIs as drug targets has 
been widely recognized by the scientific community. Quantitative, functional and structural 
studies of PPI enable the understanding of these processes at the cellular and molecular 
levels and provide a basis for designing drugs that inhibit or stimulate PPIs.  
The use of peptides to study PPIs introduces several substantial advantages over the small 
molecule drugs featured by their high affinity and specificity to interact with their targets 
together with their low toxicity profiles.
2
 Nevertheless, the main shortcoming of using 
linear peptides for therapeutic purposes is their wide conformational range and short 
lifetime. The peptide cyclization is considered one of the best methods to improve the 
stability of peptides and to capture their bioactive conformations. Cyclization imposes 
conformational constraints on the peptides and, by stabilizing peptides, conveys higher 
binding affinity, selectivity and bioavailability and enables peptides to be used as lead 
compounds for drug design.  
Peptides that modulate PPIs may be rationally developed based on a structural information 
of the binding site within a known protein that participates to the PPI,
3
 or from the 
screening of peptide sequences that do not originate from natural proteins.
4
  
In this contest, the in silico drug design has became a widely used computational method 
that helps to take rational decisions at the different steps of the drug discovery process. 
Indeed, the in silico approach is useful for the identification of a biomolecular target of 
therapeutic interest, but also for the selection or the design of new lead compounds and 
their modification to obtain better affinities, as well as pharmacokinetic and 
pharmacodynamic properties.  
Once a tight binding potential peptide sequence is identified, the peptide can be modified to 
enhance stability, uptake and delivery. Typically, this could be achieved through the 
introduction of non-natural amino acids, additional constrains and moiety as vector or 
shuttle to promote the transport. 
This modified peptide is a peptidomimetic, which has the properties of the peptide with 
respect to binding mechanism but also has higher stability and uptake potential than a 
natural peptide ligand.  
 
 
  
 
 
2 
Objectives 
This thesis was developed on two distinct projects that share a common topic regarding the 
development of cyclic peptides as modulators of the protein-protein interactions with a 
potential therapeutic effect.  
The first project, (Part I) mainly develop at the University of “Piemonte Orientale” under 
the supervision of Prof. Panza, was focused on the protein p50 NF-B, member of the 
Rel/NF-B family of transcription factors, which homodimerization was described as a 
pivotal determinant of polarized M2 inflammatory responses in TAM (Tumour Associated 
Macrophage) which promote the tumour progression. 
In this context, it is becoming clear the involvement of p50 NF-B in the defective NF-κB 
function in TAM. This defective function has been attributed to the overexpression of 
nuclear p50 and the consequent formation of p50 homo-dimers, responsible for the 
inhibition of the transcription of pro-inflammatory NF-κB-dependent genes.5 This concept 
is also supported by the observation that TAM from p50 deficient mice, regained a pro-
inflammatory (M1) phenotype associated with reduced tumour growth; which may be 
attributed to the restoration of a canonical NF-κB activity.  
Therefore, the role of NF-B in tumorigenesis and cancer therapy becomes increasingly 
evident and the inhibition of p50 homodimerization could represent an innovative method 
to modulate the TAM phenotype with a consequent therapeutic effect. 
Over the years several strategies to therapeutically modulate NF-B activation with 
different degree of specificity have been developed.
6,7
 In the field of peptides, were 
reported cell-permeable peptides that contain the nuclear localizing sequence of p50 which 
inhibits nuclear translocation of p50-containing dimers by saturating the nuclear import 
machinery. The most commonly used peptide of this family is the SN50
8
 which was 
demonstrated that not only acts on NF-B signalling but also blocks nuclear translocation 
of a number of non-NF-B transcription.9  
Recently has been also develop a short peptide against the NF-B p50 which seems to bind 
the NF-B p50 subunit inhibiting the NF-B activation and suppress the inflammation.10 
In this context, the goal was to develop a class of cyclic peptides able to selectively interact 
with the homodimerization binding site of the p50 NF-B protein preventing its 
homodimerization. The objectives of this thesis are listed below: 
1. Development and synthesis of cyclic peptides and peptidomimetics with high 
structural analogy towards p50, able to modulate the interaction between two p50 
subunits inhibiting the homodimerization process.  
2. Tune, if possible, the chemical and conformational properties of the cyclopeptides in 
order to investigate their role in the PPIs and to increase the possibility to identify a 
lead compound with a good binding affinity with the target protein. 
Perspectives and objectives  
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3. Explore the role of a sugar amino acid (SAAs) in the PPI and on the peptidomimetic 
properties. 
4. Establish a suitable method for the effective cyclopeptides cellular transport by 
conjugation of peptides onto carrier to promote the drug delivery. 
The second project (Part II) named “Cancertec”, in which I was involved during my stage 
in Prof. Giralt’s group at the Institute for Research in Biomedicine (IRB Barcelona), has, as 
main topic, the development of novel pharmacological compounds that would cross the 
blood-brain barrier (BBB) and target glioma. The two selected target PPIs are represented 
by EGF-EGFR and VEGF-VEGFR that are two of the most important cancer-enabling 
PPIs.  
The overactivation of the EGF signaling pathway is associated with several human 
carcinomas and may cause uncontrolled cell growth. For this reason, in a clinical context, 
hEGF is a popular target for anti-cancer therapies because of its potent growth-stimulating 
effect on a variety of cancer cells that overexpress EGFR on the cell surface, including non-
small cell lung cancer (NSCLC) cells. 
On the other hand, VEGF is a major regulator of developmental and reproductive 
angiogenesis. VEGF is also an important mediator of blood vessel growth associated with 
cancer, rheumatoid arthritis and proliferative retinopathy. Inhibitors of VEGF-VEGFR 
interactions could be beneficial as therapeutics for diseases caused by dysfunctional 
angiogenesis (e.g., cancer). 
The aim of the project was the development of cyclic peptides able to interact directly with 
EGF and VEGF blocking the interaction with their receptors. For the VEGF have already 
been reported short disulfide-constrained peptides that bind VEGF inhibiting its interaction 
with VEGFR;
11
 for EGF, in the field of peptides, only inhibitors that interact with EGFR 
are known. Therefore, targeting the EGF molecule itself could represent a new way to 
prevent the binding of the growth factor to the receptor and, thus, inhibit EGFR activation 
and downstream events. 
In this context, the task assigned was to develop a class of cyclic peptides able to interact 
with the EGF and/or VEGF preventing the interaction with their receptors.  
Most part of these tasks became the objectives of this thesis work, which are listed below: 
1. Development and synthesis of an explorative library of cyclic hexapeptides looking 
for anti-EGF and anti-VEGF binders.  
2. Explore the protein-ligand interactions by spectroscopic or thermodynamic methods. 
3. Investigation, by in vitro assays, of the ability of compounds to cross the blood-brain 
barrier. 
4. Explore the effect of a BBB-shuttle on the transport of the cyclopeptides and on its 
activity. 
  
 
 
4 
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1.1. NF-B: biological background  
1.1.1. Recruitment of myeloid cells at the tumour site: monocyte-macrophages 
A prominent component of solid tumours is represented by non-tumoural cells, including 
stromal cells (fibroblasts and endothelial cells) and leukocytes. In the late 1970s it was 
found that the tumor-associated macrophages (TAM) are the major leukocyte population 
present in tumors able to promote tumour growth and invasion.
1,2
 The origin of TAM has 
been studied in terms of recruitment, survival and proliferation starting from the 
observation of leukocyte infiltrations into malignant tissues, which suggested that cancers 
arise at regions of chronic inflammation. TAMs derive from circulating monocytes and are 
recruited at the tumour site by a tumour-derived chemotactic factor for monocytes
3
 
identified as the chemokine CCL2/MCP-1.
4,5
 
Among these, CCL2 is probably the most frequently found CC chemokine in tumours and 
its levels of expression correlate with the increased infiltration of macrophages.
2,6,7
 
Along with the supposed pro-tumoural role of TAM, the local production of chemokines 
and the extent of TAM infiltration have been studied as prognostic factors.
8-10
 
A variety of chemokines have been detected in neoplastic tissues as products of either 
tumour cells or stromal elements. These molecules play an important role in tumour 
progression by direct stimulation of neoplastic growth, promotion of inflammation and 
induction of angiogenesis.
11
 
Macrophages are also recruited by molecules other than chemokines. In particular, tumour-
derived cytokines interacting with tyrosine kinase receptors, such as vascular endothelial 
growth factor (VEGF) and macrophage colony stimulating factor (M-CSF), promoting 
macrophage recruitment, as well as macrophage survival and proliferation.
12,13
 
1.1.1.1. Distinct properties of M1 and M2 macrophages 
Macrophages are able to express distinct functional programs in response to different 
micro-environmental signals, in particular during pathological conditions such as infections 
and cancer.
14,15
 This plays a central role in the activation of specific transcriptional program 
expressed by tumor-associated leukocytes, either mediating pro- or anti-tumor functions.
2,16
 
Chronic infections can tightly regulate the immune responses, being able to trigger highly 
polarized type I or type II inflammation and immunity. Central to the development of type I 
or type II polarization is the specificity of the host–pathogen interaction. 
Several studies on tumour–host interaction have highlighted the importance of 
inflammatory responses in the early steps of carcinogenesis,
17
 as well as in established 
progressive tumours and are beginning now to identify the contribution of polarized 
inflammatory responses in cancer progression. 
For a long period, classical or M1 macrophage activation was recognized as the unique 
activation program in response to microbial products and interferon-c. Recently it became 
clear that anti-inflammatory molecules, such as glucocorticoid hormones, IL-4, IL-13 and 
IL-10, are also able to induce distinct M2 activation programs.
2,18-20
 
Classical or M1 macrophage activation is characterized by: high capacity to present 
antigen; high interleukin-12 (IL-12) and IL-23 production
21
 and consequent activation of a 
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polarized type I response. Furthermore, M1 is associated with high production of toxic 
intermediates (nitric oxide (NO) and reactive oxygen intermediates (ROI)). Based on this, 
M1 macrophages are generally considered to be potent effector cells that kill micro-
organisms and tumour cells and produce copious amounts of pro-inflammatory cytokines. 
Type II macrophages (M2) tune inflammatory responses and adaptive Th1 immunity, 
scavenge debris, and promote angiogenesis, tissue remodeling and repair. Various signals 
cause different M2 activation forms that commonly share selected functional 
properties.
2,14,19,22,23
  
Polarized macrophages differ also in terms of receptor expression, cytokine production and 
effector function chemokine repertoires. 
 
Figure 1. Signaling pathways regulating TAM phenotype and function. (Adapted from Clinical Cancer Research; 2010 
16, 784-789. 
Overall, evidence suggests that signals inducing M2 polarization down-regulate NF-B and 
STAT1 activities, and thus act as a common mechanism to limit the induction of 
inflammatory chemokines associated with the development of type I immunity and 
inflammation.  Defective NF-B activation in TAM correlates with impaired expression of 
NF-B-dependent inflammatory functions and cytokines (TNF, IL-1, IL-12).24 
Restoration of NF-B activity in TAM is therefore a potential strategy to restore M1 
inflammation and intra-tumoural cytotoxicity. It became clear that differential involvement 
of NF-B driven inflammation in early step of carcinogenesis as compared with advanced 
neoplasia, where the established tumour micro-environment would guide TAM functions 
toward an M2 suppressive and tumour-promoting phenotype.  
Recent evidence suggests that homodimers of the p50 subunit of NF-B (a negative 
regulator of the NF-κB pathway) are responsible for the slow activation of NF-B in TAMs 
and for the pro-tumor phenotype of these cells.
25
 It seems that NF-B functions can be 
tuned to different levels, a property that enables the extent of inflammation to be regulated. 
Such regulation allows to the vigorous inflammation that predisposes individuals towards 
developing cancer to be sustained, and enables TAMs to support the smouldering 
inflammatory microenvironment present in established metastatic neoplasia. 
By investigation the molecular basis which drives M2 polarization of TAM, it has been 
demonstrated that these cells are characterized by massive nuclear localization of the 
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inhibitory p50 NF-B homodimer. Strikingly, in p50 deficient tumor-bearing mice TAMs 
express cytokines characteristic of M1 inflammation and splenocytes produce Th1 
cytokines, an immune profile associated with tumor growth inhibition in vivo.
25
 Thus p50 
NF-B nuclear accumulation appears to promote persistent M2-inflammation associated 
with tumour progression.
26
 The massive accumulation of p50 NF-B in LPS-tolerant 
macrophages is parallel by their expression of an M2-associated profile suggesting that p50 
NF-B is a pivotal determinant of polarized M2 inflammatory responses. Preliminary 
results have also confirmed a similar activity of p50 NF-B in myeloid-derived suppressor 
cells (MDSC), in terms of both functional M2-polarization and suppressive activity, further 
indicating that targeting this molecule in the myelomonocytic compartment may restore M1 
inflammation and anticancer activity in vivo. 
1.1.2. Dimeric transcription factors: Rel/NF-B family  
Nuclear factor-B (NF-B) has been shown as an important regulator of TAM 
transcriptional programs. NF-B is a generic term for a family of transcription factors that 
play pivotal roles in inflammation and immunity. In particular, the Rel/NF-B family of 
dimeric transcription factors is involved in a wide array of cellular activities, such as 
cellular immune responses, growth, development and apoptosis.
27,28
 In mammals, these 
dimers arise from the combinatorial association of five polypeptides; RelA (p65), RelB, c-
Rel, NF-B1 (p105/p50), NF-B2 (p100/p52).29 
Rel/NF-kB polypeptides share a homologous amino-terminal region composed of 
approximately 300 amino acid residues; this homologous portion, known as the rel 
homology region (RHR), contains the amino acid sequences responsible for DNA binding, 
subunit dimerization, nuclear localization and for the interaction with the cytosolic inhibitor 
B molecule (IB).30-32 
Primary sequence comparison of the Rel/NF-B polypeptides shows 38% amino acid 
identity and more than 75% homology across the family.  
The crystal structures of the DNA-bound p50, p52, and p65 RHR homodimers and the p50-
p65 heterodimer 
33-37
 show that the RHR can be divided into three sub-regions: i) the large 
N-terminal region, contains approximately 200 amino acid residues folded into an 
immunoglobulin (Ig)-like domain, which is the major contributor of DNA-contacting 
amino acids. ii) The central region, also an Ig-like domain, consists of approximately 100 
amino acids, responsible for subunit association and iii) the short carboxyl-terminal region 
harbors a nuclear translocation signal. This last segment containing the 14 amino acids of 
the nuclear localization sequence (NLS), does not display a folded structure
38,39
 and its last 
four amino acids are known to interact with the NF-B inhibitor protein IB.30  
1.1.2.1. Canonical and non-canonical pathway 
The NF-B subunits fall into two categories, named class 1 and class 2. Class 1 includes 
the p50 and p52 subunits, they are encoded by the genes nfb1 and nfb2 and synthesized 
as precursor proteins p105 and p100 respectively. Class 2 subunits include RelA, RelB and 
c-Rel, encoded by the genes rela, relb and c-rel and are synthesized in an active form. All 
subunits contain the N-terminal Rel homology domain (RHD) but only the class 2 subunits 
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have a transactivation domain (TAD) allowing for direct control of transcription.
40
 
In resting cells, NF-B/Rel dimers are bound to IBs and retained in an inactive form in the 
cytoplasm.
41,42
 Like NF-B, IBs are also members of a multigene family containing seven 
known mammalian members including IB, IB, IB, IB, bcl-3, the precursor Rel-
proteins p100 and p105.
43,44
 The IB family is characterized by the presence of multiple 
copies of ankyrin repeats, which are protein-protein interaction motifs that interact with 
NF-B via the RHD.45-47 Upon appropriate stimulation, IB is phosphorylated mainly by 
the IB kinases (IKKs), polyubiquitinated and degraded by the 26S proteasome.48,49 
Close to the C-terminal end of the RHD lies the Nuclear Localization Signal (NLS) which 
is essential for the transport of active NF-B complex into the nucleus. The RHD contains a 
phosphorylation site for Protein Kinase A, the phosphorylation of this site has been 
described to be essential for nuclear localization of NF-B.50 Consequently, NF-B is 
released and is translocated into the nucleus to bind to the target DNA and initiate gene 
expression.
51,52
 
Activation of NF-B occurs through canonical and non-canonical pathways.  
The canonical pathway is triggered by microbial products and proinflammatory cytokines, 
such as tumor necrosis factor α (TNFα), IL-1β, and most commonly leads to the activation 
of RelA-p50 complexes. The alternative pathway
53
 is activated by lymphotoxin β (LTβ),54 
CD40 ligand (CD40L),
53
 B-cell activating factor (BAFF)
55
 and RANK ligand (RANKL)
56
 
and results in activation of RelB-p52. NF-κB proteins are usually held inactive in the 
cytoplasm of resting cells by association with inhibitor of NF-κB (IκB) proteins which 
upon stimulation are phosphorylated by IκB kinase complex (IKK). IKK consists of two 
active kinase subunits: IKKα (IKK1) and IKKβ (IKK2), and a regulatory subunit IKKγ 
(NEMO). The canonical pathway for NF-κB activation requires IKKβ-mediated IκBα 
phosphorylation, whereas the alternative pathway is regulated by IKKα-mediated 
phosphorylation and processing of p100.
40,41
 
Each subunit has distinct biological functions and with 12 known dimeric combinations 
binding DNA the range of NF-B functions is diverse.57 
 
Figure 2. Canonical and non-canonical NF-κB signalling pathways.(Adapted from Nature Reviews Drug Discovery. 
2012, 11, 109-124).58 
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1.1.2.2. Rel/NF-B polypeptides dimerization 
The five mammalian Rel/NF-B polypeptides dimerize to form, in principle, 15 unique 
homo- and heterodimers but experimental evidences suggest that Rel/NF-B family 
transcription factors exhibit variable preferences for dimer formation, because p50-p65 
heterodimer and p50 homodimer have been identified as the most prevalent NF-B dimers 
in various tissues.
32
  
The crystal structures of the dimerization domains of p50, p52, and p65
33,34,38,39,59
 illustrate 
how the dimer interfaces are created by two symmetrical beta sandwich domains which 
pack against one another. The structures reveal that a set of 14 amino acid residues from 
each monomer is primarily responsible for mediating dimer formation.
38
 Two of these 
residues participate only through their backbone, whereas the side-chains of the other 12 
residues form the dimer interface. Of these 12 seemingly critical dimer-forming residues, 
seven are identical throughout the Rel/NF-B family and the other five are homologous. 
These residues appear to mediate similar protein-protein interactions for the various subunit 
associations within the NF-B family. Selective dimerization of these family members 
plays a central role in the regulation of transcription for specific Rel/NF-B-dependent 
genes.
60
 
The diversity provided by dimerization between the different members of the Rel/NF-B 
family regulates NF-B signaling at two levels. First, it enhances the repertoire of DNA 
sequences that are regulated by these dimers. Each of the Rel/NF-B dimers has distinct 
DNA binding affinity, which determines the fate of transactivation potentials, as the dimers 
have differential transcriptional activities. Second, specific Rel/NF-B dimers display 
preferential affinity for members of the inhibitor protein family (IB)60 thus, preferential 
sequestration of Rel/NF-B dimers in the cytoplasm by IB proteins blocks early activation 
of the NF-B regulated genes.  
1.1.2.3. The p50 dimer interface
61
 
The dimer interface of p50 is comprised of roughly 40 contacts between the two monomers. 
Approximately 62% of the total buried surface area of the p50dd dimer is hydrophobic; the 
other 38% is composes of seven hydrogen bonds and four salt bridges.  
A total of 14 amino acids are involved in formation of the p50dd dimer interface and 1471 
Å
2
 solvent-accessible surface area are buried in the dimerization process. Based on their 
role in forming the interface, these residues can be divided into three classes: i) residues 
involved in Van der Waals interactions (Val251, Met253, Leu269, Phe307, Ala308, and 
Val310), ii) residues involved in both Van der Waals interactions and polar contacts 
(Arg252, Asp254, Tyr267, Cys270, Asp302, His304, and Arg305) and residue that makes 
only polar contacts (Glu265). Moreover, the side chains of Met253 and Cys270 are oriented 
in the opposite direction to the interface and thus contribute to dimer formation only 
through their backbone carbonyl oxygen atoms.  
The effects of alanine substitutions reveal that four residues (Y267, V310, L269, and D302) 
are the most critical for stabilizing the p50 dimer interface and define the hot-spot of 
binding energy. Among these, Y267 is by far the most critical determinant for the stability 
of the p50 homodimer, because Y267 contacts six different residues emanating from the 
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opposing subunit, making a total of three hydrogen bonds and a number of Van der Waals 
contacts in each subunit (six total H-bonds). Therefore, mutation of this residue to alanine 
reduces sensibly the stability of the interface. 
The Kd for p50 homodimer is in the order of 10
-6
 M
-1
, which reveals that the dimerization 
affinity for p50 is relatively low considering the extensive buried surface area upon p50 
dimer formation.
62
 
A B
C
 
Figure 3. (A) Overall view of p50 NF-B dimer bound to DNA. Depicted are residues 39 to 350 of both subunits and the 
central 11pb of DNA. The color coding is green and light blue for the two p50 subunits and orange-violet for the DNA. 
(B) View perpendicular to the direction of the DNA. (C) The ribbon diagram for the p50 homodimerization region and the 
main residues involved in the interaction Y267, L269 and V310. These figures were produced using PyMOL. 
1.1.3. TAM as targets in cancer therapy  
Given the strong association between macrophages and cancer progression TAM have 
emerged as a promising target in the battle against cancer, based on the concept to restore 
the antitumor activity of TAM and fight the cancer from within. NF-κB activation in 
macrophages has been shown to contribute to carcinogenesis in several models of 
inflammation-associated cancer.
63-65
 Nowadays, several existing anticancer agents, such as 
paclitaxel, have been proposed to act at least in part to inhibit TAM recruitment or 
function.
66-68
 Interestingly, most of these agents activate TAM to produce pro-inflammatory 
mediators by activating NF-κB. However, as with all current anticancer treatments, due to a 
lack of specificity, there are serious side effects associated with these agents.
69
 Conversely, 
strategies to target NF-κB activation in TAM are also likely to show success on the basis of 
evidence from experimental models,
64,70
 indeed targeting NF-κB activation in both 
malignant cells and TAM may be of added benefit due to the role of NF-κB in malignant 
cell survival.
64,71
 
Systemically targeting NF-κB may also have adverse effects given its fundamental role in 
innate immunity,
55
 but specific targeting of NF-κB in macrophages has been shown to 
c 
C 
B 
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increase immunity to infection associated with activation of M1 macrophages,
72
 again 
suggesting the specific targeting of NF-κB in TAM would avoid these adverse effects. 
1.1.3.1. NF-kB inhibition approach 
Most NF-κB inhibitors developed to date inhibit either NF-κB protein activation or IκB 
phosphorylation and degradation, thus preventing the release of free NF-κB and its entry 
into the nucleus. Another approach that directly inhibits NF-κB DNA binding, by 
interfering with the DNA binding of NF-κB to the promoter of targeted genes, also appears 
amenable to designing specific inhibitors. However, only a limited number of agents have 
been developed based on this approach.
73
 
Despite a variety of agents exhibit various degrees of effectiveness in suppressing NF-κB 
signaling, few of these compounds are specific, and some side effects have been reported. 
For example, glucocorticoids, which are considered as the most powerful nonspecific 
inhibitors of NF-κB, resulted in reduced bone formation and suppression of hypothalamic–
pituitary–adrenal axis function.74,75 
NF-κB activation or function can be inhibited by more specific means. For example, the 
NF-κB essential modifier (NEMO)-binding domain peptide inhibits p65 phosphorylation, 
and the SN50 peptide inhibits NF-B nuclear transport.76-78 Among various strategies 
aimed at inhibiting NF-κB activation, blocking the binding of the p65 or p50 subunit with 
the κB site may be more specific17,79 because a higher degree of specificity may be 
achieved by the inhibition of NF-κB–mediated transcription.  
In this regard, recently it has been reported a study in which a linear pentapeptide AIP6 
(RLRWR) was developed mimicking the DNA-binding motif in p50. AIP6 is able to 
selectively bind with κB elements and prevents the binding of active NF-κB complexes. 
This peptide (AIP6) seems to interact directly with p65 to inhibit the DNA-binding, the 
transcriptional activities of NF-κB and the production of inflammatory mediators in vitro.80 
This inhibitory effect of AIP6 on NF-κB appeared specific and did not involve IκB 
degradation, IkBα phosphorylation, or p65 nuclear import. The observation that the local 
administration of AIP6 inhibit inflammatory responses induced by zymosan in the joints 
and soft tissues in mice
81
 suggest that AIP inhibits inflammation by binding the NF-B p50 
subunit resulting in the inhibition of NF-B activation. 
1.2. Protein–protein interactions as emerging therapeutic targets  
Protein–protein interactions (PPIs) control the function of living cells, such as signal 
transduction, cell cycle, proliferation and metabolism and, for this reason, represent a 
promising new class of attractive therapeutic targets. Quantitative, functional and structural 
studies of PPI enable the understanding of these processes at the cellular and molecular 
levels and provide a basis for designing drugs that inhibit or stimulate PPIs. Disruption of 
PPIs is a viable strategy for example in the treatment of many types of cancer, age-related 
macular degeneration (AMD), and also in diseases that are the result of protein misfolding 
and aggregation, for example Alzheimer’s disease, Duchenne muscular dystrophy and 
Huntington’s disease.  
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However, PPIs are still considered as extremely difficult for targeting by small-molecules 
due to the structural characteristics of the interface.
82
 The inter-protein surfaces are 
generally large (approximately 1500–3000 Å), flat and lack distinguishing features,83 
making the design of small molecule antagonists a difficult task.
84,85
 Thereby, successes in 
drug discovery developments against PPI targets face two major issues, i.e. predictability of 
the chemical space dedicated to these interaction interfaces and druggability of each 
potential new PPI target identified in a biological program. Even so, recent successes in the 
inhibition of PPI with small molecules and peptidomimetics have emerged as a new way to 
modulate the activity of proteins and generate new drugs against this huge reservoir of 
potential targets. Small peptide or peptidomimetic ligands have been developed, often to 
facilitate interaction with hydrophobic α-helix, β-turn, or β-sheet binding channels or 
clefts.
86
 
1.2.1. Peptides to modulate PPI and their use as therapeutic agents  
Peptides are often used as ligands for recognition of protein surfaces
50,51
 representing one of 
the main sources for small molecule inhibitors of PPIs, leading to a successful development 
of small-molecule modulators for some of the most clinically important PPI.
87-91
 
Peptides that modulate PPIs may be rationally developed based on a binding site within a 
known protein that participates in a certain PPI,
92
 or from the screening of peptide 
sequences that do not originate from natural proteins.
93
 
The main shortcoming of using linear peptides for therapeutic purposes is their wide 
conformational range and short lifetime, a reason why many peptide drugs with exciting 
pharmacological activities in vitro have proven to be ineffective in vivo. 
The short half life is primarily due to its fast renal clearance, connected to its hydrophilic 
property and small size, and its poor metabolic stability and biodegradability as a result of 
enzymatic degradation by proteolytic enzymes (proteases and peptidases) of the blood, 
liver, and kidney. Hence different strategies for targeted modifications of peptide drugs in 
order to prolong their plasma half lives are highly demanded to improve drugs’ 
pharmacokinetic profiles.
94,95
  
The peptide cyclization is considered one of the best methods to improve the stability of 
peptides
96
 and to capture their bioactive conformations. By stabilizing peptides and 
imposing conformational constraints, cyclization conveys higher binding affinity, 
selectivity and bioavailability and enables peptides to be used as lead compounds for drug 
design. 
In addition, there are many different conformational restrictions to increase the affinity and 
the selectivity towards the target, for instance, compounds that mimic -turn motif can 
promote additionally intra-molecular hydrogen bond formation which will increase the 
rigidity of the molecule. The introduction of N-methyl amino acids along the backbone of 
the peptide may have an impact in different preferred conformations. N-methylation or 
introduction of proline increases the formation of cis-peptide bonds which has a relevant 
effect on the backbone conformation of cyclic peptides. Then the cyclic peptide 
conformation depends on the steric interaction between the introduced N-methyl group and 
the carbonyl oxygen and/or the alpha-substitution of the constituent amino acids, and not by 
the functionality of the side chains. Then by varying the specific points of N-methylation in 
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the backbone we can fine-tune the selectivity of the peptide for a specific protein target. 
The advantage of N-methylation in front of the incorporation of proline is the addition of 
more functional groups into the bioactive compound. 
Moreover, protease resistance can be conferred by substituting the natural amino acids by 
unnatural amino acids (D-), N-methyl-alpha-amino acids, or beta-amino acids. The amide 
bond between two amino acids may be replaced, the N- or C-termini may be blocked and 
carbohydrate chains can be added.  
Peptide cyclization approach evolved both in nature
97-99
 and in synthetic work. In nature, 
there are several cyclic and bicyclic peptides which have presumably evolved to confer 
stability and binding advantages to these complex structures over the linear peptides. 
Moreover, many natural peptides display two or more disulfide bridges, which enhance the 
stability of these compounds owing to the reduction of their sensitivity to proteolytic 
cleavage.
100
 The common feature of all of them is the imposed rigidity.  
 
Figure 4. Some examples of constrained peptides. a) Cyclotide with three disulfide bridges shown in gold. b) Cyclic beta-
hairpin. c) Stapled peptide with the so-called staple, or hydrocarbon link shown in gold. 
Today, there are more than 50 peptide drugs that have been approved for clinical use and 
the increasing number of peptides entering clinical trials now supports the notion that 
peptide drugs have a long and secure future.
101
 The targeted therapeutic areas of these 
peptides include, but are not limited to oncology, metabolic, cardiovascular and infectious 
diseases, all of which represent important markets.
102
 
Currently, most of the peptide drugs are peptide hormones (such as insulin) or peptides that 
mimic hormones.
103
 However, the number of peptide drugs that act as enzyme inhibitors
104
 
or as antimicrobial peptides
105
 is increasing. 
1.3. Peptide delivery 
An important limitation in the use of peptides as drug candidates is their poor uptake and 
low ability to cross biological barriers,
95
 thus different peptide carriers or delivery systems 
have been proposed to address this problem. 
For peptides which target membrane receptors, delivery to the target sites may be made 
possible with the application of liposomes or nano- and micro-particles which also enhance 
the local availability of peptides, protecting them from proteolytic action. These particles 
effected bioadhesion (residence time and absorption), biodegradability (release kinetics), 
and biocompatibility. 
Thanks to the nanotechnological advances applicable to peptide delivery,
106-108
 are 
receiving increasing attention sustained delivery systems based on biodegradable polymers 
from renewable resources (e.g. chitosan and its derivatives) or derived from petroleum 
resources (e.g. PLGA (poly-lactic-coglycolic acid) or PGA (polyglycolide)).  
c a b 
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Peptide-based strategies offer considerable advantages over other delivery systems. 
Peptides are not immunogenic molecules and they allow rapid delivery of cargoes, such as 
proteins, other peptides or nucleic acids, into cells. Furthermore, they are stable in 
physiological buffers and are usually not highly toxic. 
In this field, cell penetrating peptides (CPPs)
109
 is a novel approach to deliver drug 
molecules which involves the use of peptides to facilitate uptake of the cargo. Indeed, it 
was discovered that short peptides derived from protein-transduction domains can be 
internalized in most cell types and, more importantly, allow the cellular delivery of 
conjugated (or fused) biomolecules.
110,111
  
The interest for CPPs is mainly due to their low cytotoxicity and to the fact that there is no 
limitation for the type of cargo. Although CPPs have been used to improve delivery of 
cargo that varies greatly in size and nature (small molecules, oligonucleotide, plasmid 
DNA, peptide, protein, nanoparticle, lipid-based formulation, virus, quantum dots) most of 
the applications describe the delivery of oligopeptide/protein and nucleic acids or analogs.  
Always in the field of peptides, BBB shuttles represent another class of transporter with a 
peptidic nature that have demonstrated to be able to overcome the blood-brain barrier and 
carry therapeutic compounds that cannot cross unaided.
112
  
1.4. Peptide synthesis 
In 1901, Emil Fischer initiated peptide chemistry by the synthesis of the dipeptide 
glycylglycine, obtained by hydrolysis of the diketopiperazine of glycine. This is the first 
reported synthesis of a dipeptide and is also the first instance of the term “peptide” used to 
refer to a polymer of amino acids.
113
  
However, already twenty years ago, Theodor Curtius synthesized the first N-protected 
dipeptide, benzoylglycylglycine, by treating the silver salt of glycine with benzoyl 
chloride.
114
 Furthermore in 1904, he developed the first practical method for peptide 
synthesis, the azide coupling procedure, which enabled the synthesis of benzoylglycine 
peptides of various length.
115
 In addition, only one year later, Emil Fischer presented a new 
method for the synthesis of peptides via acylchlorides, prepared from the corresponding 
free amino acid using PCl5 in acetyl chloride as solvent.
116
 
After these first simple examples, the research in the field of peptide synthesis has 
undergone prodigious advances leading to the development of innovative and efficient 
methodologies that allow the preparation of complex molecules as well as proteins. 
1.4.1. From solution to solid-phase peptide synthesis 
The solution-phase peptide synthesis (SPS) method was based on the coupling of peptide 
fragments or a single amino acid in solution. It offers many inherent benefits: in principle, 
the whole repertoire of organic reactions can be employed; reactions can be monitored in 
real time using conventional techniques (TLC, NMR, LC-MS); the product is characterized 
after each coupling and no additional steps are required to attach and cleave substrates from 
the solid support. On the other hand, this approach imply a purification step after each 
coupling which is time consuming and can associate with product losses. 
Solid-phase peptide synthesis (SPPS) was introduce for the first time in 1963 when Bruce 
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Merrifield published a historic paper describing the principles and the applications of his 
invention.
117
 In contrast to the solution-phase methodology, the growing peptide in the 
solid-phase approach is linked to an insoluble support and therefore, after each reaction 
step, the byproducts are simply removed by filtration and washing. Moreover the solid-
phase synthesis offers the ability to use excess quantities of reagents to drive reactions to 
completion. Furthermore, because of the repetitive nature of peptide synthesis 
(deprotection, washing, coupling, washing, deprotection), the use of an insoluble support in 
a single reaction vessel allows the automatization of the processes. The mechanization of 
the SPPS process permits, in a fully automatic manner, the incorporation of more than 10 
amino acid residues per day and for this reason this techniques have been considered the 
method of choice for the production of chemical libraries. 
 
Scheme 1. Schematic principle of solid-phase peptide synthesis. 
Generally, peptide synthesis is based on the appropriate combination of protecting groups 
and an efficient method for the activation of the carboxyl group prior to reaction with the 
amino terminal. Protecting groups have to prevent on one hand bond formation between 
two incoming amino acids (N-terminal protecting group), and on the other hand formations 
between the incoming amino acids and side chain functionalities (side chain protecting 
groups). In the Merrifield synthesis, the C-terminal is protected by the polymeric carrier. 
Mainly, two protection schemes have been developed for the Merrifield synthesis. The first 
one is the tert-butoxycarbonyl (Boc)/benzyl (Bzl) strategy, which depends on the different 
acid lability of the N-terminal protecting group (Boc) and the side-chain protecting group 
(Bzl) as described in the original publication of Merrifield.
117
 The main drawback of this 
strategy is the use of hydrogen fluoride (HF) for the final cleavage and deprotection of the 
peptide. This procedure leads to various side reactions, such as Friedel-Crafts reactions 
between aromatic groups of the resin and the side chains of the peptide, and/or promotion 
of a NO acyl shift involving the side-chain groups of serine and threonine.  
The second protection strategy was developed by Carpino and Han
118
 and is based on the 
use of the base labile 9-fluorenylmethyloxycarbonyl (Fmoc) group for the protection of α–
amino groups. This approach allows the orthogonal protection of side-chain functions with 
acid labile protecting groups. 
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1.4.1.1. Solid support 
The first solid support used in solid-phase peptide synthesis was a styrene-divinylbenzene 
co-polymer, functionalized by chlorination of benzyl groups. The benzyl chloride was then 
be used to anchor the C-terminal amino acid via an ester linkage to the solid support. Thus, 
when the product of the SPPS was cleaved from the solid support a carboxylic acid was 
obtained at the C-terminal. Later on, a broad variety of resins were developed leading to 
different functionalities at the C-terminal such as acids (Wang resin, 2-Chlorotrityl resin), 
amide (Rink amide (RAM), 4-methylbenzhydrylamine (MBHA) resin), thioesters (4-
sulfamylbutyryl resin), or alcohols (4-hydroxymethylbenzoic acid (HMBA) resin).  
Among this solid support 2-Chlorotrityl chloride (Cl-Trt) resin is one of the most useful 
resins for the solid-phase synthesis of C-terminal acid peptides
119-122
 which can be used for 
the preparation of both protected and unprotected peptides. Cl-Trt resin offers many 
advantages because, allows the release of the peptide under mild acidic conditions (1% 
Trifluoroacetic Acid (TFA), 10% Hexafluoro-2-Propanol (HFIP)),
84
 it reduces the 
formation of diketopiperazine (DKP),
85
 minimizes the racemization during the 
incorporation of the first amino acid; and it allows the incorporation of partially protected 
amino acids through the side chain or the amino function.  
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Figure 5. Some examples of solid support resins: a) 2-Chlorotrityl resin, b) Aminomethyl ChemMatrix-AB, c) Fmoc-
Rink amide p-MBHA resin. 
1.4.1.2. Amide bond formation and condensing agent development 
The formation of the amide bond is a key step in the synthesis of any peptide; this step 
occurs through the activation of a carboxylic acid group which is carried out with different 
condensing agents, additives and active species.
123
  
Carboxylic acids are generally activated either by carbodiimides, formation of symmetrical 
anhydrides (anhydride formed from equivalent of the same amino acid), or formation of 
active esters. Since low yields, racemization, or degradation often accompany amide 
formation, coupling procedures are optimized not only to provide high yields, but also to 
prevent the racemization. To this purpose numerous coupling reagents have been developed 
and become commercially available.
124
 
In solution-phase peptide synthesis, racemization is encountered upon activation of the acid 
(i – iii), which might lead to the formation of an oxazolone (iv). Under mild basic 
conditions, the oxazolone is deprotonated into a conjugated anionic intermediate (v). Since 
reprotonation occurs not enantioselectively, racemates of oxazolones are obtained (vi and 
viii). Because both react with the amino terminal of the growing peptide chains, chirality 
gets lost leading to a DL- (vii) and a LL-peptide (ix) (Scheme 2). 
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Scheme 2. Racemization via oxazolone mechanism. R1, R2: side chain residues. 
In SPPS, this mechanism is prevented due to the fact that peptides are grown at the N-
terminus and N-protected amino acids are used. Nevertheless, racemization might also 
occur due to a reversible proton exchange on the C-atom forming the carbanion as 
observed with activated cysteine or histidine residues.
125,126
 Similar to the oxazolone 
mechanism, reattachment of the proton is able to occur from both sides leading again to a 
racemic mixture. Activation of the carboxylic acid allows to overcome the thermodynamic 
restrictions of the peptide bond formation as already mentioned above. 
1.4.1.2.1. Carbodiimides  
Carbodiimides rank as one of the most important classes of reagents in organic synthesis 
due to their accessibility, versatile chemical properties, and utility as in situ activating 
reagents in coupling reactions.127,128  
The most widely used carbodiimide is dicyclohexylcarbodiimide (DCC), which serves as a 
versatile coupling agent in the preparation of amides, esters and anhydrides.
129
 The 
mechanism of the reaction
130
 is depicted in Scheme 3.  
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Scheme 3. Peptide coupling via carbodiimide. R: cyclohexyl residue. R1: carboxy moiety; R2: amino moiety. 
The anion of the carboxylate (iii) is added to the protonated carbodiimide (iv) forming the 
highly reactive O-acyl-isourea (v), which further reacts with amine vi to form amide vii and 
dicyclohexylurea (DCU, viii) as a byproduct.  
The carbodiimide activation method has, however, a high propensity for racemization 
because of the high reactivity of the O-acyl-isourea, which can lead, through intramolecular 
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cyclization, to the formation of an oxazolone; this cyclic intermediate can easily racemize 
via an aromatic intermediate. 
Moreover, complete removal of the dicyclohexylurea (DCU) byproduct is difficult because 
of its low solubility and usually necessitates additional cumbersome purifications. This 
limitation has prompted the development of an array of surrogate DCC coupling reagents 
including water-soluble carbodiimide derivatives such as diisopropylcarbodiimide (DIC)
131
 
and EDC (1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride) which form 
more soluble products.
132
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Figure 6. Commonly used carbodiimides. 
In addition, in the contest of the solution phase synthesis assisted by solid-phase 
reagents
133-137 polymer-bound carbodiimides have been developed, such as polystyrene 
isopropylcarbodiimie as viable replacement for DCC.
138-142
 
The use of polymer-supported reagents is emerging as a leading strategy that combines the 
advantages of product isolation and purification of solid-phase chemistry with the benefits 
of traditional solution-phase reactions.
143
 Despite this, only a few polymer-supported 
coupling reagents are available; in particular, DCC,
127
 DIC
138
 and EDC
142
 have been 
successfully immobilised and applied to the synthesis of amides.
144
 However, these 
carbodiimides maintain the same drawbacks as their solution-phase equivalents, 
particularly in terms of epimerization in the absence of an additive. 
1.4.1.2.2. Use of additives 
In order to reduce the epimerisation level when using carbodiimides as coupling reagents, 
has been proposed to add a nucleophile which reacting faster than the competing acyl 
transfer generates an intermediate still active enough to couple with the amine and also 
prevents the side reactions. In this field HOBt (1-Hydroxybenzotriazole) has been 
introduced as the first additive,
145,146
 showing that, when it is used, yields were higher and 
epimerisation levels lower. 
HOBt is believed to work by initially reacting with the O-acylurea to give the OBt active 
ester (ii), which enhances the reactivity of the activated ester.
147
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Scheme 4. Schematic representation of the amide bond formation using HOBt as additive to minimize the formation of 
unreactive N-acylurea. 
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The successful active ester method has been extensively studied
148
 and is nowadays the 
most widely used approach in solid-phase peptide synthesis. The amino group of R3NH2 (i) 
nucleophilicly attacks the carboxyl carbon of ii leading to the tetrahedral intermediate iii 
(Scheme 5). 
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O
+ R3XN
i ii iii iv v  
Scheme 5. Formation of peptide bond by activation ester mechanism. R1: amino moiety; R2: carboxyl moiety; R3: leaving 
group. 
The formation of iii is the rate determining step in this reaction. It can be positively 
influenced by activating the carboxyl component with electron withdrawing groups. The 
second step, the peptide bond formation, is fast, if the C-X bond in iii is highly polarized. 
Since the acceptance of HOBt as epimerization suppressant, other benzotriazole derivatives 
were proposed such as 1-hydroxy-6-chlorobenzotriazole (Cl-HOBt) and 1-hydroxy-7-
azabenzotriazole (HOAt), that are reported to be more efficient additives than HOBt, 
because speed up the coupling process and reduce racemization. 
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Figure 7. Several common additives. 
1.4.1.2.3. Coupling reagents based on 1H-benzotriazole 
Several coupling reagents based on the HOBt/HOAt system and uronium/aminium salts, 
have been developed; by reaction with the carboxylic acids they form OAt/OBt active 
esters, which then react with amines.
149
 A side-reaction can often take place with the amine 
reacting with the coupling reagent to form a guanidinium by-product,
150
 nevertheless, 
coupling with aminium/uronium salts in the presence of a base have proven to be more 
effective than those carried out with carbodiimide in the presence of hydroxylamine 
derivatives.
123
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Figure 8. Structures of the most common phosphonium or uronium salts coupling reagents to form active esters for 
peptide coupling. 
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Castro et al. developed another family of coupling reagents based on HOBt/HOAt but that 
uses a phosphonium group.
151
 Phosphonium salts have the advantage of not yielding 
guanidinium by-products via reaction of the coupling reagent with amines. The first 
phosphonium salt introduced was BOP but its use has been limited due to the 
carcinogenicity and respiratory toxicity associated with HMPA 
(hexamethylphosphoramide) generated when BOP is used in coupling reactions, leading to 
the development of the pyrrolidino derivative PyBOP.
152
 Moreover, the cytotoxic aminium 
salt HBTU is often replaced by the tetrafluoro borate TBTU.
153
  
It has been proven that coupling reagents based on HOAt (compared to HOBt) give faster, 
more efficient couplings with less epimerisation.
154
 This is due to the 1H-hydroxy-7-
azabenzotriazole (OAt) esters which show an increased reactivity owing to the formation of 
a transition state stabilized by an additional H-bond.
147
 This increases the aminolytic 
reactivity and additionally inhibits racemization with a high efficiency. In the transition 
state the amino component is fixed in a certain orientation facilitating the nucleophilic 
attack, whereas the oxazolone formation is significantly reduced due to the low activation 
of the ester group (Scheme 6). 
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Scheme 6. Intramolecular base catalysis of HATU during aminolysis of OAt esters. R1: carboxy moiety; R2: amino 
moiety. 
Comparative studies using HBTU
155
 and TBTU
156
 showed that the counter-anion had no 
practical influence on the outcome of coupling reactions using these reagents. Moreover, 
reagents based on phosphonium salts are preferred to their aminium/uronium counterparts 
for cyclization, because the latter compounds can give guanilidation reactions on the amino 
group. 
1.4.1.2.4. Phosphonic acid derivatives 
A wide variety of phosphonic acid derivatives is available. Diphenylphosphoryl azide 
(DPPA) and diethylphosphoryl cyanide were the first phosphonic acid derivatives to be 
used in peptide synthesis. DPPA reacts with free carboxyl groups to form acid azides.
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Figure 9. Coupling reagents derived from phosphonic acids. 
DPPA (diphenylphosphoryl azide) was introduced as a reagent for organic synthesis in 
1972
157,158
 and in the field of peptide synthesis, has been demonstrated that DPPA is a 
coupling reagent with little epimerization and racemization and it is inactive to the 
functional groups of many amino acids avoid unwanted side chain reactions. The reaction 
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mechanism of the amide bond formation using DPPA would be as shown in Scheme 7. The 
carboxylate anion i would attack to the phosphorus atom in DPPA ii to give the acyl 
phosphates iii. The acyl azide iv would be formed by SN2 type reaction of iii with the azide 
anion, which by reaction with the amine forms the corresponding amide v. 
R1-NH2
+R
O
O PN3 (OPh)2
O
R
O
O N3
P
O
(OPh)2
+ R
O
N3 R1
O
NH2
i ii iii iv v  
Scheme 7. Reaction mechanism of amide bond formation using DPPA as coupling regent. 
In the macrocyclization DPPA is often utilized under high dilution conditions, combined 
with a inorganic base (sodium hydrogen carbonate, NaHCO3) instead of organic bases such 
as triethylamine. 
Propane phosphonic acid anhydride (PPAA) has been reported as an excellent reagent for 
amide/peptide bond formation characterized by excellent reaction selectivity, low 
epimerization with high product purities and yields. PPAA is a commercially available 
trimeric reagent that has been used in solution phase peptide synthesis and in cyclization 
reactions. It gave better results than BOP-Cl, and was found superior to HATU for 
cyclization reactions, especially for sterically hindered peptides.
159,160  
Among the many advantages of this coupling reagent the main is represented by the fact 
that the salt by-product is completely water soluble. Thus, it is readily removed via an 
aqueous wash at the conclusion of the reaction. 
The reaction mechanism involved PPAA provide the conversions of the oxygen of the 
carboxylic acid into a leaving group and the by-product formed by the leaving group can be 
easily extracted by use of an aqueous work-up.  
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Scheme 8. The reaction mechanism involved PPAA. 
1.4.2. Diketopiperazines (DKP)  
One of the most serious side reactions during peptide synthesis on solid phase, is the 
formation of diketopiperazines (2,5-piperazinediones), which are the smallest cyclic 
peptides.
161-164
 
DKPs are formed by intramolecular aminolysis at the dipeptide level and its formation has 
been established to be either acid-
162
 or base-catalysed
165,166
 and is strongly dependent on 
the nature and the sequence of the amino acids. Thus, the reaction is favoured by the 
presence, in either the first or second position, of amino acids (Gly, Pro, or N-alkyl) that can 
easily adopt a cis-conformation in the resulting amide bond. Another favourable 
combination is to have one L- and one D-amino acid in the dipeptide, due to the minimal 
steric interference between the two side-chains.
167
 Furthermore, rates of DKP formation 
differ considerably depending on the C-carboxyl ester protecting groups, or the structures of 
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the peptide-resin linkages in the solid-phase approach. 
The formation of DKP is most commonly seen in convergent solid-phase synthesis. The 
main consequence of the formation of DKPs was thought to be a decrease in the overall 
yield of the final peptide, since the hydroxyl sites formed on the polymer were considered 
to be poor nucleophiles, and therefore not predisposed to suffer acylation by the following 
protected amino acids, which would have started new peptide chains. 
Either the use of halogenomethyl resins, where the first amino acid is incorporated via a 
nucleophilic substitution, or the use of preformed handles isolated, purified, and 
characterized in a step preceding the incorporation into the polymer, are advisable.
168
 
Furthermore, the loading of the starting polymer has importance with regard to the quality 
of the final product. Thus, the Cl-Trt-resin with a limited incorporation of the first amino 
acid is suggested to be the method of choice for the preparation of protected Fmoc/tBu 
peptides. 
1.4.3. Peptide cyclization 
The peptide macrocyclization is generally considered a significant synthetic challenge.
169-
171
 As peptide macrocycles have found applications ranging from drug discovery to 
nanomaterials, many efforts were directed to develop and optimize synthetic methodologies 
for their production.
156,157
 
Depending on its functional groups, a peptide can be cyclized in four different ways: head-
to-tail (C-terminus to N-terminus), head-to-side chain, side chain-to-tail or side-chain-to-
side-chain. Of the various methods of synthesizing cyclic peptides, most often the final 
ring-closing reaction is a lactamization,
124
 a lactonization
171
 or the formation of a disulfide 
bridge.  
Ring size is the most important factor that governs the success of a head-to-tail peptide 
macrocyclization, because for small-to-medium-sized rings, the ground-state E geometry of 
the peptide bond prevents the peptides from attaining the ring-like conformation conducive 
to cyclization. On the other hand, larger ring sizes do not pose this problem because they 
can accommodate E peptide bonds. Thus, despite the synthesis of large peptides containing 
more than seven amino acids is not problematic and generally straightforward, smaller 
peptides can often be troublesome, if not impossible, to cyclize.  
Considering that, the ring-closure process is favored when the various structural elements 
of a linear precursor can accommodate the angular requirements for both termini in the 
transition state with the least amount of strain.
172
  
Over the years, various strategies for directing macrocyclizations using conformational pre-
organization have been developed.
173
 These strategies can be classified under two 
categories: (i) ‘internal’ conformational elements, which encompass covalent modifications 
of the peptide chain to facilitate the union of its ends, and (ii) ‘external’ conformational 
elements, which involve the use of molecular scaffolds that are neither covalently attached 
to the peptide, nor consumed during the course of the ring closure.  
Internal conformational elements  
One of the most important aspect during the planning of the cyclopeptide synthesis is the 
carefully chosen of ring disconnection which
174
 should be not sterically encumbered by N-
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alkyl, α,α-substituted or β-branched amino acids (that is, Val or Ile). 
The incorporation of -turns elements embedded midway along the linear precursor 
represents another important feature able to promote macrocyclization, because -turns 
elements, such as proline, -amino and N-Methyl amino acids have the potential to 
introduce cis-amide bonds into peptide sequences giving a fast cyclization.  
Recently, it has been also introduced the concept of Pseudo-prolines as a powerful 
temporary turn-inducing elements in the synthesis of short constrained cyclic 
peptides.
175,176
  
Pseudo-prolines were first introduced as structure-disrupting building blocks that prevent 
the aggregation and self-association of peptides during solid-phase synthesis.
177
 They are 
modified heterocyclic amino acids derived from serine, threonine ((4S)-oxazolidine-4-
carboxylic acid) and cysteine ((4R)-thiazolidine-4-carboxylic acid). When incorporated into 
a peptide chain, these residues predominantly induce cisoid conformations of the amide 
bond preceding them, establishing type-VI β-turn structures.178 These residues, following 
cyclization can be cleaved under acidic conditions to free the respective residue and thus 
yield cyclic peptides devoid of turn-inducing elements.  
The chirality is another important feature which influences the peptide cycliziation. Indeed, 
peptides contains only all L- or all D-amino acids prefer to adopt extended conformations 
as a result of the tendency to minimize allylic strain
179
 placing their reactive termini far 
away from each other resulting in unfavored macrocyclizations. 
The incorporation of D-amino acids into peptides plays a turn-inducing effects and promote 
the cyclization and in general, it has been demonstrated that macrocyclization is favourites 
when occurs between two residues of opposite stereochemical configuration and if the 
linear peptide contain alternating D and L residues favor cyclization.
180
  
External conformational elements 
Many different methods based on the use of external conformational elements have been 
proposed to promote the peptide cyclization.  
One of these approaches is represented by the use of external templates for assisting peptide 
macrocyclization which operate on the basis of a site-isolation mechanism.  
Polymeric scaffolds that can create reaction cavities large enough for only one linear 
peptide molecule to enter and cyclize at a time have been developed.
181
 Such distinct 
nanoenvironments isolate the peptide from the bulk solution and as a result of the isolation 
effect, these internal cavities create significantly decreases the likelihood of 
cyclooligomerization. An alternative method is represents by the molecularly imprinted 
cavities
182
 which is based on the maintaining a turn structure with cis-amide conformations 
of a linear peptide enforced by a nano-sized cavity. 
Metal ions have been introduced to conformationally pre-organize a peptide and facilitate 
the macrocyclization.
183
 To date, various alkali metals have been shown to enhance the 
cyclization of peptides. 
For instance, lithium salts was demonstrated to mediate cyclodimerization of two un-
activated dipeptide methyl esters under basic conditions avoiding the use of high dilution 
conditions, protecting or activating groups, or coupling reagents.
184
 Whereas sodium and 
Chapter 1 
 
 24 
caesium ions have demonstrated to promote peptide macrocyclization by coordination of 
the N- and C-terminus of a peptide and the amidic oxygen atoms along the chain, inducing 
the linear peptide to form a strong turn structure, thus bringing the N- and C-termini in 
close proximity for cyclization (Scheme 9).
185
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Scheme 9. Sodium ions used to enhance the head-to-tail cyclization of peptide through tandem coordination of amidic 
oxygen atoms along the peptide chain. 
It has been also shown how the silver ions could promote cyclization of thioester linear 
peptides playing a dual role as an entropic and enthalpic activator for the macrocyclization 
for an acyl-transfer ring closure.
186
 Through its thiophilic nature, Ag
+
 generates the 
enthalpic activation on complexation with the thioester, making it a better leaving group 
and thus facilitating the acyl-transfer reaction. Unprotected peptides can be cyclized 
individually or as a mixture of peptides in solution. In addition, when tyrosine and lysine, 
which are competitive nucleophilic residues, are incorporated into the backbone of the 
peptide, the chemoselectivity of the cyclization becomes dependent on the pH of the 
solution. However, like any method of macrocyclization that proceeds through a highly 
activated C-terminal ester, also with Ag
+
-ion-promoted activation the epimerization can be 
occur and this effect will be greater only if the ring closes slowly.  
Regarding the sulphur mediated cyclization many different methods for the head-to-tail 
synthesis have been reported, such as the direct aminolysis of peptide thioesters in the 
presence of imidazole,
187
 or the macrocyclization of thioesters with Sanger’s reagent.188 
Moreover, it was defined the bridge between two internal cysteine thiol groups as one of 
the most convenient and straightforward method for constraining a peptide into a 
macrocycle, because the resulting intramolecular disulfide bridges can stabilize secondary 
structure motifs. In addition, the cysteine thiol functionality can be exploited in an 
intramolecular thiol-ene reaction to generate peptide macrocycles. 
In ligation strategies based on the capture/rearrangement mechanism to link two peptide 
fragments together, the native chemical ligation displays the power to link peptide 
fragments under mild conditions.
189
 The process involves a reaction between two peptide 
fragments, one of which is a weakly activated C-terminal thioester, and the other one an 
unprotected N-terminal cysteine residue. The thermodynamic strength of an amide bond 
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over a thioester is the driving force behind this reaction, made possible through a 
proximity-driven S-to-N acyl migration. The selectivity of the reaction allows the use of 
unprotected peptide fragments. The characteristics of the chemical ligation methodology 
overcomes all the limitations of the traditional convergent approach for the synthesis of 
large peptides or proteins (i.e. poor solubility and difficulty in purifying the fully protected 
peptide fragments), and provides access to new synthetic systems. 
The native chemical ligation strategy has been applied to the end-to-end cyclization of large 
peptides that are rich in cysteine residues,
190
 moreover has been recently developed a 
method through the native chemical ligation approach to cyclize peptides that do not 
contain cysteine residues
191
 in which after an initial native chemical macrocyclization 
between an N-terminal cysteine residue and a C-terminal thioester, the cyclic peptide can be 
devoid of its cysteine sulfur through a desulfurization reaction with Raney nickel. 
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Scheme 10. Native chemical ligation applied to the head-to-tail cyclization of peptides. An N-terminal cysteine residue 
undergoes a macrocyclic trans-thioesterification with a C-terminal thioester. A subsequent S-to-N acyl transfer furnishes 
the desired lactamization product.  
The traceless Staudinger ligation was also developed as thioester-based macrocyclization 
strategy.
192
 With this approach a phosphine tethered to a thioester at the C-terminus of a 
peptide reacts intramolecularly with an azide present at the N-terminus to form a cyclic 
iminophosphorane. This ring then contracts to form an amide bond as the aza ylide attacks 
the thioester electrophile. This macrolactamization process was shown to be amenable to 
the cyclization of several globally deprotected peptides providing direct access to a cyclic 
peptide without further deprotection steps. 
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Scheme 11. Schematic representation of peptides head-to-tail macrocyclization through a traceless Staudinger ligation 
strategy. 
In addition, many other classical reactions were used in the fields of peptide and peptoid 
macrocyclization such as the clik chemistry, the Ugi four-component reaction (U-
4CR)
193,194
 and the ring closing metathesis exploiting Grubb’s catalyst.195,196 
1.4.3.1. Peptide cyclization: synthetic approaches 
Cyclic peptides have commonly being prepared entirely in solution or, on the other hand, 
taking advantage of the straightforward methodology of solid phase peptide synthesis 
(SPPS) followed by release of the linear chain from the solid support and a last step of 
cyclization in solution.
 
The peptide cyclization in solution is typically performed under high dilution 
(submillimolar concentrations) to minimize unwanted intermolecular processes such as 
oligo- and polymerizations. 
 
Alternatively, different strategies have been designed to perform the head to tail cyclization 
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on the solid support, which simplified the removal of the coupling reagents, and the organic 
solvent. Each of these strategies requires a different type of linker. The solid-support may 
be attached to the C-terminus of the peptide through a ‘safety catch linker’ or an activated 
linker, or alternatively, the solid support may be linked to the peptide through a side chain, 
or through an amide bond nitrogen. Probably, the last one is the most robust and it is 
sequence independent but all first amino acid must be previously prepared in solution as H-
AA-CO-PG and no proline or N-methyl amino acid can be used at this position. 
In cyclization on solid phase anchoring the reactive molecule to an insoluble polymer
197
 not 
only creates a pseudodilution phenomenon, but it is less prone to encounter one another 
relative to independent molecules in solution that can freely diffuse. Moreover, in the 
macrocyclizations on solid-supported the purification is accomplished by simple washing 
and filtration.  
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Introduction  
p50 NF-B nuclear accumulation seems to promote a persistent M2 inflammation 
associated with tumour progression.
1
 Preliminary results have also confirmed a similar 
activity of p50 NF-B in MDSC (myeloid-derived suppressor cells) in terms of both 
functional M2 polarization and suppressive activity, which further indicated that, targeting 
this molecule in the myelomonocytic compartment may restore the M1 inflammation and 
the anticancer activity in vivo. 
The crystallographic data of the p50 homodimerization
2
 domain reveal that just a few 
numbers of amino acids located in the binding region are directly involved in the 
homodimerization process. Among them, Leu269, Val310 and Tyr267 seem to be the most 
important in the stabilization of p50 dimer interface, defining the hot-spot of the binding 
energy. 
In order to prevent the proteins dimerization either the natural binding sequence or some 
analogues could be exploited prompting the design and the investigation of peptides 
analogues with high affinity towards the p50 NF-B binding site. These molecules will 
efficiently inhibit the protein dimerization by competitive effect. 
Nowadays, the use of peptides as therapeutic agents has been significantly increased due to 
their potential benefits, which consists on high potency and target specificity, as well as, 
low toxicity. The peptide cyclization is one of the most diffused approach to constrain 
small peptides into specific global secondary structures (-helices, -sheets, extended 
structures and -turns), and to establish their biological active conformation.3-7 In addition, 
this allows to overcome their limited pharmacokinetics properties and to extend the peptide 
half-live. 
Based on these considerations, the goal of the present thesis work was to develop new 
cyclic peptides able to prevent the p50 NF-B homodimerization and subsequently restore 
the M1 inflammation and anticancer activity. The idea is to develop structures that 
mimicking the p50 dimerization binding site could interact with the p50 subunits blocking 
their interaction. 
2.1. Peptidomimetic design and candidate selection 
The peptidomimetic rational design was based on previous reported data,
8
 where 
investigations by X-ray crystallography together with site-directed mutagenesis have 
identified the minimal sequence and the amino-acid residues needed involved in the 
binding process between two p50 subunits. 
Several cyclopeptides bearing the key residues (leucine, valine and tyrosine) but different 
in ring size were underwent to a virtual screening in silico. The ring size was varied, from 
tetra to octapeptides, considering the relative proximity among the key-residues and the 
similar previously reported scaffolds typically employed in drug discovery. This structural 
design allows the construction of a cyclopeptides library in which the backbone flexibility, 
the orientation and spatial position of the amino acidic side chains can be modulated.  
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The structures after being built using the graphical interface of Maestro, were solvated in 
explicit water and minimized with Amber11. 
One of the main problems encountered during this part of the work, was the loading of the 
pdb files generate with Maestro in the Amber software. Since this program was developed 
to perform studies of molecular dynamics of proteins and peptides, it does not recognize 
cyclic peptides that do not contain carboxyl and amine as terminal groups, showing a 
stiffness of the program. Nevertheless, the problem was solved by introducing new 
parameters that define the connectivity between the N- and C- terminal.  
The analysis of the results was performed by plotting the energy from the output file. The 
graphic profiles show that the kinetic energy is stable and also the total and potential energy 
plots show a similar trend suggesting a significantly structural rigidity of the cyclopeptides 
backbone mostly for the cyclopeptides with smaller size such as tetra-, penta- and hexa-
peptides. 
The minimized structures have been superimposed with the p50 “hot spot” region to 
evaluate which one present an analogue spatial presentation to that in the natural protein. 
The results obtaining during this qualitative structural analysis, show that the cyclopeptides 
contain five amino acids have a properly size to generate a good overlap with the three keys 
residues of the natural protein. In addition the high rigidity of these structures can results in 
a high specificity toward the binding site of the target protein.  
  
Figure 1. Example of the penta cyclopeptide analyzed in silico and subjected to conformational analysis studies. 
The following step, after the identification of the most promising ring size mimicking the 
protein binding region, consisted in the evaluation of the structures contain five amino acid 
residues. A molecular modelling investigation based on several penta cyclopeptides 
developed in silico, have suggested that the key residues must be inserted sequentially in 
the ring in order to increase the affinity to the protein. Other than the key-sequence (Leu-
Val-Tyr) two more amino acid had to be chosen in order to maximize the peptide 
cyclization and to allow structural differentiation. To achieve this goal, -turn elements 
(e.g. Pro, D-amino acids) and residues functionalizable on the side chain were inserted in 
the cyclopeptidic sequence. 
The small size of these structures provides high structural analogy with the relevant amino 
acids of p50 homodimerization site, nevertheless, the cyclopeptides can differ one from 
another just by a single amino acid in the sequence in order to keep remarkable degree of 
similarity to the natural target. Complementary, once fixed the peptidic backbone, which is 
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the most challenging step, the evaluation of different side chain to better understand the 
binding requirements and improve the interaction with the target protein is relatively easy. 
Based on these considerations, we have proposed two different cyclic pentapeptides which 
differ by a lysine or a serine as functionalizable amino acid (Figure 2). 
NH
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Figure 2. Structures of the two different cyclic pentapeptides proposed. 
The proline role is to pre-organize the linear peptides in a more suitable conformation for 
the cyclization introducing a cis-amide bond in the peptide chain. In the same time, the 
presence of a lysine (Lys) and a serine (Ser) allowed furthermore modifications in the 
cyclic peptides in order to modulate or fine tune the binding affinity towards the target 
molecule. Additionally, the Lys and Ser side functional groups could be exploited to 
conjugate the cyclopeptide to a carrier able to promote the delivery inside the cells.  
As previously mentioned, both cyclic pentapeptides contained the key residues but placed 
in a opposite order in the sequence (Val-Tyr-Leu in the cyclo-1 and Leu-Tyr-Val in the 
cyclo-2). This generates a total different conformation of the cyclopeptides which may be 
reflected by different interactions with the natural target and, probably, different biological 
activity. 
2.2. Peptide synthesis 
2.2.1. Synthesis planning and preliminary considerations 
The synthesis of linear peptides is, in general, a straightforward pathway whereas the head 
to tail cyclization is often troublesome especially in the case of peptides shorter than seven 
residues, the case of cyclic pentapeptides is among the most challenging. 
Although several cyclization methodology have been reported,
9
 many variable are still 
present affecting the ring closure such as the nature of the linear precursor, the coupling 
reagents, the concentration of the reaction solution and the reaction temperature. Among all 
these factors, the nature of the linear precursor may play a predominant role in the 
cyclization reactions as previously reported.
10,11
 Nevertheless it is hard, in general, to 
predict with accuracy the optimal linear sequence for a cyclization but some general 
guidelines can facilitate the synthetic plan of a linear peptide with good cyclization 
potential. 
The cyclization position plays an important role in ring closure, and this imply that the ring 
disconnection must be carefully chosen identifying a macrocyclization site not sterically 
hindered by any N-alkyl, α,α-substituted or β-branched amino acids.  
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Moreover, the cyclization could be promoted in other two ways: realizing the ring closure 
between two residues with opposite stereochemical configuration or, by the introduction of 
-turn promoting structural element in the linear precursor main chain 
Based on the above considerations, different epimers of a linear peptide were synthesized in 
order to identify the more efficient position in which the D-amino acid can pre-organize the 
linear peptides towards the cyclization. 
2.2.2. Synthesis of the linear peptides in solution 
The synthesis of the linear peptides was initially performed in solution using the Fmoc/Boc 
chemistry with orthogonally protected groups along the amino acid side chains.  
The carboxylic acid on the first residues was protected at the beginning of the synthetic 
pathway as fluorenylmethyl ester. The esterification of the carboxylic group was performed 
with EDC in the presence of catalytic amount of DMAP. The peptide sequence was grown 
up by coupling with Boc-protected amino acids using the standard procedure with 
carbodiimide (EDC) in presence of HOBt and DIPEA as base. 
Despite the formation of secondary amides (standard amide bond) could be carried out 
equally with different condensing agents, however for the formation of tertiary amide, 
phosphonium and uronium reagents consistently gave higher yield than carbodiimides
12,13
 
and for this reason the coupling with the proline amino group was performed using the 
uronium reagent HBTU.  
Fluorenylmethyloxycarbonil N-protected amino acid has been used as N-terminal, allowing 
a final treatment with 20% of piperidine able to simultaneously remove the protecting 
group on the C- and N- terminal leading the desiderate linear pentapeptides. 
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Scheme 1. Schematic representation of the linear peptide synthesis in solution. i) FmOH, EDC, DMAP, ii) TFA 40% in 
DCM; iii) EDC/HOBt or HBTU, DIPEA, iv) piperidine 20% in DMF. AA1= Val, AA2= Tyr, AA3= Leu, AA4= Pro, AA5= 
Lys. 
In parallel, commercially available PPAA (propane phosphonic acid anhydride), which is 
reported as an excellent coupling reagent for sterically hindered peptides
14,15
 was tested. 
The main advantage of PPAA is due to the formation, during the reactions, of water soluble 
by-products easily removable but, in our case, it did not produce any significant increase in 
the reaction yield. 
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The average coupling yield for each condensation step was more than 90%. After each 
coupling the product was isolated, purified by silica gel column flash chromatography and 
completely characterized. The linear peptide purity, determined by 
1
H-NMR, reached more 
than 95% for all the synthesized molecules.  
n Linear peptide Overall yield% Purity% 
1a H-Val-Tyr(OBzl)-Leu-Pro-Lys(Z)-OH 20 >95 
1b H-Val-Tyr(OBzl)-Leu-Pro-D-Lys(2Cl-Z)-OH 25 >95 
1c H-Val-Tyr(OBzl)-Leu-D-Pro-Lys(Z)-OH 25 >95 
Table 1. Linear peptides synthesized. The overall yields are referred to the amount of isolate final products after five 
couplings and relative purification steps. The purities were determined by 1H-NMR. 
2.2.3. Head-to-tail cyclization reaction 
2.2.3.1. Preliminary investigations and reaction set up 
Chemical synthesis of cyclic peptides is more challenging than that of linear peptides. The 
cyclization is an intramolecular process which is usually carried out in a highly dilute 
solution (1–0.5 mM). Nevertheless, cyclic dimers and oligomers are produces also in this 
condition.  
The synthesis of the cyclic peptide was performed in solution in high dilution condition by 
head-to-tail approach which consists in the formation of an amide bond between the C- and 
N- terminal of the linear sequence.  
A preliminary investigation was performed to evaluate all the possible variables, including 
the possible C-terminal epimerization,
16-18
 that can affect the head-to-tail cyclization. 
2.2.3.1.1. Effect of different coupling reagents on cyclization 
In order to study the effect of the coupling reagents on the cyclization reaction three 
commercially available condensing agents (PyBOP, HATU and PPAA) were chosen to 
cyclize the linear peptide 1a (shown in Table 1) which was selected as model peptides 
during these preliminarily investigations. 
The aim of this investigation was to identify the best coupling reagent in terms of yield in 
the desired compound and formation of by-products, mainly derived by C-terminal 
epimerization or dimerization. 
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Figure 3. Condensing reagents tested during the preliminary investigation of the cyclization reactions in solution. 
The uronium reagent HATU and the phosphonium one PyBOP were chosen due to their 
well-known capability to maximize the cyclization yield while inducing a low 
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racemisation.
13
 PPAA was selected due to the generation of water soluble by-products 
easily removable at the end of the reaction
14,15
 and because it is commercially available as 
DCM solution which allow to perform the coupling reaction in a low boiling point media 
speeding up the reaction work-up and the product isolation.  
All the cyclization reactions were carried out in highly dilute solution and monitored by 
TLC, although, due to the diluted condition it was not easy to follow the reaction progress. 
In the three reactions tested, after 72-56 hours, no traces of linear precursor were detected 
which suggested that, for this cyclization, the choice of the coupling reagent had no a great 
effect on the reaction time. 
The cyclization products were purified by silica gel column chromatography obtaining the 
final cyclic pentapeptides with purity higher than 90%, as analyzed by 
1
H-NMR. 
The experimental data (listed in the Table 2) show that the yield of cyclization using PPAA 
is much higher (56%) to the one obtained with HATU (20%) or PyBOP (12%).  
Nevertheless, the NMR characterization of the cyclopeptide 1c has shown a double set of 
signals. As consequence, a variable temperature NMR characterization was performed to 
clarify the data. The observed proton patters did not change at different temperatures (25-60 
°C) and this might suggest that the signals are related to a mixture of epimers rather than 
rotamers. 
In order to confirm this hypothesis a new cyclization reaction was carried out using again 
PPAA as coupling reagent but with a different linear peptide (1b) which differs from the 
previous sequence for a D-Lys instead of the natural one. The reaction was performed 
under the same experimental condition describe before, but in this case, during the product 
purification were isolated two distinct products that were characterized by mass 
spectrometry and nuclear magnetic resonance. 
MS-HPLC analysis indicate that the two compounds have the same molecular mass, 
whereas, their 
1
H-NMR spectrums evidences negligible differences except for the signals at 
4.00 ppm which correspond to one of the 

H proton of proline. 
Temperature dependence 
1
H-NMR investigation was performed to further characterize the 
conformation of the cyclopeptides. The spectra showed the presence of a single defined 
conformation for each peptide excluding that the two compounds were conformers. These 
results suggested that the two products should be different diastereoisomers due to a C-
epimerization induced by PPAA during the reaction. 
 
Figure 4. The two different diastereoisomers due to a C-epimerization induced by PPAA. 
Differently, the cyclopeptides obtained using PyBOP and HATU have been isolated as 
single product by flash chromatography and the subsequent characterization confirmed the 
optical purity of both. 
The obtained results suggest that, despite PPAA provides higher cyclization yield, it could 
induce the epimerization on the C-terminal leading to a mixture of the two epimers. On the 
other hand, the uroniun (HATU) and phosophonium (PyBOP) activating coupling reagents 
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provided cyclopeptides in moderate yields but strereochemically pure. Moreover, PyBOP 
and HATU provide similar yield in the desired compound but HATU was preferred due to 
the lower amount of by-products generated during the reaction. 
n Cyclic peptide Condensing agent Yield % 
cyclo-1a &Val-Tyr(OBzl)-Leu-Pro-Lys(Z)& PyBOP 12 
cyclo-1a &Val-Tyr(OBzl)-Leu-Pro-Lys(Z)& HATU 20 
cyclo-1a &Val-Tyr(OBzl)-Leu-Pro-Lys(Z)& PPAA 56
a
 
cyclo-1b &Val-Tyr(OBzl)-Leu-Pro-D-Lys(2Cl-Z)& PPAA 50
a
 
Table 2. Effects of different coupling reagents on the cyclization yields. The yields are referred to the isolated products 
after purification by column chromatography. The purities were determined by 1H-NMR. a: mixture of two epimers. 
2.2.3.1.2. The role of the solvent 
Standard peptide coupling are normally performed in DMF to ensure a complete solubility 
of all the reagents. Nevertheless, mixing the DMF with lower boiling point solvents could 
simplify the reaction work-up and speed up the product isolation reducing the risk of the 
product decomposition. For this reason, the effect on the conversion in the cyclized product 
of reaction mixture between DMF and DCM, in one case, and ACN in the second was 
investigated. DMF was kept as major solvent to ensure a complete solubility of the 
coupling reagent, and 1:2 mixtures with DCM or ACN were tested. The experimental 
results have shown that the presence of DCM or ACN was not affecting the yield in the 
desired product compared to the reaction in pure DMF. 
2.2.3.1.3. Influence of D amino acid along the sequence 
In addition to the steric hindrance, another important factor for an efficient peptide 
cyclization is the conformation of the linear peptide in solution. In fact, when the secondary 
structure of the linear peptide is ready to form turn-induced structures, it may provide 
proximity between the N- and the C-terminus and increase the chance for ring closure. A 
well-known way to induce a turn-structures is to introduce in the linear precursor residues 
with D-L alternating configuration.
19,20
  
Moreover, the yield of cyclization could be increased if the ring closure occurs between 
two residues of opposite stereochemical configuration and when the -turn-induced 
structural elements are embedded midway along the linear precursor. 
Based on these considerations, we synthesized a subset of linear analogues of the 
peptidomimetics cyclo-1 (Figure 2) characterized by the same residues in the peptide 
sequence but with different chirality (Table 3). 
The cyclization reactions of these analogues were performed with the aim to identify the 
best position in which the D-amino acid may pre-organize the linear peptide into a suitable 
structural conformational that promote the cyclization. 
A L-lysine or a L-proline were replaced with a D-lysine or a D-proline to form an 
alternated configuration structure, and the cyclization was carried out in high dilution 
conditions in DMF using HATU in presence of HOAt as coupling reagent.  
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The experimental data (listed in the Table 3) show that the linear peptides contain a D-
proline could provide a much higher cyclization yields compared to the structures 
containing all L-natural amino acid residues or a D-lysine.  
These results agree with the consideration that a D-amino acid is able to introduce a cis-
conformation in the relative amide bond, but its position along the sequence has different 
degrees of influence.
21
 
A D-amino acid in the position (i+1) generates a cis conformation in the middle of the 
peptide sequence, resulting in an enhanced cyclization yield. The D-amino acid in position 
(i), although introduces again a cis- conformation, produces a weaker positive effect due to 
the different position along the chain, on the intramolecular cyclization. 
n Cyclic peptide 
Condensing 
agent 
Time (h) Yield % 
cyclo-1a &Val-Tyr(OBzl)-Leu-Pro-Lys(Z)& HATU 72 20 
cyclo-1b &Val-Tyr(OBl)-Leu-Pro-D-Lys(2Cl-Z)& HATU 56 25 
cyclo-1c &Val-Tyr(OBzl)-Leu-D-Pro-Lys(Z)& HATU 56 45 
Table 3. Results relative to the investigation of D-amino acids position along the sequence on peptide cyclization. The 
yields are referred to the isolated products after purification by column chromatography. The purities were determined by 
1H-NMR. 
The present study suggested that an improvement of the head-to-tail intramolecular 
cyclization yield can be obtained by the introduction of a D-amino acid in the position (i+1) 
along the chain. 
Moreover, the characterization of the cyclopeptide 1b has provided the NMR spectra of the 
enantiomeric pure product which was used as references to quantify the racemisation rate 
obtained during the cyclization of the same product with PPAA as condensing agent. 
Expected stereoisomer and its Lys epimer are in ratio 2:1. 
These preliminary investigations, besides providing useful guidelines about the reaction 
conditions and the linear peptides structural features, have lead to the synthesis of three 
different cyclic pentapeptides (Figure 5) characterized by exactly the same residues but 
with a different stereochemistry. Thus, these products will show different conformational 
properties and allow exploring a wider conformational space, giving more chance to 
identify a possible candidate as p50 NF-kB homodimerization inhibitors. 
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Figure 5. Cyclic pentapeptides synthesized during the first part of this project devoted to the identification of the best 
reaction conditions and linear peptide features that promote the peptide cyclization. 
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2.2.3.2. Cyclic peptides deprotection 
The fully deprotected cyclopeptides were achieved after the removal of the benzyl (Tyr) 
and carboxybenzyl (Lys) protecting groups by hydrogenolysis palladium catalyzed. The 
reaction was performed on the pure cyclopeptides under the standard conditions with 
Pd(OH)2 on activated charcoal in hydrogen atmosphere. The progress of the reaction was 
monitored by TLC and the product formation was confirmed by MS-HPLC of the reaction 
mixture. 
Despite both TLC and MS analysis confirm the product formation and the successful 
outcome of the reaction, after the catalyst removal and the solvent evaporation, the final 
product is poorly soluble in many solvents (including MeOH in which was carried out the 
hydrogenolysis reaction) also at high temperature (50 °C), thus complicating the product 
characterization. Because of the small quantity of final product, deuterated DMSO was not 
used to attempt a NMR characterization, as would result in the loss of the product. 
At this point it was decided not to devote too much effort to search an alternative 
deprotection procedure but to settle for a limited characterization of these products. 
We suppose that the low solubility of the cyclopeptide in pure solvents could be related to 
the amphipathic character of the molecule. The hydrophilic moieties amino (Lys) and 
hydroxyl (Tyr) groups together with hydrophobic hydrocarbon (Val and Leu) and aromatic 
(Tyr) side chains provide an overall amphiphilic nature to the peptide lowering its solubility 
both in polar and apolar solvents. It has been also supposed that the pi-pi stacking between 
the Tyr aromatic rings could promoted the peptides aggregation decreasing the solubility. 
2.2.3.3. Development of serine containing cyclopeptide  
Based on the results obtained during the preliminary trials, the synthesis of a second cyclic 
pentapeptide cyclo-2a, similar to the previous one but with a serine instead of the lysine, 
has been designed. In addition, considering the important role of the cyclization position, an 
appropriate disconnection has been evaluated, avoiding the use of a -branched amino acid 
as C- or N-terminal. To this end, we have designed a new linear peptide in which the head-
to-tail amide bond will be performed between a serine and a leucine.  
NH
NH HNHO
O
O
OHNO
N
O
cyclo-2a
&Leu-Tyr-Val-D-Pro-Ser&
OH
 
Figure 6. Pentacyclic peptide synthesized based on the sequence cyclo-(LYVPS). 
Based on the previous investigation, for this sequence only the analogue with a D-proline 
has been synthesized. The synthesis of this linear peptide was performed in solution using 
orthogonally protected amino acids and the standard reaction conditions protocol. The final 
product was purified by silica gel column chromatography obtaining good overall yield and 
a high degree of purity. (Table 4)  
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n Linear peptide Yield % Purity % 
2 H-Leu-Tyr(OBzl)-Val-D-Pro-Ser-OH 25 > 95 
Table 4. Linear peptide synthesized. The overall yield is referred to the amount of isolate final products after five 
couplings and relative purification steps. The purity was determined by 1H-NMR. 
The cyclization of the linear peptide 2 (Figure 6) was performed in solution using the head-
to-tail approach in accordance with the best conditions previously identified (HATU as 
coupling reagent, in presence of HOAt at room temperature under high DMF/DCM 
dilution). The progress of the synthesis was checked at different stages by TLC and after 48 
hours the linear precursor was completely consumed. 
The crude purification by silica gel column chromatography provides the desired cyclic 
peptide cyclo-2 in very good yield. (Table 5) 
The results related to this synthesis show that for this sequence the product yield is 
significantly higher, suggesting how the peptide disconnection in the precursor sequence 
could determines the success of a cyclization reaction. The removal of the tyrosine benzyl 
group by hydrogenolysis palladium catalyzed afforded the final deprotected cyclo-2a with 
high yield and purity (95%).  
Contrary to what was observed with the Lys containing cyclopeptides, the cyclopeptide 
cyclo-2a showed good solubility in polar solvents (e.g. MeOH and solvent mixture 
ACN/water). This difference could be related to a less hydrophobic character due to the 
shorter hydrocarbon side chain of the Ser compared to the Lys one. Moreover the hydroxyl 
groups (Ser and Tyr) could improve the solvation of the molecules forming a hydrogen 
bonds pattern with polar solvents. 
n Cyclic peptide 
Condensing 
agent 
Time (h) Yield % 
cyclo-2 &Leu-Tyr(OBzl)-Val-D-Pro-Ser& HATU 48 65 
Table 5. Pentacyclic peptide synthesized. The yield is referred to the amount of isolate final product after the cyclization 
reaction and the relative purification step. The purity was determined by 1H-NMR. 
2.2.3.4. An alternative method for macrocyclization: cyclic peptide synthesis with 
thioacids. 
The results obtained with the classic head-to-tail cyclization approach provided acceptable 
results in terms of yield. Nevertheless another innovative cyclization method, recently 
proposed by Crich and Sasaky,
22
 was tested. In this procedure an amide-bond-forming 
sequence employing peptide thioacids in association with the Sanger’s reagent (1-fluoro-
2,4-dinitrobenzene) is viable for the cyclization of penta and hexapeptides. The power of 
this method, in which a carboxyl group is activated as a thioester and the cyclization occurs 
in situ in the presence of Sanger’s reagent, is due to the much shorter time (5 minutes) 
compared to the classic cyclization condition (hours or days) and to the wide range of 
compatibility with functional groups such free carboxylic acid and hydroxyl moieties. 
Moreover the C-terminal epimerization, which typically plague this kind of reactions, is 
completely suppressed. 
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Scheme 2. Schematic representation of cyclopeptide synthesis with the thioacid approach. i) Piperidine 20% in DMF, (15 
min), ii) Sanger’s reagent (1-fluoro-2,4-dinitrobenzene) in DMF 5mM, (5 min). 
In order to try this new synthetic approach, new linear peptides with C-terminal protected 
as fluorenylmethyl thioester (Fm) were prepared.  
9-Fluorenylmethanethiol 6 was previously prepared and linked as C-terminal protecting 
group in order to avoid the potential racemization on the C-terminal. 
The synthesis was performed following the reported methodology
23
 starting from the 
commercially available 9-fluorenyl methanol 3, that was subjected to nucleophylic 
substitution to give a 9-fluorenylmethyl p-toluenesulfonate 4, further treatment with 
potassium thioacetate followed by DIBAL reduction gave 9-fluorenylmethanethiol 6. 
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Scheme 3. Preparation of 9-Fluorenylmethyl (Fm).  
Boc chemistry was used during the assembly of the linear peptide due to the incompatibility 
between the Fm thioester and the Fmoc chemistry conditions.
24
 The tetrapeptide 
fluorenylmethyl thioester was constructed by standard solution phase Boc chemistry and 
the N-terminal Boc group was removed by TFA treatment. Finally the last amino acid was 
incorporate as Fmoc carbamate. 
The cyclization was carried out by an initial treatment with piperidine of the N-terminal 
Fmoc-protected and C-terminal 9-fluorenylmethylthioester peptide which releases a seco-
thioacid peptide. Without isolation, Sanger’s reagent was added and the cyclization reaction 
occurs rapidly in only in 5 minutes at room temperature. The reaction proceeds through an 
initial SNAr reaction with Sanger’s reagent to generate a reactive thioester in situ which can 
be attack by the N-terminal amino group forming the cyclopeptide. 
The experimental results (Table 6) show that, with this synthetic methodology, the linear 
precursor sequence determines the success of the cyclization reaction. The linear peptide 
1a’ reacts providing the corresponding cyclo derivative in good yield, while the analog 
(1c’), with all L amino acids, under the same reaction conditions, was not able to cyclize. 
These data suggests that, for this sequence, a D-proline is crucial to obtain the desired final 
product. On the other hand, the linear peptide 2a’ characterized by a D-proline and a serine 
instead to a lysine gives the corresponding cyclopeptide, but in a considerable lower yield 
compared to the cyclization using HATU as coupling reagent (Table 5, cyclo-2).  
Despite the short reaction time, that positively characterizes this synthetic method, in our 
experiments no improvement in the final yields was observed. In addition, the multiple 
purification steps required to isolate the cyclic compounds, due to the large number of by-
products formed, resulted in a considerable reduction of the overall yield of the peptides. 
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n Cyclic peptide 
Time 
(min) 
Yield % Purity % 
cyclo-2’ &Leu-Tyr(OBzl)-Val-D-Pro-Ser& 5 50 90 
cyclo-1a’ &Val-Tyr(OBzl)-Leu-Pro-Lys(Z)& 5 - - 
cyclo-1c’ &Val-Tyr(OBzl)-Leu-D-Pro-Lys(Z)& 5 30 90 
Table 6. Results of cyclic peptides synthesis using thioacids in association with Sanger’s reagent. The yields are referred 
to the isolated products after purification by column chromatography. The purities were determined by 1H-NMR. 
2.2.4. Design and synthesis of a cyclic pentapeptide library 
2.2.4.1. Synthesis on solid phase (Introduction) 
During the last year of my PhD studies I have spent some months at the IRB institute in 
Barcelona as a visiting student in the Prof. Giralt’s group. In this period I got the 
opportunity to learn and gain experience in the peptide solid phase synthesis (SPPS). This 
methodology, in which the peptide is synthesized keeping the C-terminus covalently bound 
to an insoluble polymeric support, presents many advantages over the classical solution 
phase method.
25,26
 First for all the synthesis is faster. The reactions are driven to completion 
using an excess of reactants and reagents and the separation of the growing peptide from 
the by-products and the unreacted amino acids is performed by a simple filtration without 
any further purification. 
No mechanical loss occurs due to the fact that the growing peptide is retained on the 
polymer in a single reaction vessel throughout the synthesis. The final peptide is released 
from the polymer support by a single cleavage step at the end of the synthesis. Moreover 
the side chain protecting groups can also be cleaved in the same step in order to simplify 
the work-up and the isolation of the final peptide.  
2.2.4.2. Library design 
The SPPS technique was exploited to synthesize a library of pentacyclic peptides, which 
will be screened as p50 NF-B homodimerization inhibitors. 
The library molecules are analogues of those developed using the peptide solution synthetic 
approach and differ one from another by a single amino acid in the sequence. 
This differentiation among the components of the library allows the evaluation of the 
different side chains and functional groups effects on the interaction with the protein and 
the identification of peptide bioactive conformation. 
Furthermore, this could provide key-information regarding the nature of interactions 
involved, which can direct further modification in order to increase and modulate the 
binding affinity. 
Several amino acids have been selected for the construction of the library, in order to 
explore a wider range of different properties. The majority of them were natural occurring 
ones such: arginine (R), glutamic acid (E), tryptophan (W), alanine (A), cysteine (C) and 
glutamine (Q). To the mentioned below, two non-natural residues were also considered: 4-
amino-phenylalanine (Phe(4NH2)) and the α,β-diaminopropionic acid (Dap). 
Amino acids with different charges, such as glutamic acid and arginine, have been selected 
to evaluate the electrostatic contribution and capability to form salt bridges with the p50 
binding site. 
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Arginine residues are broadly employed for the specific biomolecular recognition, which 
exploits the potential of the bidentate electrostatic and hydrogen-bond interaction.
27
 The R 
guanidinium group confers basic properties, due to the conjugation between the double 
bond and the nitrogen lone pairs, meaning that the positive charge is delocalized an enables 
the formation of multiple H-bonds (Figure 7). 
Hydrophobic residues such as tryptophan and alanine were selected considering the large 
number of hydrophobic interactions at the protein-protein interface. Over than providing 
hydrophobic character to the peptidomimetic, the tryptophan indole ring could be involved 
in stacking interactions with other aromatic residues of the protein. On the other hand, 
alanine, one of the simplest aliphatic α-amino acids, provides weaker hydrophobic 
character but due to a less steric hindrance and a reduced side chain flexibility could play a 
role in the affinity modulation towards the protein. 
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Figure 7. Subset of amino acids considered for the development of the cyclic pentapeptide library. 
Cysteine and glutamine were selected to test the effect, respectively, of the thiol or the 
amide groups on the protein interaction and because these groups can allow a further 
chemical modification of the cyclopeptide. 
We have also taken in account two non-natural amino acids: the 4-amino-phenylalanine 
(Phe(4NH2)) and the α,β-diaminopropionic acid (Dap). Both contain a primary amine group 
which can be exploited to conjugate or modify the cyclic peptide. Moreover, the 4-amino-
phenylalanine should provide hydrophobic and stacking interactions due to the aromatic 
ring. The α,β-diaminopropionic acid (Dap), similar to a lysine in chemical properties terms, 
bears an amino functional group at the terminus of a shorter and less flexible hydrocarbon 
side chain, which could results in a different specific recognition with the target. 
Based on these considerations we have designed a series of cyclic pentapeptides with a 
general formula cyclo-(R-Val-Tyr-Leu-D-Pro) where R is one of the amino acids with 
different functional groups described above. The target compounds common feature is 
based, as previously described, on the recognition sequence of the biological target, 
meaning that it will contain the three key amino acids involved in the p50 
homodimerization. D-proline has been selected as a -turn element based on the good 
results obtained during the preliminary investigation of this project. 
2.2.4.3. Peptide synthesis 
The linear peptides synthesis on solid phase was performed on the Barlos (2-Chlorotrityl 
chloride) resin
28
 as solid support. This is one of the most useful resins for the SPPS of C-
terminal peptide acids,
29-31
 and minimizes the formation of diketopiperazine (DKP) due to 
the presence of the hindering trityl group and of the chlorine substituent in position 2.
32
 
This is of relevance in this case because the presence of consecutive L and D amino acids, 
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that are highly prone to form this stable cycle before the incorporation of the third residue, 
results in the loss of the two first amino acids and in deletions along the sequence.
33
  
Moreover, Cl-Trt-resin reduces the risk of racemization during the incorporation of the first 
amino acid. This is related to a different coupling through a nucleophilic substitution 
instead of a carboxylic group activation required for the anchorage to hydroxyl-based 
resins. Finally, this resin allows the cleavage of the peptide under very mild acid conditions 
and in the presence of tBu-based protecting groups.
34,35
 
The synthesis was performed based on Fmoc/tBu approach, which implies the use of 
orthogonal protecting groups, that can be, respectively, removed by treatment with 
piperidine and TFA.
36
 
This approach is particularly efficient in the synthesis of complex peptides, in which 
orthogonality should be introduced.
37
 An additional advantage of the Fmoc/tBu strategy is 
that the use of strong acids, such as HF or trifluoromethanesulfonic acid is not required. 
The peptides of the proposed library presented high structural analogy one to another which 
allowed us to perform a SPPS of a common building block containing the shared sequence 
Leu-Tyr-Val-D-Pro. Subsequently the resin was split in equal portions to perform the last 
coupling with the different selected amino acids for the library construction. 
2.2.4.3.1. Preliminary investigations 
Different amino acids have been considered as starting point for the synthesis of the linear 
peptide. In particular, the use of a proline as C-terminal has been evaluated because it 
would prevent the epimerization during the cyclization reaction. On the other hand 
anchoring a D-proline on the resin could lead to diketopiperazine (DPK) formation, 
lowering the yield of the synthesis. 
n Linear sequence 
DKP 
% 
Epimerization 
% 
Cyclic peptide 
% 
Cyclic Dimer  
% 
7 H-Val-Tyr-Leu-D-Pro-Lys-OH - 6 35 20 
8 H-Lys-Val-Tyr-Leu-D-Pro-OH 30% - 45 10 
Table 7. Results of preliminary investigations. 
In order to evaluate the percentage of DKP formation using a D-proline as the first amino 
acid, two different linear peptides containing the same residues have been synthesized. The 
first one with a D-proline directly attached on solid support, and the second with the D-
proline in position (i+1).  
The experimental results show that 30% of DKP was formed when the D-Pro was the C-
terminal, despite the presence of the Cl-Trt moiety of the resin. On the other hand, DKP 
formation was not detected with the proline in the position (i+1). 
In parallel, it has been evaluated how the D-proline position along the sequence can 
promote the peptide cyclization.  
The reactions were carried out in solution under high dilution with DPPA/NaHCO3 as a 
coupling reagent. The reaction progress was monitored by HPLC and in both cases, after 48 
h the linear precursors were not detected. The fully deprotected cyclic peptides were 
obtained after removal of the t-Bu protecting groups by acidolysis with TFA. The 
purification was performed by column chromatography giving the final products. 
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The cyclization yield seems to be related to the position of the D-Pro along the sequence. 
When the D-Pro is present as C-terminal, the formation of side products (e.g. epimers, 
cyclo dimers) is reduced, on the contrary, the amount of undesired by-products derived 
from racemization and cyclo dimerization is increased when the D-Pro is shifted in the 
(i+1) position.  
 
These observations are in contrast to what was concluded after the preliminary 
investigations at the beginning of this project, in which the D-Pro in (i+1) position was 
defined as the best driving force for the peptide cyclization. Probably the divergent results 
are associated with the different condensing agents employed. The cyclization of the linear 
peptide bearing a D-Pro in (i+1) and using DPPA yielded a low amount of the desired 
product while produced large formation of the cyclo dimer derivative. This may be due to 
the high reactivity of DPPA which promotes the peptide cyclization but also its 
cyclodimerization. 
Based on these results and in order to obtain the final products in good quality and high 
yield, it was decided to perform the peptide cyclization lowering the DPPA equivalents 
(from 2 to 1.5) and placing the D-proline as C-terminal. As a consequence, the following 
efforts were directed to overcome the DKP formation. 
The DKP formation, in this context, was promoted by the basic conditions for the Fmoc 
deprotection of the second amino acid in the sequence.
38-41
  
Different approaches to avoid this problem have been evaluated. The simplest way consists 
in a shorter reaction time (2 cycles of 3 minutes) for the Fmoc removal from the second 
amino acid, which reduced but did not prevent the formation of DKP. 
A more efficient approach consists in the replacement of the N-Fmoc of the second amino 
acid with a protecting group that can be removed in neutral conditions. N-allyloxycarbonyl 
(Alloc) was chosen as protecting group because of the orthogonality to the t-Bu and Fm 
groups and the neutral condition needed for the smooth cleavage.
42-46
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Scheme 4. Schematic representation of diketopiperazine (DKP) formation under basic conditions. 
The removal of allyl carbamates involves a palladium-catalyzed transfer of the allylic unit 
to various nucleophiles/scavengers in presence of a proton source. Pd(PPh3)4 is probably 
the most used and well-known catalyst for this reaction while, special attention must be 
done on the choice of the nucleophile.
47
 Nucleophilic secondary amine such as morpholine 
as allyl acceptor leads to deprotection of Fmoc group.
45
 Similarly, the choice of 
Me2NSiMe3-CF3CO2SiMe is not compatible with t-Bu-based protecting groups.
48
 Based on 
these considerations, we decided to use phenyltrihydrosilane (PhSiH3) which has been 
reported as a neutral allyl group scavenger.
49
 
Therefore, an Alloc-Leucine has been synthesized, considering that it is placed as second 
residues in the sequence of the design cyclopeptides. The synthesis was performed 
according to the reported procedure
50
 in one pot, with free amino acids and sodium azide as 
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reagents. 
Alloc-Cl reacts with NaN3, forming the corresponding Alloc-azide, that lead to the final 
product by direct reaction with the free amino acid, without any intermediate purification.  
This procedure does not require the temporary protection of the carboxyl function of the 
amino acid and, the formation of Alloc-dipeptide and by-products is significantly reduced 
compared to the one employing Alloc-Cl as acylating agent.
51-53
 
Cl O
O 1. NaN3, r.t. H2O-dioxane, 1h
2. Leu-OH, 1% aq Na2CO3-dioxane/1:1, (pH= 8-10), r.t. 48h
O
O
H
N
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O
9  
Scheme 5. Synthesis of Alloc-leucine. 
2.2.4.3.2. Synthesis of linear peptides on solid phase  
Ten linear pentapeptides were synthesized in a stepwise way with SPPS approach starting 
from a D-proline as C-terminal amino acid. The linear peptides were load on an acid labile 
Cl-Trt resin followed by the standard Fmoc/tBu protocol. 
In agreement with the developed synthetic strategy, after the removal of the Fmoc group on 
the fourth residue, the resin was split in ten equal portions; each one was coupled with one 
of the ten selected amino acids as N-terminal of the peptidic sequences. 
Cl
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Scheme 6. Synthesis of the linear peptides members of the library. R= Lys, Dap, Cys, Glu, Gln, Arg, Ser, Ala, 
Phe(4NH2), Trp. 
The peptide backbone elongation was carried out with PyBOP/HOAt/DIEA as coupling 
reagents and DIPEA as base. The reaction progress was monitored using the Kaiser test
54
 
for primary amines and De Clercq
55
 or Chloranil
56
 test for the secondary amines. 
The Fmoc cleavage was performed according to the standard conditions (20% piperidine in 
DMF) whereas the removal of the Alloc group from the leucine was carried out under 
neutral conditions with a catalytic amount of Pd(PPh3)4 in presence of PhSiH3 as scavenger.  
After completion of the peptide chain assembly, the resin was cleaved in mild acidic 
condition (2% TFA in DCM) retaining the side chain protecting groups. 
The products were completely characterized and the HPLC analysis show high degree of 
quality (purity > 90%). for each crudes (Results listed in Table 8). As a consequence, the 
linear peptides were not further purified but directly subjected to cyclization. 
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2.2.4.3.3. Peptide cyclization 
The peptides cyclization was performed in DMF solution [5 mM] with DPPA 
(Diphenylphosphoryl azide) as condensing agent together with NaHCO3 as base.  
These conditions were chosen based on the hexapeptides cyclization one developed with 
remarkable results in the Cancertech project (data reported in the chapter 2 “Results and 
discussion” of the Part II of this thesis). 
The reaction progress was followed by HPLC and the cyclizations of the peptides were 
completed in a range of 16-48 hours (in relation to the amino acid sequence). NaHCO3 was 
simply filtered out and the solvent was removed under vacuum. The fully deprotected cyclic 
peptides were obtained after the tBu protecting groups removal by acidolytic treatment with 
TFA solution in presence of 5% of water and TIS (Triisopropylsilane) as carbocation 
scavenger.  
The crude products were purified by RP-HPLC in a semi-preparative scale and the pure 
products were characterized by RP-HPLC, RP-HPLC-MS and 
1
H-NMR. The desired 
cyclopeptides were obtained with purity higher than 95% (Table 8). The overall yields of 
the desired molecules reach 15-54% and can be considered excellent taking in account the 
multistep pathway (synthesis linear peptide, cyclization reaction, side chain deprotection 
and HPLC-purification). 
n            Peptide sequence 
Linear peptide Cyclic peptide 
Yield 
% 
Purity 
% 
Reaction 
time (h) 
Yield 
% 
Purity  
% 
Cyclic dimer 
% 
16 H-Lys-Val-Tyr-Leu-D-Pro-OH 95 95 48 40 > 98 8 
17 H-Phe(4-NH2)-Val-Tyr-Leu-D-Pro-OH 94 85 24 35 > 98 - 
18 H-Cys-Val-Tyr-Leu-D-Pro-OH 97 95 24 15 > 98 - 
19 H-Glu-Val-Tyr-Leu-D-Pro-OH 80 95 24 45 > 97 - 
20 H-Gln-Val-Tyr-Leu-D-Pro-OH 85 98 16 54 > 98 - 
21 H-Arg-Val-Tyr-Leu-D-Pro-OH 93 90 16 16 > 98 - 
22 H-Trp-Val-Tyr-Leu-D-Pro-OH 92 90 48 30 > 98 10 
23 H-Ser-Val-Tyr-Leu-D-Pro-OH 83 90 48 20 > 98 5 
24 H-Dap-Val-Tyr-Leu-D-Pro-OH 66 93 24 15 > 98 - 
25 H-Ala-Val-Tyr-Leu-D-Pro-OH 74 98 48 46 > 98 6 
Table 8. Results related to the synthesis of linear and cyclic peptides. For the linear peptides the purities were determined 
based on analytical HPLC analysis, whereas the yields were defined through the Fmoc UV quantification during the last 
Fmoc deprotection step. For the cyclic peptides, the overall yields are referred to the isolated final product (over 4 steps: 
synthesis linear peptide, cyclization, side chain deprotection and purification) and the purities were determined by HPLC 
analysis. 
The cyclic peptide cyclo-16 has the same sequence of the cyclic peptide 1c previous 
synthesized in solution and it was synthesized again by SPPS with the aim to compare the 
different methodology adopted for their synthesis. As expected, the SPPS provided the 
linear peptide with significantly higher overall yield compare to the solution approach (95% 
instead of 20%). 
Regard to the peptide cyclization, has been observed that the amide bond formation 
between a D-Pro (as C-terminal) and a Lys (as N-terminal) together with DPPA as 
condensing reagent prevents the epimerization and increase the cyclization reaction yield. 
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(Table 8, cyclo-16). On the other hand, for the cyclopeptide 1c for which were chosen a 
different disconnession and HATU as coupling reagents, has provided lower cyclization 
yield (Table 3, cyclo-1c). 
Finally, the fully deprotected cyclopeptide 9 was obtained after the cleavage of the tert-
butyl ether (Tyr) and the Boc (Lys) protecting group by acidolytic TFA treatment. The final 
product was completely soluble in pure MeOH or in a mixture of ACN/H2O, differently 
from what was observed for its analogue cyclo-1c. This different behavior may be due to 
the lysine side chain amino group which probably being in the protonated form as TFA salt 
enhanced the cyclopeptide amphiphilic character promoting its solubility in polar solvents. 
&Lys-Val-Tyr-Leu-D-Pro& (cyclo-16) 
 
&Phe(4-NH2)-Val-Tyr-Leu-D-Pro& (cyclo-17) 
 
 
&Cys-Val-Tyr-Leu-D-Pro& (cyclo-18 ) 
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&Glu-Val-Tyr-Leu-D-Pro& (cyclo-19) 
 
&Gln-Val-Tyr-Leu-D-Pro& (cyclo-20) 
  
&Arg-Val-Tyr-Leu-D-Pro& (cyclo-21) 
 
 
&Trp-Val-Tyr-Leu-D-Pro& (cyclo-22) 
  
&Ser-Val-Tyr-Leu-D-Pro& (cyclo-23) 
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&Dap-Val-Tyr-Leu-D-Pro& (cyclo-24) 
 
  
&Ala-Val-Tyr-Leu-D-Pro& (cyclo-25) 
  
Figure 8. HPLC and RP-HPLC-MS traces of the cyclic pentapeptides of the library after synthesis and purification. 
HPLC were recorded using a 0-100% B gradient in 8 min (A = 0.045% TFA in H2O, and B = 0.036% TFA in ACN). 
2.2.5. Peptide functionalization on-solid phase 
The SPPS methodology was also exploited to modify in solid state a cyclopeptide (cyclo-
16) by the acetylation of the lysine side chain amino group with the aim to evaluate the 
effect of the nitrogen electron pair (Lys-NH2) on the binding site and on the specific protein 
recognition. 
The synthesis of the linear peptide was performed using the same synthetic approach 
described before until the tetrapeptide 13, then was introduced a Boc-Lys(Fmoc)-OH as last 
amino acid (Scheme 7) which was deprotected by treatment with piperidine releasing the 
free amino group. The acetylation was carried out on solid phase using acetic anhydride 
and DIEA (DMF, 1 h). Subsequently, the peptide was cleaved from the resin and 
underwent to cyclization in high DMF dilution with DPPA. The product was purified by 
semipreparative RP-HPLC giving the final product in 30% overall yield. 
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Scheme 7. Synthesis of the acylated version of linear peptides 16. 
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&Lys(Ac)-Val-Tyr-Leu-D-Pro& (cyclo-28) 
 
           
 
 
Figure 10. HPLC and MS-HPLC traces of the acylated cyclo peptide 28 after the synthesis and the purification. HPLC 
was recorded using a 0-100% B gradient in 8 min (A = 0.045% TFA in H2O, and B = 0.036% TFA in ACN). 
2.3. Conclusion 
Several cyclic pentapeptides have been synthesized with the aim to explore and modulate 
the protein-protein interaction (PPI) between two p50 NF-B subunits, preventing their 
homodimerization.  
Despite the selection of pentacyclopeptides allow a limited structural variability, due to the 
possibility to introduce only one different amino acid in each sequence, has been generate a 
library of compounds with a moderate variability that, presenting different conformation 
and chemical properties, allow to explore a wide conformational range during their 
evaluation against the p50 homodimerization and maybe lead to identify a possible 
bioactive compound.  
The linear peptides were synthesize using both the solution and solid synthetic approach, 
observing that SPPS is a more powerful method not only in terms of higher overall yield 
and reduction of work time to obtain the final product, but also for the possibility to achieve 
a fast peptide differentiation particularly important for a chemically library production. 
The best results for the head-to-tail peptide cyclization were obtained using the standard 
approach in high diluted conditions, with HATU or DPPA as condensing reagents. 
The diversity introduced in the cyclopeptides by using residues with different properties 
enables to largely investigate the defined binding sites and precisely identify the binding 
residues and the peptide bioactive conformation. 
Once a cyclopentapeptide library is generated, the next step will be a quantitative 
characterization of the protein–peptide interactions, including its structural, biochemical 
and biophysical parameters. These may include, detecting the residues that mediate the 
interaction and their differential contribution, measuring the affinity of the interaction and 
studying its biological role in cells. Thus, a number of biological experiments will be 
performed on the cyclopeptides synthesized to determine whether some of these show 
promising results and may be further used as lead compounds to control the PPI as 
antagonists. 
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Additionally, these studies could provide important information to properly modifications 
by introduction of post-translational modifications (e.g., phosphorylation or acetylation), 
labels (e.g., biotin or fluorescein) or non-natural amino acids to increase the specificity 
toward the molecular target or to enhance their detection during the biological tests. The 
peptides can also served as the basis for further design of small molecules to target PPI. 
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3.1. Introduction
1,2
 
Peptidomimetics are compounds whose constituents (pharmacophore) mimic the natural 
peptides or proteins both in terms of 3D rearrangement and ability to interact with the 
biological targets producing the same biological effect.
3
 Peptidomimetics are designed to 
overcome some problems associated with a natural peptides as, for instance, stability 
towards proteolysis
4
 (duration of activity), poor bioavailability
5
 and to improve other 
properties, such as receptor selectivity or potency.
6
  
In the design of peptidomimetics sugars, the monosaccharides, particularly, represent an 
attractive molecular scaffold in which the amide backbone is replaced by a carbohydrate 
skeleton which keeps the proper orientation of the amino acidic substituents.
7
 This concept 
was anticipated by Farmer in 1980, who reported the linkage of amino acidic side chains to 
a cyclohexane ring, creating the first non-peptide peptidomimetics.
8
 
NHO
O
O
OCH3H3CO
O
O
N
H
HO
O
NH2
NH
a b  
Figure 1. a: non peptide peptidomimetic; b: carbohydrate-based mimic. 
Sugar amino acids (SAAs) represent an important class of multifunctional building blocks 
that have found a wide range of applications, mainly in the area of peptidomimetic studies 
as rigid templates promoting secondary structures in peptides.
9,10
 SAAs can adopt a robust 
secondary turn or helical structures which may allow them to mimic helices or sheets. 
SAAs can also be used to replace single amino acids or as dipeptide isosters.
11
 When SAAs 
replace hydrophobic residues, the sugar can also be functionalized with hydrophobic side 
chains (e.g., benzyl groups); complementary, when hydrophilic residues are replaced or the 
solubility needs to be improved, the hydroxyl groups on the sugar moieties are, in general 
kept, unprotected or functionalized with hydrophilic residues. 
In Kessler
12
 definition, a sugar (carbohydrate) amino acid is a compound with direct 
linkages of both amino and carboxyl functionalities with a carbohydrate frame. Indeed, the 
SAAs are, essentially, hybrids of carbohydrate and amino acids where the amino and the 
carboxyl functional groups have been incorporated at the two termini of regular 2,5 or 2,6 
anhydro sugar frameworks. SAAs can be found in nature largely as constitutive elements.
13 
The most prominent and well-known example is the sialic acid often located peripherally 
on glycoproteins. This family of natural SAAs consists of N- and O-acyl derivatives of 
neuraminic acid (Figure 2). 
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Figure 2. The naturally occurring sugar (carbohydrate) amino acid (SAA) sialic acid. 
There are several advantages supporting the use of SAAs as building blocks. The rigid 
furan and pyran rings of these molecules provides an adequate conformational rigidity
14
 
and make them ideal candidates as non-peptide scaffolds in peptidomimetics. Moreover, 
they can be easily incorporated by using their carboxyl and amino termini. SAAs allow also 
an efficient exploitation of the structural diversities among carbohydrate molecules. The 
presence of several stereocenters allows different orientations of the hydroxyl groups and, 
by extension, of the substituents linked to them. Moreover, the protected/unprotected 
hydroxyl groups of sugar rings can be also exploit to modulate the hydrophobic/hydrophilic 
nature of these molecules, improving their solubility.  
A different approach towards the preparation of SAAs consist in the direct coupling of the 
carbohydrate backbones with amino acidic residues by different synthetic methodologies.
12-
14
 Typically, the synthesis of SAAs is easily accomplished in few steps starting from 
commercially available or easily accessible monosaccharides, (glucose, glucosamine, 
diacetone glucose, galactose). The amino functionality of the SAA can be introduced as an 
azide, cyanide or nitromethane group, followed by subsequent reduction. The carboxylic 
function is directly installed as CO2, by Wittig reaction as hydrolysable cyanide with a 
subsequent oxidation or by selective oxidation of a primary alcohol. 
SAAs include both -, -, and -SAA, as well as both furanoside and pyranoside ring forms 
(Figure 3). 
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OCH3
-SAA -SAA -SAA
O
OH
HO
OH
COOH
NH2
Dipeptide isoester  
Figure 3. Example of SAAs. The -SAA can mimic a -turn when incorporated into a peptide, whereas the -SAA can 
mimic a -turnThe -SAA illustrated has a linear alignment of amino and carboxylic acid functionalities. The dipeptide 
isoester can introduce a flexible a -turn.
Sugar analogs in which the ring oxygen is replaced by a nitrogen atom can also be 
considered SAAs. This class of compounds has gained a large interest as inhibitors of 
glucosidases
12
 and many of them, natural as well as synthetic, containing amino and 
carboxylic acid groups, are particularly well suited as peptidomimetic scaffolds.
15
 
3.2. Development and synthesis of a peptidomimetics as p50 NF-B homodimerization 
inhibitor 
The many advantages related to the use of SAAs as peptidomimetics prompted us to 
develop and investigate a cyclic peptidomimetic as homodimerization inhibitor of p50 NF-
B. A glucose homolog (Figure 4) bearing an amino and a carboxylic group was prepared 
and used as a peptide to mimic a proline -turn residue. 
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This SAA, as analog of a -amino acid and a -turn, could promote the peptide cyclization 
by pre-organizing the linear amino acidic sequence in a suitable conformation. Moreover it 
may lead to a cyclic structure with a proper conformational rigidity and metabolic stability. 
In addition, the three hydroxyl groups could play an important role enhancing the solubility 
of the peptidomimetic and, in the same time, they represent potential sites for a further 
functionalization and chemical modification allowing a remarkable peptidomimetic 
differentiation. 
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Figure 4. The SAA developed 30 as -amino acid; its introduction in the linear peptide generates the peptidomimetic 43. 
3.2.1. Synthesis of sugar amino acid 
The SAAs synthesis consisted of four steps starting from the commercially available N-
glucosamine which was converted to 1-cycano-2-tetracholophalimido modifying a reported 
procedure.
16
 
Tetrachlorophthaloyl (NTCP) was used as protecting group of the glucosamine amino 
moiety, due to its stability towards mild basic and strong acid conditions. Moreover it can 
be introduced easily in two steps and chemoselectively removed under neutral or mild 
conditions. 
The introduction of the N-tetrachlorophalic group (TCP) into glucosamine was readily 
carried out by Lemieux’s classic procedure17,18 starting from the unprotected amine 
hydrochloridic salt 29. The free base is released by treatment with NaOMe in methanol, 
followed by addition of the tetrachlorophalic anhydride 31. TEA (1 eq) is also required to 
increase the reaction yield avoiding the precipitation of the sugar as ammonium salt. After 
the solvent evaporation in vacuo, the crude is redissolved in pyridine with an excess of 
acetic anhydride allowing the acylation of the hydroxyl groups. The mixed anhydride 33 is 
formed and, subsequently, undergoes a nucleophilic attack by the weak nucleophilic amidic 
nitrogen providing the full protected sugar 34. The purification by a single recrystallization 
from ethanol afforded the final product in 60% overall yield and with high purity (>95% by 
1
H-NMR). 
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Scheme 1. Synthesis of 1,3,4,6-Tetra-O-Acetyl-2-deoxy-2-tetrachlorophalimido--D-glucopiranoside. 
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The acetyl protecting group at C-1 of the glycosyl compound 34 was selectively replaced 
with bromine by reaction with HBr in acetic acid. The resulting 2,3,4,6-protected glycosyl 
bromide 35 was used in the next step without further purification because of relative low 
stability. The conversion of bromine compound to the corresponding cyanide was carried 
out by treatment with mercuric cyanide in nitrometane under dry condition (to avoid the 
undesired hydrolysis of bromide to a hydroxyl group). The product 36 was purified by flash 
chromatography, providing almost quantitative yield (90% over 2 steps). 
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Scheme 2. Synthesis of 3,4,6-Tri-O-Acetyl-2-deoxy-2-tetrachlorophalimido--D-glucopyranosyl carboxylic acid. 
The cyanide group was converted into the corresponding carboxyl group by acidic 
hydrolysis. Several reaction conditions were tested to obtain the effective cyanide 
hydrolysis due to the difficulty to follow the reaction evolution by TLC. The best 
conditions were identified in hydrochloric acid (4M) in dioxane at 60 °C overnight. This 
treatment not only hydrolyzes the nitrile group but also cleaves the O-acetyl protections on 
the sugar providing a hydrophilic compound 27 which has to be re-acetylated as described 
before to facilitate the product isolation and purification. The sugar amino acid 38 was 
obtain in 70% yield and with a purity higher than 95% as detected by 
1
H-NMR. 
3.2.2. Synthesis of a cyclo peptidomimetic  
The C1 -carboxylate group of SAA 38 was condensed with a serine (Ser-OtBu) previously 
protected as tert-butyl ester on the carboxyl group and as tert-butyl ether on the side chain 
hydroxyl group. 
The coupling reaction was performed by an in situ activation methodology in DMF solution 
with HATU/HOAt as condensing reagent and DIEA as a base. The product 39 was purified 
by silica-gel flash chromatography and completely characterized.  
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Scheme 3. Synthesis of cyclic peptidomimetic. 
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The N-TCP cleavage step was extensively investigated in order to obtain a simultaneous 
cleavage of the hydroxyl protecting groups. 
Several cleavage conditions were tested in regard to the amines (ethylendiamine, hydrazine 
acetate), solvents (ethanol, DMF, acetonitrile) and temperature. Moreover also the Zemplèn 
reaction was attempted but all these procedures provided complex crude and mixture of 
partially deprotected products.  
The suitable condition to achieve the full deprotection of 39 were found using ammonia 
(2M) in methanol at room temperature for 18 hours. This cleavage procedure provided the 
compound 40 which was purified by silica gel chromatography before being used in the 
next step. 
The dipeptide 40 was coupled with a tri-peptide Boc-Val-Tyr(OBzl)-Leu-OH 41 in a 
mixture DMF-DCM using HBTU as coupling reagent in a basic medium (DIPEA). The 
crude purification by silica-gel column chromatography afforded the linear peptide in 90% 
yield. Subsequent cleavage of the Boc and O
t
Bu in acidic condition provided the fully 
unprotected linear peptide 43. 
The peptide cyclization was performed in high diluted DMF solution using HATU as 
coupling reagent, HOBt as racemization suppressant and DIPEA as a base. The reaction 
was monitored by TLC and after 56 h no more linear peptide was detected. The solvent was 
removed by distillation and the crude purification by silica gel chromatography afforded the 
cyclo peptidomimetic 44 which finally was submitted to hydrogenolytic cleavage of the 
tyrosine O-benzyl group with Pd/C as catalyst leading to the formation of 45 as fully 
deprotected peptidomimetic (8 mg, 95%). 
Due to the low amount of the cyclic peptidomimetic 45 it was not attempted a 
chromatographic purification but it was performed a directly characterization on the 
reaction crude which show that the final product was obtained with a good purity (90%).  
 
Figure 5. ESI-MS+ of the final cyclic peptidomimetic 35. 
The low overall yield of the multistep synthesis of 45 may be due to a set of several factors 
such as: the purification after each step by flash chromatography which could lead to 
product loss; the checking of the reaction progression by TLC, which has a low sensibility 
for the revelation of compounds in high dilution, poorly UV-visible or by nature barely 
detectable by the classical TLC stains. Nevertheless, now that the reaction conditions and 
the purification methodology for each compound are known, the subsequent efforts will be 
addressed to the optimization of some critical steps (SAA coupling and peptidomimetic 
cyclization) with the purpose to increase the overall yield.  
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3.3. Conclusion 
A synthetic methodology to achieve a cyclic peptidomimetic with a sugar amino acid in its 
sequence has been identified and optimized. Despite the final product has been obtained in 
low amount, this will be enough to perform the preliminary biological test with the p50 NF-
B protein. However, exploiting the synthetic way developed during this stage, the same 
product as well as some analogues, could be rapidly synthesized; led to the formation of a 
series of peptidomimetic to test as potential p50 homodimerization inhibitors.  
The cyclic peptidomimetic synthesized will be subjected to extensive investigations in 
order to define how the conformational and chemical properties imposed by the sugar 
amino acid on the cyclic peptidomimetic can have an affects on the interactions between 
the peptidic inhibitor and the binding site region of the protein. 
Moreover, whether the sugar can influence the solubility and the membrane permeability of 
the peptidomimetics will be evaluate. 
The SAA structure has a huge potential, through an appropriate functionalization of the 
different hydroxyl groups present in the monosaccharide moiety, a libraries of potentially 
bioactive compounds for pharmacological screening can be achieved. Therefore the SAA 
represents an important component to achieve a peptide differentiation. 
An alternative approach, always based on sugar peptidomimetics, could be to exploit the 
sugar as a scaffold for the synthesis of a peptidomimetic in which the amide backbone is 
substituted with a different skeleton while maintaining the proper orientation of the amino 
acidic substituents. 
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4.1. Introduction 
The plasma membrane consists of a lipid bilayer into which proteins and glycoproteins are 
dispersed. The hydrophobic nature of the inner part of the double layer prevents the 
hydrophilic compounds to cross it unless specific transport mechanisms are involved. Some 
small hydrophilic molecules/ions can cross the membrane channels while others, more 
complex structures, are shuttled from the outer media to the cytoplasm by membrane 
proteins. In this case, generally, an internalization process, endocytosis, in vesicles is 
needed to encapsulate the cargo, transfer it through the membrane and finally release it in 
the cytoplasm. 
 
Figure 1. The plasma membrane. (Image from Fundamentals of Biochemistry 2006). 
Intracellular transport of different biologically active molecules is one of the key issues in 
drug delivery. Moreover, many compounds showing a promising activity in vitro, cannot be 
applied in vivo owing to bioavailability problems.  
Many different pharmaceutical carriers have been developed to increase the stability of 
administered drugs, improve their efficacy, decrease undesired side effects and, even, 
promote better intracellular delivery.
1-3
 
Nowadays, it is well-known that nanocarriers
4,5
 had a great potential for a specific delivery 
of drugs. This approach has been largely exploited to optimize the intracellular delivery of 
many small molecules as well as of macromolecules like nucleic acids, peptides or proteins, 
which are unstable in physiological conditions and generally unable to cross the cell 
membrane. It has be reported that submicronic lipid vesicles known as liposomes,
6
 as well 
as synthetic polymer nanoparticles,
7
 were able to deliver into cells, molecules that did not 
diffuse spontaneously to the cytoplasm. 
Liposomes represent the most popular and well-investigated drug carriers.
8,9
 They are 
supramolecular aggregates of natural or artificial phospholipid with the size varying from 
50 to 1000 nm, which can be loaded with a variety of drugs. They are biologically inert and 
completely biocompatible which means that they do not induce toxic or antigenic reactions. 
Moreover the phospholipid bilayer works as a shield, protecting the internalized drugs from 
any destructive effect of the external media. The association of the drugs with these carriers 
results in a delayed drug absorption, restricted drug biodistribution, decreased volume of 
drug biodistribution, delayed drug clearance and retarded drug metabolism.
10
 Finally, 
liposomes are rapidly eliminated from the blood and captured by the reticuloendothelial 
system cells (RES), primarily, in the liver and in the spleen, as the result of a rapid 
opsonization. 
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Figure 2. Some examples of drug delivery systems. 
Polymeric nanoparticles are generally based either on synthetic biodegradable polymers-
like the poly(lactic acid, PLA) and poly(lactic-co-glycolic acid, PLGA) polyesters or the 
poly(alkylcyanoacrylates, PACA) or natural polymers, like albumin.
5
 Nanospheres are 
matrices in which the drug is dispersed throughout the particles, whereas nanocapsules are 
vesicular systems in which the drug is confined into a cavity surrounded by a unique 
polymeric membrane. Other systems based on polymers include polymer micelles, 
dendritic architectures and polyplexes (formed by the electrostatic interactions of 
polycations and nucleic acids).
4
 
An alternative useful approach to deliver cargo molecules into the cell is represented by the 
cell-penetrating peptides (CPPs).
3,11,12
 
CPPs are short cationic peptide sequences that have been demonstrated to mediate the 
intracellular delivery of a range of biological molecules. They are able to reach the 
cytoplasmic and/or nuclear compartments in live cells upon internalization and to deliver 
the conjugated (or fused) biomolecules.
13,14
 These peptides have been used for intracellular 
delivery of various biological compounds with molecular weights several times higher than 
their own
15
 such as antigenic peptides,
16
 peptide nucleic acids,
17
 antisense 
oligonucleotides,
18
 full-length proteins,
19-21
 or even nanoparticles
22
 and liposomes.
23
 
Conjugation of therapeutic agents with CPPs could become a key-strategy to improve their 
pharmacological properties. 
4.2. Peptide delivery: our approach  
Despite the liposome technology and the CCPs method have shown large potential to 
deliver a wide range of large molecules and potential drugs overcoming the cellular 
barriers, in this project taking advantage of the great experience in the carbohydrate 
synthesis in our research group, has been evaluated an alternative approach for the transport 
of the peptidomimetics into the cells. 
The approach proposed is focused on the protein regulating transport of glucose across the 
plasma membranes (GLUTs). 
The idea is based on the functionalization of the cyclopeptide with a glucose-derived carrier 
which being recognized by the GLUTs, can translocate the cargos through the cellular 
membranes thereby, enhancing the cyclopeptide delivery inside the cells. 
Transmembrane transport  
 
 72 
This approach is one of the methods used to promote the drug transport across the BBB.
24
 
Because, the BBB expresses a number of specific carrier-mediated inward transport 
mechanisms that ensure an adequate nutrient supply for the brain.
25
 These endogenous 
BBB transporters can be exploited for a drug molecules active transport
26
 which can be 
realized by the conjugation of an endogenous transporter substrate to the active drug 
molecule according to the prodrug approach.
27
 
In this context, GLUT1 transports glucose and other hexoses have the highest transport 
capacity of the carrier-mediated transporters present at the BBB, being therefore an 
attractive transporter for prodrug delivery.
28
  
In addition, many transporters have been reported to be differentially up-regulated in cancer 
cells compared to normal tissues, suggesting that the differential expression of transporters 
in cancer cells may provide good targets for enhancing drug delivery as well as diagnostic 
markers for cancer therapy.
29
 The overexpression of glucose transporter proteins, which 
facilitate the glucose uptake by cells, was widely observed in tumor tissues,
28
 indeed, 
cancer cells have an increased rates of glucose metabolism compared with healthy one and, 
this increased GLUT levels and transport activity would contribute significantly to tumor 
growth.
30
 
For instance, GLUT1 is ubiquitously expressed in normal tissue and expressed at high 
concentrations in some tumors, including hepatic, pancreatic, breast, esophageal, brain, 
renal, lung, cutaneous, colorectal, endometrial, ovarian, and cervical carcinoma.
31
 Thus, 
GLUT1 expression in tumor tissues is one of the most characteristic biochemical markers 
for the transformed phenotype. 
4.3. Transcellular sugar transport: the mammalian glucose transporter family 
Sugars are hydrophilic molecules that are unable to cross lipid cell membranes without a 
protein-transporter. Two different families of associated membrane carrier proteins are 
known: the sodium-dependent glucose transporter (SGLT) and the facilitated-diffusion 
glucose transporter (GLUT) as shown in Table 1. These proteins mediate the sugars 
transport with different efficiencies and kinetics.  
 
Figure 3. Structure of the GLUT family. (Adapted from Nature Reviews Molecular Cell Biology 2002, 3, 267-277). 
GLUTs proteins allow the energy independent transport of glucose across the hydrophobic 
cell membrane, driven by the concentration gradient.  
The GLUT family members have the structural sequence of 12 transmembrane domains 
with intracellular N- and C- terminals (Figure 3).  
The human GLUT family consists of 14 members that can be classified in three sub 
families based on the sequence homology and on the structural similarity.
32-34
 The class I 
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comprises the well characterized GLUTs 1-4 as glucose transporters. The class II comprises 
the fructose transporter GLUT5 and three proteins, GLUT7, GLUT9, and GLUT11. 
Finally, the class III comprises five newly described proteins, GLUT6, GLUT8, GLUT10, 
GLUT12, and the H
+
/myoinositol transporter HMIT. These are structurally atypical 
members of the GLUT family, which are, so far, not clearly defined. 
Each member of the GLUT family is different in terms of functional characteristics and, in 
addition, they exhibit different substrate specificity, kinetic properties and expression 
profiles.
35
  
Transporter Major site of expression 
Na+-dependent glucose transporter (SGLT) 
SGLT 1 small intestine, kidney 
SGLT 2 kidney 
Facilitated-diffusion glucose transporter (GLUT) 
GLUT 1 brain, erythrocytes, placenta, fetal tissue 
GLUT 2 small intestine, liver, kidney, pancreatic -cell 
GLUT 3 brain 
GLUT 4 skeletal muscle, adipose tissue 
GLUT 5 small intestine 
GLUT 6 pseudogene which is not expressed at the protein level 
GLUT 7 intestine, colon, testis (the physiological relevance is being 
investigated) 
GLUT 8 testis 
GLUT 9 kidney, liver 
GLUT 10 heart, lung, brain, liver 
GLUT 11 lung, brain, liver 
GLUT 12 heart, muscle, brown adipose tissue 
HMIT brain 
Table 1. The family of glucose transporters. (Modified from Blanco et al. International Journal of Endocrinology 2010): 
4.4. Development and synthesis of glycosidic carrier 
The increased glucose transport and the associated overexpression of GLUT proteins during 
the tumors progression has been exploited to promote the transmembrane transport of the 
cyclopeptide inhibitors developed in this project. 
The idea was focused on the combination of the peptidomimetic with a sugar moiety which 
can be recognized by the GLUT transporter protein family. 
Based on reported data, a glycosidic carrier, analog of the glucose, was designed. This 
molecule bears a free hydroxyl in the position 6 which is not primary involved in the 
GLUTs recognition process.
24
 In our synthetic pathway, the 6-hydroxy would be replaced 
by a carboxylic function able to form a stable covalent bond with the side chain groups of 
the cyclopeptides. Moreover the introduction of a short aliphatic chain between the sugar 
moiety and the carboxylic group will prevent any interference from the peptidomimetics in 
the glucose recognition process.  
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Scheme 1. Synthesis of the glucose-base glycosidic carrier. 
 
   
 
 
Figure 4. RP-HPLC and RP-HPLC-ESI- traces of the glycosidic carrier 51. HPLC were recorded using a 50-100% B 
gradient in 8 min (A = 0.045% TFA in H2O, and B = 0.036% TFA in ACN).  
4.5. Condensation of cyclic peptides with the glycosidic carrier  
The conjugation of the glycosidic carrier with the cyclopeptides containing lysine, Dap and 
4-aminophenilalanine, implies the formation of a stable amide bond between the carboxylic 
group of the carrier and the primary amino group on the cyclopeptide side chain. 
To this end, two different approaches were evaluated one based on the coupling of the 
carrier with the final cyclopeptide and the other one involving the condensation on the 
carrier on the linear peptide followed by the cyclization reaction.  
4.5.1. Coupling reaction with the cyclopeptide in solution 
i) HATU, DIEA, DMF, r.t., 16h
ii) Pd(OH)2/C, H2 atm, CH3OH
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Scheme 2. Condensation of the cyclopeptide with the glycosidic carrier in solution. 
The coupling reaction, in two different conditions sets, between the glycosidic carrier and 
the cyclopeptide was initially performed in solution using the sequence with a lysine as a 
model. 
In the first one (A), the pre-activated carboxylic acid as succinimidyl ester was coupled 
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with the amine in basic (DIEA) dichloromethane. This pathway was justified by the rapid 
and clean reaction of the N-Hydroxysuccinimide esters forming water soluble co-products 
easy to remove during the work-up. 
The second approach (B) consisted in the activation of the carboxylic acid by an uronium 
(HATU) coupling reagent in DMF. The reaction was monitored by TLC and after 16 hours 
no free carrier was detected. 
In both cases, after the formation of the amide bond and the solvent evaporation, the crudes 
were subjected to the benzyl ester cleavage by a palladium catalyzed hydrogenolysis. After 
purification by column chromatography the products were isolated, as mixture of / 
anomers, with high purity (>95%) and satisfactory yield (60-70% over 2 steps). 
n Cyclic peptide Method Yield % Purity % 
56a &Lys(carrier)-Val-Tyr-Leu-D-Pro& A 60 > 95 
56a &Lys(carrier)-Val-Tyr-Leu-D-Pro& B 70 > 98 
Table 2. Results of the coupling reaction between the cyclopeptide and the glycosidic carrier performed in solution. The 
overall yields are referred to the final products isolated after the purification by flash chromatography. The purities were 
determined by 1H-NMR. 
Both strategies present similarities in terms of mechanism and quality of the final crudes 
despite the slightly different reactions time. Nevertheless the HATU way gave higher yield, 
which could be due to higher reactivity of the 7-azabenzotriazol-1-yl esters compared to the 
succinimidyl one thanks to an intramolecular general base-catalysis. 
N N
N
N
O
O
N
H
H
 
Figure 5. HATU active species 
The cyclopeptide conjugated with the sugar moiety shows a remarkable solubility in polar 
solvents, differently to what observed for its unconjugated analogue (cyclo-1c), indicating 
that the glucose hydroxyl groups together with the tyrosine one provide an overall 
hydrophilic character to the peptide promoting its solubility. 
4.5.2. Coupling reaction with the linear peptides on solid phase 
Solid phase coupling was also tested to conjugate the carrier with the cyclopeptide in order 
to exploit all the advantages related with the SPPS technique. This methodology was used 
to condense the carrier with peptides containing primary amino groups on their side chains 
(Lysine, Dap and 4-amino phenylalanine). It was used an analogue synthetic approach to 
that employed for the Lys side chain acetylation on solid phase. (Chapter 2, scheme 8) 
The crucial step in this pathway focuses on the proper selection of orthogonal protecting 
groups that will allow the formation of the free amine without cleaving the protecting 
groups on the N-terminal group or the resin. 
We have introduced a Boc protecting group at the N-terminal in order to remove it in the 
same acid condition needed to cleave the resin, while the amino acids side chains were 
protected with Fmoc. 
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The synthesis of the linear peptides on solid phase (Scheme 3) was performed using the 
standard Fmoc/tBu protocol. The side chains of the resulting linear peptides 52 were 
deprotected by treatment with piperidine releasing the free amino group. The condensation 
between the free acid of glycosidic carrier 51 and the amino functionalities on the linear 
peptide 53, were performed under the typical activation conditions (PyBOP-HOAt-DIEA). 
Finally, the peptides were cleaved from the solid support by TFA treatment which removes 
at the same time also the Boc protecting group on the N-terminal giving the unprotected 
linear peptide 54. The products were isolated and characterized by HPLC, showing high 
degree of quality without further purifications. 
i) piperidine 20% DMF
ii) Boc-R-(Fmoc)-OH
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13
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Scheme 3. Synthesis on solid phase of cyclopeptides functionalized with the glycosidic carrier. R represents the residues: 
Lysine, Dap and 4-aminophenilalanine. 
The peptide cyclizations were carried out in high diluted DMF solution using DPPA as 
condensing agent together with an inorganic base (NaHCO3). The reactions progress was 
monitored by HPLC and after 48 h the reactions were stopped.  
The fully deprotected cyclopeptides 56 were obtained after the cleavage of the benzyl ester 
groups on the sugar by palladium catalyzed hydrogenolysis in methanol. Finally the 
products were purified by semipreparative RP-HPLC to provide the desired products with 
good overall yield and high purity (Table 3). The experimental data show that the presence 
of a sugar near the N-terminal reactive end of the linear peptide does not affect the peptide 
cyclization by bulk effect or steric hinderance. Both, the cyclization reactions time and the 
quality of the final crudes are comparable with the one obtained for the cyclization of the 
linear peptide without the sugar. 
n Cyclic peptide Yield % Purity % 
56a &Lys(carrier)-Val-Tyr-Leu-D-Pro& 25 > 95 
56b &Phe(4NH(carrier))-Val-Tyr-Leu-D-Pro& 35 > 95 
56c &Dap(carrier)-Val-Tyr-Leu-D-Pro& 25 > 95 
Table 3. Results of the synthesis of the cyclopeptides functionalized with the glycosidic carrier (c) totally performed on 
solid phase. The overall yields are referred to the final products isolated after the purification by HPLC chromatography. 
The purities was determined by HPLC. 
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Figure 6. Three different cyclic pentapeptides labelled with the glycosidic carrier. 
This approach, in which the carrier was attached to the linear peptide on solid support, 
allows to carry out just a single purification of the final product reducing the overall 
working time, product loss and material cost. 
In addition, the validation of this method offers the ability to attach many different types of 
labels just before the cyclization, or to modify, again on solid phase, some functional 
groups on the residues side chain. These aspects are particularly relevant for a rapid 
develop of a series of cyclic peptides conjugate with different carriers or probes to evaluate 
the transport of the peptide or to detect its localization during the biological assay giving 
the opportunity to have access to a large range of different experimental tests. 
&Lys(carrier)-Val-Tyr-Leu-D-Pro& (56a) 
           
&Phe(4NH-carrier)-Val-Tyr-Leu-D-Pro& (56b) 
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&Dap(carrier)-Val-Tyr-Leu-D-Pro& (56c) 
 
Figure 7: HPLC and HPLS-MS traces of the cyclopeptides conjugate to the glycosidic carrier. HPLC were recorded using 
a 20-50% B gradient in 8 min (A = 0.045% TFA in H2O, and B = 0.036% TFA in ACN). 
4.6. Conclusion 
An alternative approach to the classical drug delivery methods (e.g. liposomes, CCPs) 
based on the glucose transport protein (GLUTs) was evaluated to shift the cyclopeptides 
inside the cells. A glucose-based carrier was first synthesized and then linked by an amide 
bond to the cyclopeptides. The ongoing biological investigation of these compounds will 
clarify whether the GLUTs mediated transport has the ability to shuttle the peptidomimetic 
inside the cytoplasm, supporting the original idea of this work, or not. Moreover, based on 
the biological results, this transport methodology could be further investigated or 
discharged moving to the classic drug delivery methods. 
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5.1. Synthesis linear peptides 
5.1.1. Synthesis of linear peptides in solution 
All the general procedures are reported in details in the section 6.6 of the chapter 6 General 
methods and procedures. The yield of each synthetic step was calculated on the base of 
pure product recovered after each reaction coupling and subsequent chromatography 
purification. The purity of each compound was determined through the 
1
H-NMR 
spectroscopy. 
Fmoc-Val-Tyr(OBzl)-Leu-Pro-Lys(z)-OFm (1a) 
1a (I)
Boc-Lys(Z)-OH Boc-Lys(Z)-OFm
Fm-OH
i) TFA 
ii) Boc-Tyr(OBzl)-OH
i) TFA 
ii) Fmoc-Val-OH
H-Lys(Z)-OFm
Boc-Leu-Pro-OBzl Boc-Leu-Pro-OH
Boc-Leu-Pro-Lys(Z)-OFm
Boc-Tyr(OBzl)-Leu-Pro-Lys(Z)-OFmFmoc-Val-Tyr(OBzl)-Leu-Pro-Lys(Z)-OFm
Boc-Leu-OH       +     H-Pro-OBzl
1a (II)
1a (III) 1a (IV) 1a (V)
1a (VI)
1a (VII)1a
TFA
Pd/C, H2
+
 
Boc-Lys(Z)-OFm [1a(I)]  
The reaction was performed according to the methodology reported in the section 6.6.1.1. 
Purification of the crude by silica gel chromatography (hexane/Acetone= 85/15) gave the 
product as a white foam (1.5 g, 85%). Purity> 98%. Rf = 0.2 (hexane-Acetone, 8:2). [α]D
20
(c 
0.5, CHCl3) = - 14.62°  
1
HNMR (300 MHz, CDCl3): δ 7.77 (d, 2H, J=7.3 Hz, Har-Fm); 7.57 (m, 2H, Har-Fm); 7.35 
(m, 9H); 5.09 (s, 2H, CH2-Cbz); 4.84 (bs, 1H, NH); 4.54 (m, 2H, CH2-Fm); 4.28 (m, 1H, 
H
α
-Lys); 4.22 (t, 1H, J=6.1 Hz, CH-Fm); 3.15 (bd, 2H, J=6.1 Hz, 2H

-Lys); 1.64 (m, 1H, 
1H-Lys); 1.47 (m, 12H, 3H-Lys, 3CH3-tBu); 1.26 (m, 6H, 2CH3-Leu). 
13
C NMR (CDCl3, 75 MHz): δ 170.53 (1C, s); 154.46 (1C, s); 153.43 (1C, s); 141.13 (2C, 
s); 139.06 (2C, s); 134.42 (1C, s); 126.24 (2C, d); 125.50 (3C, d); 125.64 (2C, d); 124.94 
(2C, d); 122.70 (2C, d); 117.80 (2C, d); 77.67 (1C, s); 64.24 (1C, t), 64.31 (1C, t); 51.29 
(1C, d); 48.09 (1C, d); 38.25 (1C, t); 29.66 (1C, t); 27.10 (1C, t); 26.08 (3C, q); 20.07 (1C, 
t). 
H-Pro-OBzl [1a(III)]  
This compound was synthesized in accordance to the previous reported procedure.
1
 The 
characterization data match with the literature.
1
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Boc-Leu-Pro-OBzl [1a(IV)] 
The product was synthesized according to the protocol B reported in the section 6.6.2. 
Purification by silica gel chromatography: EtOAc/cyclohexane 8:2; gave the product as a 
colorless syrup (980 mg, 97%). Purity > 98%. Rf = 0.23 (EtOAc/cyclohexane, 2:8). [α]D
20
 (c 
0.25, CHCl3) = - 75.42° 
1
H NMR (CDCl3, 300 MHz): δ 7.31 (m, 5H, Har-OBzl); 5.19-5.04 (m, 3H, 1NH, CH2-
OBzl); 4.57 (m, 1H, H
α
-Pro); 4.43 (bm, 1H, H
α
-Leu); 3.75 (m, 1H, 1H

-Pro); 3.57 (m, 1H, 
1H

-Pro); 2.17 (1H, H-Pro); 1.98 (m, 3H, H-Pro); 1.69 (m, 1H, H

-Leu); 1.38 (m, 11H, 
2H

-Leu, 9H-tBu); 0.89 (d, 3H, J=6.7 Hz, 1CH3-Leu); 0.85 (d, 3H, J=6.7 Hz, 1CH3-Leu). 
13
C NMR (CDCl3, 75MHz,):  172.10; 156.0; 141.6; 135.8; 128.6; 128.5; 127.6; 127.1; 
79.7, 67.1; 65.2; 50.5; 46.9; 42.2; 29.2; 25.11; 24.8; 23.6; 21.9. 
Boc-Leu-Pro-OH [1a(V)] 
Boc-Leu–Pro–OBn (420 mg, 2.05 mmol) was dissolved in dry MeOH (8 ml) and 10% 
(w/w) Pd/C (4 mg) was added. H2 was introduced with a balloon and the suspension was 
stirred at room temperature for 12 h. The solution was filtered through a pad of celite and 
concentrated in vacuo. The resulting product was obtained without purification as a white 
foam (675 mg, 100 %). Purity > 98%. Rf = 0.06 (EtOAc/cyclohexane, 4:6). [α]D
20
 (c 0.25, 
CHCl3) = - 73.22° 
1
H NMR (CDCl3, 300 MHz): δ 5.28 (bd, 1H, J=8.8 Hz, NH); 4.57 (m, 1H, H
α
-Pro); 4.50 
(bm, 1H, H
α
-Leu); 3.78 (m, 1H, 1H

-Pro); 3.58 (m, 1H, 1H

-Pro); 2.18 (m, 2H, 2H-Pro); 
2.03 (m, 2H, 2H-Pro); 1.71 (m, 1H, H

-Leu); 1.38 (m, 11H, 2H

-Leu, 3CH3-tBu); 0.97-0.85 
(m, 6H, 2CH3-Leu). 
13
C NMR (CDCl3, 75 MHz): δ 174.08 (1C, s); 173.61 (1C, s); 155.88 (1C, s); 79.90 (1C, s); 
59.41 (1C, d); 50.50 (1C, d); 47.27 (1C, t); 41.66 (1C, t); 29.81 (3C, q); 28.46 (1C, t); 24.97 
(1C, d); 24.66 (1C, q); 23.46 (1C, q); 21.86 (1C, d). 
Boc-Leu-Pro-Lys(Z)-OFm [1a(VI)]  
The product was synthesized according to the protocol A reported in the section 6.6.2. 
Reaction time 12 h. Purification by silica gel chromatography: EtOAc/cyclohexane 7:3; 
gave the product as a white foam (1.26 g, 92%). Purity > 98%. Rf = 0.1 
(EtOAc/cyclohexane, 3:7). [α]D
20
 (c 0.5, CHCl3) = - 50.81° 
1
H NMR (CDCl3, 300 MHz): δ 7.75 (d, 2H, J=7.3 Hz, Har-Fm); 7.56 (m, 2H, Har-Fm); 
7.35 (m, 9H, 4Har-Fm, 5Har-Bzl); 6.84 (bd, 1H, J= 7.3 Hz, NH); 5.66 (bs, 1H, NH); 5.12 
and 5.21 (2 d, 2H, J=12.2Hz, CH2-Cbz); 4.52 (m, 4H, CH2-Fm, 1H
α
-Lys, 1H
α
-Leu); 4.38 
(m, 1H, H
α
-Pro); 4.19 (t, 1H, J=6.12 Hz, CH-Fm); 3.76 (m, 1H, 1H

-Pro); 3.55 (m, 1H, 
1H

-Pro); 3.31 (bd, 2H, J= 6.1Hz, H

-Lys); 2.17 (m, 2H, H-Pro); 1.94 (m, 2H, H-Pro); 1.70 
(m, 2H, 1H

-Leu, 1H-Lys); 1.39 (m, 15H, 4H-Lys, 3CH3-tBu, 2H

-Leu); 1.14 (m, 1H, 1H-
Lys); 0.95 (d, 3H, J=6.7 Hz, 1CH3-Leu); 0.87 (d, 3H, J=6.7 Hz, 1CH3-Leu). 
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13
C NMR (CDCl3, 75 MHz): δ 171.05 (1C, s); 169.59 (1C, s); 168.62 (1C, s); 154.19 (1C, 
s); 141.31 (1C, s); 141.13 (1C, s); 139.19 (1C, s); 139.10 (1C, s); 134.74 (1C, s); 126.13 
(2C, d); 125.75 (1C, d); 125.64 (2C, d); 125.58 (2C, d); 124.88 (2C, d); 122.56 (2C, d); 
117.74 (2C, d); 77.28 (1C, s); 64.37 (1C, t); 64.15 (1C, t); 59.30 (1C, d); 49.79 (1C, d); 
48.22 (1C, d); 45.06 (1C, t); 44.72 (1C, d); 39.56 (1C, t); 38.10 (1C, t); 29.24 (1C, t); 26.71 
(1C, t); 26.10 (3C, q); 25.49 (1C, t); 22.89 (1C, t); 22.31 (1C, d); 20.98 (1C, q); 19.51 (1C, 
t); 19.47 (1C, q). 
Boc-Tyr(OBzl)-Leu-Pro-Lys(Z)-OFm [1a(VII)] 
The product was synthesized according to the protocol A described in the section 6.6.2. 
Reaction time 12 h. Purification by silica gel chromatography: EtOAc/n-hexane 45:55; 
gave the product as a white foam (1.22 g, 95%). Purity > 98%. Rf = 0.42 (EtOAc/n-hexane, 
6:4). [α]D
20
(c 0.25, CHCl3) = - 29.10°  
1
H NMR (CDCl3, 300 MHz): δ 7.76 (d, 2H, J=7.3 Hz, Har-Fm); 7.56 (m, 2H, Har-Fm); 
7.38-7.25 (m, 14H, 4Har-Fm, 5Har-Cbz, 5Har-OBzl); 7.05 (bd, 2H, J=8.5 Hz, Har-Tyr); 
6.84 (d, 2H, J=8.5 Hz, Har-Tyr); 5.23 (bs, 2H, CH2-OBzl); 4.99 (s, 2H, CH2-Cbz); 4.82 (m, 
1H, H
α
-Leu); 4.51 (m, 5H, CH2-Fm, 1H
α
-Lys, 1H
α
-Pro, 1H
α
-Tyr); 4.18 (t, 1H, J=6.1 Hz, 
CH-Fm); 3.78 (m, 1H, 1H

-Pro); 3.58 (m, 1H, 1H

-Pro); 3.15 (bm, 3H, 2H

-Lys, 1H

-Tyr); 
2.85 (m, 1H, 1H

-Tyr); 2.13 (m, 2H, H-Pro); 1.95 (m, 2H, H-Pro); 1.66 (m, 1H, H

-Leu); 
1.49 (m, 2H, H

-Leu); 1.38-1.21 (m, 15H, 3CH2-Lys, 3CH3-tBu); 0.96 (d, 3H, J=6.1 Hz, 
1CH3-Leu); 0.88 (d, 3H, J=6.4 Hz; 1CH3-Leu). 
13
C NMR (CDCl3, 75 MHz): δ 169.69 (2C, s); 168.85 (1C, s); 155.49 (1C, s); 153.02 (1C, 
s); 141.63 (1C, s); 141.36 (1C, s); 141.17 (1C, s); 140.55 (1C, s);139.20 (1C, s); 139.11 
(1C, s); 135.00 (1C, s); 134.62 (1C, s); 128.53 (2C, d); 126.23 (4C, d); 125.50 (2C, d); 
125.61 (4C, d); 125.07 (2C, d); 124.90 (2C, d); 122.60 (2C, d); 117.77 (2C, d); 112.84 (2C, 
d); 77.28 (1C, s); 67.90 (2C, t); 64.37 (2C, t); 60.01 (1C, t); 59.80 (1C, t); 58.73 (1C, d); 
58.50 (1C, t); 58.10 (1C, d); 49.85 (1C, d); 46.89 (1C, d); 45.23 (1C, t); 44.73 (1C, d); 
39.31 (1C, t); 36.06 (1C, t); 29.23 (1C, t); 26.09 (3C, q); 22.94 (1C, t); 22.27 (1C, d); 21.06 
(1C, q); 19.61 (1C, q). 
Fmoc-Val-Tyr(OBzl)-Leu-Pro-Lys(Z)-OFm [1a] 
The product was synthesized according to the protocol A described in the section 6.6.2. 
Reaction time 12 h. Purification by silica gel chromatography: CHCl3/Acetone, 9:1; gave 
the product as a white solid (970 mg, 92%). Purity > 98%. Rf = 0.2 (CHCl3/Acetone, 9:1). 
[α]D
20
(c 0.25, CHCl3) = - 29.19°  
1
H NMR (CDCl3, 300 MHz): δ 7.72 (d, 4H, J=6.1 Hz, 2Har-Fm, 2Har-Fmoc); 7.57 (m, 4H, 
2Har-Fm, 2Har-Fmoc); 7.31 (m, 18H, 4Har-Fm, 4Har-Fmoc, 5Har-Cbz, 5Har-OBzl); 7.05 
(d, 2H, J=8.5 Hz, Har-Tyr); 6.84 (d, 2H, J=8.5 Hz, Har-Tyr); 5.28 (bs, 1H, NH); 5.17 (s, 
2H, CH2-Cbz); 4.91 (s, 2H, CH2-OBzl); 4.76 (m, 2H, 1NH, 1H

); 4.54 (m, 5H, 1H
α
, CH2-
Fmoc, CH2-OFm); 4.35 (m, 2H, 2H
α
); 4.22 (m, 3H, 1H
α
, CH-Fm, CH-Fmoc); 3.95 (bs, 1H, 
1H
α
); 3.74 (m, 1H, 1H

-Pro); 3.54 (m, 1H, 1H

-Pro); 3.17 (bm, 3H, 2H

-Lys, 1H

-Tyr); 
2.87 (m, 1H, 1H

-Tyr); 2.15 (m, 3H, 2H-Pro, 1H
β
-Val); 1.95 (m, 2H, 2H-Pro); 1.75 (m, 4H, 
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2H

-Lys, 2H

-Leu); 1.60 (1H, H

-Leu); 1.41 (m, 4H, 2H

-Lys, 2H

-Lys); 0.89-0.80(m, 
12H, 2CH3-Leu, 2CH3-Val). 
13
C NMR (CDCl3, 75 MHz): δ 172.10 (1C, s); 171.15 (1C, s); 170.99 (1C, s); 170.67 (1C, 
s); 153.02 (1C, s); 157.90 (1C, s); 157.81 (1C, s); 156.35 (1C, s); 144.10 (1C, s); 144.0 (1C, 
s); 143.60 (1C, s); 143.4 (1C, s); 143.20 (1C, s); 141.51 (2C, s); 141.36 (2C, s); 137.25 (1C, 
s); 137.20 (1C, s); 136.76 (1C, s); 130.64 (1C, d); 128.63 (4C, d); 128.27 (1C, d); 127.99 
(4C, d); 127.77 (2C, d); 127.51 (4C, d); 127.25 (4C, d); 127.40(2C, d); 125.28 (1C, 
d);125.10 (1C, d); 124.96 (1C, d); 120.12 (2C, d); 120.05 (2C, d); 114.69 (1C, d); 69.99 
(1C, t); 67.08 (1C, t); 67.76 (1C, t); 61.10 (1C, d); 60.82 (1C, d); 54.11 (1C, d), 51.84 (1C, 
d); 49.10 (1C, d); 48.15 (1C, t); 47.90 (1C, t); 47.37 (1C, d); 46.96 (1C, d); 42.13 (1C, t); 
41.95 (1C, t); 41.08 (1C, t); 40.95 (1C, t); 31.50 (1C, d); 31.32 (1C, t); 28.62 (1C, t); 25.42 
(1C, t); 25.59 (1C, d); 23.44 (1C, q); 21.93 (1C, q); 21.05 (1C, t); 19.37 (1C, q); 17.74 (1C, 
q). 
Fmoc-Val-Tyr(OBzl)-Leu-Pro-D-Lys(2Cl-Z)-OFm (1b)  
Fmoc-Val-Tyr(OBzl)-Leu-Pro-D-Lys(2Cl-Z)-OFm
1b (I)
1b
Boc-D-Lys(2Cl-Z)-OH Boc-Pro-D-Lys(2Cl-Z)-OFm Boc-Leu-Pro-D-Lys(2Cl-Z)-OFm
Boc-Tyr(OBzl)-Leu-Pro-D-Lys(2Cl-Z)-OFm
1b(III)
1b (IV)
Boc-D-Lys(2Cl-Z)-OFm
Fm-OH
i) TFA 
ii) Boc-Pro-OH
1b(II)
i) TFA 
ii) Boc-Leu-OH
i) TFA 
ii) Boc-Tyr(OBzl)-OH
i) TFA 
ii) Fmoc-Val-OH
 
Boc-D-Lys(2Cl-Z)-OFm [1b(I)]  
The reaction was performed according to the methodology reported in the section 6.6.1.1. 
Purification of the crude by silica gel chromatography (n-hexane/AcOEt= 85/15) gave the 
product as a pale yellow syrup (2.09 g, 98%). Purity > 98%. Rf = 0.1 (n-hexane/AcOEt, 
85:15). [α]D
20
 (c 1, CHCl3) = + 2.67° 
1
H NMR (CDCl3, 300 MHz): δ 7.76 (d, J=7.3 Hz, 2Har); 7.57 (m, 2H, 2Har); 7.39-7.25 (m, 
8Har); 5.20 (s, 2H, CH2-Cbz); 5.10 (bd, 1H, J= 6.4 Hz, NH); 4.91 (bs, 1H, NH); 4.51 (m, 
2H, CH2-Fm); 4.28 (bm, 1H, H
α
-Lys); 4.20 (t, 1H, J=6.1 Hz, CH-Fm); 3.15 (bd, 2H, J= 5.8 
Hz, 2H

-Lys); 1.64 (bm, 1H, H-Lys); 1.26 (m, 12H, 9H-tBu, 3H-Lys); 1.22 (m, 2H, 2H-
Lys). 
13
C NMR (CDCl3, 75 MHz): δ 172.72 (1C, s); 157.31 (1C, s); 155.54 (1C, s); 143.64 (1C, 
s), 143.48 (1C, s); 141.49 (1C, s); 141.42 (1C, s); 134.45 (1C, s); 133.64 (1C, s), 129.86 
(1C, d); 129.59 (1C, d); 129.42 (1C, d); 12.99 (2C, d); 127.27 (2C, d); 126.94 (1C, d); 
125.00 (2C, d), 120.15 (2C, d); 80.05 (1C, s); 66.80 (1C, t); 63.98 (1C, t); 53.32 (1C, d); 
46.96 (1C, d); 40.72 (1C, t); 32.29 (1C, t); 29.44 (1C, t); 28.42 (3C, q); 22.35 (1C, t). 
Boc-Pro-D-Lys(2Cl-Z)-OFm [1b (II)] 
The reaction was performed according to the protocol C reported in the section 6.6.2. 
Purification of the crude by silica gel chromatography (n-hexane/AcOEt= 55/45) gave the 
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product as a white foam (2.3 g, 90%). Purity > 98%. Rf = 0.3 (n-hexane/AcOEt, 1:1). [α]D
20
 
(c 0.5, CHCl3) = - 29.60° 
1
H NMR (CDCl3, 300 MHz): δ 7.75 (d, J= 7.6 Hz, 2Har); 7.55 (m, 2Har); 7.39-720 (m, 
8Har); 5.27 (s, 2H, CH2-Cbz); 4.95 (bs, 1H, NH); 4.53 (m, 3H, CH2-Fm, 1H
α
-Lys); 4.25 
(bm, 1H, H
α
-Pro); 4.18 (t, 1H, J= 6.1 Hz, CH-Fm); 3.99 (bm, 2H, H

-Pro), 3.11 (m, 2H, H

-
Lys); 2.17 (bm, 1H, H-Pro), 2.01 (bm, 1H, H-Pro), 1.85 (bm, 3H, 1H-Lys, 2H-Pro); 1.43 
(m, 12H, 9H-tBu, 5H-Lys). 
13
C NMR (CDCl3, 75 MHz): δ 172.08 (2C, s); 156.23 (1C, s); 155.54 (1C, s); 143.63(1C, 
s); 143.44 (1C, s); 141.52 (1C, Cq); 141.41(1C, s); 134.66 (1C, s); 133.53 (1C, s), 129.68 
(1C, d); 129.49 (1C, d); 129.23 (1C, d); 127.95 (2C, d); 127.25 (2C, d); 126.85 (1C, d); 
124.88 (2C, d), 120.10 (2C, d); 80.56 (1C, s); 66.74 (1C, t); 63.82 (1C, t); 60.70 (1C, d); 
51.90 (1C, d); 47.21 (1C, t); 47.03 (1C, d); 40.80 (1C, t); 32.03 (1C, t); 29.32 (1C, t); 28.43 
(3C, q); 24.16 (1C, t); 22.25 (1C, t). 
Boc-Leu-Pro-D-Lys(2Cl-Z)-OFm [1b(III)]  
The reaction was performed according to the protocol C reported in the section 6.6.2. 
Purification of the crude by silica gel chromatography (cyclohexane/AcOEt= 8/2) gave the 
product as a white solid (1.7 g, 93%). Purity > 98%. Rf = 0.28 (cyclohexane/AcOEt, 8:2). 
[α]D
20
 (c 0.5, CHCl3) = - 46.53° 
1
H NMR (CDCl3, 300 MHz): δ 7.76 (d, J=7.3 Hz, 2Har); 7.55 (m, 2H, 2Har); 7.40 (m, 
8Har); 7.15 (bd, 1H, J= 9.0 Hz, NH); 5.45 (bs, 1H, NH); 5.23 (s, 2H, CH2-Cbz); 4.60-4.47 
(m, 5H, CH2-Fm, 1H
α
-Lys, 1H
α
-Pro, 1H
α
-Leu); 4.21 (t, 1H, J=6.1 Hz, CH-Fm); 3.37 (bm, 
1H, 1H

-Pro); 3.53 (m, 1H, 1H

-Pro), 3.16 (m, 2H, 2H

-Lys); 2.29 (bm, 1H, 1H-Pro), 2.01 
(bm, 3H, 3H-Pro), 1.75 (bm, 2H, 1H

-Leu, 1H-Lys); 1.46 (m, 13H, 9H-tBu, 2H

-Leu, 2H-
Lys); 1.25 (m, 3H, 3H-Lys); 0.94 (d, 3H, J= 6.4 Hz, 1CH3-Leu); 0.88 (d, 3H, J= 6.6 Hz, 
1CH3-Leu). 
13
C NMR (CDCl3, 75 MHz): δ 173.96 (1C, s); 171.88 (1C, s); 170.76 (1C, s); 156.21 (1C, 
s); 155.79 (1C, s); 143.62 (1C, s); 143.33 (1C, s); 141.49 (1C, s); 141.36 (1C, s); 134.68 
(1C, s); 133.82 (1C, s), 129.49 (2C, d); 129.22 (1C, d); 127.97 (2C, d); 127.25 (1C, d); 
127.21 (1C, d); 126.90 (1C, d); 124.91 (2C, d); 120.11 (2C, d); 79.76 (1C, s); 66.73 (1C, t); 
63.73 (1C, t); 60.10 (1C, d); 51.87 (1C, d); 50.55 (1C, d); 47.29 (1C, t); 46.90 (1C, d); 
42.13 (1C, t); 40.43 (1C, t); 31.33 (1C, t); 29.04 (1C, t); 28.39 (3C, q); 27.38 (1C, t); 25.07 
(1C, t); 24.71 (1C, d); 23.62 (1C, q); 21.69 (1C, q); 21.50 (1C, t). 
Boc-Tyr(OBzl)-Leu-Pro-D-Lys(2Cl-Z)-OFm [1b (IV)] 
The reaction was performed according to the protocol C reported in the section 6.6.2. 
Reaction time 12 h. Purification of the crude by silica gel chromatography 
(cyclohexane/AcOEt= 1/1) gave the product as a white foam (1.2 g, 94%). Purity > 95%. Rf 
= 0.18 (cyclohexane/AcOEt, 1:1). [α]D
20
 (c 0.5, CHCl3) = - 35.10° 
1
H NMR (CDCl3, 300 MHz): δ 8.44 (bd, 1H, J= 7.6 Hz, NH); 7.76 (dd, J=7.3 Hz, J=3 Hz, 
2Har); 7.55 (m, 2Har); 7.39-7.25 (m, 13Har); 7.04 (m, 2Har); 6.86 (m, 2Har); 6.71 (bd, 1H, 
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J= 8.2 Hz, NH); 6.60 (bs, 1H, NH); 5.35-5.16 (m, 3H); 5.00 (s, 2H, CH2-OBzl); 4.75 (m, 
1H); 4.48 (m, 5H); 4.18 (t, 1H, J=6.1 Hz); 3.81-3.50 (bm, 2H); 3.28 (m, 1H); 3.12 (m, 1H); 
2.95 (bm, 2H); 2.24-1.85 (bm, 4H), 1.55-1.25 (bm, 18H); 0.90 (m, 6H). 
13
C NMR (CDCl3, 75 MHz): δ 174.26 (1C, s); 172.53 (1C, s); 171.90 (1C, s); 157.82 (1C, 
s); 156.21 (1C, s); 155.32 (1C, s); 143.60 (1C, s); 143.30 (1C, s); 141.64 (1C, s); 141.35 
(1C, s); 137.08 (1C, s); 136. 23 (1C, s); 134.60 (1C, s); 130.63 (1C, d); 130.7 (1C, d); 
129.77 (1C, d);129.55 (1C, d); 129.28 (1C, s); 129.38 (2C, d); 128.61 (2C, d); 127.97 (3C, 
d); 127.48 (2C, d); 127.24 (2C, d); 124.89 (1C, d); 124.83 (1C, d); 120.13 (2C, d); 114.91 
(1C, d); 114.63 (1C, d); 79.76 (1C, s); 70.04 (1C, t); 66.74 (1C, t); 64.34 (1C, t); 63.85 (1C, 
t); 60.89 (1C, d); 59.92 (1C, d); 51.88 (1C, d); 51.19 (1C, d); 49.21 (1C, d); 47.35 (1C, t); 
41.88 (1C, t); 40.68 (1C, t); 39.51 (1C, t); 31.66 (1C, t); 29.22 (1C, t); 28. 61 (1C, t);  28.12 
(3C, q); 24.93 (1C, t);  24.59 (1C, d); 23.28 (1C, q); 20.04 (1C, q). 
Fmoc-Val-Tyr (OBzl)-Leu-Pro-D-Lys(2Cl-Z)-OFm (1b) 
The reaction was performed according to the protocol C reported in the section 6.6.2. 
Reaction time 12 h. Purification of the crude by silica gel chromatography 
(CH2Cl2/Acetone= 9/1) gave the product as a white foam (1.2 g, 94%). Purity > 98%. Rf  = 
0.18 (CH2Cl2/Acetone, 9:1). [α]D
20
 (c 0.5, CHCl3) = - 40.62° 
1
H NMR (CDCl3, 300 MHz): δ 8.48 (bd, 1H, J= 7.0 Hz, NH); 7.75 (d, J=7.3 Hz, 4Har); 
7.57 (m, 4Har); 7.33 (m, 17Har); 7.05 (d, 2H, J= 8.2 Hz, 2Har); 6.79 (d, 2H, J= 8.2 Hz, 
2Har); 6.71 (bs, 1H, NH); 6.56 (bs, 1H, NH); 6.42 (bs, 1H, NH); 5.29 (m, 3H); 4.90 (m, 
3H); 4.45 (m, 7H); 4.20 (m, 2H); 3.63 (bm, 2H); 3.12 (m, 2H); 2.97 (m, 2H); 2.03 (bm, 
4H), 1.68 (bm, 3H); 1.37 (bm, 5H); 1.25 (bm, 2H); 0.88 (bm, 12H). 
13
C NMR (CDCl3, 75 MHz): δ 172.10 (1C, s); 171.15 (1C, s); 170.99 (1C, s); 170.67 (1C, 
s); 153.02 (1C, s); 157.90 (1C, s); 157.81 (1C, s); 156.35 (1C, s); 144.10 (1C, s); 144.0 (1C, 
s); 143.60 (1C, s); 143.4 (1C, s); 143.20 (1C, s); 141.51 (2C, s); 141.39 (2C, s); 137.25 (1C, 
s); 137.20 (1C, s); 136.76 (1C, s); 136. 68 (1C, s); 130.52 (1C, s); 130.33 (1C, d); 129.67 
(1C, d); 129.41 (1C, d); 129.26 (1C, d); 128.41 (2C, d); 127.81 (2C, d); 127.64 (2C, d); 
127.38 (2C, d); 127.07 (1C, d); 126.83 (1C, d); 125.12 (1C, d); 124.74 (2C, d); 119.96 (2C, 
d); 114.56 (1C, d); 69.72 (1C, t); 66.95 (1C, t); 66.76 (1C, t); 61.10 (1C, d); 60.82 (1C, d); 
54.11 (1C, d), 51.84 (1C, d); 49.10 (1C, d); 48.15 (1C, t);  47.90 (1C, t); 47.37 (1C, d); 
46.96 (1C, d); 42.13 (1C, t); 41.95 (1C, t); 41.08 (1C, t); 40.95 (1C, t); 31.50 (1C, d); 31.32 
(1C, t); 28.62 (1C, t); 25.42 (1C, t); 25.59 (1C, d); 23.44 (1C, q); 21.93 (1C, q); 21.05 (1C, 
t); 19.37 (1C, q); 17.74 (1C, q). 
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Fmoc-Val-Tyr(OBzl)-Leu-D-Pro-Lys(2Cl-Z)-OFm (1c) 
Fmoc-Val-Tyr(OBzl)-Leu-D-Pro-Lys(Z)-OFm
1a (II)
1c
Boc-Lys(Z)-OH Boc-D-Pro-Lys(Z)-OFm Boc-Leu-D-Pro-Lys(Z)-OFm
Boc-Tyr(OBzl)-Leu-D-Pro-Lys(Z)-OFm
1c (II)
1c (III)
Boc-Lys(Z)-OFm
Fm-OH
i) TFA 
ii) Boc-D-Pro-OH
1c (I)
i) TFA 
ii) Boc-Leu-OH
i) TFA 
ii) Boc-Tyr(OBzl)-OH
i) TFA 
ii) Fmoc-Val-OH
 
Boc-D-Pro-Lys(Z)-OFm [1c(I)]  
The reaction was performed according to the methodology A reported in the section 6.6.1. 
Purification of the crude by silica gel chromatography (n-hexane/Acetone= 75/25) gave the 
product as a white foam. (970 mg, 85%). Purity > 98%. Rf  = 0.16 (n-hexane/Acetone, 
75:25). [α]D
20
 (c 0.5, CHCl3) = + 39.61° 
1
H NMR (CDCl3, 300 MHz): δ 7.75 (d, J= 6 Hz, 2Har); 7.56 (t, 2H, J= 7.5, 2Har); 7.34 (m, 
9Har); 5.08 (s, 2H, CH2-Cbz); 4.56 (m, 3H, CH2-Fm, 1H
α
-Lys); 4.20 (m, 2H, 1H
α
-Pro, CH-
Fm); 3.41 (bm, 2H, H

-Pro); 3.11 (m, 2H, H

-Lys), 1.82 (m, 2H, H-Pro), 1.42 (s, 12H, 2H-
Pro, 9H-tBu, H-Lys), 1.21 (bm, 4H, H-Lys); 0.88 (t, 1H, J=7.1 Hz, 1H-Lys). 
13
C NMR (CDCl3, 75 MHz): δ 172.08 (2C, s); 156.23 (1C, s); 155.54 (1C, s); 143.63 (1C, 
s); 143.44 (1C, s); 141.52 (1C, s); 141.41(1C, s); 134.66 (1C, s); 133.53 (1C, d), 129.68 
(1C, d); 129.49 (1C, d); 129.23 (1C, d); 127.95 (2C, d); 127.25 (2C, d); 126.85 (1C, d); 
124.88 (2C, d), 120.10 (2C, d); 80.05 (1C, s); 66.80 (1C, t); 63.98 (1C, t); 53.32 (1C, d); 
46.96 (1C, d); 40.72 (1C, t); 32.29 (1C, t); 29.44 (1C, t); 28.42 (3C, q); 22.35 (1C, t).  
Boc-Leu-D-Pro-Lys(Z)-OFm [1c(II)]  
The reaction was performed according to the methodology B reported in the section 6.6.2. 
Reaction time 16 h. Purification by silica gel chromatography (PE/Acetone= 75/25) gave 
the product as a white foam. (1.1 g, 90%). Purity > 98%. Rf  = 0.20 (PE/Acetone, 75:25). 
[α]D
20
 (c 0.5, CHCl3) = + 35.35° 
1
H NMR (CDCl3, 300 MHz): δ 7.75 (d, 2H, J=7.3 Hz, Har-Fm); 7.56 (m, 2H, Har-Fm); 
7.35 (m, 9H, 4Har-Fm, 5Har-Bzl); 6.84 (bd, 1H, J= 7.3 Hz, NH); 5.15 (s, 2H, CH2-Cbz); 
4.52 (m, 4H, CH2-Fm, 1H
α
-Lys, 1H
α
-Leu); 4.38 (m, 1H, H
α
-Pro); 4.19 (t, 1H, J=6.1 Hz, 
CH-Fm); 3.76 (m, 1H, 1H

-Pro); 3.55 (m, 1H, 1H

-Pro); 3.31 (bd, 2H, J= 6.1, H

-Lys); 2.17 
(m, 2H, H-Pro); 1.94 (m, 2H, H-Pro); 1.70 (m, 2H, 1H

-Leu, 1H-Lys); 1.39 (m, 15H, 4H-
Lys, 3CH3-tBu, 2H

-Leu); 1.14 (m, 1H, 1H-Lys); 0.95 (d, 3H, J=6.7 Hz, 1CH3-Leu); 0.87 
(d, 3H, J=6.7 Hz, 1CH3-Leu). 
13
C NMR (CDCl3, 75 MHz): δ 171.05 (1C, s); 169.59 (1C, s); 168.62 (1C, s); 154.19 (1C, 
s); 141.31 (1C, s); 141.13 (1C, s); 139.19 (1C, s); 139.10 (1C, s); 134.74 (1C, s); 126.13 
(2C, d); 125.75 (1C, d); 125.64 (2C, d); 125.58 (2C, d); 124.88 (2C, d); 122.56 (2C, d); 
117.74 (2C, d); 77.28 (1C, s); 64.37 (1C, t); 64.15 (1C, t); 59.30 (1C, d); 49.79 (1C, d); 
48.22 (1C, d); 45.06 (1C, t); 44.72 (1C, d); 39.56 (1C, t); 38.10 (1C, t); 29.24 (1C, t); 26.71 
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(1C, t); 26.10 (3C, q); 25.49 (1C, t); 22.89 (1C, t); 22.31 (1C, d); 20.98 (1C, q); 19.51 (1C, 
t); 19.47 (1C, q). 
Boc-Tyr(OBzl)-Leu-D-Pro-Lys(Z)-OFm [1c(III)]  
The reaction was performed according to the methodology C reported in the section 6.6.2 
Purification of the crude by silica gel chromatography (cyclohexane/Acetone= 7/3) gave 
the product as a white foam (1.1 g, 85%). Purity > 98%. Rf  = 0.2 (cyclohexane/Acetone, 
7:3). [α]D
20
 (c 0.25, CHCl3) = + 3.28° 
1
H NMR (CDCl3, 300 MHz): δ 7.76 (d, 2H, J=7.3 Hz, Har-Fm); 7.56 (m, 2H, Har-Fm); 
7.38-7.25 (m, 14H, 4Har-Fm, 5Har-Cbz, 5Har-OBzl); 7.05 (bd, 2H, J=8.5 Hz, Har-Tyr); 
6.84 (d, 2H, J=8.5 Hz, Har-Tyr); 5.14 (s, 2H, CH2-OBzl); 5.00 (s, 2H, CH2-Cbz); 4.80 (m, 
1H, H
α
-Leu); 4.51 (m, 5H, CH2-Fm, 1H
α
-Lys, 1H
α
-Pro, 1H
α
-Tyr); 4.17 (t, 1H, J=6.1 Hz, 
CH-Fm); 3.79 (m, 1H, 1H

-Pro); 3.55 (m, 1H, 1H

-Pro); 3.13 (bm, 3H, 2H

-Lys, 1H

-Tyr); 
2.89 (bm, 1H, 1H

-Tyr); 2.15 (m, 2H, H-Pro); 1.97 (m, 2H, H-Pro); 1.44-1.58 (m, 3H, 1H

-
Leu, 2H

-Leu); 1.38-1.21 (m, 15H, 3CH2-Lys, 3CH3-tBu); 0.96 (d, 3H, J=6.1 Hz, 1CH3-
Leu); 0.88 (d, 3H, J=6.4 Hz; 1CH3-Leu). 
13
C NMR (CDCl3, 75 MHz): δ 169.69 (2C, s); 168.85 (1C, s); 155.49 (1C, s); 153.02 (1C, 
s); 141.63 (1C, s); 141.36 (1C, s); 141.17 (1C, s); 140.55 (1C, s);139.20 (1C, s); 139.11 
(1C, s); 135.00 (1C, s); 134.62 (1C, s); 128.53 (2C, d); 126.23 (4C, d); 125.50 (2C, d); 
125.61 (4C, d); 125.07 (2C, d); 124.90 (2C, d); 122.60 (2C, d); 117.77 (2C, d); 112.84 (2C, 
d); 77.28 (1C, s); 67.90 (2C, t); 64.37 (2C, t); 60.01 (1C, t); 59.80 (1C, t); 58.73 (1C, d); 
58.50 (1C, t); 58.10 (1C, d); 49.85 (1C, d); 46.89 (1C, d); 45.23 (1C, t); 44.73 (1C, d); 
39.31 (1C, t); 36.06 (1C, t); 29.23 (1C, t); 26.09 (3C, q); 22.94 (1C, t); 22.27 (1C, d); 21.06 
(1C, q); 19.61 (1C, q). 
Fmoc-Val-Tyr(OBzl)-Leu-D-Pro-Lys(Z)-OFm (1c) 
The reaction was performed according to the methodology C reported in the section 6.6.2. 
Purification of the crude by silica gel chromatography (cyclohexane/Acetone= 7/3) gave 
the product as a white foam. (1.2 g, 98%). Purity > 98%. Rf = 0.12 (cyclohexane/Acetone, 
7:3). [α]D
20
 (c 0.5, CHCl3) = + 18.14° 
1
H NMR (CDCl3, 300 MHz): δ 7.89 (m, 4H, 2Har-Fm, 2Har-Fmoc); 7.75 (m, 4H, 2Har-
Fm, 2Har-Fmoc); 7.31 (m, 18H, 4Har-Fm, 4Har-Fmoc, 5Har-Cbz, 5Har-OBzl); 7.10 (d, 
2H, J=8.5 Hz, Har-Tyr); 6.84 (d, 2H, J=8.5 Hz, Har-Tyr); 6.60 (bd, 1H, J= 4.8 Hz, NH); 
6.49 (bs, 1H, NH); 5.31 (bs, 1H, NH); 5.09 (s, 2H, CH2-Cbz); 4.91 (s, 2H, CH2-OBzl); 4.58 
(m, 2H, 1H

-Tyr, 1H

-Pro); 4.45 (m, 5H, 1H

-Lys, 1H

-Leu, CH2-Fmoc, CH-Fmoc); 4.30 
(m, 1H, CH-Fm); 4.17 (m, 2H, CH2-Fm); 3.94 (bm, 1H, H
α
-Val); 3.79 (bm, 1H, 1H

-Pro); 
3.34 (bm, 1H, 1H

-Pro); 3.14 (m, 2H, 2H

-Lys); 2.99 (d, 2H, J=6.4 Hz, 2H

-Tyr); 2.30 (bm, 
1H, 1H-Pro), 1.95 (m, 4H, 3H-Pro, 1H
β
-Val); 1.73 (m, 1H, H-Lys); 1.48 (m, 5H, 2H-Lys, 
2H

-Leu, 1H

-Leu); 1.27 (m, 2H, 2H-Lys); 0.88 (d, 6H, J=6.1 Hz, 2CH3). 0.80 (d, 6H, 
J=6.7 Hz, 2CH3). 
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13
C NMR (CDCl3, 75 MHz): δ 172.57 (1C, s); 171.50 (1C, s); 170.13 (1C, s); 157.97 (1C, 
s); 156.72 (1C, s); 156.50 (1C, s); 157.81 (1C, s); 156.35 (1C, s); 143.92 (1C, s); 143.83 
(1C, s); 143.73 (1C, s); 143.47 (1C, s); 143.20 (1C, s); 141.46 (2C, s); 141.38 (3C, s); 
136.99 (1C, s); 136.89 (1C, s); 130.48 (1C, d); 128.68 (2C, s); 128.60 (4C, d); 128.55 (2C, 
d); 128.11 (2C, d); 128.03 (1C, d); 127.91 (4C, d); 127.82 (4C, d); 127.53 (2C, d); 127.24 
(1C, d); 127.17 (1C, d); 125.15 (2C, d); 125.00 (1C, d); 120.09 (2C, d); 115.05 (1C, d); 
69.94 (1C, t); 67.08 (1C, t); 66.89 (1C, t); 66.60 (1C, t); 60.67 (1C, d); 60.56 (1C, d); 54.30 
(1C, d), 52.14 (1C, d); 50.66 (1C, d); 47.51 (1C, t); 47.26 (1C, d); 46.86 (1C, d); 40.73 (1C, 
t); 40.04 (1C, t); 36.85 (1C, t); 31.01 (1C, t); 30.95 (1C, d); 29.33 (1C, t); 28.96 (1C, t); 
24.70 (1C, d); 24.46 (1C, t); 23.36 (1C, q); 22.30 (1C, t); 21.85 (1C, q); 19.27 (1C, q); 
17.71 (1C, q). 
Fmoc-Ser-D-Pro-Val-Tyr(OBzl)-Leu-OFm (2)   
Fmoc-Ser-D-Pro-Val-Tyr(OBzl)-Leu-OFm
2
Boc-Leu-OH Boc-Tyr(OBzl)-Leu-OFm Boc-Val-Tyr(OBzl)-Leu-OFm
Boc-D-Pro-Val-Tyr(OBzl)-Leu-OFm
a (III)
Boc-Leu-OFm
Fm-OH
i) TFA 
ii) Boc-Tyr(OBzl)-OH
i) TFA 
ii) Boc-Val-OH
i) TFA 
ii) Boc-D-Pro-OH
i) TFA 
ii) Fmoc-Ser-OH
2(I) 2 (II)
2 (IV)  
Boc-Leu-OFm [2 (I)] 
The reaction was performed according to the methodology reported in the section 6.6.1.1. 
Reaction time 3 h. Purification by silica gel chromatography (cyclohexane/AcOEt= 9/1) 
gave the product as a colorless syrup. (1.5 g, 85%). Purity > 98%. Rf  = 0.45 
(cyclohexane/AcOEt, 8:2). [α]D
20
 (c 0.5, CHCl3) = - 24.27° 
1
H NMR (CDCl3, 300 MHz): δ 7.77 (d, 2H, J=7.6 Hz, 2H, Har-Fm); 7.62 (m, 2H, Har-Fm); 
7.41 (m, 4H, Har-Fm); 4.91 (bd, 1H, J= 8.2 Hz, NH); 4.50 (d, 2H, J= 6.1 Hz, CH2-Fm); 
4.35 (m, 1H, H
α
-Leu); 4.42 (t, 1H, J=6.1 Hz, CH-Fm); 1.57 (m, 12H, 2H

-Leu, 1H

-Leu, 
3CH3-tBu); 0.89 (m, 6H, 2CH3-Leu). 
13
C NMR (CDCl3, 75 MHz): δ 171.28 (1C, s); 156.08 (1C, s); 145.55 (2C, s); 141.65 (2C, 
s); 128.15 (2C, d); 127.45 (2C, d); 125.32 (2C, d); 120.32 (2C, d), 80.17 (1C, s); 67.01 (1C, 
t); 52.63 (1C, d); 47.18 (1C, d); 42.08 (1C, t); 28.64 (3C, q); 25.04 (1C, d); 23.09 (1C, q); 
22.23 (1C, q). 
Boc-Tyr(OBzl)-Leu-OFm [2 (II)]  
The product was synthesized according to the protocol A reported in the section 6.6.2. 
Reaction time 4 h. Purification by silica gel flash chromatography (EtOAc/cyclohexane, 
2:8) yielded the final product (1.5 g, 92%). Purity > 98%. Rf = 0.3 (EtOAc/cyclohexane, 
2:8). [α]D
20
 (c 0.5, CHCl3) = -9.54° 
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1
H NMR (CDCl3, 300 MHz): δ 7.75 (d, 2H, J=7.6 Hz, Har-Fm); 7.62 (m, 2H, Har-Fm); 
7.42 (m, 9H, 4Har-Fm, 5Har-OBzl); 7.13 (d, 2H, J=8.5 Hz, Har-Tyr); 6.87 (d, 2H, J= 8.5 
Hz, Har-Tyr); 5.15 (bd, 1H, J= 9.0 Hz, NH); 4.95 (s, 2H, CH2-OBzl); 4.51 (m, 1H, H
α
-Tyr); 
4.49 (m, 2H, CH2-Fm); 4.33 (m, 1H, H
α
-Leu); 4.20 (t, 1H, J= 6.1 Hz, CH-Fm); 3.01 (d, 2H, 
J=8.2 Hz, CH

-Tyr); 1.43 (bm, 12H, 2H

-Leu, CH

-Leu, 9H-tBu); 0.87 (m, 6H, 2CH3-Leu). 
13
C NMR (CDCl3, 75 MHz): δ 172.72 (1C, s); 171.44 (1C, s); 158.14 (1C, s); 155.76 (1C, 
s); 145.95 (1C, s); 143.68 (1C, s); 141.73 (1C, s); 141.66 (1C, s); 137. 32 (1C, s); 130.74 
(2C, d); 129.50 (1C, s); 128.50 (3C, d); 128.10 (2C, d); 128.0 (3C, d); 127.80 (2C, d); 125. 
27 (1C, d), 120.36 (2C, d), 115.27 (2C, d); 80.46 (1C, s); 70.27 (1C, t); 67.06 (1C, t); 56.07 
(1C, d); 52.63 (1C, d); 47.13 (1C, d); 42.88 (1C, t); 37.62 (1C, t); 28.60 (3C, q); 24.96 (1C, 
d); 23.03 (1C, q), 22.31 (1C, q). 
Boc-Val-Tyr(OBzl)-Leu-OFm [2 (III)] 
The product was synthesized according to the protocol A reported in the section 6.6.2. 
Reaction time 4 h. Purification by silica gel flash chromatography (EtOAc/cyclohexane, 
25:75) gave the final product as a white solid (1.60 g, 97%). Purity >98%. Rf = 0.33 
(EtOAc/cyclohexane, 3:7). [α]D
20
 (c 0.5, CHCl3) = - 23.84° 
1
H NMR (CDCl3, 300 MHz): δ 7.76 (d, 2H, J=7.6 Hz, Har-Fm); 7.60 (m, 2H, Har-Fm); 
7.36 (m, 9H, 4Har-Fm, 5Har-OBzl); 7.10 (d, 2H, J=8.5 Hz, Har-Tyr); 6.85 (d, 2H, J=8.5 
Hz, Har-Tyr); 6.52 (bd, 1H, J= 5.8 Hz, NH); 6.29 (bs, 1H, NH); 5.03 (bd, 1H, NH); 4.97 (s, 
2H, CH2-OBzl); 4.51 (m, 4H, 1H
α
-Tyr, 1H
α
-Leu, CH2-Fm); 4.20 (t, 1H, J=6.1 Hz, CH-Fm); 
3.92 (m, 1H, H
α
-Val); 3.04 (m, 2H, 2H

-Tyr); 1.15 (m, 1H, H
β
-Val); 1.42 (bm, 12H, 2H

-
Leu, 1H

-Leu, 9H-tBu); 0.91 (d, 6H, J=6.7 Hz, 2CH3-Leu); 0.85 (d, 6H, J=6.4 Hz, 2CH3-
Val). 
13
C NMR (CDCl3, 75 MHz): δ 172.27 (1C, s) 171.51 (1C, s); 170.59 (1C, s); 157.37 (1C, 
s); 156.03 (1C, s); 143.74 (1C, s); 143.55 (1C, s); 141.48 (1C, s); 141.41 (1C, s); 136.90 
(1C, s); 130.47 (2C, d); 128.65 (2C, d); 128.61 (1C, s); 128.03 (2C, d); 127.95 (2C, d); 
127.53 (2C, d); 127.26 (2C, d); 125.16 (1C, d); 120.11 (2C, d); 115.06 (2C, d); 80.46 (1C, 
s); 69.97 (1C, t); 66.85 (1C, t); 60.21 (1C, d); 54.26 (1C, d); 51.07 (1C, d); 46.86 (1C, d); 
41.38 (1C, t); 37.24 (1C, t); 30.65 (1C, d); 28.39 (3C, q); 24.70 (1C, d); 22.77 (1C, q); 
20.05 (1C, q); 19.36 (1C, q); 17.53 (1C, q). 
Boc-D-Pro-Val-Tyr(OBzl)-Leu-OFm [2 (IV)] 
The product was synthesized according to the protocol A reported in the section 6.6.2. 
Reaction time 2 h. Purification by silica gel flash chromatography (EtOAc/cyclohexane, 
4:6) gave the final product as a white solid (1.2 g, 97%). Purity > 98%. Rf = 0.3 
(EtOAc/cyclohexane, 1:1). [α]D
20
 (c 0.5, CHCl3) = + 0.59° 
1
H NMR (CDCl3, 300 MHz): δ 7.71 (d, 2H, J=7.6 Hz, Har-Fm); 7.60 (d, 2H, J=7.3 Hz, Har-
Fm); 7.30 (m, 9H, 4Har-Fm, 5Har-OBzl); 7.09 (bd, 2H, J= 7.3 Hz, Har-Tyr); 6.79 (d, 2H, 
J=7.3 Hz, Har-Tyr); 4.95 (bs, 2H, CH2-OBzl); 4.61 (bs, 1H, H
α
); 4.41 (m, 3H, 1H
α
, CH2-
Fm); 4.17 (m, 3H, 2H
α
, CH-Fm); 3.42 (bm, 2H, H

-Tyr), 3.15 (bm, 1H, 1H

-Pro); 2.86 (m, 
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1H, 1H

-Pro); 2.20-1.68 (m, 5H, 1H
β
-Val, 4H-Pro); 1.42 (bm, 12H, 2H

-Leu, 1H

-Leu, 9H-
tBu); 0.87 (m, 12H, 2CH3-Leu, 2CH3-Val). 
13
C NMR (CDCl3, 75 MHz): δ 172.61 (2C, s); 171.33 (2C, s), 157.91 (1C, s); 156.03 (1C, 
s); 144.00 (1C, s); 141.64 (2C, s); 141.58 (1C, s); 137.27 (1C, s); 132.74 (2C, d); 130.74 
(1C, s); 129.10 (2C, d); 128.80 (2C, d); 128.60 (2C, d), 127.50 (2C, d), 127.0 (2C, d);125.0 
(1C, d); 120.23 (2C, d); 115.06 (2C, d); 80.98 (1C, s); 70.23 (1C, t); 67.04 (1C, t); 61.94 
(1C, d); 60.17 (1C, d); 54.74 (1C, d); 52.40 (1C, d); 47.59 (1C, t); 47.07 (1C, d); 41.06 (1C, 
t); 37.24 (1C, t); 31.15 (1C, t); 31.25 (1C, t); 28.69 (3C, q); 24.87 (1C, d), 22.94 (2C, q); 
22.36 (1C, d); 19.44 (1C, q); 17.53 (1C, d). 
Fmoc-Ser-D-Pro-Val-Tyr(OBzl)-Leu-OFm (2) 
The product was synthesized according to the protocol B reported in the section 6.6.2. The 
purification was done in two steps: after the first silica gel flash chromatography 
(EtOAc/PE, 9:1) the product was triturated with diethyl ether to remove the residues of 
tetramethyl urea (TMU). The final product was recovered as a white solid (350 mg, 64%). 
Purity > 98%. Rf = 0.28 (EtOAc/PE, 9:1). [α]D
20
 (c 0.25, CHCl3) = -26.80° 
1
H NMR (CDCl3, 300 MHz): δ 7.75 (d, 4H, J=7.3 Hz, Har); 7.56 (m, 4H, Har); 7.30 (m, 
13H, 4Har-Fm, 5Har-OBzl); 7.09 (d, 2H, J=8.5 Hz, Har-Tyr); 6.81 (d, 2H, J=8.5 Hz, Har-
Tyr); 5.82 (d, 1H, J=8.2 Hz, NH); 4.89 (s, 2H, CH2-OBzl); 4.76 (m, 1H, H
α
); 4.62 (m, 2H); 
4.54 (m, 1H); 4.42 (m, 5H); 4.19 (m, 2H); 3.93 (m, 2H); 3.71 (m, 2H, ); 3.03 (m, 2H); 2.19 
(m, 1H, H
β
-Val); 2.98 (m, 4H, H-Pro); 1.44 (m, 3H, 2H
β
-Leu, 1H

-Leu); 0.84 (m, 12H, 
2CH3-Leu, 2CH3-Val). 
13
C NMR (CDCl3, 75 MHz): δ 172.42 (1C, s); 172.29 (1C, s); 172.17 (1C, s); 171.55 (1C, 
s); 170.71 (1C, s); 157.96 (1C, s); 156.75 (1C, s); 144.03 (1C, s); 143.92 (1C, s); 143.73 
(1C, s); 143.48 (1C, s); 141.45 (2C, s); 141.33 (2C, s); 137.20 (1C, s); 130.45 (1C, d); 
129.38 (1C, s); 128.82 (1C, d); 128.57 (2C, d); 127.86 (1C, d); 127.87 (2C, d); 127.77 (2C, 
d); 127.44 (2C, d); 127.23 (2C, d); 127.14 (2C, d); 126.74 (2C, d); 125.46 (1C, d); 125.29 
(1C, d); 125.02 (1C, d); 119.97 (2C, d); 119.82 (1C, d); 115.05 (1C, d); 70.06 (1C, t); 67.55 
(1C, t); 66.57 (1C, t); 62.71 (1C, t); 60.98 (1C, d); 59.37 (1C, d); 54.48 (1C, d); 54.25 (1C, 
d); 51.18 (1C, d); 47.72 (1C, t); 47.20 (1C, d); 46.89 (1C, d); 41.08 (1C, t); 36.28 (1C, t); 
29.42 (1C, d); 28.65 (1C, t); 25.26 (1C, t); 24.47 (1C, d); 22.74 (1C, q); 21.96 (1C, q); 
19.42 (1C, q); 17.15 (1C, q). 
Fmoc-Val-Tyr(OBzl)-Leu-Pro-Lys(z)-SFm (1a’) 
Fmoc-Val-Tyr(OBzl)-Leu-Pro-Lys(Z)-SFm
1a' (I)
1a'
Boc-Lys(Z)-OH Boc-Pro-Lys(Z)-SFm Boc-Leu-Pro-Lys(Z)-SFm
Boc-Tyr(OBzl)-Leu-Pro-Lys(Z)-SFm
1a' (III)
1a' (IV)
Boc-Lys(Z)-SFm
Fm-SH
i) TFA 
ii) Boc-Pro-OH
1a' (II)
i) TFA 
ii) Boc-Leu-OH
i) TFA 
ii) Boc-D-Pro-OH
i) TFA 
ii) Fmoc-Val-OH
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Boc-Lys(Z)-OFm [1a’(I)]  
The product was synthesized according to the procedure described in the section 6.6.1.2. 
Purification of the residue by silica gel chromatography (cyclohexane/EtOAc= 8/2 to 4/6) 
gave the product as a yellow foam (990 mg, 93%). Purity > 95%. Rf = 0.16 
(cyclohexane/AcOEt= 8/2). [α]D
20
 (c 0.5, CHCl3) = − 29.0° 
1
H NMR (CDCl3, 300 MHz): δ 7.73 (d, J=7.3 Hz, 2H); 7.62 (d, J=7.3 Hz, 2H); 7.37 (m, 
9H); 5.09 (s, 2H, CH2-Cbz); 5.01 (bs, 1H, NH); 4.76 (bm, 1H, HN); 4.19 (m, 2H, CH-SFm, 
1H

-Lys); 3.56 (m, 2H, CH2-SFm); 3.14 (bm, 2H, 2H

-Lys); 1.68 (m, 2H, H-Lys); 1.41 
(bm, 12H, 9H-tBu, 2H-Lys), 1.24 (m, 2H, H-Lys). 
Boc-Pro-Lys(Z)-OFm [1a’(II)] 
The product was synthesized according to the protocol A reported in the section 6.6.2. 
Reaction time 2 h. The purification by silica gel flash chromatography (Toluene/Acetone, 
9:1) gave the product as a white foam (572 mg, 92%). Purity >95%. Rf = 0.46 
(Toluene/Acetone= 8/2. [α]D
20
 (c 0.5, CHCl3) = − 61.5° 
1
H NMR (CDCl3, 300 MHz): δ 7.73 (d, J=7.3 Hz, 2H); 7.57 (d, J=7.3 Hz, 2H); 7.31 (m, 
9H); 5.07 (s, 2H, CH2-Cbz); 4.94 (bs, 1H, NH); 4.50 (bm, 1H, 1H

-Pro); 4.26 (bs, 1H, H

-
Lys); 4.16 (t, 1H, J= 6.1 Hz, CH-SFm); 3.53 (m, 2H, CH2-SFm); 3.40 (bm, 2H, H

-Pro); 
3.09 (bd, 2H, J= 6.1 Hz, 2H

-Lys); 2.32 (bm, 1H, H-Pro); 1.83 (bm, 3H, H-Pro); 1.63 (bm, 
1H, H-Lys); 1.42 (bm, 12H, 9H-tBu, 3H-Lys), 1.24 (m, 2H, H-Lys). 
13
C NMR (CDCl3, 75 MHz): δ 200.10 (1C, s); 173.20 (1C, s); 171.50 (1C, s); 156.35 (1C, 
s); 156.47 (1C, s), 145.13 (1C, s); 141.15 (1C, s); 141.12 (1C, s); 137.71 (1C, s); 136.82 
(1C, s); 129.01 (1C, d); 128.42 (2C, d); 128.21 (1C, d); 128.00 (1C, d); 127.94 (1C, d); 
127.70 (2C, d); 127.02 (2C, d); 125.30 (1C, d); 124.62 (1C, d); 124.57 (1C, d); 119.82 (1C, 
d); 79.80 (1C, s); 80.48 (1C, t); 66.37 (1C, t); 58.92 (1C, d); 47.06 (1C, t); 46.41 (1C, d); 
40.53 (1C, t); 32.83 (1C, t); 21.66 (1C, t); 29.20 (1C, t); 28.32 (3C, q); 24.33 (1C, t); 22.17 
(1C, t); 21.43 (1C, d). 
Boc-Leu-Pro-Lys(Z)-SFm [1a’(III)]   
The product was synthesized according to the protocol A reported in the section 6.6.2. 
Reaction time 12 h. The purification by silica gel flash chromatography 
(cyclohexane/AcOEt, 1:1) gave the product as a white foam (530 mg, 80%). Purity >98 %. 
Rf  = 0.36 (cyclohexane/AcOEt = 1/1). [α]D
20
 (c 0.5, CHCl3) = − 68.33° 
1
H NMR (CDCl3, 300 MHz): δ 7.73 (d, J=7.3 Hz, 2H); 7.57 (d, J=7.3 Hz, 2H); 7.31 (m, 
9H); 6.95 (bd, 2H, J= 7.6 Hz, NH); 5.05 and 4.94 (2d, 2H, J=12.2 Hz, CH2-Cbz); 4.45 (bm, 
3H, 1H

-Pro, 1H

-Lys, 1H

-Leu); 4.15 (t, 1H, J=6.1 Hz, CH-SFm); 3.76 (m, 1H, 1H

-Pro); 
3.55 (m, 3H, CH2-SFm, 1H

-Pro); 3.13 (m, 2H, 2H

-Lys); 2.18 (bm, 2H, H-Pro); 1.94 (m, 
2H, H-Pro); 1.64 (m, 2H, H-Lys); 1.43 (m, 16H, 4H-Lys, 2H

-Leu, 1H

-Leu, 9H-tBu); 0.94 
(d, 3H, J=6.4 Hz, 1CH3-Leu); 0.88 (d, 3H, J=6.4 Hz, 1CH3-Leu). 
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13
C NMR (CDCl3, 75 MHz): δ 200.27 (1C, s); 173.08 (1C, s); 171.30 (1C, s); 156.43 (1C, 
s); 156.14 (1C, s); 145.33 (1C, s), 145.29 (1C, s); 141.09 (1C, s); 141.01 (1C, s); 136.64 
(1C, s); 128.43 (2C, d); 128.23 (2C, d); 127.99 (1C, d); 127.64 (2C, d); 127.03 (1C, d); 
124.78 (2C, d); 124.71 (2C, d); 119.79 (1C, d); 79.86 (1C, s); 66.49 (1C, t); 61.05 (1C, d); 
60.31 (1C, t); 58.34 (1C, d); 50.75 (1C, d); 47.27 (1C, t); 46.51 (1C, d); 40.68 (1C, t); 31.88 
(1C, t); 30.63 (1C, t); 28.88 (1C, t); 28.43 (3C, q); 27.95 (1C, t); 25.50 (1C, t); 23.30 (1C, 
q); 21.97 (1C, t); 21.59 (1C, d). 
Boc-Tyr(OBzl)-Leu-Pro-Lys(Z)-SFm [1a’(IV)] 
The product was synthesized according to the protocol A reported in the section 6.6.2. 
Reaction time 2 h. The purification by silica gel flash chromatography 
(cyclohexane/AcOEt, 1:1 to 3:7) gave the product as a white foam (600 mg, 88%). Purity 
>98%. Rf = 0.45 (cyclohexane/AcOEt = 4/6). [α]D
20
 (c 0.25, CHCl3) = − 64.87° 
1
H NMR (CDCl3, 300 MHz): δ 7.72 (d, 2H, J=7.3 Hz); 7.57 (m, 2H); 7.31 (m, 14H); 7.04 
(d, 2H, J=8.5 Hz, Har-Tyr); 6.76 (d, 2H, J=8.5 Hz, Har-Tyr); 4.99 (bs, 2H, CH2-OBzl); 4.91 
(s, 2H, CH2-CBz); 4.63 (bm, 1H, H
α
-Leu); 4.25 (bm, 3H, 1H
α
-Pro, 1H
α
-Lys, 1H
α
-Tyr); 4.06 
(t, J=6.1 Hz, 1H, CH-SFm); 3.65 (bm, 1H, 1H

-Pro); 3.47 (bm, 1H, 1H

-Pro); 3.44 (d, 2H, 
J=6.1 Hz, CH2-SFm); 3.01 (m, 3H, 2H

-Lys, 1H

-Tyr); 2.72 (bm, 1H 1H

-Tyr); 2.25-1.93 
(bm, 4H, H-Pro); 1.69 (m, 1H, 1H

-Leu); 1.25 (m, 17H, 6H-Lys, 2H

-Leu, 9H-tBu); 0.91 
(d, 3H, J=6.4 Hz, 1CH3-Leu); 0.85 (d, 3H, J=6.4 Hz, 1CH3-Leu). 
13
C NMR (CDCl3, 75 MHz): δ 199.95 (1C, s); 172.10 (1C, s); 171.30 (1C, s); 171 (1C, s); 
158.12 (1C, s); 157.98 (1C, s); 156.88 (1C, s); 145.61 (1C, s), 145.40 (1C, s); 141.29 (2C, 
s); 137.08 (2C, s); 130.59 (1C, d); 128.80 (1C, s); 128.71(2C, d); 128.58 (2C, d); 128.30 
(1C, d); 128.20 (2C, d); 128.10 (2C, d); 127.77 (2C, d); 127.50 (2C, d); 127.21 (2C, d); 
124.90 (2C, d); 119.92 (2C, d); 115.11 (2C, d); 82.00 (1C, s); 70.11 (1C, t); 66.58 (1C, t); 
60.83 (1C, d); 50.58 (1C, d); 55.0 (1C, d); 50.58 (1C, d); 47.30 (1C, t); 46.69 (1C, d); 40.80 
(1C, t); 40.66 (1C, t); 37.40 (1C, t); 32.10 1C, t); 31.10 (1C, t); 29.08 (2C, t); 28.96 (3C, q); 
24.76 (1C, d); 24.50 (1C, t); 24.45 (1C, q); 23.43 (1C, t); 21.84 (1C, q). 
Fmoc-Val-Tyr(OBzl)-Leu-Pro-Lys(Z)-SFm [1a’]  
The product was synthesized according to the protocol A reported in the section 6.6.2. 
Reaction time 16 h. The purification by silica gel flash chromatography 
(cyclohexane/AcOEt, 6:4 to 3:7) gave the product as a white foam (564 mg, 80%). Purity 
>98%. Rf = 0.33 (cyclohexane/AcOEt = 4/6). [α]D
20
 (c 0.25, CHCl3) = − 43.74° 
1
H NMR (CDCl3, 300 MHz): δ 7.65 (m, 4H, 2Har-SFm, 2Har-Fmoc); 7.57 (m, 4H, 2Har-
SFm, 2Har-Fmoc); 7.24 (m, 18H, 4Har-SFm, 4Har-Fmoc, 5Har-Cbz, 5Har-OBzl); 6.98 (d, 
2H, J=8.5 Hz, Har-Tyr); 6.71 (d, 2H, J=8.5 Hz, Har-Tyr); 5.06 (bs, 2H, CH2-Cbz); 4.2 (s, 
2H, CH2-OBzl); 4.58 (bm, 2H); 4.35 (m, 3H); 4.25 (m, 1H); 4.12 (m, 3H); 3.80 (bm, 1H, 
1H

-Pro); 3.59 (bm, 1H, 1H

-Pro); 3.46 (d, 2H, J=6.1 Hz, CH2-SFm); 3.03 (bm, 3H, 2H

-
Lys, 1H

-Tyr); 2.81 (bm, 1H, 1H

-Tyr); 1.97 (m, 5H, 4H-Pro, 1H
β
-Val); 1.33 (m, 9H, 6H-
Lys, 2H

-Leu, 1H

-Leu); 0.79 (bm, 12H, 2CH3-Leu, 2CH3-Val). 
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13
C NMR (CDCl3, 75 MHz): δ 200.31 (1C, s); 171.76 (2C, s); 171.63 (2C, s); 171.42 (1C, 
s); 157.88 (1C, s); 156.55 (1C, s); 145.46 (1C, s); 145.26 (1C, s); 143.89 (1C, s); 143.75 
(1C, s); 141.30 (2C, s); 141.17 (1C, s); 141.13 (1C, s); 136.91 (1C, s); 136.81 (1C, s); 
130.39 (1C, d); 128.51 (1C, s); 128.47 (4C, d); 127.96 (4C, d); 127.75 (4C, d); 127.46 (4C, 
d); 127.12 (2C, d); 125.11 (2C, d); 124.82 (2C, d); 124.76 (2C, d); 120.02 (2C, d); 119.85 
(2C; d); 114.97 (1C, d); 69.84 (1C, t); 67.06 (1C, t); 66.60 (1C, t); 60.80 (2C, d); 59.22 (1C, 
d); 54.31 (1C, d), 50.66 (1C, d); 47.18 (1C, d); 46.52 (1C, d); 40.85 (2C, t); 39.88 (1C, t); 
36.72 (1C, t); 31.95 (2C, t); 31.14 (1C, t); 30.91 (1C, d); 29.17 (1C, t); 24.66 (1C, d); 24.40 
(1C, t); 23.38 (1C, q); 22.26 (1C, t); 21.72 (1C, q); 19.23 (1C, q); 17.84 (1C, q). 
Fmoc-Val-Tyr(OBzl)-Leu-Pro-Lys(z)-SFm (1c’) 
Fmoc-Val-Tyr(OBzl)-Leu-D-Pro-Lys(Z)-SFm
1a' (I)
1c'
Boc-Lys(Z)-OH Boc-D-Pro-Lys(Z)-SFm Boc-Leu-D-ProLys(Z)-SFm
Boc-Tyr(OBzl)-Leu-D-Pro-Lys(Z)-SFm
1c' (II)
1c' (III)
Boc-Lys(Z)-SFm
Fm-SH
i) TFA 
ii) Boc-D-Pro-OH
1c' (I)
i) TFA 
ii) Boc-Leu-OH
i) TFA 
ii) Boc-D-Pro-OH
i) TFA 
ii) Fmoc-Val-OH
 
Boc-D-Pro-Lys(Z)-SFm [1c’(I)]  
The reaction was performed according to the methodology A reported in the section 6.6.1.2. 
Purification of the crude by silica gel chromatography (Toluene/Acetone= 9/1) gave the 
product as a white foam. (555 mg, 89%). Purity > 98%. Rf = 0.20 (Toluene/Acetone, 9:1). 
[α]D
20
 (c 0.5, CHCl3) = + 58.29° 
1
H NMR (CDCl3, 300 MHz): δ 7.75 (d, 2H, J=7.3 Hz, 2Har); 7.56 (m, 2H, 2Har); 7.29 (m, 
9Har); 5.08 (s, 2H, CH2-Cbz); 4.50 (bm, 1H, H
α
-Lys); 4,26 (bm, 1H, H
α
-Pro); 4.16 (t, 1H, 
J=6.1 Hz, CH-SFm); 3.53 (bm, 3H, CH2-SFm, 1 H

-Pro); 3.20 (bm, 1H, 1H

-Pro); 3.10 (m, 
2H, H

-Lys), 2.01 (m, 2H, H-Pro), 1.81 (m, 2H, H-Pro), 1.60 (m, 1H, 1H-Lys); 1.42 (m, 
14H, 9H-tBu, 5H-Lys).  
13
C NMR CDCl3, 75 MHz): δ 200.31 (1C, s); 171.70 (1C, s); 171.63 (1C, s); 171.42 (1C, s); 
156.47 (1C, s); 145.13 (1C, s); 141.15 (1C, s); 137.71 (1C, s); 136.82 (1C, s); 129.01 (1C, 
d); 128.42 (2C, d); 128.21 (1C, d); 128.00 (1C, d); 127.94 (1C, d); 127.70 (1C, d); 127.06 
(2C, d); 125.30 (1C, d); 124.62 (1C, d); 124.47 (1C; d); 119.82 (1C, d); 80.48 (1C, s); 66.37 
(1C, t); 58.92 (1C, t); 47.06 (1C, t); 46.41 (1C, d); 40.57 (1C, t); 31.83 (1C, t); 31.66 (1C, 
t); 29.20 (1C, t); 28.32 (3C, q); 24,33 (1C, t); 22.17 (1C, t); 21.44 (1C, d). 
Boc-Leu-D-Pro-Lys(Z)-SFm [1c’(II)] 
The reaction was performed according to the methodology A reported in the section 6.6.2. 
Reaction time 12 h. Purification of the crude by silica gel chromatography 
(cyclohexane/AcOEt= 1/1) gave the product as a white foam. (550 mg, 97%). Purity > 
98%. Rf = 0.35 (AcOEt/petroleum ether, 7:3). [α]D
20
 (c 0.5, CHCl3) = + 38.15° 
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1
H NMR (CDCl3, 300 MHz): δ 7.73 (d, 2H, J= 7.3 Hz); 7.57 (m, 2H); 7.34 (m, 9H); 7.05 
(bd, 1H, J=8.2 Hz, NH); 6.04 (bs, 1H, NH); 5.08 (s, 2H, CH2-Cbz); 4.59 (bm, 1H, 1H

-
Leu); 4.46 (m, 1H, 1H

-Pro); 4.31 (bm, 1H, H

-Lys); 4.14 (t, 1H, J=6.1 Hz, CH-SFm); 3.84 
(bm, 1H, 1H

-Pro); 3.41 (m, 3H, CH2-SFm, 1H

-Pro); 3.19 (m, 2H, 2H

-Lys); 2.22 (bm, 
1H, H-Pro); 1.94 (m, 3H, H-Pro); 1.80 (m, 1H, 1H

-Leu); 1.43 (m, 17H, 6H-Lys, 2H

-Leu, 
9H-tBu); 0.86 (m, 6H, 2CH3-Leu). 
13
C NMR (CDCl3, 75 MHz): δ 200.27 (1C, s); 173.08 (1C, s); 171.30 (1C, s); 156.43 (1C, 
s); 156.14 (1C, s); 145.33 (2C, s), 141.07 (2C, s); 136.64 (1C, s); 128.43 (2C, d); 128.23 
(2C, d); 127.99 (1C, d); 127.64 (2C, d); 127.03 (1C, d); 124.78 (2C, d); 124.71 (2C, d); 
119.79 (1C, d); 79.86 (1C, s); 66.49 (1C, t); 61.05 (1C, d); 60.31 (1C, t); 58.34 (1C, d); 
50.75 (1C, d); 47.27 (1C, t); 46.51 (1C, d); 40.68 (1C, t); 31.88 (1C, t); 30.63 (1C, t); 28.88 
(1C, t); 28.43 (3C, q); 27.95 (1C, t); 25.50 (1C, t); 23.30 (1C, q); 21.97 (1C, t); 21.59 (1C, 
d). 
Boc-Tyr(OBzl)-Leu-Pro-Lys(Z)-SFm [1c’(III)]   
The product was synthesized according to the protocol A reported in the section 6.6.2. 
Reaction time 12 h. The purification by silica gel flash chromatography 
(cyclohexane/AcOEt, 4:6) gave the product as a white foam (460 mg, 75%). Purity > 98%. 
Rf  = 0.35 (cyclohexane/AcOEt, 4:6). [α]D
20
 (c 0.25, CHCl3) = + 1.95° 
1
H NMR (CDCl3, 300 MHz): δ 7.72 (d, 2H, J=7.3 Hz); 7.57 (m, 2H); 7.33 (m, 14H); 7.07 
(d, 2H, J=8.5 Hz, Har-Tyr); 6.88 (d, 2H, J=8.5 Hz, Har-Tyr); 5.08 (bs, 2H, CH2-OBzl); 4.98 
(s, 2H, CH2-Z); 4.58 (bm, 2H, 1H
α
-Leu, 1H
α
-Pro); 4.40 (bm, 1H, H
α
-Lys); 4.24 (bm, 1H, 
H
α
-Tyr); 4.14 (t, 1H, J=6.1 Hz, CH-SFm); 3.84 (bm, 1H, 1H

-Pro); 3.53 (m, 1H, 1H-CH2-
SFm); 3.43 (bm, 2H, 1H

-Pro, 1H-CH2-SFm); 3.14 (m, 2H, 2H

-Lys); 2.98 (bm, 2H, 2H

-
Tyr); 2.30 (bm, 1H, H-Pro); 1.97 (bm, 3H, H-Pro); 1.76 (m, 1H, 1H

-Leu); 1.41 (bm, 16H, 
6H-Lys, 2H

-Leu, 9H-tBu); 1.25 (m, 1H, H-Lys); 0.89 (bd, 6H, J=6.7 Hz, 2CH3-Leu). 
13
C NMR (CDCl3, 75 MHz): δ 200.01 (1C, s); 172.10 (1C, s); 171.30 (1C, s); 171 (1C, s); 
158.12 (1C, s); 157.98 (1C, s); 156.88 (1C, s); 145.61 (1C, s), 145.40 (1C, s); 141.29 (2C, 
s); 137.08 (2C, s); 130.59 (1C, d); 128.80 (1C, s); 128.71(2C, d); 128.58 (2C, d); 128.30 
(1C, d); 128.20 (2C, d); 128.10 (2C, d); 127.77 (2C, d); 127.50 (2C, d); 127.21 (2C, d); 
124.90 (2C, d); 119.92 (2C, d); 115.11 (2C, d); 82.00 (1C, s); 70.11 (1C, t); 66.58 (1C, t); 
60.83 (1C, d); 50.58 (1C, d); 55.0 (1C, d); 50.58 (1C, d); 47.30 (1C, t); 46.69 (1C, d); 40.80 
(1C, t); 40.66 (1C, t); 37.40 (1C, t); 32.10 1C, t); 31.10 (1C, t); 29.08 (2C, t); 28.96 (3C, q); 
24.76 (1C, d);  24.50 (1C, t); 24.45 (1C, q); 23.43 (1C, t); 21.84 (1C, q). 
Fmoc-Val-Tyr(OBzl)-Leu-D-Pro-Lys(Z)-SFm (1c’)  
The product was synthesized according to the protocol A reported in the section 6.6.2. 
Reaction time 12 h. The purification by silica gel flash chromatography 
(cyclohexane/AcOEt, 6:4 to 2:8) gave the product as a white foam (550 mg, 98%). Purity > 
98%. Rf = 0.45 (cyclohexane/AcOEt, 2:8). [α]D
20
 (c 0.25, CHCl3) = − 24.06° 
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1
H NMR (CDCl3, 300 MHz): δ 7.75 (m, 4H, 2Har-SFm, 2Har-Fmoc); 7.54 (m, 4H, 2Har-
SFm, 2Har-Fmoc); 7.30 (m, 18H, 4Har-SFm, 4Har-Fmoc, 5Har-Cbz, 5Har-OBzl); 7.09 (d, 
2H, J=8.5 Hz, Har-Tyr); 6.82 (d, 2H, J=8.5 Hz, Har-Tyr); 6.71 (bs, 1H, NH); 5.35 (bs, 1H, 
NH); 5.06 (s, 2H, CH2-Cbz); 4.89 (s, 2H, CH2-OBzl); 4.56 (bm, 3H, 2H
α
, 1H-CH2-Fmoc); 
4.40 (m, 3H, 2H
α
, 1H-CH2-Fmoc); 4.17 (m, 2H, 1CH-SFm, 1CH-Fmoc); 3.94 (bm, H
α
-
Leu); 3.79 (bm, 1H, 1H

-Pro); 3.54 (m, 2H, 1H

-Pro, 1H-CH2-SFm); 3.13 (m, 2H, 2H

-
Lys); 2.97 (bm, 2H, 2H

-Tyr); 2.29 (m, 1H, 1H
β
-Val); 1.94 (m, 4H, 4H-Pro,); 1.44 (m, 9H, 
6H-Lys, 2H

-Leu, 1H

-Leu); 0.79 (bm, 12H, 2CH3-Leu, 2CH3-Val). 
13
C NMR (CDCl3, 75 MHz): δ 200.31 (1C, s); 171.83 (3C, s); 157.90 (2C, s); 156.61 (2C, 
s); 145.46 (1C, s); 145.33 (1C, s); 143.70 (1C, s); 143.75 (1C, s); 141.30 (3C, s); 141.23 
(1C, s); 136.94 (1C, s); 136.88 (1C, s); 130.44 (1C, d); 128.62 (1C, s); 128.52 (2C, d); 
128.47 (2C, d); 127.97 (2C, d); 127.93 (1C, d); 127.91 (2C, d); 127.76 (2C, d); 127. 71 (1C; 
d); 127.47 (4C, d); 127.12 (2C, d); 125.11 (2C, d); 124.83 (2C, d); 124.76 (2C, d); 120.03 
(2C, d); 119.86 (2C; d); 114.95 (1C, d); 69.85 (1C, t); 67.10 (1C, t); 66.65 (1C, t); 60.87 
(2C, d); 59.31 (1C, d); 54.31 (1C, d), 50.66 (1C, d); 47.25 (1C, d); 46.21 (1C, d); 40.85 
(2C, t); 39.88 (1C, t); 36.72 (1C, t); 31.97 (2C, t); 31.09 (1C, t); 30.91 (1C, d); 29.17 (1C, 
t); 24.66 (1C, d); 24.40 (1C, t); 23.38 (1C, q); 22.26 (1C, t); 21.72 (1C, q); 19.23 (1C, q); 
17.84 (1C, q). 
Fmoc-Ser-D-Pro-Val-Tyr(OBzl)-Leu-SFm (2’) 
Fmoc-Ser-D-Pro-Val-Tyr(OBzl)-Leu-SFm
2' (I)
2'
Boc-Leu-OH Boc-Tyr(OBzl)-Leu-SFm Boc-Val-Tyr(OBzl)-Leu-SFm
Boc-D-Pro-Val-Tyr(OBzl)-Leu-SFm
2' (III)
2' (IV)
Boc-Leu-SFm
Fm-SH
i) TFA 
ii) Boc-Tyr(OBzl)-OH
2' (II)
i) TFA 
ii) Boc-Val-OH
i) TFA 
ii) Boc-D-Pro-OH
i) TFA 
ii) Fmoc-Ser-OH
 
Boc-Leu-SFm [2’(I)] 
The product was synthesized according to the protocol A reported in the section 6.6.1.2. 
Purification of the residue by silica gel chromatography (cyclohexane/EtOAc = 98/2 to 
95/5) gave the product as a white foam (1.16 g, 85%). Purity >95%. Rf  = 0.26 
(cyclohexane/AcOEt= 9/1). [α]D
20
 (c 0.5, CHCl3) = − 79.62° 
1
H NMR (CDCl3, 300 MHz): δ 7.77 (d, 2H, J=7.3 Hz, 2H, Har-SFm); 7.64 (d, 2H, J=7.3 
Hz, Har-SFm); 7.35 (m, 4H, Har-SFm); 4.79 (bd, 1H, J=8.2 Hz, NH); 4.26 (bm, 1H, H
α
-
Leu); 4.16 (t, 1H, J=5.8 Hz, CH-Fm); 3,53 (d, 2H, J=5.8 Hz, CH2-SFm); 1.57 (m, 2H, 2H

-
Leu) 1.43 (m, 9H, 9H-tBu); 1.25 (m, 1H, 1H

-Leu); 0.88 (d, 6H, J=6.7 Hz, 2CH3-Leu). 
13
C NMR (CDCl3, 75 MHz): δ 202 (1C, s); 155.42 (1C, s); 145.65 (2C, s); 141.37 (2C, s); 
130.03 (2C, d); 128.88 (2C, d); 125.60 (2C, d); 120.03 (2C, d); 80.25 (1C, s); 59.53 (1C, d); 
46.96 (1C, d); 41.57 (1C, d); 32.11 (1C, t); 28.60 (3C, q); 24.86 (1C, d); 23.86 (1C, q); 
21.62 (1C, q). 
Experimental section 
 
 
97 
Boc-Tyr(OBzl)-Leu-SFm [2’(II)] 
The product was synthesized according to the protocol A reported in the section 6.6.2. 
Reaction time 2 h. The purification by silica gel flash chromatography 
(cyclohexane/EtOAc, 9:1 to 8:2) gave the product as a white foam (1.50 g, 97%). Purity 
>98%. Rf = 0.28 (cyclohexane/AcOEt, 8:2). [α]D
20
 (c 0.5, CHCl3) = ˗ 37.67° 
1
H NMR (CDCl3, 300 MHz): δ 7.72 (d, 2H, J =7.3 Hz, Har-SFm); 7.59 (dd, 2H, J=7.3 Hz, 
J=2 Hz, Har-SFm); 7.38 (m, 9H, 4Har-SFm, 5Har-OBzl); 7.10 (d, 2H, J =8.5 Hz, Har-Tyr); 
6.85 (d, 2H, J= 8.5 Hz, Har-Tyr); 6.24 (bd, 1H, J=8.5 Hz, NH); 4.99 (bs, 2H, CH2-OBzl); 
4.56 (m, 1H, H
α
-Tyr); 4.26 (m, 1H, H
α
-Leu); 4.12 (t, 2H, J =5.8 Hz, CH-SFm); 3.48 (d, 1H, 
J= 5.8 Hz, CH2-SFm); 2.98 (d, 2H, J=7 Hz, 2H

-Tyr); 1.67 (bm, 1H, CH

-Leu); 1.42 (m, 
11H, 2H

-Leu, 9H-tBu); 0.82 (d, 6H, J=6.7 Hz, 2CH3-Leu). 
13
C NMR (CDCl3, 75 MHz): δ 200.21 (1C, s); 171.62 (1C, s); 158.03 (1C, s), 155.78 (1C, 
s); 145.48 (2C, s); 141.36 (2C, s); 137.20 (1C, s); 130.67 (2C, d), 129.03 (1C, s); 80.41 (1C, 
s); 70.15 (1C, t); 58.01 (1C, d); 55.95 (1C, d); 46.91 (1C, d); 41.66 (1C, t); 37.14 (1C, t); 
32.17 (1C, t); 28.49 (3C, q); 24.71 (1C, d); 24.74 (1C, q); 21.98 (1C, q). 
Boc-Val-Tyr(OBzl)-Leu-SFm [2’(III)] 
The product was synthesized according to the protocol A reported in the section 6.6.2. 
Reaction time 2 h. The purification by silica gel flash chromatography 
(cyclohexane/EtOAc, 7:3) gave the product as a white solid (1.45 g, 90%). Purity > 98%. Rf 
= 0.25 (cyclohexane/AcOEt, 7:3). [α]D
20
 (c 0.5, CHCl3) = −56.85 ° 
1
H NMR (CDCl3, 300 MHz): δ 7.72 (d, 2H, J=7.3 Hz, Har-Fm); 7.60 (dd, 2H, J=7Hz, J= 
3Hz, Har-Fm); 7.36 (m, 9H, 4Har-Fm, 5Har-OBzl); 7.10 (d, 2H, J= 8.5 Hz, Har-Tyr); 6.85 
(d, 2H, J= 8.5 Hz, Har-Tyr); 6.49 (bd, 1H, J= 7.6 Hz, NH); 6.38 (bd, 1H, J= 5.5 Hz, NH); 
4.96 (s, 2H, CH2-OBzl); 4.83 4.85 (bd, 1H, J= 6.1 Hz, NH); 4.62 (bm, 1H, H
α
-Leu); 4.45 
(m, 1H, H
α
-Tyr); 4.12 (t, 2H, J= 5.8 Hz, CH-SFm); 3.88 (m, 1H, H
α
-Val); 3.47 (d, 1H, J= 
5.8 Hz, CH2-SFm); 3.01 (m, 2H, 2H

-Tyr); 1.14 (m, 1H, H
β
-Val); 1.78 (bm, 1H, H

-Leu); 
1.36 (bm, 9H, 9H-tBu); 1.25 (m, 2H, 2H

-Leu); 0.91 (d, 6H, J=6.7 Hz, 2CH3-Val); 0.81 (d, 
6H, J=6.1 Hz, 2CH3-Leu). 
13
C NMR (CDCl3, 75 MHz): δ 200.45 (1C, s); 172.50 (2C, s); 157.89 (1C, s), 156.08 (1C, 
s); 145.83 (2C, s); 145.78 (2C, s); 137.51 (1C, s); 130.84 (1C, d), 129.14 (1C, s); 128.49 
(2C, d), 127.87 (2C, d), 127.68 (1C, d), 127.54 (2C, d), 127.34 (1C, d), 127.34 (1C, d), 
127.23 (1C, d), 125.11 (1C, d), 24.97 (1C, d), 120.03 (2C, d); 115.16 (2C, d); 79.38 (1C, s); 
69.74 (1C, t); 54.56 (1C, d); 47.14 (1C, d); 41.15 (1C, t); 38.04 (1C, t); 32.42 (1C, t); 31.17 
(1C, d); 28.91 (3C, q); 24.91 (1C, d); 23.18 (1C, q); 22.11 (1C, q); 19.47 (1C, q); 18.79 
(1C, q). 
Boc-D-Pro-Val-Tyr(OBzl)-Leu-SFm [2a’(IV)] 
The product was synthesized according to the protocol A reported in the section 6.6.2. 
Reaction time 12 h. The purification by silica gel flash chromatography (Toluene/Acetone, 
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90:10 to 85:15) gave the product as a white solid (1.45 g, 93%). Purity > 98%. Rf = 0.32 
(Toluene/Acetone, 85:15). [α]D
20
 (c 0.25, CHCl3) = − 15.74° 
1
H NMR (CDCl3, 300 MHz): δ 7.71 (m, 4H, Har-SFm); 7.37 (m, 9H, 4Har-SFm, 5CHar-
OBzl); 7.10 (d, 2H, J = 8.5 Hz, Har-Tyr); 6.87 (d, 2H, J= 8.5 Hz, Har-Tyr); 6.43 (bd, 1H, 
J= 6.4 Hz, NH); 4.99 (s, 2H, CH2-OBzl); 4.71 (m, 1H, H
α
); 4.51 (m, 1H, H
α
); 4.15 (m, 3H, 
1CH-SFm, 2H
α
); 3.43 (bm, 5H, 2H-SFm, 2H

-Pro, 1H

-Tyr); 2.98 (m, 1H, 1H

-Tyr); 2.08 
(bm, 5H, 1H
β
-Val, 4H-Pro); 1.41 (bs, 12H, 2H

-Leu, 1H

-Leu, 3CH3-tBu); 0.90 (m, 12H, 
2CH3-Leu, 2CH3-Val). 
13
C NMR (CDCl3, 75 MHz): δ 202.07 (1C, s); 171.28 (3C, s); 157.89 (1C, s), 156.08 (1C, 
s); 145.55 (2C, s); 145.78 (2C, s); 141.18 (1C, s); 130.35 (2C, d); 129.14 (1C, s); 128.57 
(2C, d); 127.4 (2C, d); 127.71 (2C, d); 127.42 (2C, d); 127.16(2C, d); 119.81 (2C, d); 
115.16 (2C, d); 80.71 (1C, s); 70.10 (1C, t); 62.08 (1C, d); 61.14 (1C, d); 58.11 (1C, d); 
54.56 (1C, d); 47.33 (1C, t); 46.83 (1C, d); 41.11 (1C, t); 36.84 (1C, t); 32.27 (1C, t); 28.85 
(1C, t); 28.59 (3C, q); 24.59 (1C, t); 24.50 (1C, q); 23.01 (1C, d); 22.10 (1C, q); 19.34 (1C, 
q); 16.92 (1C, q). 
Fmoc-Ser-D-Pro-Val-Tyr(OBzl)-Leu-SFm (2’) 
The product was synthesized according to the protocol A reported in the section 6.6.2. 
Reaction time 2 h. The purification by silica gel flash chromatography (AcOEt/PE, 8:2) 
gave the product as a white solid (870 mg, 70%). Purity > 98%. Rf = 0.3 (AcOEt/PE = 9/1). 
[α]D
20
 (c 0.5, CHCl3) = − 36.15° 
MS-HPLC calcd for: C64H69N5O9S, expected: 1083.48, found: 1106.55 [M+Na]
+
 
1
H NMR (CDCl3, 300 MHz): δ 7.68 (m, 9H, Har); 7.35 (m, 18H, Har); 6.80 (d, 2H, J= 8.5 
Hz, Har-Tyr); 6.80 (d, 2H, J= 8.5 Hz, Har-Tyr); 6.51 (d, 1H, J=7.8 Hz, NH); 6.38 (d, 1H, 
J=8.1 Hz, NH); 4.93 (s, 2H, CH2-OBzl); 4.62 (m, 2H, 1H
α
-Ser, 1H
α
-Tyr); 4.55 (m, 1H, H
α
-
Leu); 4.3 (m, 5H, CH2-Fmoc, CH-Fmoc, 1H
α
-Val, 1H
α
-Pro); 4.01 (m, 3H, CH-SFm, 2H

-
Ser); 3.66 (m, 2H, H

-Pro); 3.30 (d, 2H, J=5.8 Hz, CH2-SFm); 3.06 (m, 2H, H

-Tyr); 2.20 
(5H, 1H
β
-Val, 4H-Pro); 1.33 (m, 3H, 2H
β
-Leu, 1H

-Leu), 0.88 (d, 6H, J= 6.7 Hz, 1CH3-
Val), 0.77 (m, 6H, 2CH3-Leu); 0.61 (d, 3H, J= 6.7 Hz, 1CH3-Val).
 
13
C NMR (CDCl3, 75 MHz): δ 202.07 (1C, s); 172.27 (1C, s); 171.49 (1C, s); 171.39 (1C, 
s); 170.60 (2C, s); 157.79 (1C, s), 156.67 (1C, s); 145.39 (2C, s); 144.02 (1C, s); 143.77 
(1C, s); 141.29 (1C, s); 141,21 (1C, s); 141.04 (1C, s); 137.03 (1C, s); 134.77 (1C, d); 
130.39 (2C, d); 129.35 (1C, s); 129.10 (2C, d); 127.89 (2C, d); 127.63 (2C, d); 127.40 (2C, 
d); 127.14 (2C, d); 127.06 (2C, d); 125.49 (2C, d); 125.22 (2C, d); 124.75 (1C, d); 119.90 
(1C, d); 119.77 (2C, d); 115.03 (2C, d); 69.90 (1C, t); 67.53 (1C, t); 62.63 (1C, t); 62.80 
(1C; d); 59.24 (1C; d); 58.05 (1C; d); 54.03 (1C; d); 53.50 (1C; d); 47.66 (1C, t); 47.03 (1C, 
d); 46.63 (1C; d); 40.01 (1C, t); 35.85 (1C, t); 31.97 (1C, t); 29.25 (1C, d); 28.63 (1C, t); 
25.21 (1C, t); 24.45 (1C, d); 22.80 (1C, q); 21.69 (1C, q); 19.34 (1C, q); 16.87 (1C, q). 
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5.1.2. Synthesis of linear peptides on solid phase 
Linear peptides (16-25) 
All the linear peptides were synthesized by SPPS using the Fmoc/tBu strategy and Cl-Trt 
resin (f=1.60 mmol/g) in accordance to the experimental procedures reported in the section 
6.5 of the chapter 6 General methods and procedures. Synthesis of a common tetra-peptide 
13 was performed at 800 µmol scale, then the peptide-resin was split in 10 equal portions 
and the coupling with the fifth amino acid was performed. 
Each coupling was carried out using PyBOP, HOAt and DIEA (3:3:6) as coupling reagents. 
Solvents and soluble reagents were removed by suction. Washings between synthetic steps 
were done with DMF (5 x 30 s) and DCM (5 x 30 s). During couplings the mixture was left 
to react with intermittent manual stirring and the good outcome of each coupling was 
verified by ninhydrin, chloranil or p-nitrophenyl ester test. The Fmoc group were removed 
by treatment with 20% of piperidine in DMF, the Leu Alloc protecting group was removed 
by treatment with Pd(PPh3)4 as described in the section 6.5.15. The cleavage of the peptide 
from the resin was accomplished by treatment with a solution of 2% TFA in DCM (5x 1 
min). Crude products were analyzed by RP-HPLC and MS-HPLC. HPLC chromatograms 
were recorded on a Waters Alliance 2695 separation module using a Sunfire C18 column 
flow 1ml/min, solvents H2O (0.045% TFA) and ACN (0.036% TFA). The gradient (G) is 
expressed as % of ACN in H2O.  
The initial resin loading was determined by UV spectroscopy as reported in the section 
6.5.6. The overall yields of each linear peptide synthesis was estimated by Fmoc UV 
detection related to the last cleavage step, whereas the purity of the crudes were determined 
through analytical HPLC analysis (peak detected at =220 nm).  
Linear peptide 28 
This compound was synthesized using the same experimental conditions described before 
until the intermediate 13. Then a mixture of Boc-Lys(Fmoc)-OH (3eq), PyBOP (3eq), and 
HOAt (3eq) was dissolved in the minimum volume of DMF and pre-activated by adding 
DIEA (6 eq). After 1 min the mixture was added to the peptide-resin 13 and the couplings 
were performed at r.t. with intermittent manual stirring. Treatment with piperidine (20% in 
DMF, 2x10 min) removed the Fmoc pretecting group on the Lys-side chain amino group. 
Amine acetylation was accomplished with treatment with Ac2O/DIEA according to the 
conditions reported in the section 6.5.14. The peptide resin 27 was treated with a solution of 
TFA-H2O-TIS/95:2.5:2.5 (5 ml) at r.t. for 30 min obtaining the linear peptide 28. 
Linear peptides characterization  
H-Lys(Boc) Val-Tyr(tBu)-Leu-D-Pro-OH (16) 
Initial loading: 0.72 mmol/g 
HPLC: tR (min, G0100 ACN in 8 min)= 5.44 
MS-HPLC calcd for: C40H66N6O9, expected: 774,49, found: 775.24 [M+1]
+
  
Yield: 95 % 
Purity: 95 % 
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H-Phe(4-NH-Boc)-Val-Tyr(tBu)-Leu-D-Pro-OH (17) 
Initial loading: 0.75 mmol/g 
HPLC: tR (min, G0100 ACN in 8 min)= 5.78  
MS-HPLC calcd for: C43H64N6O9, expected: 808,47,  found: 809.0 = [M+H]
+
 
Yield: 94 % 
Purity: 85 % 
H-Cys(Trt)-Val-Tyr(tBu)-Leu-D-Pro-OH (18) 
Initial loading: 0.75 mmol/g 
HPLC: tR (min, G0100 ACN in 8 min)= 6.49  
MS-HPLC calcd for: C51H65N5O7S, expected: 891,46, found: 892.45 = [M+H]
+ 
Yield: 97 % 
Purity: 95 % 
H-Glu(OtBu)-Val-Tyr(tBu)-Leu-D-Pro-OH (19) 
Initial loading: 0.75 mmol/g 
HPLC: tR (min, G0100 ACN in 8 min)= 6.38  
MS-HPLC calcd for: C38H61N5O9, expected: 731,45, found: 732.43 = [M+H]
+ 
Yield: 80 % 
Purity: 95 % 
H-Gln(Trt)-Val-Tyr(tBu)-Leu-D-Pro-OH (20)  
Initial loading: 0.75 mmol/g 
HPLC: tR (min, G0100 ACN in 8 min)= 6.28 
MS-HPLC calcd for: C53H68N6O8, expected: 916,51, found: 917.50 = [M+H]
+ 
Yield: 85 % 
Purity: 98 % 
H-Arg(Pbf)-Val-Tyr(tBu)-Leu-D-Pro-OH (21) 
Initial loading: 0.75 mmol/g 
HPLC: tR (min, G0100 ACN in 8 min)= 6.02  
MS-HPLC calcd for: C48H74N8O10S, expected: 954,52, found: 955.53 = [M+H]
+ 
Yield: 93 % 
Purity: 90 % 
H-Trp(Boc)-Val-Tyr(tBu)-Leu-D-Pro-OH (22) 
Initial loading: 0.75 mmol/g 
HPLC: tR (min, G0100 ACN in 8 min)= 6.19  
MS-HPLC calcd for: C45H64N6O9, expected: 832,47, found: 833.50 = [M+H]
+ 
Yield: 92 % 
Purity: 90 % 
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H-Ser(tBu)-Val-Tyr(tBu)-Leu-D-Pro-OH (23) 
Initial loading: 0.75 mmol/g 
HPLC: tR (min, G0100 ACN in 8 min)= 5.28 
MS-HPLC calcd for: C36H59N5O8, expected: 689,44, found: 690.86 = [M+H]
+ 
Yield: 82 % 
Purity: 90 % 
H-Dap(Boc)-Val-Tyr(tBu)-Leu-D-Pro-OH (24) 
Initial loading: 0.75 mmol/g 
HPLC: tR (min, G0100 ACN in 8 min)= 5.52  
MS-HPLC calcd for: C37H60N6O9, expected: 732,44, found: 733.38 = [M+H]
+ 
Yield: 66 % 
Purity: 93 % 
H-Ala-Val-Tyr(tBu)-Leu-D-Pro-OH (25) 
Initial loading: 0.75 mmol/g 
HPLC: tR (min, G0100 ACN in 8 min)= 4.88 
MS-HPLC calcd for: C32H51N5O7, expected: 617,38, found: 661.42 = [M-tBu)]
+ 
Yield: 74 % 
Purity: 95% 
H-Lys(NHAc)-Val-Tyr-Leu-D-Pro-OH (28) 
Initial loading: 0.75 mmol/g 
HPLC: tR (min, G0100 ACN in 8 min)= 4.43 
MS-HPLC calcd for: C33H52N6O8, expected: 660,38, found: 661.28 = [M+H]
+
 
Yield: 90 % 
Purity: 98 % 
5.2. Synthesis of cyclic peptides  
All the experimental conditions are reported in the section 6.7 of the chapter 6 General 
methods and procedures. 
Fmoc-Val-Tyr(OBzl)-Leu-Pro-Lys(Z)-OFm &Val-Tyr(OBzl)-Leu-Pro-Lys(Z)&
i) Piperidine 
ii) HATU
&Val-Tyr-Leu-Pro-Lys&
iii) Pd(OH)2/C, 
CH3OH, H2 atm
1a= Pro, Lys
1b= Pro, D-Lys
1c= D-Pro, Lys
cyclo-1a= Pro, Lys
cyclo-1b= Pro, D-Lys
cyclo-1c= D-Pro, Lys
cyclo-1A= Pro, Lys
cyclo-1B= Pro, D-Lys
cyclo-1C= D-Pro, Lys  
&Val-Tyr-Leu-Pro-Lys& (cyclo-1A) 
The Fmoc and OFm protecting groups of the linear pentapeptide 1a (600 mg, 0,48 mmol) 
were removed by treatment with piperidine (20% in DMF, 2 ml) at r.t. under stirring for 1 
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h. The solvent was evaporated and the remaining residue was triturated with diethyl ether, 
filtrated and dried under vacuum to yield the product as a white solid (400 mg, 97%). Purity 
> 95%. Rf= 0.3 (ACN/MeOH/H2O, 8:1:1) 
HATU mediated cyclization.The linear peptide cyclization (100 mg, 0.12 mmol) was 
performed in accordance to the protocol E. Reaction time 72 h. Purification by silica gel 
flash chromatography (AcOEt/iPrOH, 95:5) gave the title compound cyclo-1a as a white 
solid (20 mg, 20%). Purity = 95%.  
PyBOP mediated cyclization.The linear peptide cyclization (100 mg, 0.12 mmol) was 
performed in accordance to the procedure described in the protocol F. Reaction time 72 h. 
Purification by silica gel flash chromatography (AcOEt/iPrOH, 95:5) gave the title 
compound cyclo-1a as a white solid (12 mg, 12%). Purity= 95%.  
PPAA mediated cyclization The linear peptide cyclization (100 mg, 0.12 mmol) was 
performed in accordance to that described in protocol G. Reaction time 56 h. Purification 
by silica gel flash chromatography (AcOEt/iPrOH, 95:5) gave the title compound cyclo-1a 
as a white solid (54 mg, 56%). Purity=95%.  
Rf = 0.25 (AcOEt/iPrOH, 95:5). [α]D
20
 (c 0.5, CHCl3) = − 40.15° 
MS-HPLC calcd for: C46H60N6O8, expected: 824,45, found: 825.90 =[M+H]
+
, 848.08 = 
[M+Na]
+
, 823.76 [M-H]
-
. 
1
H NMR (CD3OD, 300 MHz): δ 7.3 (m, 9H); 7.13 (d, 2H, J=8.5 Hz, 2H-Tyr); 6.9 (d, 2H, 
J=8.5 Hz, 2H-Tyr); 5.13 (s, 4H, CH2-OBzl, CH2-(Cbz); 4.66 (m, 1H); 4.43 (m, 1H); 4.15-
4.03 (m, 2H); 3.96, (d, 1H, J= 9.1 Hz); 3.71 (m, 1H); 3.56 (m, 1H); 3.34- 3.10 (m, 4H); 
2.31-1.85 (m, 6H), 1.75- 1.4 (m, 8H); 0.98 (m, 6H); 0.88 (d, 3H, J= 6.6 Hz); 0.78 (d, 3H, J= 
6.4 Hz). 
To a solution of a Z/OBzl-protected peptide cyclo-1a (30 mg, 0.036 mmol) in dry MeOH (4 
ml) was added Pd(OH)2/C (4mg) on activated charcoal) and the mixture was hydrogenated 
overnight under atmospheric pressure using an H2-filled balloon. The catalyst was removed 
by filtration through a pad of celite and the solvent evaporated under reduced pressure 
yielding the final product cyclo-1A as a white solid (20 mg, 97%). Rf = 0.1 
(ACN/MeOH/H2O, 7:2:1).  
MS-HPLC calcd for: C31H48N6O6, expected: 600,36, found: 601.32 [M+H]
+
 623.31 
[M+Na]
+ 
&Val-Tyr-Leu-Pro-D-Lys& (cyclo-1B) 
The Fmoc and OFm protecting groups of the linear pentapeptide 1b (230 mg, 0,18 mmol) 
were removed by treatment with piperidine (20% in DMF, 2 ml) at r.t. under stirring for 1 
h. The solvent was evaporated and the remaining residue was triturated with diethyl ether, 
filtrated and dried under vacuum to yield the product as a white solid (157 mg, 100%). 
Purity > 95%. Rf= 0.27 (ACN/MeOH/H2O, 8:1:1)  
The peptide cyclization (150 mg, 0.17 mmol) was performed with HATU in accordance to 
the procedure described in the protocol E. Reaction time 56 h. Purification by silica gel 
flash chromatography (DCM/ACN/iPrOH, 8:1.5:0.5) gave the title compound cyclo-1b as a 
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white solid (39 mg, 25%). Purity >95%. Rf  = 0.25 (DCM/ACN/iPrOH, 8:1.5:0.5). [α]D
20
 (c 
0.5, CHCl3) = − 36.10° 
MS-HPLC calcd for: C46H59ClN6O8, expected: 858,41, found: 859.33 = [M+H]
+
. 
1
H NMR (CD3OD, 300 MHz): δ 7.25 (m, 9H); 7.57 (m, 4H); 7.09 (d, 2H, J=8.5 Hz, 2H-
Tyr); 6.78 (d, 2H, J=8.5 Hz, 2H-Tyr); 5.13 (s, 2H, CH2-OBzl); 4.90 (m, 4H, CH2-(2Cl-Z), 
2H

); 4.17 (m, 2H, 2H

); 4.10 (d, 1H, J=9.6 Hz, H

-Val); 3.68 (bm, 1H, H

-Pro); 3.53 (bm, 
1H, H

-Pro); 3.08 (m, 3H, 1H

-Tyr, 2H

-Lys); 2.01 (m, 5H, 4H-Pro, 1H

-Val); 1.38 (bm, 
9H, 1H

-Leu, 2H

-Leu, 6H-Lys), 1.02 (d, 3H, J=6.7 Hz, 1CH3-Leu); 0.88 (m, 9H, 1CH3-
Leu, 2CH3-Val). 
To a solution of a Z/OBzl-protected peptide cyclo-1b (30 mg, 0.035 mmol) in dry MeOH 
(3ml) was added Pd(OH)2/C (3 mg) and the mixture was hydrogenated overnight under 
atmospheric pressure using an H2-filled balloon. The catalyst was removed by filtration 
through a pad of celite and the solvent evaporated under reduced pressure yielding the final 
product cyclo-1B as a white solid (27 mg, 95%). Rf = 0.1 (ACN/MeOH/H2O, 7:2:1).  
MS-HPLC calcd for: C31H48N6O6, expected: 600.36, found: 601.32 [M+H]
+
, 623.31 
[M+Na]
+ 
&Val-Tyr-Leu-D-Pro-Lys& (cyclo-1C) 
The Fmoc and OFm protecting groups of the linear pentapeptide 1c (150 mg, 0,12 mmol) 
were removed by treatment with piperidine (20% in DMF, 2 ml) at r.t. under stirring for 1 
h. The solvent was evaporated and the remaining residue was triturated with diethyl ether, 
filtrated and dried under vacuum to yield the product as a white solid (100 mg, 100%). 
Purity > 95%. Rf= 0.3 (ACN/MeOH/H2O, 8:1:1)  
The peptide cyclization (100 mg, 0.12 mmol) was performed with HATU in accordance to 
the procedure described in the protocol E. Reaction time 56 h. Purification by silica gel 
flash chromatography (DCM/ACN/iPrOH, 8:1.5:0.5) gave the title compound cyclo-1c as a 
white solids (60 mg, 45%). Purity > 95%. Rf  = 0.25 (DCM/ACN/iPrOH, 8:1.5:0.51/1). 
[α]D
20
 (c 0.5, MeOH) = -125.84 
MS-HPLC calcd for: C46H60N6O8, expected: 824.45, found: 847.49 = [M+Na]
+
, 823.26 = 
[M-H]
-
. 
1
H NMR (CD3OD, 300 MHz): δ 7.32 (m, 9H); 7.12 (d, 2H, J=8.5 Hz, 2H-Tyr); 6.87 (d, 2H, 
J=8.5 Hz, 2H-Tyr); 5.04 (s, 4H, CH2-OBzl, CH2-(Cbz)); 4.68 (bm, 1H, H

-Lys); 4.42 (bm, 
1H, H

-Leu); 4.15 (m, 1H, H

-Pro); 4.03 (m, 1H, H

-Tyr); 3.90 (d, 1H, J=9.6 Hz, 1H

-
Val); 3.71 (m, 1H, 1H

-Pro); 3.54 (m, 1H, 1H

-Pro); 3.30 (m, 2H, 2H

-Tyr); 3.09 (t, 2H, 
J=7.0 Hz, 2H

-Lys); 2.17 (m, 5H, 4H-Pro, 1H

-Val); 1.50 (bm, 9H, 1H

-Leu, 2H

-Leu, 6H-
Lys), 0.97 (m, 12H, 2CH3-Leu, 2CH3-Val). 
13
C NMR (CD3OD, 75 MHz): δ 173.04 (1C, s); 172.90 (1C, s); 172.82 (1C, s); 172.68 (1C, 
s); 172.17 (1C, s); 158.0 (1C, s); 157.85 (1C, s), 137.49 (1C, s); 137.39 (1C, s); 129.85 (1C, 
d); 129.26 (1C, d); 128.17 (2C, d); 128.14 (1C, s); 127.62 (2C, d); 127.48 (2C, d); 127.45 
(2C, d); 127.13 (2C, d); 114.73 (2C, d); 69.62 (1C, t); 66.53 (1C, t); 62.39 (1C, t); 60.92 
(1C; d); 59.11 (1C; d); 52.68 (1C; d); 50.42 (1C; d); 40.68 (1C; t); 40.54 (1C, t); 39.98 (1C, 
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t); 30.69 (1C, t); 29.35 (1C, t); 29.23 (1C, t); 29.25 (1C, t); 28.83 (1C, d); 24.67 (1C, d); 
24.56 (1C, t); 22.77 (1C, d); 22.44 (1C, q); 20.71 (1C, q); 18.41 (1C, q); 18.00 (1C, q). 
To a solution of a Z/OBzl-protected peptide cyclo-1c (50 mg, 0.06 mmol) in dry MeOH 
(5ml) was added Pd(OH)2/C (5 mg) and the mixture was hydrogenated overnight under 
atmospheric pressure using an H2-filled balloon. The catalyst was removed by filtration 
through a pad of celite and the solvent evaporated under reduced pressure. The purification 
by silica gel flash chromatography (ACN/H2O, 7:3) gave the final product cyclo-1C as a 
white solids (34 mg, 95%). Purity >95%. Rf  = 0.15 (ACN/H2O, 7:3). [α]D
20
 (c 0.5, MeOH) 
= -120.22 
MS-HPLC calcd for: C31H48N6O6, expected: 600,36, found: 601.13 = [M+H]
+
 
&Val-Tyr(OBzl)-Leu-D-Pro-Lys(Cbz)& (cyclo-1c’)  
To a solution of 1c’ (100 mg, 79 mol) in DMF (700 l) was added piperidine (155 l, 
1.58 mol) at 0 °C. The reaction mixture was stirred for 15 min, then the volatiles were 
removed under high vacuum. The residual piperidine was removed by azeotropic 
distillation with toluene in vacuo. The residue was dissolved in DMF (15.8 ml) and 2,4-
dinitrofluorobenzene (11.6 l, 90 mol) was added to it and the reaction mixture was 
stirred for 5 min at r.t. DMF was removed under high vacuum, obtaining a yellow oil as a 
crude. The purification was done in two steps: a first silica gel flash chromatography 
(Toluene/AcOEt, 50:50 to 0:100) to remove the non-polar by-products, then a second silica 
gel flash chromatography (AcOEt/iPrOH= 98:2 to 95:5) yielded the final product as a white 
solid (25 mg, 30%). Purity =90%. Rf  = 0.45 (AcOEt/iPrOH, 9:1). [α]D
20
 (c 0.5, CHCl3) = − 
34.33° 
MS-HPLC calcd for: C46H60N6O8, expected: 824.45, found: 825.90 =[M+H]
+
, 848.08 = 
[M+Na]
+
, 823.76 [M-H]
-
. 
1
H NMR (CD3OD, 300 MHz): 7.34 (m, 10H, 5Har-OBzl, 5Har-Cbz); 7.16 (d, 2H, J= 8.5 
Hz, Har-Tyr), 6.90 (d, 2H, J= 8.5 Hz, Har-Tyr); 5.05 (s, 4H, 2H-CH2-OBzl, 2H-CH2-Cbz); 
4.66 (m, 1H, H
α
); 4.41 (1H, H
α
); 4.10 (m, 2H, 2H
α
); 3.95 (d, 1H, J= 9.6 Hz, H
α
-Val); 3.72 
(m, 1H, 1H
–Pro); 3.56 (m, 1H, 1H–Pro); 3.20 (d, 2H, 2H-Tyr); 3.10 (t, J= 7.0 Hz, 2H-
Lys), 2.01 (m, 7H, 4H-Pro, 1H
β
-Val, 2H
β
 Leu); 1.70 (m, 7H, 6H-Lys, 1H

-Leu); 0.98 (m, 
2CH3-Leu); 0.88 (d, J=6.4 Hz, 3H, 1CH3-Val); 0.78 (d, 3H, J=6.4 Hz, 1CH3-Val). 
13
C NMR spectrum is in agreement with that obtained for the analogue product titled cyclo-
1c. 
&Ser-Pro-Val-Tyr-Leu& (cyclo-2a) 
The Fmoc and OFm groups of the linear pentapeptide 2 (80 mg, 0,075 mmol) were 
removed by treatment with piperidine (20% in DMF, 2 ml) at r.t. under stirring for 1 h. The 
solvent was evaporated and the remaining residue was triturated with diethyl ether, filtrated 
and dried under vacuum to yield the product as a white solid (45 mg, 90%). Purity > 95%. 
Rf= 0.1 (DCM/MeOH, 9:1). 
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The peptide cyclization was performed with HATU, in accordance to the procedure 
described in the protocol E. Reaction time 48 h. The crude residue was purified by silica gel 
flash chromatography (DCM/cyclohexane/iPrOH, 7:2:1), then the resulting oil was 
crystallized from diethyl ether/DCM yielding the title compound cyclo-a as a white solid 
(28.5 mg, 65%). Purity >95%. Rf  = 0.25 (DCM/ACN/iPrOH, 8:1:1). [α]D
20
 (c 0.5, MeOH) = 
− 32.85 
MS-HPLC calcd for: C35H47N5O7, expected: 649.35, found: 673.08= [M+Na]
+
, 823.26 = 
[M-H]
-
 
1
H NMR (CDCl3, 300 MHz): 8.02 (bd, 1H, J=6.6 Hz; NH), 8,06 (bd, 1H, J=8.7 Hz; NH), 
7.60 (bd, 1H, J= 8.5 Hz; NH),7.39 (m, 5H, 5Har-OBzl); 7.13 (d, 2H, J= 8.5 Hz, Har-Tyr), 
6.89 (d, 2H, J= 8.5 Hz, Har-Tyr); 6.14 (bd, 1H, J=6.7 Hz; NH), 4.99 (s, 4H, CH2-OBzl); 
4.84 (m, 2H, H
α
); 4.29 (1H, H
α
); 4.18 (m, 2H, 2H
α
); 3.90 (dd, 1H, J= 8.2, J= 3Hz, 1H

-Ser); 
3.74 (dd, 1H, J= 8.2, J= 3Hz, 1H

-Ser); 3.46 (m, 1H, 1H

-Pro); 3.32 (m, 2H, 1H

-Pro, 1H

-
Tyr); 3.18 (m, 2H, 1H

-Tyr); 1.87 (m, 5H, 4H-Pro, 1H
β
-Val,); 1.21 (m, 2H, 2H
β
-Leu); 1.50 
(m, 1H, H

-Leu); 0.99 (d, 3H, J= 6.7 Hz, CH3); 0.94 (d, 3H, J= 6.4 Hz, CH3); 0-78 (d, 3H, 
J= 6.4 Hz, CH3);0.67 (d, 3H, J= 6.4 Hz, CH3). 
To a solution of cyclo-2 (28 mg, 44 mol) in dry MeOH (2 ml), was added Pd(OH)/C (3 
mg, 10% on activated charcoal) and the mixture was hydrogenated overnight under 
atmospheric pressure using an H2-filled balloon. The catalyst was removed by filtration 
through a pad of celite and the solvent evaporated under reduced pressure. The residue 
purification by silica gel chromatography (CHCl3/ACN/iPrOH= 8:1.5:0.5 to 8:1:1) yielded 
the product cyclo-2a as a white solid (22 mg, 90%). Purity >95%. Rf = 0.28 
(DCM/ACN/iPrOH, 7:1:2). [α]D
20
 (c 0.5, MeOH) = −28.63 
MS-HPLC calcd for: C28H41N5O7, expected: 559.3, found: 560.60 [M+H]
+
, 582.81 [M-
Na]
+
. 
1
H-NMR (CD3OD, 300 MHz): δ 7.06 (d, 2H, J=8.2 Hz, Har-Tyr); 6.71 (d, 2H, J=8.2 Hz, 
Har-Tyr); 4.77 (t, 1H, J=7.5 Hz, H
α
-Ser); 4.41 (t, 1H, J=8.0 Hz, H
α
-Tyr); 4.04 (d, 1H, J=5.8 
Hz, H
α
-Val); 3.83 (m , 1H, 1H
α
-Pro); 3.72 (m, 3H, 1H
α
-Leu, 2H

-Ser); 3.65 (m, 1H, 1H

-
Pro); 3.34 (m, 1H, 1H

-Pro); 3.04 (d, 2H, J=8Hz, 2H

-Tyr); 2.09 (m, 4H, 1H
β
-Val, 3H-Pro); 
1.56 (m, 1H, 1H-Pro); 1.28 (m, 1H, 1H

-Leu, 2H

-Leu); 0.99 (m, 9H, 2CH3-Val, 1CH3-
Leu); 0.77 (d, 3H, J=6.3 Hz, 1CH3-Leu). 
&Ser-Pro-Val-Tyr-Leu& (cyclo-2a’) 
To a solution of linear peptide 2’ (200 mg, 184 mol) in 1.8 ml of DMF was added 
piperidine (360 l, 3.6 mmol) at 0 °C. The reaction mixture was stirred for 15 min, then the 
volatiles were removed under high vacuum. The residual piperidine was removed by 
azeotropic distillation with toluene in vacuo. The residue was dissolved DMF (36.8 ml) and 
2,4-Dinitrofluorobenzene (27 l, 215 mol) was added to it, and the reaction mixture was 
stirred for 5 min. DMF was removed under high vacuum, and the residue was purified by 
silica gel chromatography (CHCl3/iPrOH= 95/5) to give cyclo-2’ as yellow solid (59 mg, 
50%). Purity >95%. Rf  = 0.43 (CHCl3/iPrOH, 9:1).  
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MS-HPLC calcd for: C35H47N5O7, expected: 649.35, found: 672.69 [M+Na]
+
, 648.26 [M-
H]
-
. 
1
H-NMR (CD3OD, 300 MHz): δ 7.06 (d, 2H, J=8.5 Hz, Har-Tyr); 6.71 (d, 2H, J=8.5 Hz, 
Har-Tyr); 4.77 (t, 1H, J= 7.5 Hz, H
α
-Ser); 4.37 (m, 3H, 1H
α
-Tyr, 1H
α
-Pro, 1H
α
-Leu); 4.03 
(d, 1H, J=5.8 Hz, H
α
-Val); 3.74 (m, 3H, 2H

-Ser, 1H

-Pro); 3.65 (m, 1H, 1H

-Pro); 3.04 (d, 
2H, J=8.0 Hz, 2H

-Tyr); 2.09 (m, 5H, 1H
β
-Val, 4H-Pro); 1.53 (m, 1H, 1H

-Leu); 1.28 (m, 
2H, 2H

-Leu); 0.99 (d, 6H, J=6.7 Hz, 2CH3-Val); 0.85(d, 3H, J=6.4, 1CH3-Leu); 0.73 (d, 
3H, J=6.4, 1CH3-Leu). 
To a solution of cyclo-2’(40 mg, 60 mol) in dry MeOH (2 ml), was added Pd(OH)2/C (4 
mg, 10% on activated charcoal) and the mixture was hydrogenated overnight under 
atmospheric pressure using an H2-filled balloon. The catalyst was removed by filtration 
through a pad of celite and the solvent evaporated under reduced pressure. The titled cyclo-
2a’ product was obtained as a pale yellow solid (31 mg, 90%). Purity >95%. The physical 
and spectroscopic data are the same to those obtained for its analogue cyclo-2a 
&Lys-Val-Tyr-Leu-D-Pro& (cyclo-16)  
The cyclization of the linear peptide 16 was performed in accordance to the protocol G. 
Reaction time 48 h. The crude cyclopeptide was dissolved in TFA-TIS-H2O/95:2.5:2.5 (10 
ml), at r.t. and stirred for 1 h. Excess TFA was removed under a stream of nitrogen. The 
residue was dissolved in ACN/H2O and lyophilized. The purification was performed by 
automated flash chromatography with RediSepC18 (0:20 to 20:50 H2O/ACN + 0.1% TFA, 
linear gradient over 30 min) yielding the product as a white solid (104 mg, 40%). Purity > 
98%. 
HPLC: tR (min, G0100 ACN in 8 min) = 4.623  
MS-HPLC calcd for: C31H48N6O6, expected: 600.36, found: 601.32 [M+H]
+ 
1
H-NMR (CD3OD, 400MHz): 7.06 (d, 2H, J=8.5 Hz, 2H-Tyr), 6.69 (d, 2H, J=8.5 Hz, 2H-
Tyr), 4.64 (m, 1H, H

-Leu), 4.43 (m, 1H, H

-Pro), 4.20 (m, 2H, H

-Lys), 4.09 (m, 1H, H

-
Tyr), 3.95 (t, 1H, J= 9.1 Hz, H

-Val), 3.71 (m, 1H, 1H

-Pro); 3.55 (m, 1H, 1H

-Pro); 3.17 
(m, 2H, H

-Tyr; 2.91 (t, 2H, J= 7.3 Hz, H-Lys), 2.22 (m, 2H, 1H-Val, 1H-Pro); 2.00 (m, 
4H, 3H-Pro, 1H-Lys), 1.77- 1.39 (m, 8H, 1H

-Leu, 2H

-Leu, 5H-Lys), 0.99 (m, 6H, 2CH3-
Leu); 0.91 (d, 3H, J=6.7 Hz, 1CH3-Val); 0.85 (d, 3H, J= 6.7 Hz, 1CH3-Val). 
&Phe(4-NH2)-Val-Tyr-Leu-D-Pro& (cyclo-17)  
The cyclization of the linear peptide 17 was performed in accordance to the protocol G. 
Reaction time 24 h. The crude cyclopeptide was dissolved in TFA-TIS-H2O/95:2.5:2.5 (10 
ml), at r.t. and stirred for 30 min. Excess TFA was removed under a stream of nitrogen. The 
residue was dissolved in ACN/H2O and lyophilized. The purification by HPLC-semi-
preparative (SunFirePrepC18, 25:50 H2O/ACN + 0.1% TFA, linear gradient over 25 min) 
gave the product as a white solid (30 mg, 35%). Purity > 98%. 
HPLC: tR (min, G2550 ACN in 8 min) = 3.57  
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MS-HPLC calcd for: C34H46N6O6, expected: 634.35, found: 635.42 [M+H]
+ 
1
H-NMR (CD3OD, 400MHz): 7.40 (d, 2H, J=6.4 Hz, 2H-Phe(4-NH2)); 7.25 (d, 2H, J=8.4 
Hz, 2H-Phe(4-NH2)); 7.07 (d, 2H, J=8.5 Hz, 2H-Tyr); 6.70 (d, 2H, J=8.5 Hz, 2H-Tyr); 4.61 
(m, 1H, H

-Leu); 4.51 (m, 1H, H

-Phe(4-NH2)); 4.36 (m, 1H, H

-Pro); 4.17 (m, 1H, H

-
Tyr); 3.93 (d, 1H, J=9.6 Hz, H

-Val); 3.63 (m, 1H, 1H

-Pro); 3.53 (m, 1H, 1H

-Pro); 3.30 
(m, 1H, 1H

-Phe(4-NH2)); 3.16 (d, 2H, J=8.1 Hz, 2H

-Tyr); 2.88 (m, 1H, 1H

-Phe(4-
NH2)); 2.20-2.11 (m, 2H, 1H

-Val, 1H Pro); 1.93 (m, 2H, 2H-Pro); 1.83-1.49 (m, 5H, 1H

-
Leu, 2H

-Leu, 1H-Pro); 1.00 (m, 6H, 2CH3-Leu); 0.90 (d, 3H, J=6.7 Hz, 1CH3-Val); 0.85 
(d, 3H, J=6.7 Hz, 1CH3-Val). 
&Cys-Val-Tyr-Leu-D-Pro& (cyclo-18) 
The cyclization of the linear peptide 18 was performed in accordance to the protocol G. 
Reaction time 24 h. The crude cyclopeptide was dissolved in TFA-TIS-H2O/95:2.5:2.5 (10 
ml), at r.t. and stirred for 30 min. Excess TFA was removed under a stream of nitrogen. The 
residue was dissolved in ACN/H2O and lyophilized. The purification by HPLC-semi-
preparative (SunFirePrepC18, 20:80 H2O/ACN + 0.1% TFA, linear gradient over 30 min) 
yielded the product as a white solid (30 mg, 15%). Purity > 98%. 
HPLC: tR (min, G2080 ACN in 8 min) = 5,48 
MS-HPLC calcd for: C28H41N5O6S, expected: 575.28, found: 576.27 [M+H]
+ 
1
H-NMR (CD3OD, 400MHz):  7.07 (d, 2H, J= 8.5 Hz, 2H-Tyr); 6.70 (d, 2H, J=8.5 Hz, 
2H-Tyr); 4.64 (dd, 1H, J= 9.8 Hz, J= 4.2 Hz); 4.47 (t, 1H, J= 7.1 Hz); 4.30-4.21 (m, 2H); 
3.95 (m, 2H); 3.58 (m, 1H); 3.19 (dd, 2H, J=9.7 Hz, J= 4.2 Hz); 2.93 (dd, 1H, J= 13.4 Hz, 
J= 7.3 Hz ); 2.71 (dd, 1H, J= 7.1, Hz, J= 2.4 Hz ); 2.32 (m, 1H), 2.08- 2.97 (m, 4H); 1.62 
(m, 2H), 1.48 (m, 1H), 0.99 (d, 6H, J=6.4 Hz), 0.93 (d, 3H, J=6.6 Hz), 0.87 (d, 3H, J=6.6 
Hz). 
&Glu-Val-Tyr-Leu-D-Pro& (cyclo-19) 
The cyclization of the linear peptide 19 was performed in accordance to the protocol G. 
Reaction time 24 h. The crude cyclopeptide was dissolved in TFA-TIS-H2O/95:2.5:2.5 (10 
ml), at r.t. and stirred for 30 min. Excess TFA was removed under a stream of nitrogen. The 
residue was dissolved in ACN/H2O and lyophilized. This compound was synthesized 
following the protocol G reported in the section 6.7. Reaction time 24 h. The purification 
was performed by automated flash chromatography with RediSepC18 (0:25 to 25:50 
H2O/ACN + 0.1% TFA, linear gradient over 30 min) yielding the product as white solid. 
(37 mg, 45%). Purity > 98%. 
HPLC: tR (min, G0100 ACN in 8 min) = 5.69 min 
MS-HPLC calcd for: C30H43N5O8, expected: 601.31, found: 602.25 [M+H]
+
 
1
H-NMR (CD3OD, 400MHz): d J=8.5 Hz, H-Tyr); 6.70 (d, 2H, J=8.5 Hz, 2H-
Tyr); 4.67 (dd, 1H, J= 10.5 Hz, J= 3.9 Hz, H
; 4.41(dd, 1H, J= 7.1 Hz, J= 4.4 Hz, H); 
4.22 (dd, 1H, J= 9.1 Hz, J= 4.8 Hz, H

); 4.04 (t, 1H, J=7.6 Hz, H

-Tyr); 3.97 (d, 1H, J=9.4 
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Hz, H

-Val); 3.71 (m, 1H, 1H

-Pro); 3.56 (m, 1H, 1H

-Pro); 3.22 (m, 2H, 2H

-Tyr); 2.42 
(m, 2H); 2.23-1.87 (m, 7H); 1.69 m, 1H); 1.59 (m, 1H); 1.51 (m, 1H); 1.00 (m, 6H); 0.91(d, 
3H, J=6.6 Hz), 0.81 (d, 3H, J=6.6 Hz).  
&Gln-Val-Tyr-Leu-D-Pro& (cyclo-20) 
The cyclization of the linear peptide 20 was performed in accordance to the protocol G. 
Reaction time 24 h. The purification by HPLC-semi-preparative (SunFirePrepC18, 20:50 
H2O/ACN + 0.1% TFA, linear gradient over 25 min) yielded the product as a white solid 
(35 mg, 54%). Purity > 98%. 
HPLC: tR (min, G2050 ACN in 8 min) = 6,35  
MS-HPLC calcd for: C30H44N6O7, expected: 600.33, found: 601.32 [M+H]
+ 
1
H-NMR (CD3OD, 400MHz): 7.07 (d, 2H, J=8.5 Hz, 2H-Tyr); 6.70 (d, 2H, J=8.5 Hz, 2H-
Tyr); 4.67 (m, 1H, H

-Leu); 4.0 (dd, 1H, J= 10.4 Hz, J=4.0 Hz, H

-Gln); 4.21 (m, 1H, H

-
Pro); 4.07 (t, 1H, J=7.6 Hz, H

-Tyr), 3.98 (d, 1H, J=9.4 Hz, H

-Val), 3.71 (m, 1H, 1H

-
Pro), 3.57 (m, 1H, 1H

-Pro), 3.19 (dd, 2H, J= 7.6 Hz, J=4.7 Hz, 2H

-Tyr), 2.34 (m, 2H, 
2H

-Gln), 2.18-1.93 (m, 7H, 1H

-Val, 4H-Pro, 2H

-Gln), 1.72 (m, 1H, CH

-Leu), 1.61-
1.49(m, 2H, 2H

-Leu), 0.99 (m, 6H, 2CH3-Leu), 0.92 (d, 3H, J=6.6 Hz, 1CH3-Val), 0.85 (d, 
3H, J=6.6 Hz, 1CH3-Val). 
&Arg-Val-Tyr-Leu-D-Pro& (cyclo-21) 
The cyclization of the linear peptide 21 was performed in accordance to the protocol G. 
Reaction time 16 h. The purification by HPLC-semi-preparative (SunFirePrepC18, 30:40 
H2O/ACN + 0.1% TFA, linear gradient over 25 min) yielded the product as a white solid 
(15 mg, 16%). Purity > 99%. 
HPLC: tR (min, G2050 ACN in 8 min) = 4,34  
MS-HPLC calcd for: C31H48N8O6, expected: 628.37, found: 629.33 [M+H]
+ 
1
H-NMR (CD3OD, 400MHz): d, J=8.5 Hz, H-Tyr); 6.70 (d, 2H, J=8.5 Hz, H-
Tyr); 4.6 (dd, 1H, J= 10.6 Hz, J= 4.0 Hz, H

-Leu4.44 (dd, 1H, J= 7.5 Hz, J= 4.4 Hz); 
4.22 (dd, 1H, J= 9.0 Hz, J= 4.8 Hz); 4.12 (t, 1H, J= 7.6 Hz, H

-Tyr); 3.96 (d, 1H, J=9.4 Hz, 
H

-Val); 3.69 (m, 1H, 1H

-Pro); 3.55 (m, 1H, 1H

-Pro); 3.30 (m, 4H, 2H

-Trp, 2H

-Arg); 
2.20 (m, 6H, 1H

-Leu, 2H

-Leu, 3H-Arg); 1.71 (m, 5H, 4H-Pro, 1H-Arg); 1.58 (m, 1H, 
1H

-Val); 0.99 (m, 6H, 2CH3-Val); 0.91 (d, 3H, J=6.6 Hz, 1CH3-Leu); 0.85 (d, 3H, J=6.6 
Hz, 1CH3-Leu).  
&Trp-Val-Tyr-Leu-D-Pro& (cyclo-22) 
The cyclization of the linear peptide 22 was performed in accordance to the protocol G. 
Reaction time 48 h. The purification was performed by automated flash chromatography 
with RediSepC18 (0:25 to 20:50 H2O/ACN + 0.1% TFA, linear gradient over 30 min) 
yielding the product as a white solid (30 mg, 30%). Purity > 95%. 
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HPLC: tR (min, G4070 ACN in 8 min) = 4,71 min 
MS-HPLC calcd for: C36H46N6O6, expected: 658.35, found: 659.25 [M+H]
+ 
1
H-NMR (CD3OD, 400MHz): d,  J=7.7 Hz, H-Trp), 7.33 d, J=7.9 Hz, H-
Trp), 7.10 (m, 4H, 2H-Trp, 2H-Tyr), 6.70 (d, 2H, J=8.5 Hz, 2H-Tyr), 4.66-4.57 (m, 2H, H

-
Trp, H

-Leu), 4.41 (m, 1H, H

-Pro), 4.14 (t, 1H, J=8.4 Hz, H

-Tyr), 3.90 (d, 1H, J=9.5 Hz, 
H

-Val), 3.64 (m, 1H, 1H

-Pro), 3.52 (m, 1H, 1H

-Pro), 3.42-3.36 (dd, 1H, J= 14.7 Hz, 
J=4.3 Hz, 1H

-Trp), 3.19 (dd, 2H, J= 8.4 Hz, J= 2.6 Hz, H

-Tyr), 3.07 (dd, 1H, J= 14.7 Hz, 
J=4.8 Hz, 1H

-Trp), 2.15 (m, 2H, 1H

-Val, 1H-Pro), 1.92 (m, 3H, 3H-Pro), 1.71-1.50 (m, 
4H, H

-Leu, 2H

-Leu, 1H

-Trp), 1.00 (m, 6H, 2CH3-Leu), 0.81 (t, 6H, J=6.4 Hz, 2CH3-
Val).  
& Ser-Val-Tyr-Leu-D-Pro& (cyclo-23) 
The cyclization of the linear peptide 23 was performed in accordance to the protocol G. 
Reaction time 48 h. The purification by HPLC-semi-preparative (SunFirePrepC18, 20:50 
H2O/ACN + 0.1% TFA, linear gradient over 25 min) yielded the product as a white solid 
(22 mg, 20%). Purity > 99%. 
HPLC: tR (min, G0100 ACN in 8 min) = 5,38  
MS-HPLC calcd for: C28H41N5O7, expected: 559.30, found: 560.14 [M+H]
+ 
1
H-NMR (CD3OD, 400MHz):  (d, 2H, J=8.5 Hz, H-Tyr); 6.70 (d, 2H, J=8.5 Hz, H-
Tyr); 4.67 (dd, 1H, J= 10.5 Hz, J= 4.0 Hz, H

-Leu); 4.46 (dd, 1H, J= 7.4 Hz, 4.8 Hz, 1H

-
Pro); 4.29 (t, 1H, J=4.2 Hz, H

-Ser); 4.07 (t, 1H, J= 7.6 Hz, H

-Tyr); 4.03 (d, 1H, J=9.4 Hz, 
H

-Val); 3.87 (m, 2H, H

-Ser), 7.73 (m, 1H, 1H

-Pro); 3.58 (m, 1H, 1H

-Pro); 3.18 (m, 2H, 
2H

-Tyr), 2.16-1.99 (m, 5H, 2H-Pro, 1H

-Val), 1,72 (m, 1H, 1H

-Leu), 1.62 (m, 2H, 2H

-
Leu), 1.01 (m, 6H, 2CH3-Leu), 0.93 (d, 3H, J=6.7 Hz, 1CH3-Val), 0.86 (d, 3H, J=6.7 Hz, 
1CH3-Val). 
&Dap-Val-Tyr-Leu-D-Pro& (cyclo-24) 
The cyclization of the linear peptide 24 was performed in accordance to the protocol G. 
Reaction time 24 h. The purification by HPLC-semi-preparative (SunFirePrepC18, 20:80 
H2O/ACN + 0.1% TFA, linear gradient over 25 min) yielded the product as a white solid 
(10 mg, 15%). Purity > 99%. 
HPLC: tR (min, G0100 ACN in 8 min) = 4.70  
MS-HPLC calcd for: C28H42N6O6, expected: 558.32, found: 559.37 [M+H]
+ 
1
H-NMR (CD3OD, 400MHz):  (d, 2H, J= 8.5 Hz, H-Tyr); 6.71 (d, 2H, J=8.5 Hz, H-
Tyr); 4.71 (dd, 1H, J= 8.3 Hz, J= 5.2 Hz, H

-Dap); 4.45 (m, 2H, 1H

-Pro, 1H

-Leu); 4.30 
(t, 1H, J=8.1 Hz, H

-Tyr); 3.76 (d, 1H, J=9.8 Hz, H

-Val), 3.65 (m, 1H, 1H

-Pro), 3.55 (m, 
1H, 1H

-Pro); 3.41 (dd, 1H, J=13.1 Hz, J= 5.2 Hz, 1H

-Dap); 3.19 (dd, 1H, J=13.1 Hz, J= 
8.3 Hz, 1H

-Dap); 3.40 (d, 2H, J=8.1 Hz, H

-Tyr), 2.35 (m, 1H, H

-Val), 2.11-1.96 (m, 4H, 
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H-Pro), 1,60 (m, 3H, 1H

-Leu, 2H

-Leu), 0.98 (m, 9H, 1CH3-Val, 2CH3-Leu), 0.87 (d, 3H, 
J=6.6 Hz, 1CH3-Val).  
&Ala-Val-Tyr-Leu-D-Pro& (cyclo-25) 
The cyclization of the linear peptide 25 was performed in accordance to the protocol G. 
Reaction time 48 h. The purification was performed by automated flash chromatography 
with RediSepC18 (0:25 to 20:50 H2O/ACN + 0.1% TFA, linear gradient over 30 min) 
yielding the product as white solid (40 mg, 46%). Purity > 99%. 
HPLC: tR (min, G30100 ACN in 8 min) = 3.58  
MS-HPLC calcd for: C28H41N5O6, expected: 543.31, found: 544.30 [M+H]
+ 
1
H-NMR (CDCl3, 300 MHz): d,  J= 9.1 Hz, NH); 7.38 d,  J= 8.4 Hz, NH); 
7.16 (d, 1H, J= 7.0Hz, NH); 7.09 (d, 1H, d, J=7.4 Hz, NH-Ala); 7.02 (d, 2H, J=8.5 Hz, H-
Tyr); 6.72 (d, 2H, J=8.5 Hz, H-Tyr); 4.77 (q, 1H, J= 7.2 Hz, -Ala); 4.42 (m, 1H, H-
Pro); 4.33 (t, 1H, J= 7.4 Hz, H

-Leu); 4.07 (m, 1H, H

-Tyr); 3.82 (m, 1H, 1H

-Pro); 3,72 (t, 
1H, J= 9.1 Hz, H

-Val

); 3.50 (m, 1H, 1H

-Pro); 3.29 (m, 2H, H

-Tyr); 2.20 (m, 3H, 3H-
Pro); 1,95 (m, 2H, 1H

-Leu, 1H-Pro); 1.59 (m 3H, 1H

-Val, 2H

-Leu); 1.40 (d, 3H, J=7.2 
Hz, CH3-Ala); 0.96 (m, 6H, 2CH3-Val); 0.84 (d, 3H, J=6.6 Hz, 1CH3-Leu); 0.76 (d, 3H, 
J=6.6 Hz, 1CH3-Leu). 
&Lys(NHAc)-Val-Tyr-Leu-D-Pro& (cyclo-28) 
The cyclization of the linear peptide 28 was performed in accordance to the protocol G. 
Reaction time 48 h. The crude cyclopeptide was dissolved in TFA-TIS-H2O/95:2.5:2.5 (10 
ml), at r.t. and stirred for 30 min. Excess TFA was removed under a stream of nitrogen. The 
residue was dissolved in ACN/H2O and lyophilized  
The purification by HPLC-semi-preparative (SunFirePrepC18, 20:50 H2O/ACN + 0.1% 
TFA, linear gradient over 25 min) yielded the product as a white solid (15 mg, 26%). Purity 
> 98%. 
HPLC: tR (min, G2050 MeCN in 8 min) = 6,53  
MS-HPLC calcd for: C33H50N6O7, expected: 642.37, found: 643.27 [M+H]
+ 
1
H-NMR (CD3OD, 400MHz): 7.06 (d, 2H, J=8.5 Hz, 2H-Tyr), 6.69 (d, 2H, J=8.5 Hz, 2H-
Tyr), 4.71 (m, 1H, H

-Leu), 4.42 (m, 1H, H

-Pro), 4.13 (m, 2H, H

-Lys), 3.96 (m, 2H, H

-
Tyr, H

-Val), 3.72  (m, 1H, 1H

-Pro); 3.57 (m, 1H, 1H

-Pro); 3.20-3.13 (m, 4H, 2H

-Tyr, 
H-Lys), 2.24-1.98 (m, 6H, 1H-Val, 4H-Pro, 1H-Lys), 1.90 (s, 3H, NH-Ac), 1.71- 1.46 
(m, 8H, 1H

-Leu, 2H

-Leu, 5H-Lys), 0.99 (m, 2CH3-Leu); 0.91 (d, 3H, J=6.7 Hz, 1CH3-
Val); 0.85 (d, 3H, J= 6.4 Hz, 1CH3-Val). 
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5.3. Synthesis peptidomimetic 
1,3,4,6-Tetra-O-acetyl-2-deoxy-2-tetrachlorophthalimido--D-glucopyranoside (34). 
This compound was synthesized following previous reported procedure. The 
characterization data match with the literature.
2
 
3,4,6-tri-O-acetyl-2-deoxy-2-tetrachlorophthalimido--D-glucopyranosyl cyanide. (36) 
To a solution of 34 (300 mg, 0.488 mmol) in DCM (3 ml) was added HBr (33 wt. % in 
AcOH, 1.8 ml, 8.5 mmol). After stirring in darkness for 12 h, the reaction mixture was 
diluted with CH2C12 and poured onto ice cold H2O. The layers were separated and the 
organic portion was washed with H2O and with a saturated solution of NaHCO3, dried and 
concentrated to a syrup 35 which was used without any further purification for the 
subsequent reaction. To a solution of 35 in dry nitromethane (3 ml) was added mercuric 
cyanide (135.6 mg, 0.537 mol) at 0°C and the reaction was allowed to proceed under 
stirring at r.t. for 2 h, according to the method reported in literature.
3
 The mixture was 
filtrated on a pad of celite and the filtrate was concentrated in vacuo. The residue was 
diluted in CH2Cl2 and washed with an aqueous solution of KBr 1M (2x50 ml). The organic 
layers was combined, washed with brine, dried over Na2SO4, filtered and concentrated in 
vacuo.  
Purification by silica gel column chromatography (PE/EtOAc, 7/3) furnished the compound 
36 as a white solid (255 mg, 90% over 2 steps). Purity =98%. Rf= 0.3 (n-hexane/EtOAc, 
7:3) 
1
HNMR (CD3OD, 300MHz): 5.64 (dd, 1H, J3,4=9.2 Hz; J2,3=10.1 Hz, H3); 5.36 (d, 1H, 
J=10.7 Hz, H1); 5.24 (dd, 1H, J3,4=9.2 Hz; J4,5=10.1 Hz, H4); 4.64 (dd, 1H, J1,2=10.7 Hz; 
J2,3=10.1, H2); 4.28 (dd, 1H, J5,6=4.6 Hz, J6,6’=12.5 Hz, 1H); 4.19 (dd, 1H, J5,6’=2.2 Hz, 
J6,6’=12.5 Hz, 1H); 3.84 (m, 1H, H5); 2.13 (s, 3H, OAc); 2.04 (s, 3H, OAc); 1,90(s, 3H, 
OAc). 
13
C NMR (CD3OD, 75 MHz): 170.50 (3C, s); 170.46 (2C, s); 141.17 (2C, s); 130.45 (2C, 
s); 126.78 (2C, s); 114.08 (1C, s); 76.78 (1C, d); 70.47 (1C, d); 67.56 (1C, d); 61.50 (1C, t); 
53.11 (1C, d); 20.72 (3C, q).  
2,6,-anhydro-3,4,7-tri-O-acetyl-2-tetrachlorophthalimido-2-deoxy-D-glycero-D-gulo- 
Heptonic acid (38) 
The solution of 36 (250 mg, 0,43 mmol) in HCl/dioxane [4M] (4.5 ml) was heated to 60°C 
and stirred overnight. The solvent were removed in vacuo, then the residue was treated with 
acetic anhydride (0.5 ml, 6.88 mmol) in pyridine (1.4 ml, 13.76 mol) for 12 h at room 
temperature. The mixture was concentrate in vacuo, the residue was dissolved in CH2Cl2 
and washed with HCl (1N), aqueous saturated NaHCO3 (20 ml) and brine (20 ml), dried 
over sodium sulfate (Na2SO4), and concentrated in vacuo. The purification by silica flash 
chromatography (PE/AcOEt, 75:35) yielded the title compound 38 as a white solid (180 
mg, 70%). Rf= 0.28 (PE/EtOAc, 7:3). 
MS-HPLC calcd for: C21H17Cl4NO11, expected: 598.96, found: 597.67 = [M-H]
-
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1
HNMR (CD3OD, 300MHz): 83 (t, 1H, J= 9.1 Hz, H3); 5.13 (t, 1H, J= 9.1 Hz, H4); 4.93 
(d, 1H, J= 9.0 Hz, H1); 4.51 (t, 1H, J= 9.1 Hz, H2); 4.32 (dd, 1H, J=12.5 Hz, J=4.8 Hz, 
1H6); 4.20 (dd, 1H, J=12.5 Hz, J=4.8 Hz, 1H); 4.01 (m, 1H, H5); 2,93 (s, 3H, OAc); 2.04 
(s, 3H, OAc); 1.87(s, 3H OAc). 
13
C NMR (CD3OD, 75 mHz): 171.48 (1C, s); 170.80 (1C, s); 170.04 (C, s); 163.33 (1C, s), 
139.16 (1C, s); 129.39 (2C, s); 127.84 (2C, s); 75.60 (1C, d); 71.70 (1C, d); 68.91 (1C, d); 
62.43 (1C, t); 53.13 (1C, d); 29.40 (1C, d); 20.72 (1C, q); 19.43 (1C, q); 19.29 (1C, q); 
19.17 (1C, q).  
Compound (39) 
To a stirred solution of 38 (150 mg, 0.25 mmol) in dry CH2Cl2/DMF (2:1 v/v, 3 ml) was 
added sequentially HBTU (113.7 mg, 0.3 mmol) and DIPEA (130.6 l, 0.75 mmol). After 
15 min, serine(tBu)-tert-butyl ester (65.15 mg, 0.3 mmol); in dry CH2Cl2/DMF (2:1 v/v, 2 
ml). The reaction mixture was allowed to proceed at room temperature under stirring for 
2.5 h. Then it was diluted with CH2Cl2 (20 ml), washed with  HCl 1N (20 ml), water (10 
ml), saturated aqueous NaHCO3 solution (20 ml) and brine (20 ml). The combined organic 
layers were dried over Na2SO4 and concentrated in vacuo. Purification by silica gel column 
chromatography (n-hexanes/EtOAc, 8:2 to 7:3) yielded the compound 39 (192 mg, 96%). 
Purity = 98%. Rf= 0.3 (n-hexanes/AcOEt, 7:3). 
1
HNMR (CDCl3, 300MHz,): (d, 1H, J= 7.9 Hz, NH); 85 (t, 1H, J= 9.0 Hz, H3); 
5.18 (t, 1H, J= 9.0 Hz, H4); 4.90 (d, 1H, J= 10.7 Hz, H1,); 4.44 (t, 1H, J= 10.4 Hz, H2); 4.32 
(m, 1H, H

-Ser); 4.29 (dd, 1H, J=8.8 Hz, J=3.0 Hz, 1H6); 4.12 (dd, 1H, J=8.8 Hz, J=3.0 Hz, 
1H6); 3.92 (m, 1H, H5); 3.68 (dd, 1H, J= 8.8 Hz, J= 3 Hz, 1H

-Ser); 3.46 (dd, 1H, J= 8.8 
Hz, J= 3Hz, 1H

-Ser); 2.11 (s, 3H, OAc), 2.04 (s, 3H, OAc); 1.91 (s, 3H, OAc); 1.46 (s, 
3H, OtBu); 1.10 (s, 3H, OtBu). 
Compound (40) 
Compound 49 (192 mg, 0,240 mmol), was dissolved in a solution of NH3 in MeOH [2M] 
(4ml), the mixture was allowed to react under stirring at room temperature for 18 h, then 
the solution was concentrated in vacuo. The residue was triturated first with toluene, then 
with cold ethyl ether affording 40 as a white solid. (93 mg, 96%). Purity 98%. Rf = 0.44 
(ACN/MeOH/H2O, 7:2:1). 
1
HNMR (CD3OD, 300 MHz):  (t, 1H, J= 3.9 Hz, H

-Ser,); 4.14 (d, 1H, J= 10.1 Hz, 
H1); 4.02 (t, 1H, J= 9.7 Hz, H2); 3.85 (dd, 1H, J= 11.9 Hz; J= 2.1Hz, 1H6); 3.76 (m, 3H, H3, 
1H6, 1H

-Ser); 3.58 (m, 1H, 1H

-Ser); 3.45 (t, 1H, J= 9.4 Hz, H4,); 3.89 (m, 1H, H5); 1.87 
(3H, s, OtBu); 1.18 (s, 3H, OtBu). 
13
CNMR (CD3OD, 75 MHz):  (1C, s);  (1C, s); 81.81 (1C, s); 80.57 (1C, d); 
76.80 (1C, d); 76.03 (1C, d); 73.28 (1C, s); 69.42 (1C, d); 61.72 (1C, t); 61.34 (1C, t); 
55.01 (1C, d); 53.5 (1C, d); 27.01 (3C, q); 26.33 (3C, q).  
 
Experimental section 
 
 
113 
Boc-Val-Tyr(OBzl)-Leu-SAA-Ser-(OtBu) (42) 
Boc-Val-Tyr(OBzl)-Leu-OH 41 (134 mg, 0.23 mmol) and HBTU (87.3 mg, 0.23 mmol) 
were dissolved in dry DCM/DMF (2:1 v/v, 3 ml), and the reaction mixture was stirred for 3 
h at r.t. under nitrogen atmosphere. DIPEA (100l, 0.57 mmol) was added, followed by a 
solution of 40 (85 mg, 0.21 mmol) in DCM/DMF (2:1 v/v, 3 ml). The reaction mixture was 
stirred for further 12 h, and then the mixture was diluted with CH2Cl2, and washed with 1 N 
aqueous HCl solution (2 x 20ml), aqueous saturated solution of NaHCO3 (2 x 20ml) and 
brine (1 x 20 ml). The combined organic layer was dried over Na2SO4 and concentrated in 
vacuo. Purification of the residue by silica gel chromatography (DCM/MeOH = 95/5) gave 
the product 42 as a yellow solid (111 mg, 60%). Purity =95%. Rf = 0.44 (DCM/MeOH, 
9:1). 
MS-HPLC calcd for: C50H77N5O14, expected: 971.55, found: 972.14 = [M+H]
+
, 994.31 = 
[M+Na]
+
  
1
H NMR (CDCl3, 300 MHz):  7.60 (bs, 1H, NH); 7.35 (m, 5H); 7.01 (d, 2H, J= 8.5 Hz); 
6.88 (d, 2H, J= 8.5 Hz); 4.98 (d, 2H); 4.49 (bm, 2H); 4.32 (bm, 1H); 3.87 (m, 8H); 3.51 (m, 
1H); 3.40 (m, 1H); 3.00 (bm, 2H); 3.64 (bm, 1H, OH); 2.08 (bm, 1H); 1.51 (m, 18H); 1.6 
(s, 3H); 1.12 (d, 9H, J= 6.9 Hz); 0.86 (m, 12H). 
13
C NMR (CDCl3, 75 MHz): 173.49 (1C, s); 173.07 (1C, s); 172.32 (1C, s); 169.75 (1C, s); 
168.81 (1C, s); 158.12(1C, s); 156.70 (1C, s); 137.16 (1C, s); 137.0 (1C, s); 130.39 (1C, d); 
128.69 (1C, d); 128,29 (2C, d); 128.22 (1C, s); 127.62 (2C, d); 115.38 (1C, d); 115.10 (1C, 
d); 82.36 (1C, s); 82.27 (1C, s); 75.99 (1C, d); 73.56 (1C, t); 70.05 (1C, t); 62.29 (1C, t); 
61.71 (1C, t); 61.14 (1C, d); 55.24 (1C, d); 54.75 (1C, d); 54.47 (1C, d); 53.30 (1C, d); 
53.17 (1C, d); 30.13 (1C, d); 29.83 (1C, t); 28.36 (9C, q); 27.17 (9C, q); 27.45 (9C, q); 
24.63 (1C, d); 23.32 (1C, q); 21.34 (1C, q); 19.45 (1C, q); 17.78 (1C, q).   
Cyclo-(Val-Tyr(OBzl)-Leu-SAA-Ser) (44) 
The compound 42 (54 mg, 55 mol) was dissolved in 40% TFA/CH2Cl2 (800 l), and the 
solution was stirred for 15 min. The volatiles were removed in vacuo, and the residual TFA 
was removed by azeotropic distillation with toluene in vacuo yielding the product 43 which 
was not purified but used directly in the next reaction.  
To a solution of HATU (67.8 mg, 0.22 mmol), HOBt (29.7 mg, 0.22 mmol), and DIPEA 
(76.6 l, 0.44 mmol) in dry DMF was added dropwise, in an ice bath, a solution of 43 in dry 
DMF (final concentration 8·10
-4 
M). The reaction mixture was stirred for 56 h at r.t., then 
was concentrate in vacuo. Purification of the residue by silica gel chromatography 
(ACN/MeOH= 93:7) gave the title compound 44 as a white solid (18 mg, 46%). Purity 
=90%. Rf= 0.18 (ACN/MeOH, 90:10). 
MS-HPLC calcd for: C37H51N5O11, expected: 741.36, found: 764.04 = [M+Na]
+
, 739.86 = 
[M-H]
-
  
1
H NMR (CD3OD, 300 MHz):  7.36 (m, 5H); 7.07 (d, 2H, J=8.5 Hz); 6.88 (d, 2H, J=8.5 
Hz); 5.06 (s, 2H); 4.70 (m, 1H); 4.50 (bm, 3H); 4.26 (d, 1H, J=4.5 Hz); 4.03 (m, 2H); 3.86 
(m, 4H); 3.45 (m, 2H); 3.00 (bm, 2H); 1.70 (m, 3H); 0.89 (m, 6H); 0.77 (m, 6H). 
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Cyclo-(Val-Tyr-Leu-SAA-Ser) (45) 
Cyclo-(Val-Tyr(OBzl)-Leu-SAA-Ser) 44 (10 mg, 0.013 mmol) was dissolved in dry MeOH 
(2 ml) and 10% Pd(OH)2/C (2 mg) was added to it. The suspension was stirred for 12 h 
under H2 atmosphere (balloon). The reaction mixture was filtrated through a pad of celite, 
and the filtrate was concentrated in vacuo giving 45 (8.8 mg, 100%) as a white solid. Purity 
90%. Rf= 0.10 (ACN/MeOH, 90:10). 
MS-HPLC calcd for: C30H45N5O11, expected: 651.31, found: 674.09 = [M+Na]
+
, 649.86 = 
[M-H]
-
  
1
H NMR (300 MHz, CD3OD):  6.88 (d, 2H, J=8.4 Hz); 6.72 (d, 2H, J=8.4 Hz); 4.50 (s, 
4H); 4.28 (m, 1H); 4.03 (bm, 2H); 4.85 (m, 6H,); 3.30 (m, 2H); 3.06 (bm, 2H); 2.01 (m, 
1H) 1.65 (m, 3H); 0.93 (m, 12H). 
5.4. Synthesis glycosidic carrier  
-D-glucose pentabenzoate (37) 
This compound was synthesized following previous reported procedure. The 
characterization data match with the literature.
4
  
Benzyl 6-O-acetyl-2,3,4-tri-O-benzyl--D-glucopyranoside (38) 
This compound was synthesized following previous reported procedure.
4
 The crude was 
recrystallized from MeOH affording 38 as a white solid (856 mg, 78%). Purity= 98% Rf= 
0.41 (toluene/AcOEt, 8:2). [α]D
20
 (c 1, CHCl3) = -2.9° 
1
H-NMR (CDCl3, 300MHz,) : 7.32 (m, 20H); 4.96-4.49 (m, 9H); 4.35 (dd, 1H, J= 4.5 Hz, 
J= 1.8 Hz); 4.27 (dd, 1H, J= 4.5 Hz, J=1.8 Hz); 3.67 (d, 1H, J= 9 Hz); 3.54 (m, 3H); 2.08 (s, 
3H). 
13
C NMR spectrum is in agreement with those published.
4
 
Benzyl 2,3,4-tri-O-benzyl--D-glucopyranoside (39) 
To a solution of 38 (4.2g, 7.21 mmol) in CH2Cl2/MeOH (2:1 v/v, 50ml) was added 
dropwise sodium methoxide (freshly prepared 1.0 M solution in MeOH, 2.16 ml) at r.t and 
left to stir for 3 h. The solution was acidified to pH 7 by the addition of Dowex 50 (H
+
), 
then the mixture was filtrated and the solvent removed in vacuo. 
Purification by silica gel chromatography (n-hexane/AcOEt= 8/2) affording 39 as a white 
solid (2.6g, 67%). Purity= 98%. Rf= 0.17 (n-hexane/AcOEt, 8:2). [α]D
20
 (c 1, CHCl3) = -
9.2° 
1
H-NMR (CDCl3, 300MHz,) : 7.32 (m, 20H); 4.96-4.49 (m, 9H); 3.86 (m, 1H); 3.71-3.49 
(m, 4H); 3.38 (m, 1H); 1.86 (m, 1H).   
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Benzyl 2,3,4-tri-O-benzyl-6-O-(t-butylcarboxymethyl)--D-glucopyranoside (40) 
To a solution of 39 (1.30 g, 2.4 mmol) in toluene (13 ml) were added NaOH (40% aqueous 
solution, 13 ml) and Bu4NHSO4 (981 mg, 2.89 mmol) and left to stir for 10 min, then tert-
Butyl bromoacetate (1.07 ml, 7.22 mmol) was added and the reaction mixture was stirred at 
r.t. for 5 h. The mixture was diluted with H2O and the product extracted with CH2Cl2. The 
organic layers were combined, washed with brine, dried over Na2SO4, filtered and 
evaporated to give a yellow oil. Crystallization from MeOH gave 40 as a white solid (1.44 
g, 91%). Purity= 99%. Rf= 0.46 (n-hexane/AcOEt, 8:2).  
1
H-NMR (CDCl3, 300MHz,) : 7.29 (m, 20H); 4.96-4.48 (m, 8H); 4.5 (d, 1H, J= 11.7 Hz) 
4.04 (s, 2H); 3.84 (m, 2H); 3.63 (m, 2H); 3.51 (m, 2H); 1.47 (s, 9H). 
13
CNMR (CDCl3, 75 MHz,) : 169.87 (1C, s); 139.01 (1C, s); 138.78 (1C, s); 138.64 (2C, 
s); 137.83 (1C, s); 128.74-128.18 (20C, d); 130.0 (1C, d); 85. 06 (1C, d); 82.59 (1C, d); 
81.76 (1C, t); 77.99 (1C, d); 77.09 (1C, t); 75.41 (1C, d); 71.53 (1C, t); 70.59 (1C, t); 69.93 
(1C, d); 28.50 (3C, q). 
Benzyl 2,3,4-tri-O-benzyl-6-O-(carboxymethyl)--D-glucopyranoside (41) 
The title compound 40 (800 mg, 1.22 mmol) was dissolved in 40% TFA/CH2Cl2 (5 ml), 
and the solution was stirred for 2 h at r.t. The volatiles were removed in vacuo, and the 
residual TFA was removed by azeotropic distillation with toluene in vacuo to give the 
product as a white solid (730 mg, 100%). Purity 95%. Rf = 0.54 (DCM/MeOH, 9:1).  
HPLC: tR (min, G0100 ACN in 8 min) = 9.39 
MS-HPLC calcd for: C36H38O8, expected: 598.26, found: 621.26 [M+Na]
+
  
1
H-NMR (CDCl3, 300MHz,) : 7.39 (m, 20H); 5.03-4.16 (m, 9H); 4.16 (s, 2H); 3.88-3.60 
(m, 6H). 
5.5. Synthesis of cyclic peptides functionalized with the glycosidic carrier  
5.5.1. Condensation in solution 
&Lys(carrier)-Val-Tyr-Leu-D-Pro& (56a) 
Method A: carboxylic acid pre-activation as succinimidyl ester. 
To a solution of 51 (100 mg, 0.167 mmol) and NHS (76.0 mg, 0.668 mmol) in a 2:1 
mixture of CH2Cl2/DMF (3 ml), EDC (35 mg, 0.184 mmol) was added and the mixture was 
stirred for 12 h at r.t. The reaction mixture was diluted with CH2Cl2 and washed with H2O. 
The organic layers were combined, dried over Na2SO4, filtered and evaporated to give a 
colorless syrup 52 which has greater than 95% purity and was used directly for the next 
coupling reaction. Rf= 0.16 (cyclohexane/Acetone, 1:1)  
To a solution of 52 (35 mg, 0.5 mmol), cyclo-1c (25 mg, 0.042 mmol) in CH2Cl2 (5 ml) 
was added DIPEA (36.5 l, 0.21 mmol). The reaction was left to stir at r.t. for 20 h, then 
the mixture was washed with a 5% solution of citric acid, saturated aqueous solution of 
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NaHCO3 and brine. The organic phase was dried over Na2SO4, filtered and the solvent was 
removed in vacuo. 
Purification by silica gel flash chromatography (toluene/iPrOH= 9:1) yielded 55a as a white 
solid (29 mg, 60%). Purity =98%. Rf= 0.4 (toluene/iPrOH, 9:1).  
MS-HPLC calcd for: C67H84N6O13, expected: 1180.61, found: 1203.73 = [M+Na]
+
 
To a solution of a 55a (29 mg, 0.025 mmol) in dry MeOH (2 ml) was added Pd(OH)2/C (3 
mg, 10% on activated charcoal) and the mixture was hydrogenated overnight under 
atmospheric pressure using an H2-filled balloon. The catalyst was removed by filtration 
through a pad of celite and the solvent was evaporated under reduced pressure. The product 
56a was recovered as a white solid (18 mg, 90%). Purity 98%. 
Method b: HATU mediated condensation 
To a solution of 51 (15 mg, 0.025 mmol), in DMF (1ml) is added HATU (11.40 mg, 0.030 
mmol), DIEA (10.45 l, 0.06 mmol) and cyclo-1c (18 mg, 0.030 mmol). The reaction was 
allowed to stir at r.t. for 16 h. The mixture was diluted with CH2Cl2, washed with HCl 1N, 
a saturated aqueous solution of NaHCO3 and brine. The organic phase was dried over 
Na2SO4, filtered and the solvent was removed in vacuo. The product was directly 
underwent to hydrogenolysis according to the procedure describe before. 
Purification by HPLC-semi-preparative (SunFirePrepC18, 0:80 H2O/ACN + 0.1% TFA, 
linear gradient over 25 min) yielded the product 56a as white solid (14 mg, 70%, over two 
steps). Purity = 99%. 
5.5.2. Synthesis of peptides functionalized with a glycosidic carrier on solid phase 
Peptide (13) 
The linear peptide was synthesized manually by SPPS using the Fmoc/tBu strategy and Cl-
Trt resin following the experimental conditions reported in the section 6.5 of the chapter 6 
General methods and procedures. The synthesis was performed at a 400 µmol scale. 
Peptide chain elongation was carried out using PyBOP, HOAt and DIEA as coupling 
reagents, according to the conditions reported in the section 6.6. During couplings the 
mixture was left to react (45 min) with intermittent manual stirring and the good outcome 
of each coupling was verify by ninhydrin or chloranil test. The Fmoc groups were removed 
by treatment with 20% of piperidine in DMF and the Leucine Alloc protecting group was 
removed by treatment with Pd(PPh3)4 as described in the section 6.5.15. After the synthesis, 
the peptide-resin 13 was splitted in 3 different polypropylene syringes.  
Peptide (54a) 
The peptide-resin 13 was subjected to a standard treatment with piperidine (20% in DMF, 
1x1 min, 2x10 min). Then the coupling with the Boc-Lys-(Fmoc)-OH, carried out under the 
same conditions described before (PyBOP/HOAt/DIEA), gave the pentapeptide 52a. 
Treatment with piperidine (20% in DMF) removed the Fmoc protecting group on the Lys 
side chain amino group providing the intermediate 53. Subsequently, a mixture of 51 
(45mg), PyBOP (39 mg) and HOAt (10.4 mg) was dissolved in DMF (400 l) and pre-
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activated by adding DIEA (26 l). After 1 min the mixture was added to the peptide-resin 
53. The coupling was performed at r.t. with intermittent manual stirring, for 1.5 h. 
Treatment with the cocktail cleavage solution TFA/TIS/H2O-94:3:3 (1h) provided the 
peptide complete deprotection and cleavage from the resin, yielding the product 47a. 
Crude products were analyzed by RP-HPLC and MS-HPLC. 
HPLC: tR (min, G0100 ACN in 8 min) = 7.06 
MS-calcd for: C67H86N6O14, expected: 1198.62, found: 1199.71 [M+H]
+
 
Peptide (54b) 
This compound was synthesized following the previous reported procedure for 54a. The 
coupling was performed with Phe(4NH-Fmoc)-OH instead of with Boc-Lys-(Fmoc)-OH.  
HPLC: tR (min, G0100 MeCN in 8 min) = 7.06 
MS-calcd for: C70H84N6O14, expected: 1232.60, found: 233.68 [M+H]
+
; 1255.81 [M+Na]
+
  
Peptide (54c) 
This compound was synthesized following the previous reported procedure for 54a. The 
coupling was performed with Dap(4NH-Fmoc)-OH instead of with Boc-Lys-(Fmoc)-OH. 
HPLC: tR (min, G0100 MeCN in 8 min) = 7.06 
MS-calcd for: C64H80N6O14, expected: 1156.57, found: 1157.69 [M+H]
+ 
Synthesis cyclic peptides 54 (a-c) 
The head-to-tail peptide cyclizations of linear peptide 54 (a-c) were performed with DPPA 
according to the protocol G described in the section 6.7. The linear peptides were dissolved 
in DMF (5 mM solution) and to the solution were added NaHCO3 (8 eq) and DPPA (1.5 
eq). The reaction was left to proceed at r.t. under stirring and monitored by analytical 
HPLC. NaHCO3 was removed by filtration e the solvent was evaporated under reduced 
pressure. 
Complete deprotection of each cyclopeptide was performed by treatment with Pd(OH)2/C 
(10% w/w) under hydrogen atmosphere in MeOH according to the conditions described in 
the section 6.6.5. The cyclopeptides were purified by semi-preparative-HPLC. Peaks of 
interest were analyzed by analytical HPLC, combined and lyophilized. 
The final products were analyzed and fully characterized by RP-HPLC, HPLS-MS and 
1
H-
NMR. CD3OD was used for the analysis of the compounds because of the hydrofilic 
character of the carrier induced by the hydroxyl groups. Nevertheless, the solvent peak 
overlapped with some molecule patterns preventing a complete assignation of the protons.  
Cyclo-(Lys(carrier)-D-Pro-Leu-Tyr-Val) (56a) 
Cyclization reaction time 48 h. Purification by HPLC-semi-preparative (SunFirePrepC18, 
0:80 H2O/ACN + 0.1% TFA, linear gradient over 25 min) yielded the product as white 
solid. (10 mg, 25%). Purity: 98%. 
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HPLC: tR (min, G080 ACN in 8 min) = 5.79 
MS-HPLC calcd for: C39H60N6O13, expected: 820.42, found: 821.88 [M+H]
+
; 843,89 
[M+Na]
+
  
1
H-NMR (CD3OD, 300 MHz): 7.06 (d, 2H, d, J=8.5 Hz), 6.69 (d, 2H, J=8.5 Hz), 5.12 (d, 
0.5 H, J= 3.7 Hz, H1); 4.70 (m, 1H); 4.51 (d, 0.5 H, J= 7.6 Hz, H1); 4.45 (m, 1H), 4.15 (m, 
1H); 4.02-3.92 (m, 4H), 3.78-3.66 (m, 3H), 3.57 (m, 1H); 3.40-3.15 (m, 8H); 2.21-1.87 (m, 
6H); 1.74 (m, 2H); 1.60- 1.45 (m, 6H); 0.99 (m, 6H); 0.91 (d, 3H, J=6.7 Hz); 0.85 (d, 3H, 
J= 6.7 Hz). 
Cyclo-(Phe(4-NH-carrier)-D-Pro-Leu-Tyr-Val) (56b) 
Cyclization reaction time 48 h. Purification by HPLC-semi-preparative (SunFirePrepC18, 
20:35 H2O/ACN + 0.1% TFA, linear gradient over 25 min) yielded the product as white 
solid. (8 mg, 35%). Purity: 98% 
HPLC: tR (min, G2050 ACN in 8 min) = 6.13 
MS-HPLC calcd for: C42H58N6O13, expected: 854.41, found: 858 [M+H]
+ 
1
H-NMR (CD3OD, 300 MHz): 7.55 (m, 2d); 7,24 (d, 2H, J= 8.5 Hz); 7.07 (2H, d, J=8.5 
Hz); 6.70 (d, 2H, J= 8.5 Hz); 5.18 (d, 0.3H, J= 3.5 Hz, H1); 4.52 (d, 0.7 H, J= 7.6 Hz, H1); 
4.75 (m, 1H); 4.52 (m, 1H); 4.37 (m, 1H); 4.11 (m, 3H); 3.88 (m, 2H); 3.81 (m, 2H); 3.64 
(m, 2H); 3.52 (m, 2H); 3.33 (m, 4H); 3.15 (m, 3H); 2.88 (dd, 1H, J= 10.7, J= 3.6 Hz); 2.14 
(m, 2H); 1.2 (m, 3H); 1.57 (m, 3H); 0.98 (t, 6H, J= 7.1 Hz); 0.85 (t, 6H, J=7.1 Hz). 
Cyclo-(Dap(NH-carrier)-D-Pro-Leu-Tyr-Val) (56c) 
Cyclization reaction time 48 h. Purification by HPLC-semi-preparative (SunFirePrepC18, 
20:35 H2O/ACN + 0.1% TFA, linear gradient over 25 min) yielded the product as white 
solid. (8 mg, 25%). Purity: 98% 
HPLC: tR (min, G2050 ACN in 8 min) = 5.0 
MS-HPLC calcd for: C36H54N6O13, expected: 778.37, found: 779.48 [M+H]
+
 
1
H-NMR (CD3OD, 300 MHz):  (2H, d, J= 8.5 Hz), 6.70 (2H, d, J= 8.5 Hz), 5.18 (d, 
0.3H, J= 3.5 Hz, H1); 4.70 (m, 1H); 4.47 (m, 2H), 4.13 (m, 1H); 3.85 (m, 5H); 3.66 (m, 
8H); 3.15 (d, 2H, J= 6.4 Hz); 2.06 (m, 5H); 1.71 (m, 1H); 1.62 (m, 2H); 1.00 (m, 9H); 0.86 
(3H, d, J=6.7 Hz).  
5.6. Synthesis of other products 
Alloc-Leu (9).  
This compound was synthesized in one step following previous reported procedure. The 
characterization data match with the literature.
5
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9-fluorenylmethanethiol (6).  
This compound was synthesized in three steps following previous reported procedure. The 
characterization data match with the literature.
6
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6.1. Solvents and reagents 
Reagents for synthesis, if not otherwise specified, were purchased from Aldrich, Fluka and 
Acros. Amino acid derivatives, condensing reagents and additives were purchased from 
Albatros Chem Inc, Iris Biotech, and Luxemburg Industries. PPAA was purchase from 
Archimica. Linker AB and PyBOP was from Novabiochem. Aminomethyl-ChemMatrix 
was purchase from PCAS BioMatrix Inc whereas the 2-Chlorotrityl chloride resin was from 
CBL Patras. D-glucose and N-glucosamine were from A.C.E.F 
Solvents, acid and base, were purchased from Aldrich and Fluka. Acetonitrile and methanol 
used for products purification and characterization were HPLC grade purity. Buffer 
solutions were prepared with deionized water over a milli-Q plus system. Dry solvents were 
prepared over molecular sieves (3 or 4 Å) and stored under nitrogen atmosphere.  
6.2. General equipments 
Balances Mettler Toledo0020 (3 decimal) 
Precisa Balances (3 decimal)  
pH-meter GLP21, Crison 
Centrifuge Allegra 21R, Beckmann Coulter 
Lyophilizer Vitris; Freezemobil 12EL; Edwards RV12 pump 
Rotavapors Laborota, 4003, Heidolph 
Agitator orbital Unimax 1010, Heidolph 
Eppendorf 5415 benchtop 
Fluorescence plate Reader Bio-Tek Instruments; Bio-Tek FL600 
Magnetic stirrer IKA; Werke 
Micropipete Gilson P2, P20, P200 and P1000 
MilliQ system Millipore MilliQ gradient A10; 
Ovens Mettler Toledo; PB303-S, AB204 
Rotator stirrer Labnet; labroller 
UV Shimadzu UV mini 1240 UV-Vis spectrophotometer 
6.3. Chromatography 
6.3.1. Thin layer chromatography (TLC) 
Analytical thin layer chromatography (TLC) was performed on aluminum sheets (20 x 20 
cm) covered with silica gel 60 (Merck
®
 K 60 F254) using a specific mixture of eluent for 
each compound. The revelation of the TLC was performed using different methods in 
relation to the nature of the compound to detect. Direct revelation under UV-lamp was used 
to detect compounds with aromatic and chromophore groups. Specific TLC stains were 
employed for the revelation of compounds with specifying functional groups. 
6.3.1.1. TLC stains 
Ninhydrin: detection of primary and secondary amines. Spray plates and heat gently, the 
development of blue spots correspond to primary amine, whereas, brown spots are related 
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to Boc protected amines or secondary amines. Preparation: 200 mg ninhydrin, 95 ml 2-
propanol, 5 ml 10% AcOH. 
Dragendorff Reagent: detection of primary and secondary amines. Spray plates, orange 
spots develop. Spots intensify if sprayed later with HCl, or 50% water-phosphoric acid. 
Preparation: solution A: 1.7 g basic bismuth nitrate in 100 ml water/acetic acid (4:1). 
Solution B: 40 g potassium iodide in 100 ml of water. Mix reagents together as follows: 5 
ml A + 5 ml B + 20 ml acetic acid + 70 ml water.  
Cerium Molybdate: detection of all functional groups (multifunctional group stain). Spray 
plates and heat vigorously, blue spots develop on light background. Preparation: solution A: 
ammonium molibdate (21g) in 450 ml water. Solution B: 40 g cerium sulfate (1g) in 31 ml 
of H2SO4 + and 20 ml water . Mix reagents together.  
Sulfuric Acid: general detection method for most oxidable compounds such as 
carbohydrates. After dipping with the reagent the TLC plate is heated and many compounds 
are charred to give grey or black spots. Preparation: 5% sulfuric acid in methanol. 
Permanganate (KMnO4): detection method for functional groups which are sensitive to 
oxidation. Alkenes and alkynes will appear readily on a TLC plate following immersion 
into the stain and will appear as a bright yellow spot on a bright purple background. 
Alcohols, amines, sulfides, mercaptans and other oxidizable functional groups may also be 
visualized, however it will be necessary to gently heat the TLC plate following immersion 
into the stain. These spots will appear as either yellow or light brown on a light purple or 
pink background. Preparation: dissolve 1.5g of KMnO4, 10g K2CO3, and 1.25mL 10% 
NaOH in 200mL water. 
6.3.2. Column chromatography 
Column chromatography was carried out on silica gel 60 (Fluka, 40-63 m). Samples were 
loaded dissolved in the eluent mixture or loaded as a solid (by dissolving the sample in a 
strong solvent followed by adsorbing the sample onto silica by removing the solvent). 
Purifications were run using linear gradients. Fraction detected by TLC, spots of interest 
were combined and concentrated in vacuo. 
6.3.3. Analytical HPLC 
HPLC chromatograms were recorded on a Waters Alliance 2695 separation module 
equipped with a Waters 2998 photodiode array detector and Empower software (Waters) 
using a Sunfire C18 column (100 mm x 4.6 mm, 3.5 µm; Waters); flow 1ml/min, solvents 
H2O (0.045% TFA) and ACN (0.036% TFA). The gradient (G) is expressed as % of ACN 
in H2O. 
6.3.4. Semi-preparative HPLC 
The cyclopeptides were purified using reverse phase semi-preparative HPLC. Samples were 
dissolved in the appropriate solvent (low percentage ACN-aqueous solutions are preferred), 
filtered through a 0.45 µm nylon filter and injected onto the semi-preparative HPLC system 
provided with a loading loop of 10 ml. Purifications were run using 20 min linear gradients 
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of ACN in H2O. Flow = 15 ml/min. Detection λ= 220 nm. Peaks of interest were analyzed 
by analytical HPLC, combined and lyophilized. 
6.3.5. Isco Combi Flash Chromatography 
The cyclopeptides were purified using automated flash chromatography. Samples were 
dissolved in the appropriate solvent (low percentage ACN-aqueous solutions are preferred), 
filtered through a 0.45 µm nylon filter and injected onto the Isco system. Purifications were 
run using 30 min linear gradients of ACN (0.1% TFA) in H2O (0.1% TFA), C18 Reversed-
phase RediSep Rf columns. Flow= 30 ml/min. Detection λ= 220 nm. Peaks of interest were 
analyzed by analytical HPLC, combined and lyophilized. 
6.4. Methods for structural determination e product characterization  
6.4.1. Mass Spectroscopy 
6.4.1.1. HPLC-MS 
HPLC-MS were recorded using a Waters Alliance 2695 equipped with a Waters 2998 
photodiode array detector, ESI-MS micromass ZQ (Waters) and Masslynx software 
(Waters) using a Sunfire C18 column (100mm x 2.1 mm, 3.5 µm, Waters); flow rate = 0.3 
ml/min, solvents H2O (0.1% formic acid) and ACN (0.07% formic acid). 
6.4.1.2. ESI-HRMS  
ESI-HRMS (Electron Spray Ionization High Resolution Mass Spectroscopy) were 
performed, respectively, on a QSTAR Pulsar (AB/MDS Sciex) and DFS- Thermofischer 
and are reported as mass-per-charge ratio m/z calculated and observed. 
6.4.1.3. MALDI-TOF 
Mass spectra were obtained using a MALDI-TOF Applied Biosystem 4700 with a N2 laser 
of 337 nm. Sample preparation: a mix of peptide solution (1 µl) and matrix (1 µl) was 
placed on a MALDI-TOF plate and dried by air. 
Matrices:  
20 mg/ml ACH in 50%/ 49.9% H2O/ 0.1% TFA 
20 mg/ml DHB in 50%/ 49.9% H2O/ 0.1% TFA 
6.4.2. Nuclear magnetic resonance 
1
H and 
13
C spectra were recorded either on a Bruker 400 MHz, or Jeol 300 MHz 
spectrometer and were processed by Mestrenova software. Chemical shift are reported in 
ppm downfield relative to TMS ( = 0) internal reference in the solvents. Spin multiplicities 
are reported as singlet (s), doublet (d), triplet (t) and quartet (q) with coupling constants (J) 
given in Hz or multiplet (m). 
1
H and 
13
C resonances were assigned with the aid of 
additional 1D and 2D NMR spectra (H,H-COSY, DEPT 135 and HSQC). 
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6.4.3. Optical rotation  
The optical rotation values [] were determined using a Perkin-Elmer Model 241 
polarimeter and were recorded at room temperature. Optical rotation was determined 
according to equation 1: 
  
 
6.5. Solid-Phase Peptide Synthesis (SPPS) 
6.5.1. General considerations for SPPS 
All peptides were synthesized by SPPS using mostly the 9-fluorenylmethoxycarbonyl/tert-
butyl (Fmoc/tBu) strategy.
1
 Syntheses were performed at a 200-µmol scale. Solid-phase 
peptide elongation and other solid-phase manipulations were done manually in 
polypropylene syringes, each fitted with a polyethylene porous disk. Solvents and soluble 
reagents were removed by suction. Washings between synthetic steps were done with DMF 
(5 x 30 s) and DCM (5 x 30 s) using 5 ml of solvent/g resin each time. During couplings the 
mixture was allowed to react with intermittent manual stirring. 
6.5.2. Colorimetric tests 
6.5.2.1. Kaiser test
2
 
The Kaiser test, also known as ninhydrin test, allows the detection of primary amines and is 
used during solid-phase peptide chain assembly to monitor deprotection and coupling steps. 
The peptide-resin is washed with DCM and vacuum dried. A few peptide-resin beads are 
transferred to a small glass tube. Six drops of reagent solution A and 2 drops of reagent 
solution B are added to the tube and the mixture is heated at 110 ºC for 3 min. The 
formation of a blue color on the beads or the supernatant is indicative of the presence of 
free amines and thus of an incomplete coupling, while a yellow coloration is characteristic 
of a negative test. The method is highly sensitive and a negative test assures a coupling rate 
higher than 99%. 
Reagent solution A: 400 g of phenol are dissolved in 100 ml of absolute EtOH and the 
mixture is heated until complete dissolution of the phenol. 20 ml of 10 mM KCN (65 mg in 
100 ml of H2O) are added to 1000 mL of freshly distilled pyridine over ninhydrin. Both 
solutions are stirred for 45 min with 40 g of Amberlite MB-3 resin ion exchange resin, 
filtered, and combined. 
Reagent solution B: 2.5 g of ninhydrin are dissolved in 50 ml of absolute EtOH; the 
resulting solution is kept in flask protect from light. 
 
   Observed rotation in degrees.  
l    Cell path length in decimeters.  
c    Concentration in g ml
-1
  
[α]D = 
𝛼
𝑙·𝑐
      (1) 
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6.5.2.2. Chloranil test
3
 
Chloranil test detects secondary amines during solid-phase chain assembly and is used to 
evaluate couplings onto proline or N-methylated residues. 
The peptide-resin is washed with DCM and vacuum dried. A small portion of peptide resin 
beads is transferred to a small glass tub and 20 µl of a saturated chloranil solution (0.75 mg 
of 2,3,5,6-tetrachloro-1,4-benzoquinone in 25 ml of toluene) and 200 µl of acetone are 
added and mixed for 5 min at room temperature. The solution is shaken at room 
temperature for 5 min. A blue-greenish color is indicative of the presence of free secondary 
amines and is thus considered a positive test.   
6.5.2.3. p-Nitrophenyl ester test
4
 
p-Nitrophenyl ester test is used to detect secondary amines or hindered amines, with higher 
sensitivity than chloranil test.  
After washing the peptide-resin beads with DCM and dry it with vacuum a few beads are 
transferred to a small glass tube; 0.3 ml of 2 mM p-nitrophenyl ester in ACN are added and 
the suspension is heated at 70ºC for 8 min. Resin beads are washed with MeOH (3 times), 
DMF (3 times), and DCM (3 times). The presence of free amines is indicated by red-
colored beads whereas a negative test yield naturally colored beads. 
Reagent synthesis: the p-nitrophenyl ester is readily accessible from commercial disperse 
red 1 by a high-yielding three-step procedure. (A) To a solution of 20 mmol of disperse red 
1 (6.28 mg) and 0.34 mmol of Rh2(OAc)4 (150 mg) in a mixture of DCM (100 mL) and 
toluene (100 ml) is added at 40ºC a solution of 80 mmol of ethyl diazoacetate (8.4 ml) in 
toluene (40 ml) over 1h period. The reaction mixture is stirred overnight at room 
temperature and purified by chromatography. (B) 62.5 mmol of KOH (4.062 g) are added 
to a solution of the product obtained in step (a) 12.5 mmol (5 g) in MeOH (300 ml) and 
toluene (70 ml) and refluxed under N2 for 1.5h. The product is purified by a series of 
extractions. (C) To a solution of 6 mmol of the product obtained in step (b) (2.322 g) and 6 
mmol of p-nitrophenol (0.834 g) in pyridine (100 ml) and DCM (120 ml) at -15ºC 10.8 
mmol of POCl3 (1.006 mL in 10 mL DCM) are added over 1h period. The product is 
purified by a series of extractions. The p-nitrophenyl ester of disperse red 1 is used at a 
concentration of 0.02 M in ACN. 
6.5.3. Analysis of amino acids 
A known volume of sample in solution was transferred to an analysis tube. Sample was 
lyophilized and the solid was hydrolyzed with HCl 6 N at 110ºC for 8 h. The resulting 
solution was evaporated under vacuum and derivatized according to the derivatization 
protocol provided with the derivatization kit (AccQ-Tag™, Waters). Amino acid 
concentration was determined by HPLC. 
6.5.4. Initial conditioning of resin and coupling of the first amino acid 
The initial conditioning of the resins and the coupling of the first amino acid were 
performed as follows: 
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 2-chlorotrityl chloride resin (Cl-Trt): 
Step Treatment Reagents 
1 Wash 1x DCM (15 min) 
2 Coupling 0.8 eq Fmoc-AA-OH 
8 eq DIEA, DCM (1 h) 
3 Capping (without filtration) 1x MeOH (1ml/g resin, 15 min) 
4 Wash 5 x DCM (1 min) 
 Aminomethyl-ChemMatrix functionalized with the Fmoc-Rink linker: 
Step Treatment Reagents 
1 Wash 3x DMF (1 min) 
2 Wash 3x DCM (1 min) 
3 Wash 3x DIEA/DCM (1:19, 1 min) 
4 Wash 3x DCM (1 min) 
5 Wash 3x DMF (1 min) 
6 Linker coupling 3 eq Fmoc-Rink linker 
3 eq TBTU 
9 eq DIEA, DMF (60 min) 
7 Wash 3x DMF (1 min) 
8 Wash 3x DCM (1 min) 
9 Wash 3x DMF (1 min) 
10 Capping 10 eq Ac2O 
10 eq DIEA, DMF (15 min) 
11 Wash 3x DMF (1 min) 
12 Deprotection piperidine 20% in DMF (1x1, 2x10 min) 
 Aminomethyl-ChemMatrix functionalized with the AB linker: 
Step Treatment Reagents 
1 Wash 3x DMF (1 min) 
2 Wash 3x DCM (1 min) 
3 Wash 3x DIEA/DCM (1:19, 1 min) 
4 Wash 3x DCM (1 min) 
5 Wash 3x DMF (1 min) 
6 Linker coupling 3 eq AB linker 
3 eq DIPCDI, 3 eq HOBt 
9 eq DIEA, DMF (15 min) 
7 Capping 10 eq Ac2O 
10 eq DIEA, DMF (15 min) 
8 Wash 3x DMF (1 min) 
9 Wash 3x DCM (1 min) 
10 Coupling 5 eq Fmoc-AA, 5 eq DIPCDI 
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0.5 eq DMAP,  
DCM (1x2 h, overnight)  
11 Wash 1 x DCM (1 min) 
12 Wash 1 x DMF (1 min) 
13 Deprotection piperidine 20% in DMF (1x1, 2x10 min) 
6.5.5. Fmoc group removal 
The Fmoc group was removed by treating the resin with 20% piperidine in DMF (3-4 ml/g 
resin, 2 x 1 min and 1 x 10 min). In order to remove the Fmoc group from Fmoc-Pro-OH 
and additional treatment with DBU, toluene, piperidine and DMF (5:5:20:70, 2 x 3 min) 
was performed. 
6.5.6. Fmoc group quantification and resin loading capacity 
Piperidine washes were collected and measured by UV spectroscopy (λ= 290 nm) to 
determine the loading capacity of the resin after the coupling of the first amino acid and the 
yield of the linear peptide syntheses after the last coupling. Loading capacity was 
determined according to equation 2: 
 
 
 
 
6.5.7. Peptide chain elongation 
The amino acid couplings were performed according to the following protocol: a mixture of 
Fmoc-AA-OH (3eq), PyBOP (3eq), and HOAt (3eq) was dissolved in the minimum volume 
of DMF and pre-activated by adding DIEA (6 eq). After 1 min the mixture was added to the 
peptide-resin. 
Step Treatment Reagents 
1 Wash 5x DCM (1 min) 
2 Deprotection 1 x 20% piperidine in DMD (1 min) 
3 Deprotection 2 x 20% piperidine in DMD (10 min) 
4 Coupling 3 eq Fmoc-Aa-OH 
6 eq HOAt, 3 eq PyBOB, 6 eq DIEA (1 h) 
5 Wash 5 x DCM (1 min) 
Couplings were performed at room temperature with intermittent manual stirring. The 
extent of the coupling reaction was controlled by the ninhydrin, or chloranil test and re-
couplings were judiciously performed. Fmoc deprotection from proline residues was 
carried out using an extra treatment of DBU, toluene, piperidine and DMF as described in 
point 6.5.5. 
A    Absorbance 
X    Volume of solvent (ml) 
ε     Molar absorbance coefficient (5800 L mol-1 cm-1) 
Y    Resin weight (g) 
l     Length of the cell (cm) 
Z    Loading of the resin 
Z = 
𝐴· 𝑋 
𝜀·𝑌·𝑙
      (2) 
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6.5.8. Coupling with Fmoc-8-amino-3,6-dioxaoctanoic acid  
Fmoc-O2O–OH (3 eq), HBTU (3 eq) were sequentially added to the peptide-resin in DMF, 
followed by DIEA (6 eq). The mixture was allowed to react with intermittent manual 
stirring for 1 h. The solvent was removed by filtration, and the resin was washed with DMF 
(5 x 30 s) and DCM (5 x 30 s). The extent of coupling was checked by the Kaiser an 
chloranil test. 
6.5.9. Coupling with 5(6)-carboxyfluorescein  
A mixture of 5(6)-carboxyfluorescein (3 eq), PyBOP (3eq) and HOAt (3 eq) was dissolved 
in the minimum volume of DMF and pre-activated by adding DIEA (6 eq). After 1 min the 
mixture was added to the peptide-resin. The mixture was allowed to react with intermittent 
manual stirring overnight. The solvent was removed by filtration and the resin was washed 
with DMF (5 x 30 s) and DCM (5 x 30 s). The extent of coupling was checked by the 
ninhydrin, and chloranil test. 
6.5.10. Coupling with 4,4,4-Trifluoro-3-(trifluoromethyl)butanoic acid  
A mixture of 4,4,4-Trifluoro-3-(trifluoromethyl)butanoic acid (20 eq), PyBOP (20 eq) and 
HOAt (60 eq), was dissolved in the minimum volume of DMF and pre-activated by adding 
DIEA (60 eq). After 1 min the mixture was added to the peptide-resin. The mixture was 
allowed to react with intermittent manual stirring 1.5 h. The solvent was removed by 
filtration and the resin was washed with DMF (5 x 30 s) and DCM (5 x 30 s). The extent of 
coupling was checked by the ninhydrin, and chloranil test. 
6.5.11. Coupling with glycosidic carrier on solid phase  
The coupling whit the carrier was performed as followed reported: a mixture of 41 (1.5 eq), 
PyBOP (1.5 eq), and HOAt (1.5 eq) was dissolved in the minimum volume of DMF and 
pre-activated by adding DIEA (3 eq). After 1 min the mixture was added to the peptide-
resin. Couplings were performed at room temperature with intermittent manual stirring. 
The extent of the coupling reaction was controlled by the ninhydrin, or chloranil test.  
6.5.12. Disulfide bond formation between Cys(Trt) on Cl-Trt resin 
To the peptide-resin in DMF was added iodine (2.5 eq for each Trt group). The mixture was 
left to react with intermittent manual stirring for 15 min. Then the solvent was removed by 
suction and the treatment was repeat again. The solvent was removed by filtration and the 
resin was washed with DMF (5 x 30 s), a saturated solution of NaHSO4 (5x1 min) and 
CHCl3 (5x1 min). The reaction was checked by Ellman's test. 
6.5.13. Peptide synthesis using microwave assisted technology 
Aminomethyl ChemMatrix resin was used as solid support. It was swelled and 
functionalized with the linker as describe in the procedure reported in the section 6.5.4. The 
peptide chain elongation was performed through coupling–deprotection cycle performed by 
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automated microwaves assisted heating technology, using TBTU/DIEA for the amino acid 
coupling reaction and piperidine 20% in DMF for the Fmoc deprotection. 
Microwaves conditions:  
Treatment Reagents 
Deprotection 3min, 28W, 78ºC Piperidine/DMF  
Coupling 5min, 15W, 75ºC (0.2M aa/0.5M TBTU/2M DIEA) 
Arg Coupling 1° cycle 30 min, 0W, 75ºC (0.2M Arg/0.5M TBTU/2M DIEA 
2º cycle 5 min, 18W, 75ºC (0.2M Arg/0.5M TBTU/2M DIEA) 
Cys/His Coupling 5min, 15W, 50ºC (0.2M His/0.5M TBTU/2M DIEA) 
6.5.14. Amine acetylation on 2-Cl-Trt resin 
The peptide-resin in DMF was treated with Ac2O (15 eq) then DIEA was added (30 eq).The 
mixture was allowed to react with intermittent manual stirring for 1h. The solvent was 
removed by suction and the resin washed with DMF (5 x 1 min), and DCM (5x1 min). The 
reaction was checked by Ninhydrin test. 
6.5.15. Alloc removal group 
The peptide-resin protect with an Allyl group was solvated in DCM, then Pd(PPh3)4 (0.1 
eq) was added in presence of PhSiH3 (10 eq). The mixture was allowed to react with 
intermittent manual stirring for 15 min. The solvent was removed by suction and the 
treatment was repeated twice more. The resin was washed with DMF (5x1 min), and DCM 
(5x1 min). The reaction was checked by Ninhydrin test. 
6.5.16. Cleavage of the peptides from the resin 
The peptide cleavage from the resin was accomplished by treatment with a 2% of TFA 
DCM solution (5 x 1 min), or with a 25% Hexafluoro-2-propanol solution in DCM (2 x 15 
min) both treatments ensure do not remove the side chain acid labile protecting group. 
6.5.17. Complete peptide deprotection 
Complete deprotection of the peptide was performed by acidolytic treatment with a TFA 
solution containing the appropriate scavengers in order to minimize the unwanted side 
reactions. 
The peptide was transferred to a 50 ml centrifuge tube. The freshly made cleavage cocktail 
solution (3 ml) was added and the reaction was carried out at room temperature for 1 h with 
gentle agitation. As an exception, in the cleavage of peptides containing Arginine, reaction 
time was increased up to 3 h in order to ensure the complete removal of all Arg side-chain 
protecting group (Pbf). The corresponding peptide was precipitated through addition of 
cold tert-butyl methyl ether. The suspension was centrifuged at 4000 rpm and 4ºC during 
10 min. The ether fraction was discarded and the process repeated up to 3 times, in order to 
remove all scavengers and by-products from cleavage of side-chain protecting groups. The 
peptide residue thus obtained was dried by means of a N2 flow stream, resuspended in a 
mixture of H2O and ACN (1:1) and lyophilized. 
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Election of the cleavage cocktail is crucial and highly dependent on the presence of 
sensitive residues within the peptide sequence. The following flow-chart was used as a 
general selection guide: 
Does  the peptide contain a N-
terminal Fmoc group? 
Does  the peptide contain 
Arg(Mtr) or unprotected Trp? 
Does  the peptide contain ˃ 2 
Arg(Mtr) residues? 
Cleavage with: 1M TMS Br/thioanisole in 
TFA whit m-cresol/EDT
Does  the peptide contain Cys
(Trt) or Met?
Remove the N-terminal
Fmoc group
Cleavage with: 
81.5% TFA : 5% thioanisole : 5% phenol : 
5% H2O : 2.5 EDT : 1% TIS
Yes
No
No
No
Cleavage with: 
95% TFA : 2.5% H2O : 2.5 TIS
Yes
Cleavage with: 
94% TFA : 2.5% H2O : 
2.5 EDT : 1% TIS
Yes
Yes Yes
Yes
 
6.5.18. Split resin 
To the peptide-resin was added a properly volume of DMF and with the aid of a 
micropipette was generated a homogeneous suspension. A known volume of the suspension 
was withdrawn with the pipette and divided among the various polypropylene syringes, 
each fitted with a polyethylene porous disk. The procedure is repeated until the peptide 
resin on the initial syringe has been completely transferred. 
6.6. Solution-phase peptide synthesis 
6.6.1. Introduction carboxylic protecting groups 
6.6.1.1. 9-Fluorenylmethyl esters (OFm) 
N -protected amino acid was treated with 9-fluorenylmethyl methanol (0.8 eq), EDCI (1 
eq) and catalytic amount of DMAP (0.04 eq) in DCM/DMF (5:1) at room temperature for 3 
h. The reaction was quenched by adding water (50 ml). The reaction mixture was added to 
a separation funnel and the product was extracted with DCM (3 x 100 ml). 
Dichloromethane layers were combined, washed with brine (3 x 100 ml) and dried over 
Na2SO4. Solvent was removed under vacuum and the crude was purify by silica gel column 
chromatography to give the Boc-AA-OFm. 
6.6.1.2. 9-Fluorenylmethyl thioesters (SFm) 
S-(9-Fluorenylmethyl) N-tert-butoxycarbonyl-AA was prepared according to the procedure 
described by Sasaki et al.
5
 To a solution of Boc-AA-OH and 9-fluorenylmethylthiol (0.8 
eq) in DCM/DMF (5/1) were added EDCI (1eq) and DMAP (0.04 eq), and the reaction 
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mixture was stirred for 1 h. The reaction was quenched with water (100 ml) and the mixture 
was extracted with CH2Cl2 (3 x 50 ml). The combined organic layer was washed with brine 
(100 ml), dried over Na2SO4, and concentrated in vacuo. Purification of the residue by 
silica gel chromatography give the final product. 
6.6.2. Peptide chain elongation 
The amino acid couplings were performed according to three different protocols. Protocol 
A was used for couplings onto primary amines, Protocol B was used for coupling onto 
secondary amines, (proline), while the Protocol C was used to test the efficiency of the 
PPAA as condensing coupling reagent. 
Protocol A 
In a reaction flask, Boc-AA-OH (1.2 eq) and HOBt (1.5 eq) were suspended in DCM/DMF 
(5/1) and EDCI (1.2 eq) was added. The reaction mixture was stirred for 15 min, and 
DIPEA (1eq) was added, followed by a solution containing the N-deprotected residue in 
DCM/DMF (5/1). The reaction mixture was stirred for further 1 h, and then poured to water 
(100 ml). The mixture was extracted with EtOAc, and the combined organic layer was 
washed with brine (100 ml), dried over Na2SO4, and concentrated in vacuo. Purification of 
the residue by silica gel chromatography gave the desired product. 
Protocol B 
In a reaction flask, Boc-AA-OH (1.2 eq) and HBTU (1.3 eq) were dissolved in DMF. The 
reaction mixture was stirred at room temperature for 1 h to obtain the activate ester. DIEA 
(2 eq) was added, followed by a solution containing the N-deprotected peptide in DMF. The 
reaction mixture was stirred at room temperature overnight. The reaction mixture was 
diluted with DCM, added to a separation funnel and washed with HCl 1N, saturated 
solution of NaHCO3 and brine. The combined organic layer was dried over Na2SO4 and the 
solvent was removed under vacuo. Purification of the peptide by silica gel chromatography 
gave the product. 
Protocol C 
A suspension of N-Boc-AA-OH and the N-deprotected peptide in DCM is cooled in a ice 
bath before addition of DIEA. A solution of PPAA (50wt% in DCM) is then added slowly. 
The mixture is removed from the cooling bath and allowed to stir overnight at room 
temperature. Water is added and the mixture was stirred vigorously for 1 h. The reaction 
mixture was added to a separation funnel, the two phases were separated and the aqueous 
phase washed with Et2O (2 x 50 ml). The combined organic layer were washed with brine 
and dried with anhydrous Na2SO4. Solvent was removed under vacuo and purification of 
the peptide by silica gel chromatography gave the product. 
6.6.3. Boc-deprotection 
The Boc-AA-OFm (or Boc-AA-SFm) was dissolved in 40% TFA/DCM and the solution 
was stirred for 15 min at room temperature. The volatiles were removed in vacuo, and the 
residual TFA was removed by azeotropic distillation with toluene in vacuo. 
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6.6.4. Fmoc/OFm – deprotection 
To a solution of Fmoc-AA-OFm (or Fmoc-AA-SFm) in DMF [5 mM] was added 
piperidine (20 eq). The reaction mixture was stirred for 1 h, then the volatiles were removed 
under high vacuum. The residual piperidine was removed by azeotropic distillation. 
6.6.5. Hydrogenolytic deprotection 
To a solution of a Z-protected peptide in dry MeOH was added Pd(OH)2/C (w/w 10% on 
activated charcoal) and the mixture was hydrogenated overnight under atmospheric 
pressure using an H2-filled balloon. The catalyst was removed by filtration through a pad of 
celite and the solvent evaporated under reduced pressure.  
6.7. Peptide cyclization 
The head-to-tail peptide cyclizations were performed according to four different 
condensing reagents and relatives protocols.  
Protocol D: PPAA mediated cyclization  
To a solution of the C- and N-terminal un-protected linear peptide in DCM [5 mM] is added 
DMAP (6 eq) and then cooled in a ice bath. Then maintaining the reaction mixture under 
vigorous agitation, a solution of PPAA (50wt% in DCM, 1.5 eq) is added dropwise. The 
reaction flask is removed from the cooling bath and the mixture was stirred at r.t. until the 
starting material was consumed. (TLC). 
The volume of the reaction mixture is concentrated by distillation in vacuo, then water is 
added and the mixture was stirred vigorously for 1 h. The reaction mixture was added to a 
separation funnel, the two phases were separated and the aqueous phase washed with Et2O 
(2 x 50 ml). The combined organic layer were washed with brine and dried over Na2SO4 
and the solvent was removed under vacuo. Purification of the peptide by silica gel 
chromatography gave the product. 
Protocol E: HATU mediated cyclization  
To a stirred solution of the C- and N-terminal un-protected linear peptide in dry DMF under 
N2, was added dropwise at 0°C a solution of HATU (1.5 eq), HOAt (1.5 eq) and DIPEA (4 
eq) in dry DMF (final peptide concentration [5 mM]). The reaction was allowed to proceed 
at r.t. under nitrogen atmosphere monitoring its evolution by TLC. The solvent was 
removed under reduced pressure and the crude residue was purified by silica gel flash 
chromatography to give the pure cyclic peptide.  
Protocol F: PyBOP mediated cyclization  
To an ice-cold solution of PyBOP (3 eq) and DIEA (4 eq) in dry DMF [3 mM] was added 
dropwise a solution of C- and N-terminal un-protected linear peptide (1 eq) in DMF to 
reach a final peptide concentration of [5 mM]. The reaction evolution was followed by 
TLC. The solvent was removed under reduced pressure and the crude was purified by silica 
gel flash chromatography. 
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Protocol G: DPPA mediated cyclization 
The C- and N-terminal un-protected linear peptide was dissolved in DMF [5 mM] and to 
the solution were added NaHCO3 (8 eq) and DPPA (1.5 eq for the cyclic peptides of the 
part I of this thesis and 2 eq for the cyclopeptides of the part II) under stirring. The reaction 
was allowed to proceed at r.t. and monitored by analytical HPLC. The sodium bicarbonate 
was removed by filtration, then the solvent was evaporated under reduced pressure. The 
crude cyclopeptide was completely deprotected by treatment with a solution TFA-TIS-H2O/ 
95:2.5:2.5 and then purified by semi-preparative HPLC or automated flash 
chromatography.  
Protocol H: Sanger’s reagent mediated cyclization  
The C- and N-terminal un-protected linear peptide was dissolved in DMF [5 mM], 2,4-
Dinitrofluorobenzene (1.2 eq) was added to it, and the reaction mixture was stirred for 5 
min at r.t. DMF was removed under high vacuum, and the residue was purified by silica gel 
chromatography. 
6.8. Parallel artificial membrane permeability assay (PAMPA) 
Parallel artificial membrane permeability assay (PAMPA) was used to determine the 
capacity of compounds to cross the BBB by passive diffusion. The effective permeability 
(Pe) of the compounds was measured at an initial concentration of 200 µM. 
The buffer solution was prepared from a concentrate one, commercialized by pION, and 
following manufacturer’s instructions. pH was adjusted to 7.4 using 0.5 M NaOH solution. 
The compound of interest was dissolved in buffer solution to the desired concentration. The 
PAMPA sandwich was separated and each acceptor well was filled with 200 µl of buffer 
solution. The donor plate was then placed into the acceptor plate ensuring that the underside 
of the membrane was in contact with buffer. 4 µl of a mixture of phospholipids (20 mg/ml) 
in dodecane was added to each well filter and 200 µl of the compound of interest in buffer 
solution was added to each acceptor well. The plate was covered and incubated at room 
temperature in a saturated humidity atmosphere for 4 h under orbital agitation (100 rpm). 
After 4h the content of the acceptors and donors compartments was analyzed by HPLC. 
6.9. Fluorescence polarization (FP) 
Direct binding FP assays 
Wells of a black Corning 384-well polystyrene plate (384 Flat Bottom Black Polystyrol) 
contained fluorescent peptide tracer (67 nM for tracers) and increasing concentrations (from 
57.6 µM to 0.49 nM) of VEGF protein in FP buffer (50 mM NaCl, 16.2 mM Na2HPO4, 3.8 
mM KH2PO4, 0.15 mM NaN3, 0.15 mM EDTA, and 0.5 mg/ml Pluronic, pH 7.4). Plates 
were read after a 2 h incubation at room temperature using an PerkinElmer EnVision 
multilabel plate reader (PerkinElmer, Wellesley, MA, USA) with polarized filters and 
optical modules for fluorescein (ex = 480 nm, em = 535 nm) mP values were calculated 
from raw parallel and perpendicular fluorescence intensities.
6
 GraphPad Prism 4.03 
(GraphPad, San Diego, CA, USA) was used to plot mP versus VEGF concentration, and the 
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curve was fit to a single-site binding model to extract a binding dissociation constant (Kd 
value).
7
 Experiments were performed in duplicate.  
Competition binding FP assays 
Wells of a 384-well plate contained 67 nM tracer peptide, 1 µM VEGF protein, and tested 
inhibitor (v107) dissolved in DMSO (final concentration from 160 µM to 0.02 nM) in a 
final volume of 50 l in FP buffer. Plates were read after a 2 h incubation at room 
temperature, the time necessary for complete equilibration. Experiments were performed in 
duplicate. The equilibrium dissociation constant (Ki)
8
 was calculated, and the error was 
given as the 95% confidence interval as calculated by GraphPad Prism.  
6.10. Molecular modeling 
The experimental structures entries as pdb files were built using Maestro 6.0. The input 
files were created whit the program LEaP which reads in force field, topology and 
coordinate information and produces the files necessary for production calculations (i.e. 
minimization, molecular dynamics, analysis). In particular, it has been used the graphical 
versions of this program called xleap. 
The structures were solvated in an explicit truncated octahedral box of water and TIP3P 
water model was used for simulations of each structures. The net charge of the structures 
were neutralized with sodium ions as explicit counterions.  
Each structures were subject to energy minimization before the molecular dynamics 
analysis using Sander module of the Amber software suite. The minimization was run using 
the most commonly steepest descent minimization algorithms, with 500 steps with a 1 fs 
time step giving simulation lengths of 100 ps. In this simulation the non-bonded cut off was 
fixed to 12 angstroms as a reasonable tradeoff, given that a larger cut off introduces less 
error in the non-bonded force evaluation but increases the computational complexity and 
thus calculation time system error and long process time. The temperature of the system has 
been set at 300 K. 
MD simulations of each cyclopeptide was performed using Amber11 and its FF03 force 
fields which is recommended for the simulation of proteins and nucleic acids in explicit 
solvent. The obtained trajectory were analyzed and seen as a movie using VMD as methods 
of visualization, whereas the energy profile was plotted using GRACE. The analysis of the 
results was performed by plotting temperature, total energy, kinetic energy and potential 
energy from the output file. 
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Introduction 
Gliomas are the most frequent tumours of the brain. Glioma can be classified into four 
clinical grades on the basis of their histology and prognosis. Grade IV gliomas 
(glioblastoma multiforme, GBM) is one of the most malignant human tumors affecting 
approximately 13,000 people/year in the EUs.
1
  
GBMs are highly malignant tumours, usually resistant to radio- and chemotherapy and 
affected patients have a median survival of 1-2 years. GBMs are extremely invasive 
resulting in the failure of surgery to completely eradicate the tumor. Radiation therapy 
improves overall survival for each tumour grade, yet no patients are median survival by 2.5 
months compared with radiation therapy alone. Thus temozolamide has become a standard 
adjuvant therapy for gliomas although it offers modest clinical benefit.  
Many different compounds have been tested as anti-glioma agents during the last 10 years 
with barely any success. Among many different reasons, the presence of the blood-brain-
barrier (BBB) and the intra-tumoral heterogeneity are the two characteristics of brain 
tumours that make them especially recalcitrant to the treatments. 
Indeed, cerebral vessels have a physiological barrier (BBB) that prevents the proper 
delivery of compounds to the tumours and, cell within a tumour are different and have 
different sensitivities to treatments. Among the different cell subpopulations present in a 
tumour, cancer stem cells are the most malignant, being responsible for recurrence and 
therapeutic resistance. 
Many efforts have been directed to the identification of novel molecular-targeted therapies 
against these kinds of tumours and to the development of novel pharmacological 
compounds that would cross the BBB and target glioma. 
1.1.  The selected target protein-protein interactions 
A variety of environmental, genetic and epigenetic factors induce the reprogramming of 
cancer-initiating cells and the acquisition of physical and molecular features that promote 
tumorigenesis and provide resistance to therapeutics. These characteristics, including 
sustained proliferative signaling and evasion of growth suppressors, permit the 
development and progression of cancer and have been recognized as distinctive hallmarks 
of cancer. Importantly, PPIs represent the basic units within such vital networks. In cancer, 
PPIs form signalling nodes and hubs that transmit pathophysiological cues along molecular 
networks to achieve an integrated biological output, thereby promoting tumorigenesis, 
tumor progression, invasion, and/or metastasis. Thus, disruption of PPIs critical for cancer, 
offers a novel and effective strategy for curtailing the transmission of oncogenic signals. 
EGF-EGFR and VEGF-VEGFR are two of the important cancer-enabling PPIs.  
1.1.1. VEGF and VEGFR complex 
Angiogenesis plays an essential role in the growth of most primary tumors as well as their 
subsequent metastasis. Sufficient nutrients and oxygen are needed by tumors, and growth 
beyond a certain size requires the elaboration of vascular supply. This is usually done by 
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recruiting neighbouring mature vasculature and sprouting of new capillaries that eventually 
infiltrate the tumor mass.
2,3
  
Angiogenesis has become an attractive drug target, since Folkman
4
 proposed that 
antiangiogenesis would be a novel antitumor strategy,
5,6
 especially, Vascular Endothelial 
Growth Factor (VEGF) and its receptors (VEGFR). 
VEGF is a 45 KDa homodimeric glycoprotein.
7
 Each monomer has a central antiparallel 
four-stranded β-sheet core and a characteristic cysteine knot motif, fixed by a network of 
three disulfide bonds. VEGF is overexpressed in most tumors and its activity is mediate by 
binding to specific VEGF receptors, leading to receptor dimerization and activation of the 
receptor’s kinase activity through autophosphorilation. This in turn induces 
phosphorylation on a variety of protein substrates, activating a series of intracellular 
signalling pathways and unchaining several processes common to other growth factors: cell 
migration, survival and proliferation. 
VEGF is a member of the platelet-derived growth factor (PDGF)/vascular endothelial 
growth factor (VEGF) family, which comprises seven members (VEGF-A, VEGF-B, 
VEGF-C, VEGF-D, VEGF-E, VEGF-F and PIGF), each one binding to their receptor/s. 
VEGF-A is expressed in the human body in at least seven isoforms, containing 121, 145, 
148, 165, 183, 189 and 206 residues per monomer.
8
 
                        
Figure 1. Structures of VEGF-A and VEGFR-1 domain 2. Ribbon representations of (A) the non-liganded VEGF-A109 
(bottom view looking up from the cell membrane) and (B) the complex between VEGF-A109 and VEGFR-1 domain 2 
(bottom view). The two VEGF monomers are shown in blue and light orange, respectively; the VEGFR-1 domain 2 in 
red. Disulfide bonds are shown as yellow sticks. The secondary structure elements are labeled according to the original 
references. (Adapted from Biochimica et Biophysica Acta 2010, 1804, 567–580). 
VEGF gene expression is triggered by several host stimuli such as estrogen, nitric oxide 
and other growth factors (e.g., bFGF, TNF-α, EGF); but its production is particularly 
sensitive to oxygen tension, for instance the hypoxic conditions typically found in tumors 
rapidly upregulate VEGF. As a result, VEGF is overexpressed in most tumours and has a 
direct effect on their development by relieving tumor masses from stress conditions through 
oxygen and nutrients recruitment, but also acting as a survival factor by enhancing the 
expression of anti-apoptotic factors such as Bcl-2.  
VEGF activity is mediated by binding to specific VEGF receptors, leading to receptor 
dimerization and activation of the receptor’s kinase activity through autophosphorilation. 
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This in turn induces phosphorylation on a variety of protein substrates, activating a series of 
intracellular signalling pathways and unchaining several processes common to other growth 
factors: cell migration, survival and proliferation. 
S-S S-S
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Figure 2. Schematic representation of VEGF family ligands and their receptors. (Adapted from Nature Reviews Cancer 
2008, 8, 579-591).  
The role of VEGF-A as therapeutic target has been extensively described
8
 because it is a 
major regulator of normal and abnormal angiogenesis, including that associated with 
tumors and several intraocular syndromes. It binds to two receptors tyrosine kinases (RTK), 
VEGFR-1 (flt-1), and VEGFR-2 (KDR, flk-1). In particular, VEGFR-2 is the major 
mediator to the mitogenic, angiogenic and permeability-enhancing effects of VEGF-A. 
Generally, VEGF-A up regulation is associated with tumours growth, facilitating the spread 
of blood vessels and blood supply of the tumour. Inhibition of VEGF-induce angiogenesis 
hinders this growth
10
 and increase the tumor response to radiotherapy.
11
 In addition to 
tumor growth VEGF-A is involved in a number of pathological conditions, including 
cardiovascular diseases, diabetic retinopathy, rheumatoid arthritis and psoriasis. 
Furthermore, VEGF-A is required for the normal functioning and development of 
mammals, thus making it an attractive target for both antiangiogenic and proangiogenic 
therapy.  
In the field of peptide ligands, peptides that inhibit binding of VEGF to its receptors were 
produced using phage display.
12
 Libraries of short disulfide-constrained peptides yielded 
three distinct classes of peptides that bind to the receptor-binding domain of VEGF with 
micromolar affinities. 
 
Figure 3. The most remarkable peptidic ligands v107, identified by a phage display strategy (Kd = 0.2 µM). 
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In the field of biologics, the monoclonal antibody bevacizumab (selective for VEGF-A) is 
used for the treatment of certain cancer types; however its cost-benefit ratio is high. In the 
case of small organic molecules, orally available inhibitors lapatinib, sunitinib, sorafenib, 
axitinib and pazopanib target multiple kinases, including VEGFRs are used for treatment. 
Serious side effects of these inhibitors include gastrointestinal perforation, wound healing 
complications and hemorrhage. 
Currently, there are three Food and Drug Administration-approved drugs for treatment of 
diseases related to overexpression of VEGF: Bevacizumab (Avastin),
13
 Ranibizumab 
(Lucentis),
14 and Pegaptanib (Macugen).15 Each of these drugs blocks the signalling by 
binding to VEGF and thereby preventing interaction with cell surface receptors.  
In addition, a number of small molecules that inhibit the kinase activity of VEGFR-1 and/or 
VEGFR-2 are currently in clinical trials.
16
 Despite the success of the therapeutic antibodies 
inhibitors of the VEGF–VEGFR interaction with lower molecular weight (e.g., peptides or 
small molecules) might offer advantages in terms of production, stability, and/or 
administration.
17
 It is very challenging to identify small molecules that bind tightly and 
specifically to a given protein surface.
18,19
 In principle, steric inhibition of VEGF–VEGFR 
interaction could be accomplished via a molecule that binds to the recognition surface on 
VEGF or a molecule that binds to the recognition surface on a receptor. All steric inhibitors 
in the clinic or in clinical trials function by binding to VEGF rather than a receptor.
16
 An 
agent that binds to VEGF can be specific for one type of biological response, whereas an 
agent that binds to a VEGF receptor may block interaction of this receptor with other 
natural ligands (other members of the VEGF superfamily), thereby affecting processes 
other than angiogenesis.
20
 
1.1.2. EGF and EGFR complex 
Human epidermal growth factor (EGF) is a small protein consisting of 53 amino acid 
residues including six Cys residues that form three disulfide bonds. The solution structure 
of monomeric EGF consists of one antiparallel β-sheet and two α-helices that adopt a αβα-
fold that is stabilized by the three disulfide bridges. EGF performs its biological function by 
binding to a specific transmembrane receptor (EGFR) of the receptor tyrosine kinase (RTK) 
family. The EGFR family of RTK comprises four members collectively referred to as the 
ErbB family: EGFR itself, ErbB2, ErbB3 and ErbB4. 
ErbR receptors are composed of an extracellular region (~620 amino acids), a single 
transmembrane helix, an intracellular tyrosine kinase domain (~270 amino acids) and a 
~200 amino acids C-terminal tail. The extracellular region of EGFR, containing two ligand 
binding-domains (domains I and III) and two cysteine-rich domains (domains II and IV), is 
thought to exist in a dynamic equilibrium sampling multiple conformations. Binding to 
EGF shifts the equilibrium to a dimerization-competent extended configuration, driving the 
system towards the active dimeric form.
21
 EGFR dimerization is achieved only by receptor-
receptor interactions. In the dimeric EGF-EGFR complexes (2:2), each EGF molecule 
binds simultaneously to the domains I and III of the same receptor molecule and is distant 
from the dimer interface.
22
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Figure 4. Crystal structure of the 2:2 EGF-EGFR complexes. Ribbon diagram with the approximate two-fold axis 
oriented vertically. One EGF chain in the 2:2 EGF•EGFR complex is pale green, and the other EGF chain is pink. 
Domains I, II, III, and IV in one receptor in the dimer are colored yellow, orange, red, and gray, respectively. Domains I, 
II, III, and IV in the other receptor are colored cyan, dark blue, pale blue, and gray, respectively. Most of domain IV is 
disordered. The disulfide bonds are shown in yellow. The intervening parts that were not assigned are transparent. (Extract 
from Cell 2002, 110, 775-787) 
The receptor dimerization interface is centred on a -hairpin arm (residues 242-259) that 
projects from domain II in each of the two EGFR molecules in the dimer. In the inactive, 
ligand-free tethered configuration of EGFR (Figure 4), this -hairpin arm is buried by 
intramolecular interactions with the domain IV inhibiting receptor dimerization. However, 
simply exposing the dimerization arm in the absence of EGF is not sufficient to promote 
EGFR dimerization.
23
 EGF binding is accompanied by a drastic conformational change that 
remodels the entire dimerization interface. EGF binding promotes a domain reorientation 
that leads to an extended receptor configuration, but also imposes a precise bend on the 
domain II that defines the optimal trajectory of the -hairpin arm allowing multiple weak 
contacts outside this arm which can cooperate effectively in driving high-affinity 
dimerization.  
Ligand-induced homo- and/or heterodimerization is essential for the activation of the 
intracellular kinase domain and the subsequent receptor autophosphorylation. EGFR 
activation initiates a signalling pathway that regulates many cellular processes including 
proliferation, cell motility and differentiation. Aberrant EGFR signalling, caused by 
overexpression of the EGFR protein or by the presence of activating mutations, is 
associated with a wide range of epithelial cancers, including those of the breast, colon, head 
and neck, kidney, lung, pancreas and prostate.
24,25
 
Therapies that target EGFR are of major clinical importance in the treatment of cancer.
25
 
Current clinical therapeutics either target the extracellular region of EGFR with monoclonal 
antibodies (mAbs) or interfere with the intracellular EGFR tyrosine kinase activity with 
small molecule defined as tyrosine kinase inhibitors (TKIs).
25,26
 Small molecule TKIs, such 
as erlotinib and gefitinib, compete with ATP to bind to the intracellular tyrosine kinase 
catalytic domain inhibiting EGFR autophosphorylation. The most important antibodies 
targeting the extracellular domain of EGFR are cetuximab and panitumumab.
27
 On binding 
to the domain III of EGFR, these antibodies compete with EGF binding, prevent EGFR 
activation and therefore inhibit proliferation of tumor cells.
28,29
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Although those mAbs and TKIs are an effective treatment for patients, their use has several 
drawbacks including exorbitant costs, severe side effects
30
 and a considerable incidence of 
primary or acquired drug resistance, which support the need for development of additional 
inhibitors for the EGFR signalling.
31
 Peptides that mimic the dimerization arm of ErbB 
receptors
32,33
 and small molecules targeting the dimerization of EGFR
34
 have been recently 
described as inhibitors of EGFR activity. As an alternative approach, an EGFR-directed 
fusion protein composed of human EGF and the catalytic and translocation domains of 
diphteric toxin has been tested for antitumor activity with promising results.
35
 
In the field of the small molecules has been demonstrate that Suramin can prevent the 
interaction between hEGF and EGFR by interacting to the receptor binding region on 
hEGF. Consequently to the binding, Suramin blocks the conformational change of hEGF.
36
 
This blocking ability is one of the reasons for which Suramin has antiproliferative activity 
against cancer cells that overexpress EGFR on their cell surfaces.
37
 Nowadays, Suramin is 
in the Phase II of clinic trials for glioblastoma.
38
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Figure 5. A. Stereo representation of the interaction between hEGF (in green) and Suramin (in pink). On the left the 
Suramin structure. 
Suramin, a symmetrical polysulfonated naphthylurea, is a growth factor blocker with anti-
cancer activity.
39
 Several investigators have reported that Suramin has an antiproliferative 
activity against cancer cells by inhibiting the binding of growth factors to their receptors.
40
 
It has also been employed therapeutically in a variety of disorders, including HIV, with 
limited success.
41
 Most recently, it has been evaluated as an anti-tumor agent.
42
 The 
mechanism by which Suramin disrupts the activity of growth factors is not fully understood 
yet but it is supposed to involve a direct binding of the drug to the growth factor itself 
rather than its complementary receptor.
43
 
Targeting the EGF molecule itself could represent an effective way to prevent the binding 
of the growth factor to the receptor and thus, inhibit the EGFR activation and downstream 
events. Peptide ligands directed to the individual sites observed in the crystal structure may 
be active in preventing EGFR binding, representing a new therapeutic approach against 
cancer. 
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The X-ray structure of the complex of human EGF and the extracellular region of EGFR 
has revealed the EGF-EGFR interactions.
22
 The protein-receptor interface on each receptor 
consists of three sites, designated as site 1 to 3, involving domains I and III. The residues 
20-31 of EGF interact with the site 1 in the domain I, the EGF region containing residues 6-
19 and Arg41 interacts with the site 2 in the domain III, and the C-terminal region around 
Arg45 interacts with site 3 in domain III. Mutagenesis studies have identified that Ile23
44
 
and Arg41
45
 in EGF are critical determinants for receptor binding. EGF binds much more 
strongly to the domain III of EGFR than to the domain I, although the interaction with the 
domain III is sensitive to pH and can be disrupted at low pH.
46
 This observation suggests 
that the EGF binding ability of some interaction sites may be easily modulated.  
 
Figure 6. Mapping the interaction sites onto ribbon representations of EGFR and EGF. Three binding sites in the interface 
are outlined. (Extract from Cell 2002, 110, 775-787) 
1.2. Transport through the BBB 
The blood-brain barrier (BBB) is located in brain capillaries and is considered the most 
important barrier to tackle in order to achieve drug delivery to the brain. This barrier is 
composed of a continuous layer of highly specialized vascular endothelial cells whose 
primary function is to maintain the brain homeostasis. The BBB is a highly efficient 
physical and enzymatic barrier, restricting and regulating the flow of substances from the 
blood to the brain, thus providing an optimal environment for the function of this organ. 
The barrier effect is achieved in part by a complex network of tight junctions between 
endothelial cells
47-49
 that hinders paracellular transport.
50-54
 
Furthermore, transcellular transport from blood to brain is also limited as a result of low 
vesicular transport, high metabolic activity, lack of fenestrae and the expression of a variety 
of enzymes.  
Most central nervous system (CNS) drugs enter the brain by transcellular passive diffusion, 
due to the tight junction structure and limited transport pathways. There are also two active 
processes in the BBB that influence penetration
55,56
 active influx transporters (e.g. amino 
acid, peptide) and active efflux transporters (e.g. P-glycoprotein, multi-drug resistant 
proteins). In addition, partial or complete metabolism of a compound will limit its 
penetration into the brain. 
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Figure 7. Schematic representation of a brain capillary. The BBB is formed by capillary endothelial cells, surrounded by a 
basal membrane and astrocytic perivascular end-feet. Tight junctions between the cerebral endothelial cells form a 
diffusion barrier, which severely restricts the penetration of water soluble compounds, including polar drugs, into the 
brain. Astrocytic end-feet appear to be critical for the induction and maintenance of the endothelial barrier. Furthermore, 
pericytes intimately embrace the brain capillaries and seem to contribute to the development, maintenance, and regulation 
of the BBB. The tightness of the endothelial barrier results in the paracellular transport of substances being negligible 
under physiological conditions. (Adapted from J. Pharm. Pharmaceut. Sci. 2003, 6(2), 252-273.) 
To bypass the BBB and deliver drugs to the brain, several strategies have been used: 
temporarily opening the BBB, administration of very high doses of a drug and direct 
injection of a drug into the spinal cord. However, these approaches imply risks of infection 
and toxicity. Other strategies have been developed such as modifying the structure of a drug 
to increase its permeability by passive diffusion. Another option is to couple a drug to a 
“Trojan horse”, a compound that passes the BBB by receptor-mediated transcytosis (RMT) 
and can carry the drug across the barrier.
50,54,57-59
 
There are several in vitro methods and computational models that have been used in drug 
discovery to predict the BBB penetration potential of test compounds. In vitro methods 
include log P /log D,
60
 D log P,
61
 immobilized artificial membrane (IAM),
62
 polar surface 
area (PSA),
63
 linear free energy equations,
64,65
 surface tension,
66,67
 and membrane 
permeability across cell culture systems.
68
 These methods are useful, but the reliability of 
prediction and resources required may be limiting. 
There are also numerous cell-based assays to predict the permeability of compounds across 
the BBB, such as bovine brain microvessel endothelial cells (BBMEC),
69,70
 porcine brain 
microvessel endothelial cells (PBMEC),
71,72
 rat brain microvascular endothelial cells 
(rBMEC)
73
 and Madin Darby canine kidney cells (MDCK).
74
 Despite these cell methods 
have the advantage to incorporate both passive transport and active transporters, their 
application, as a high throughput screening tool, is limited by the elaborate membrane 
preparation and cost of resources.  
1.2.1. BBB permeability by passive diffusion  
This is a non-saturable and spontaneous transport process. It has been reported that some 
small lipophilic molecules (< 400 Da) cross the BBB by this mechanism, but most 
molecules do not. The classical approach of medicinal chemistry to bypass this limitation is 
the modification of the molecules in order to increase their lipid solubility by blocking 
hydrogen bond-forming groups on the parent drug molecule. A gain in lipid solubility 
increases permeation across all biological membranes of the body, including the BBB, thus 
Introduction 
 
 
143 
potentially leading to side effects. Moreover, lipidization may enhance binding to plasma 
proteins, which could offset the increase in membrane permeation caused by greater lipid 
solubility. Nevertheless, many plasma protein-bound drugs are available for transport 
across the BBB in vivo via a mechanism of enhanced dissociation at the brain capillary 
endothelial surface.
75
 
Recent years have witnessed several key advances in the development of peptides as 
therapeutic agents and drug carriers for brain disorders. Although from a classical point of 
view passive diffusion has been considered probable only for small molecules, peptides are 
no longer considered too large to cross the BBB. Many large peptides cross this barrier by 
simple diffusion;
76-80
 therefore molecular weight does not appear to be the only key point 
for peptide penetration into the brain. Indeed, some peptides have already been used to 
shuttle drugs into the CNS.
76,81,82
 In general, shuttles with the ability to cross the BBB by 
passive diffusion do so because of its unique physicochemical properties. If the cargo 
linked to the BBB-shuttle is a small molecule that does not affect the properties of the 
shuttle, then the latter will be able to transport the cargo into the CNS. In contrast, if the 
cargo affects the physical and/or chemical properties of the shuttle, which is likely to 
happen with nanoparticles, proteins or peptides, the cargo will not penetrate the BBB. 
1.2.2. BBB permeability by active transport: carried-mediated transport (CMT) 
This is a saturable and energy-dependent mechanism. Endothelial membranes contain 
several specific transport (carrier) proteins that provide essential nutrients and endogenous 
compounds to the brain. These transport systems include the glucose transporters, large 
neutral and cationic amino acid transporters and nucleoside transporters, to mention a 
few.
83
 CMT systems are potential points of drug entry to the brain, but these are highly 
stereospecific pore-based transporters and there are significant structural requirements for 
transport affinity. The medicinal chemistry approach to achieve drug delivery to the brain 
by means of CMT has been the modification of the structure of drugs to resemble the native 
substrate of the transporter. The challenge is to preserve the activity of the drug after these 
modifications.
84
 An alternative approach is to link a cargo to a substrate of a given 
endogenous transporter system. Since CMT is highly substrate structure-specific, it is 
difficult to make a drug that is normally not transported across the BBB transportable by 
the simple coupling to a substrate of a given transporter. However, there are some examples 
of drug delivery into the CNS that include linking the drug to a substrate of a CMT 
system.
85,86
  
Glycosylation of the linear opioid peptide H-Tyr-D-Thr-Gly-Phe-Leu-Ser-NH2 on Ser6 or 
the attachment of various sugar moieties to the cyclic opioid peptide enkephalin increases 
their penetration and allows the resulting glycopeptide analogs to function as analgesic 
drugs. This finding could be attributed, at least in part, to the transport of the analogs by the 
glucose transporter GLUT-1 and to the organic anion-transporting polypeptide transporter 
(OATP).
87,88
  
CMT requires high affinity consequently, the cargo conjugated to a BBB-shuttle that 
crosses the barrier by this mechanism should preserve substrate ability to be recognized by 
the receptor. Even when recognition is preserved, the drug-BBB shuttle construct might 
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have insufficient affinity for a BBB transporter to achieve significant uptake and/or 
transport across the BBB. In addition, it might be limited by competition with endogenous 
substrates. Since CMT is highly stereospecific, it is not particularly amenable for the 
transport of large-molecule therapeutics. 
1.2.3. Receptor-mediated transcytosis (RMT) 
Although CMT is a highly selective way to overcome the BBB is limited to small cargos, 
whereas the RMT is not limited for the size of the cargos and represents one of the most 
promising mechanisms to transport cargos across the BBB. This system enables large 
molecules such as peptides, proteins and nucleic acids to specifically enter the brain, since 
this approach uses vesicle-based transport rather than a stereoselective carrier. Three types 
of receptors are present on brain endothelial cells: bi-directional receptors, reverse receptors 
and receptor-mediated endocytosis systems.
84
 In terms of the delivery of compounds to the 
brain, the most interesting are the bi-directional receptors. Some of these receptors are well 
known and have been used for the delivery of various types of cargo into the CNS. The 
most important receptors are represented by: transferrin receptor, insulin receptor, low-
density lipoprotein receptor, nicotinic acetylcholine receptor, membrane-bound precursor 
heparin binding epidermal growth factor, lactotransferrin receptor and leptin receptor. 
Among all of them, transferrin receptor (TfR) is one of the most widely studied receptor for 
drug targeting. TfR is expressed in practically all the cells of the body, including brain 
capillaries and it mediates the delivery of iron to the brain.
89
 Despite its expression differs 
depending on the cell type,
90
 in general, highly proliferating cells, such as cancer cells, 
overexpress TfR because of their increased metabolism.
91
 This makes TfR very attractive 
for drug targeting and explains why it has received so much attention for drug delivery. 
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2.1 Aim of the work 
Peptides are considered excellent candidates for the recognition of proteins surface; indeed, 
over the last few years, many examples showing the ability of peptides to recognize 
efficiently the surface regions on relevant proteins have been reported.
1-3
 
Inspired by those works, we have focussed our attention on this class of molecules to 
develop novel pharmacological compounds able to selectively bind the proteins surface of 
EGF and VEGF. This competitive interaction will prevent the proteins to bind with the 
respective receptor and, as a consequence, will affect the protein activity towards the 
glioma progression. 
We have designed an explorative library of cyclic hexapeptides, named “EXORIS”, as 
rigid scaffolds bearing the functional groups involved in the protein interaction. These 
small cyclohexapeptides could act as ligand traps binding to EGF or VEGF. 
Cyclic peptides present well-known advantages compared to the linear one. Among them, 
the cyclization enables to reduce the conformational space, to increase the binding affinity 
and selectivity to a receptor and enhances the stability of the peptide toward the proteases. 
We have been focussed on symmetric cyclic hexapeptides because of their straightforward 
synthesis and also due to the reduced conformational space required starting from the C2 
symmetry. 
The insertion of prolines and D-amino acids as -turn motifs was also evaluated to confer 
structural rigidity and to promote the cyclization. In addition, D-amino acids provide 
resistance towards proteases and proline promotes the transport and BBB permeability. 
The library has been developed considering a representative reduce dataset composed by 
seven different amino acids (Trp, Glu, Ile, Arg, Ser, Val, Pro) that were chosen to represent 
all the proteinogenic amino acids. Based on these residues, it was possible to identify 36 
different cyclic peptides and, in addition, one epimer was synthesized for each 
combination. The epimer allows the detection of side-reactions during the cyclization step 
(C-terminal epimerization) and the exploration of the protein binding interaction when the 
symmetry is broken. 
2.2. Reaction set up 
2.2.1. Diketopiperazine (DKP) evaluation 
A preliminary investigation was performed to evaluate the more efficient way to start the 
synthesis of the linear peptide, taking into account that using a proline as C-terminal 
prevents the epimerization but, on the other hand, could lead to the formation of 
diketopiperazine (DKP). This side reaction is more relevant especially when D and L 
amino acids are alternate as first and second residues along the peptide sequence (D-Pro-L-
XXa or L-XXa-D-Pro).
4
 
The studies on the DKP formations were performed with different peptide sequences and 
the amount of DKP was quantified by UV intensities of the Fmoc group. The obtained 
results (Table 1) show that when Fmoc group is removed under standard conditions (a) the 
DKP amount reaches 50%. The DKP formation is lowered but not prevented using the 
same conditions with shorter cleavage time (b) followed by a subsequent coupling with a 
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large excess (6 eq) of the third amino acid. These results evidenced that the use of D-
proline as C-terminal was not a suitable choice. 
Peptide Sequence Fmoc cleavage % DKP 
H-Arg-D-Trp-Pro-OH a 50 
H-Ala-Ser(tBu)-Pro-OH b 9 
H-Ala-D-Ser(tBu)-Pro-OH b 8 
H-Gly-Ala-D-Pro–OH b 21 
H-Ser(tBu)-Ala-D-Pro-OH b 42 
Table 1. Linear peptides subjected to investigation of DKP formation. Cleavage conditions: a: 20% piperidine in DMF: 2 
cycles of 10 minutes followed by coupling with 3 eq of the third amino acid. b 20% piperidine in DMF, 2 cycles of 2 
minutes followed by coupling with 6 eq of the third amino acid. 
2.2.2. Investigation of D-amino acids position along the sequence 
Additional studies were performed to evaluate the best relative position along the peptide 
chain in which the D-amino acids and the proline can promote the peptide cyclization, 
considering that these residues will be common elements in within the cyclic hexapeptides 
library. 
Keeping the C2 symmetry, peptide analogues, characterized by the same amino acid 
composition but shifting the D-residues position along the chain, were synthesized. 
Moreover, the sequence with all natural amino acids was also synthesized as negative 
control to evaluate the real efficiency of the D-amino acid to induce the cyclization. 
H-AA1-Pro-AA2-AA1-Pro-AA2-OH
AA2-AA1-Pro
Pro-AA1-AA2  
Figure 1. General scheme of the investigated peptide sequences. 
The cyclization of the different analogues, were performed using two different coupling 
reagents system: DPPA (Diphenylphosphoryl azide) and PS-DCC (N’-methyl polystyrene 
supported N-Cyclohexylcarbodiimide) in order to identify the synthetic procedure that 
maximize the cyclo peptide yield and purity. 
The polymer-supported activating reagent, PS-DCC, was chosen due to the possibility to 
remove both the coupling reagent and its related by-products bound to the polymer support 
by easy filtration. This allows a fast recovery of the final product and an easier purification. 
DPPA (Diphenylphosphonic azide) was selected as an efficient condensing reagent for 
peptide cyclization because it allows the use of an inorganic base (NaHCO3) which can be 
removed by filtration and does not interfere in the following side chain deprotection step, 
avoiding the formation of undesired by-products. 
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n Peptide sequence PS-DCC (h) DPPA (h) 
1a H-Trp(Boc)-Pro-Arg(Pbf)-Trp(Boc)-Pro-Arg(Pbf)-OH > 96 36 
1b H-D-Trp(Boc)-Pro-Arg(Pbf)-D-Trp(Boc)-Pro-Arg(Pbf)-OH 48 24 
1c H-Trp(Boc)-D-Pro-Arg(Pbf)-Trp(Boc)-D-Pro-Arg(Pbf)-OH - 4 
1d H-Trp(Boc)-Pro-D-Arg(Pbf)-Trp(Boc)-Pro-D-Arg(Pbf)-OH - 18 
2a H-Arg(Pbf)-Pro-Trp(Boc)-Arg(Pbf)-Pro-Trp(Boc)-OH  > 96 36 
2b H-D-Arg(Pbf)-Pro-Trp(Boc)-D-Arg(Pbf)-Pro-Trp(Boc)-OH  48 24 
2c H-Arg(Pbf)-D-Pro-Trp(Boc)-Arg(Pbf)-D-Pro-Trp(Boc)-OH - 4 
2d H-Arg(Pbf)-Pro-D-Trp(Boc)-Arg(Pbf)-Pro-D-Trp(Boc)-OH - 18 
Table 2. Cyclization results relative to the D-amino acids position along the sequence. PS-DCC: cyclization reaction 
time (h) using PS-DCC (18 eq), DIPEA(18 eq), DCM-DMF/4:1 [50 mM], 37°C. DPPA: cyclization reaction time (h) 
using DPPA (2 eq), NaHCO3 (8 eq), DMF [5 mM], r.t. 
2.2.3. N’-methyl polystyrene supported N-Cyclohexylcarbodiimide PS-DCC 
The cyclization reaction with the polystirene supported N-Cyclohexylcarbodiimide was 
performed initially using a large excess (18 eq) of condensing agent, in high diluted DCM 
solution [5 mM] at room temperature. The reaction progress was monitored by HLPC and 
after 96 hours the reactions were not yet completed. Thus has been evaluated to change the 
reaction conditions in order to push the cyclization. A second trial was performed using the 
same equivalents of condensing agent together with a basic medium DIEA (18 eq), in a 
more concentrated solution (DCM-DMF/4:1) [50 mM] at 37°C. The obtained results show 
that, under these last conditions, the reactions involving the linear peptides with a D-amino 
acid were completed in 48 h, whereas the sequences with all natural amino acids required 
more than 96 hours to achieve a complete cyclization. 
These data underline how the presence of a D-amino acid in the sequence is essential in 
promoting the peptide cyclization. 
2.2.4. Diphenylphosphonic azide (DPPA)  
The cyclization using DPPA was carried out in high DMF dilution [5 mM], using 2 eq of 
condensing agent associate with NaHCO3 (8 eq) as an inorganic base. 
The experimental results show that, as expected, the introduction of a D-amino acid speed 
up the reaction. Whereas related to the position of D-amino acid respected to the proline, 
the data revealed that the linear peptide containing a D-amino acid in the position (i+1) 
leads to the cyclic peptide with a reaction time slightly lower than those with a D-amino 
acid shifted in position (i+2). 
However, the best results were obtained when a D-proline was present along the sequence, 
obtaining the desired product in just 4 h. 
Based on the experimental results, the DPPA method was selected for the synthesis of the 
cyclic hexapeptide library due to the fact that, in association with two D-prolines in the 
peptide sequence, reduces the cyclization time and produces fairly pure crudes. 
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2.2.5. The role of protecting groups on the cyclization  
The side chain bulky effect of the protecting groups on the peptide reactivity was also 
investigated during the preliminary investigation.  
Some unprotected linear peptides, were subjected to cyclization under the same reaction 
conditions shown before using both PS-DCC and DPPA. The obtained results show that, 
independently of the peptide sequence, the cyclization of unprotected linear peptides, lead 
to the formation of many by-products and crudes with low quality, suggesting that the 
functional groups on the peptide side chain could be involved in side reactions. The side 
chain reactions may compete with the cyclization, extending the reaction time and 
promoting the by-products formation.  
Table 3. Side chain protecting groups effect on peptide cyclization yield. PS-DCC: Time (h) is the cyclization reaction 
time expressed in hours using PS-DCC (18 eq), DIPEA (18 eq), DCM-DMF/4:1 [50 mM], 37°C. DPPA: Time (h) is the 
cyclization reaction time expressed in hours, using DPPA (2 eq), NaHCO3 (8 eq), DMF [5 mM]. The purities for both 
methodologies were determined by analytical HPLC analysis (peaks detected at =220 nm).  
The best conditions and the definition of the synthetic approach for the development of the 
hexacyclic peptide library were identified based on the data obtained during this first stage. 
The key points of the optimized synthetic procedure are represented by the introduction of 
D-proline as D-residues along the sequence (but not as first amino acid to avoid the DKP 
formation) and to performed the cyclization in solution, on protected linear peptides, using 
DPPA as coupling reagent. 
2.3. Peptide synthesis 
2.3.1. Synthesis of the linear peptides 
The synthesis of the linear peptides were performed by solid-phase peptide synthesis 
(SPPS) following the Fmoc/tBu strategy and using all the advantages of solid-phase 
chemistry.
5
 The 2-chlorotrityl chloride resin was chosen as a polymeric support to obtain 
the side-chain protected linear precursors. The synthesis of the linear peptides started with 
the C-terminal residues loaded on the solid support, then, all the peptide couplings were 
performed using PyBOP, HOAt and DIPEA in DMF followed by Fmoc deprotection under 
the standard conditions.  
The amino acid couplings and the deprotection steps were monitored by the ninhydrin 
Kaiser test,
6
 the chloranil test
7
 or De Clercq,
8
 according to the type of amine which should 
be detected. The cleavage of the peptide from the resin was accomplished by acidolytic 
treatment with a 2% TFA solution, which retains the protecting groups on the residues side 
chain.  
n Peptide sequence 
PS-DCC DPPA 
Time (h) Purity % Time (h) Purity % 
1a' H-Trp-Pro-Arg-Trp-Pro-Arg-OH > 96 ˂ 50 24 40 
1b’ H-D-Trp-Pro-Arg-D-Trp-Pro-Arg-OH > 96 ˂ 50 36 70 
2a’ H-Arg-Pro-Trp-Arg-Pro-Trp-OH  > 96 ˂ 50 24 45 
2b’ H-D-Arg-Pro-Trp-D-Arg-Pro-Trp-OH  > 96 ˂ 50 24 70 
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The HPLC analyses of the crude linear peptides show the high quality of all the crudes 
which were subjected to the cyclization without any further purification. 
  n Linear peptide Yield % Purity % 
1a H-Trp(Boc)-Pro-Arg(Pbf)-Trp(Boc)-Pro-Arg(Pbf)-OH  82  83  
1a’ H-Trp-Pro-Arg-Trp-Pro-Arg-OH  86  80  
1b H-D-Trp(Boc)-Pro-Arg(Pbf)-D-Trp(Boc)-Pro-Arg(Pbf)-OH  70  94  
1b’ H-D-Trp-Pro-Arg-D-Trp-Pro-Arg-OH  90  70  
1c H-Trp(Boc)-D-Pro-Arg(Pbf)-Trp(Boc)-D-Pro-Arg(Pbf)-OH  75  83  
1d H-Trp(Boc)-Pro-D-Arg(Pbf)-Trp(Boc)-Pro-D-Arg(Pbf)-OH  70  92  
2a H-Arg(Pbf)-Pro-Trp(Boc)-Arg(Pbf)-Pro-Trp(Boc)-OH  77  88  
2a’ H-Arg-Pro-Trp-Arg-Pro-Trp-OH  90  83  
2b H-D-Arg(Pbf)-Pro-Trp(Boc)-D-Arg(Pbf)-Pro-Trp(Boc)-OH  91  90  
2b’ H-D-Arg-Pro-Trp-D-Arg-Pro-Trp-OH  85  70  
2c H-Arg(Pbf)-D-Pro-Trp(Boc)-Arg(Pbf)-D-Pro-Trp(Boc)-OH  75  90  
2d H-Arg(Pbf)-Pro-D-Trp(Boc)-Arg(Pbf)-Pro-D-Trp(Boc)-OH  89  73  
3a H-Ser(tBu)-D-Pro-Trp(Boc)-Ser(tBu)-D-Pro-Trp(Boc)-OH  80  91  
3b H-Ser(tBu)-D-Pro-Trp(Boc)-Ser(tBu)-D-Pro-D-Trp(Boc)-OH  80  90  
4a H-Glu(OtBu)-D-Pro-Trp(Boc)-Glu(OtBu)-D-Pro-Trp(Boc)-OH  89  87  
4b H-Glu(OtBu)-D-Pro-Trp(Boc)-Glu(OtBu)-D-Pro-D-Trp(Boc)-OH  85  83  
5a H-Ile-D-Pro-Trp(Boc)-Ile-D-Pro-Trp(Boc)-OH  84  95  
5b H-Ile-D-Pro-Trp(Boc)-Ile-D-Pro-D-Trp(Boc)-OH  78  97  
6a H-Ser(tBu)-D-Pro-Glu(OtBu)-Ser(tBu)-D-Pro-Glu(OtBu)-OH  88  80  
6b H-Ser(tBu)-D-Pro-Glu(OtBu)-Ser(tBu)-D-Pro-D-Glu(OtBu)-OH  80  80  
7a H-Ser(tBu)-D-Pro-Ile-Ser(tBu)-D-Pro-Ile-OH  80  94  
8a H-Glu(OtBu)-D-Pro-Ile-Glu(OtBu)-D-Pro-Ile-OH  77  95  
Table 4. Linear peptides synthesized for the Exoris library. The overall yields of the linear peptides synthesis were 
calculated by Fmoc UV detection related to the last cleavage step, whereas the purities of the crudes were determined 
through analytical HPLC analysis (peaks detected at =220 nm).   
2.3.2. Peptides cyclization 
Cyclic peptides have been synthesized by head-to-tail approach; the reactions were 
performed in solution using DPPA as coupling reagent, with NaHCO3 as base under high 
DMF dilution [5 mM]. The progress of each synthesis was checked by HPLC, and the 
cyclizations were completed within 4 to 24 h (according to the specific peptide sequence). 
The base was removed by filtration and the DMF was evaporated in vacuo. Finally, the 
complete removal of the side chain protecting groups was accomplished by acidolytic 
treatment with a TFA solution containing appropriate scavengers.  
The final cyclic hexapeptides were obtained after the purification by automated flash 
chromatography. 
The pure products were fully characterized by HPLC, HRMS, MALDI-TOF and amino 
acids analysis. All the cyclo peptides were obtained with excellent yields and purity (Table 
5). 
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The differences in the yields of the final products could be reasonably related to the 
purification step and not to the linear peptide synthesis or to the cyclization efficiency, as 
evidenced by the comparable yields obtained for the linear peptides and the few amounts of 
by-products detected during the cyclization of each sequence. 
The two cyclic peptides (cyclo-1a, cyclo-2a) containing all L-amino acids present crudes 
more complex and it was decided to perform their purification further in case of positive 
results in terms of protein binding affinity of their analogues. These results underline the 
importance of the introduction along the peptide sequence of elements able to promote the 
cyclization. If the peptide is not properly preorganized to cyclize the ring closure will be 
slow and could favour the side reactions, leading to the formation of many by-products that 
affect the isolation of the final product. 
n Cyclic peptide Purity % Yield % 
cyclo-1a &Trp-Pro-Arg-Trp-Pro-Arg& ˂ 60 - 
cyclo-1b &D-Trp-Pro-Arg-D-Trp-Pro-Arg& > 90 75 
cyclo-1c &Trp-D-Pro-Arg-Trp-D-Pro-Arg& > 90 80 
cyclo-1d &Trp-Pro-D-Arg-Trp-Pro-D-Arg& > 95 20 
cyclo-2a &Arg-Pro-Trp-Arg-Pro-Trp–OH  ˂ 50 - 
cyclo-2b &D-Arg-Pro-Trp-D-Arg-Pro-Trp& > 95 84 
cyclo-2c &Arg-D-Pro-Trp-Arg-D-Pro-Trp& > 95 80 
cyclo-2d &Arg-Pro-D-Trp-Arg-Pro-D-Trp& > 95 30 
cyclo-3a &Ser-D-Pro-Trp-Ser-D-Pro-Trp& > 98 69 
cyclo-3b &Ser-D-Pro-Trp-Ser-D-Pro-D-Trp& > 95 58 
cyclo-4a &Glu-D-Pro-Trp-Glu-D-Pro-Trp& > 97 50 
cyclo-4b &Glu-D-Pro-Trp-Glu-D-Pro-D-Trp& > 90 60 
cyclo-5a &Ile-D-Pro-Trp-Ile-D-Pro-Trp& > 94 75 
cyclo-5b &Ile-D-Pro-Trp-Ile-D-Pro-D-Trp& > 96 68 
cyclo-6a &Ser-D-Pro-Glu-Ser-D-Pro-Glu& > 95 15 
cyclo-6b &Ser-D-Pro-Glu-Ser-D-Pro-D-Glu& > 95 41 
cyclo-7a &Ser-D-Pro-Ile-Ser-D-Pro-Ile& > 98 47 
cyclo-8a &Glu-D-Pro-Ile-Glu-D-Pro-Ile& > 90 70 
Table 5. Cyclic peptides synthesized for the Exoris library. The yields are referred to the recovered products after the 
chromatography purification. The purities were determined by analytical HPLC analysis (peaks detected at =220 nm). 
&D-Trp-Pro-Arg-D-Trp-Pro-Arg& (cyclo-1b) 
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&Trp-D-Pro-Arg- Trp-D-Pro-Arg& (cyclo-1c) 
                  
&Trp-Pro-D-Arg- Trp-Pro-D-Arg& (cyclo-1d) 
    
&D-Arg-Pro-Trp-D-Arg-Pro-Trp& (cyclo-2b) 
               
&Arg-D-Pro-Trp-Arg-D-Pro-Trp& (cyclo-2c) 
      
&Arg-Pro-D-Trp-Arg-Pro-D-Trp& (cyclo-2d) 
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&Ser-D-Pro-Trp-Ser-D-Pro-Trp& (cyclo-3a) 
                  
&Ser-D-Pro-Trp-Ser-D-Pro-Trp& (cyclo-3b) 
                  
&Glu-D-Pro-Trp-Glu-D-Pro-Trp& (cyclo-4a) 
                  
&Glu-D-Pro-Trp-Glu-D-Pro-D-Trp& (cyclo-4b) 
                  
&Ile-D-Pro-Trp-Ile-D-Pro-Trp& (cyclo-5a) 
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&Ile-D-Pro-Trp-Ile-D-Pro-D-Trp& (cyclo-5b) 
                    
&Ser-D-Pro-Glu-Ser-D-Pro-Glu& (cyclo-6a) 
                    
&Ser-D-Pro-Glu-Ser-D-Pro-D-Glu& (cyclo-6b) 
                 
&Ser-D-Pro-Ile-Ser-D-Pro-Ile& (cyclo-7a) 
                
&Glu-D-Pro-Ile-Glu-D-Pro-Ile& (cyclo-8a) 
                
Figure 2. HPLC traces and MS-HPLC of cyclic hexapeptides. HPLC were recorded using a 0-100% B gradient in 8 min 
(A = 0.045% TFA in H2O and B = 0.036% TFA in ACN). 
Once a set of cyclohexapeptides of the library have been prepared, different NMR studies 
have been done to characterize the cyclic peptide structures and to perform a primary 
screening for the identification of possible candidates able to interact with the target 
proteins.  
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2.4. NMR characterization and binding studies 
Different NMR studies have been done (in collaboration with Sonia Ciudad and Jesus 
Garcia) to characterize the structure of the cyclic peptides. 
1
H-NMR spectra at different 
temperatures showed the presence of only one defined conformation per each peptide, 
which is in accordance with rigid structures. 
The conformation of trans-proline has been determined by using the chemical shift 
difference between 
13
C and 
13
C of the proline residues and by looking at the NOE’s 
patters.
9
 
trans cis
trans cis
 
Figure 3. All the studied peptides showed the same pattern of NOEs, confirming that the Xaa-D-Pro bonds are in the 
trans conformation.  
Temperature coefficients (-ΔδNH/ΔT) were used as an indication of solvent accessibility to 
amide protons and to explore the presence of hydrogen bonds in the cyclic hexapeptides. 
Considering that small temperature coefficients (0 < -ΔδNH/ΔT < 5 ppb/K) are related to 
low accessibility and are often interpreted as evidence for intramolecular hydrogen 
bonding, compared to grater values (6 < -ΔδNH/ΔT < 10 ppb/K) for amide groups in a 
random coil conformation.
10
 It has been observed that the NH of the residue preceding the 
D-proline is more solvent shielded independently on the amino acid present in this position, 
probably due to the formation of an hydrogen bond in this position. These results are 
compatible with the presence of two consistent -turn motives. 
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Figure 4. The NMR results suggest that the cyclic hexapeptides form hydrogen bonds between the residues preceding the 
prolines, which is totally consistent with a conformation containing two β-turns. 
2.5. Binding evaluation by Nuclear Magnetic Resonance  
NMR spectroscopy has been used as initial screening method to test the different binding 
behaviors of the cyclic peptides towards 
13
CMet VEGF protein. The cyclohexapeptides 
binding evaluation was initially performed using VEGF as target protein, because it was 
previously expressed (as labelled protein by overexpression in E. coli.)
11
 and already 
available in the laboratory at the time of this screening.  
The Chemical Shift Perturbation (CSP) has been used for a primary screening to identify 
the binding site of the ligands to the protein target. This assay is based on the variation of 
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the chemical shifts of both ligand and protein proton resonances upon binding, especially 
for the nuclei located within the binding site.
12
 Once the protein has been enriched with 
15
N 
(or 
13
C) and the chemical shift assignments are known, the protein is titrated with a ligand 
and the chemical shift changes are monitored. 2D 
1
H-
15
N (or 
1
H-
13
C) heteronuclear single 
quantum coherence (HSQC) spectroscopy is the most common method to monitor the 
backbone chemical shifts. Only the protein resonances are visible in such spectra and, 
therefore, the ligand can be included at a high concentration.
13
 Information on where the 
ligand is bound can be obtained by comparing the HSQC spectra with and without ligand. 
Moreover, binding constants and stoichiometry can be obtained through the titration of the 
protein with the ligand observing the chemical shifts of selected residues. 
Two cyclopeptides as candidates that showed a promising binding affinity with the VEGF 
have been identified by this preliminary assay (performed by Sonia Ciudad). Small changes 
in the chemical shift in some residues of the protein (e.g. Met18 and Met81 that are known 
to be in the binding site of VEGF with its receptors) were observed in the presence of 
different equivalents of these cyclopeptides. An estimated Kd was obtained by the titration 
assay, which reveals that two peptides are VEGF binders in a low-mM range (Table 6). 
n Cyclic peptide Kd (mM) 
cyclo-4a &Glu-D-Pro-Trp-Glu-D-Pro-Trp& 2.9 
cyclo-4b &Glu-D-Pro-Trp-Glu-D-Pro-D-Trp& 14.8 
Table 6. NMR titration assay results.  
It is worth to notice that the two identified candidates are epimers. They have the same 
peptide sequence but differ one for another only in the chirality of the C-terminal amino 
acid (Trp). This observation, in addition to provide information about the key-residues for 
the protein binding interaction, suggests that breaking the symmetry in the cyclopeptide 
might have a role to modulate the affinity and to increase the specificity towards the 
protein. 
Moreover, based on NMR investigation, it seems that the presence of aromatic residues 
(Trp) in the cyclopeptide is important to induce small but detectable chemical shift 
perturbation in the VEGF signals. On the other hand, non-Trp containing peptides, show 
negligible changes in the chemical shifts of all the protein methionines. 
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Figure 5. The two cyclic hexapeptides that show better affinity for VEGF. 
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2.6. Evaluation of BBB-permeability 
The next step in the characterization of the cyclohexapeptides of the EXORIS library 
focused on the evaluation of their ability to overcome the cellular membrane. 
These assays were initially performed on the two cyclic hexapeptides identified as the best 
candidates for the interaction with VEGF (compounds cyclo-4a and cyclo-4b, Table 6). In 
parallel, the same cyclopeptides were tested as conjugated with a well-known BBB shuttle 
(THRre) able to cross the BBB using the active transport via transferrin receptor.
14
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Figure 6. Cyclic peptides (cyclo-4a and cyclo-4b) conjugated with the THRre underwent to BBB permeability evaluation. 
2.6.1. Evaluation of BBB permeability by passive diffusion  
2.6.1.1. Parallel artificial membrane permeability assay (PAMPA) 
The parallel artificial membrane permeability assay (PAMPA), is a phospholipid-based 
transport assay, widely used in the pharmaceutical industry as a high throughput 
permeability method to predict oral absorption.
15-17
 
Since its introduction,
18
 several variants of the experimental conditions have been proposed 
to improve the correlation between this artificial membrane model system and human 
absorption data.
19
 This technique is utilized as an evaluation tool to determine whether a 
compound can cross a biological barrier, such as the BBB, the gastro-intestinal barrier or 
skin,
20-22
 depending on the mixture of phospholipids used or not. In addition, numerous 
statements have been made about the utility of the PAMPA also as a tool for medicinal 
chemists to elucidate structure–permeability relationships.23 
The PAMPA phospholipidid membrane mimics the cell membrane, but it has no means for 
active or paracellular transport of drug molecules. So, it models only the passive transport 
system.  
The parallel artificial membrane permeability assay for the blood−brain barrier (PAMPA-
BBB),
20
 is a very simple, rapid and inexpensive technique compared to cell-based assay
24
 
or chromatography-based approaches
25
. Due to these reasons, it is considered one of the 
most powerful and versatile physicochemical screening tools in early stage CNS targeted 
drug discovery practice.
26,15
 
It has been also demonstrated that PAMPA correlated with in situ brain diffusion 
remarkably better than MDR1-MDCKII for a broad range of CNS drugs with diverse 
physicochemical properties available on the market.
27
 
Results and discussion 
 
 
163 
APICAL
BASOLATERAL
Tight junctions
Endothelial cell
Basement membrane
Filter support
Astrocytic endfeet
Bload-brain barrier in vivo
Capillary blood flow
NO FLOW
• pH=7.4
• Plasma protein: 6-8%
• No UWL
• pH=7.3
• ISF/CSF protein ˂0.5%
• No UWL
Bload-brain barrier in vitro
UWL: variable
UWL: variable
• pH=7.4
• Serum protein: variable
• pH=7.4
• Serum protein: variable
 
Figure 7. The differences between the properties at the endothelial surface of blood-brain barrier capillaries in vivo and 
those generated by in vitro cell monolayer systems. UWL: unstirred water layer. ISF: iron-sulfur proteins, CFS: 
cerebrospinal fluid.  (Adapted from Drug Discovery Today, 2003, 8 (21), 997-1003). 
The transport across an artificial membrane barrier is a combination of diffusion through 
the membrane and diffusion through the aqueous boundary layers (ABL) (also called the 
unstirred water layer UWL) at the two sides of the membrane. Convective forces (e.g. from 
stirring) and diffusion quickly translocate solute molecules in the bulk aqueous phase. 
However, their transport through the ABL is driven mainly by diffusion, which can be very 
slow if the ABL is very thick or if the solute molecules are very large. If the thickness of 
the ABL is greater than the thickness of the phospholipid membrane barrier, the water layer 
becomes the rate-limiting component in the transport of lipophilic molecules hiding the 
membrane contributions to transport. If the assays ignore the ABL effect with lipophilic 
test compounds, the resulting permeability values will not correctly indicate the in vivo 
conditions of permeability and will merely reveal properties of water rather than membrane 
permeation. However, it has been demonstrated that stirring the sample in the wells 
displays the in vivo relevant ABL and in some cases also reduces the assay time because 
the excessive ABL resistance is lessened.  
2.6.1.2. PAMPA experimental results 
The first investigation was performed by a PAMPA assay to figure out whether the 
cyclopeptides alone and conjugated with the BBB-shuttle are able to cross the BBB 
membrane by a passive diffusion process or not. 
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HPLC chromatogram 
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+ 
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tR tR
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Donor (compound + SS pH 7.4)  
t= 0h
HPLC chromatogram 
 
Figure 8. Schematic representation of the PAMPA assay. PBLEP: polar brain lipid extract porcine. SS: system solution 
(buffer solution and 20% 1-propanol as cosolvent). 
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The assay was carried out using a porcine polar brain lipid extract which better mimics the 
lipid composition of the endothelial cells of the BBB. The candidates were placed in the 
donor compartment at a concentration of 220 µM and the polycarbonate filters of the 
PAMPA plate was coated with a lipid extract, then the peptides were incubated at room 
temperature for 4 hours under stirring in a gut box. Propranolol has been used as positive 
control compound in this assay due to its known ability to cross the BBB by passive 
diffusion (Pe in the high permeability range).
28
 After 4 hours the apical and basal solution 
in the wells were analyzed by RP-HPLC and MALDI-TOF in order to obtain the effective 
permeability (Pe) of each compound.  
The HPLC analysis showed that it was possible to detect the compound in the acceptor 
compartments only for the unconjugated cyclopeptides, indicating that these candidates 
crossed the cellular barrier by passive diffusion mechanism transport. Whereas, as 
expected, their analogues, conjugated with the BBB-shuttle, have not crossed the 
membrane. The effective permeability (Pe) was determined using the equation 1: 
Pe =  
−218.3
t
 Log  1 –  
2  CA t 
CD t0 
 10−6  cm s               (1) 
Where t is the time express in hours, CA(t) is the compound concentration at the acceptor 
compartment after the experiment (time: 4 h) and CD(t0) is the initial concentration of 
sample applied to the donor compartment (time: 0 h). 
The percentage of transport was calculated following the equation 2: 
T% =
CA t 
CD t0 
· 100                             2  
The effective permeability results are summarized in Table 7. The permeability of the 
candidates was confirmed by MALDI-TOF analysis of the acceptor compartments. 
The ability of a certain compound to permeate this barrier is affected by its pKa and, as the 
assay is performed at pH 7.4, only the fraction of compound not ionised at this pH should 
be able to partition through the barrier into the acceptor chamber. 
Compound 
% Membrane 
retention 
Pe x 10
-6
 
(cm/s) 
% PAMPA transport 
after 4h 
cyclo-4a < 5  0.8 1.6  
cyclo-4b < 5  0.8 1.6  
THRre cyclo-4a < 5  0.047 0.1  
THRre cyclo-4b < 5  0.095 0.2  
Propranolol < 5  19.3 28  
Table 7. Membrane retention (%), effective permeability (Pe) and percentage of transport, after 4 h in the PAMPA assay 
of the candidates (unconjugate and conjugate with the BBB-shuttle) and the control compounds (Propranolol). Low 
permeability: Pe (cm/s) < 0.1 x 10
-6.Medium permeability Pe (cm/s) 0.1 x 10
-6 ≤ Pe < 1x 10
-6. High permeability: Pe (cm/s) 
≥ 1x10-6. 
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The peptides alone exhibit a medium permeability towards the artificial membrane, 
probably due to their intrinsic lipophilic character and to the intramolecular hydrogen 
bonds (suggested by the NMR results) which increase their lipid solubility. 
The PAMPA experiment provided a general indication on the ability of these candidates to 
cross the cell barrier. Nevertheless, due to the artificial nature of the assay membrane (non-
bilayer lipid structure) and the only passive transport mechanisms considered, the PAMPA 
assay will never be a precise model of the brain endothelial cell membrane. To overcome 
this limitation, the peptides were also evaluated in a more realistic BBB model. 
2.6.2. BBB transport evaluation using a BBB in vitro model. 
Two BBB shuttle-cyclopeptides and the unconjugated ones have been tested in an in vitro 
BBB model in the group of Prof. Giralt (IRB) by Benjamin Ollèr. 
The BBB transport evaluation was done with the most widely used in vitro BBB model, 
which consist on a co-culture of bovine brain endothelial cells (BBECs) and rat 
astrocytes.
29-32
 This type of model shows a remarkable correlation between in vitro and in 
vivo BBB permeability data, both for passive diffusion and active transport.  
 
Figure 9. Mono-culture of brain endothelial cells in transwells. Cells are seeded in the filter of the transwell and are 
cultured until confluence. 
The in vitro BBB model that will be used in this project is formed by a co-colture of 
BBECs and newborn rat aristrocytes that are co-coltured until the transendothelial electrical 
resistance (TEER) measures showed that the system was ready for transport studies.  
In parallel, the permeability assay was performed with Lucifer yellow (LY) to check the 
integrity of the barrier in vitro, in order to validate the analysis. 
After incubation, the contents of the acceptor and donor compartments were analyzed by 
RP-HPLC and the permeability and percentage of the transport was determined according 
to equations 1 and 2 (see page 165). The transport of the peptides was confirmed by 
MALDI-TOF analysis of the acceptor compartment. Pe and transport results are 
summarized in Table 8. 
All the compounds tested are able to cross the endothelial membrane. The conjugated 
cyclopeptides with the BBB shuttle have lower permeability efficiency compared to the 
unconjugated one and they have to cross the BBB by using the active transport via 
transferrin receptor, resulting in a more selective transport. On the other hand, the high 
values observed for the cyclic peptides alone are not surprising due to their permeability by 
passive diffusion through the membrane. 
Nevertheless, this model is highly sensitive and any external influence can easily disturb 
the cell barrier, causing the premature disruptions between the cell junctions. This fact may 
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induce false positives during the permeability assays and it must be repeated to confirm and 
validate the obtained results. 
Compound 
% Membrane 
retention 
Pe x 10
-6
 
(cm/s) 
% Transport 
after 4h 
THRre 9.0 3.1 3.7 
cyclo-4a 22.5 4.2 5.0 
cyclo-4b 16.7 5.1 6.0 
THRre cyclo-4a 6.2 0.7 0.8 
THRre cyclo-4b 5.3 0.5 0.6 
Table 8. Ranking of the results obtained using the BBB cellular model. Candidates were incubated with the cells at a 
concentration of 50 µM for 24 h at 37ºC using HBSS as buffer.  
2.7. Validation of NMR result for VEGF-ligand binding 
Different biophysical assays have been considered to validate the VEGF-ligand binding 
results obtained by NMR technique. Methods such as surface plasmon resonance (SPR), 
isothermal titration calorimetry (ITC), surface acoustic wave coupled to mass spectrometry 
(SAW)
33-35
 and competition fluorescence polarization assay (FP) can be used to perform 
the thermodynamic and kinetic studies of VEGF-ligand binding.
36
 
Among these techniques, we have focused on the competition fluorescence polarization 
assay (FP) because this method has been recently reported to identify molecules that bind 
to the VEGF dimer in the region that is recognized by the cell surface receptors
37
 and 
because the experimental conditions are already known and may be used to screen our 
candidates. Moreover, FP does not required 
15
N-labelled protein which expression 
represents one of the limiting factors for the NMR analysis allowing the use of 
commercially available protein. Nevertheless, FP requires a tracer fluorescent ligand that 
could be displaced by the candidate inhibitors. 
Fluorescence polarization is based on the observation that fluorescent molecules in solution 
that are excited with plane-polarized light will emit light in a fixed plane. However, as the 
molecules rotate and tumble, the plane into which the light is emitted may vary from the 
plane used for the initial excitation. The rate at which a molecule rotates and tumbles 
depends on the size. If a molecule is very large, little rotation will occur whereas if a 
molecule is small, the rotation will be faster. Therefore, a molecule can be excited with 
vertically polarized light and the intensity of emitted light can be monitored in the vertical 
and the horizontal planes to determine the relative mobility of the fluorescently labeled 
molecule. If the fluorescent probe is bound to the protein, the emission light will remain 
highly polarized relative to the excitation plane, but if the probe is free in solution it will 
rotate quicker and the light will be depolarized relative to the excitation plane. 
The reported FP assays are performed employing two different fluorescent tracers based on 
the same peptide sequence but with different fluorophore moieties: BODIPY or 
fluorescein. 
BODIPY is defined as a red-shifted fluorophore that tend to lower common assay 
interferences, such as those arising from compound aggregation or fluorescent impurities. 
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We have performed the first PF experiment using a BODIPY-labeled ligand as fluorescent 
tracer using the experimental conditions reported in literature
37
 with unsuccessful results, 
probably due to the low quality of the tracer or to the perturbation of the outcome 
fluorescent signal by the cyclic peptides, for example due to the peptide aggregation. 
To overcome this problem, a new synthesis was developed to obtain a fluorescein-labeled 
ligand which has reported to have a Kd greater than the BODIPY-analogue and for this 
reason may be displaced by the candidate which present a low affinities towards the VEGF, 
representing a throughput method with a high sensitivity to identify weakly binding 
inhibitors. 
2.7.1. Synthesis of the FP-tracer 
The FP tracer is a peptide composed of 15 amino acids (CDIHVMWEWECFERL), bearing 
a disulfide bridge between the two cysteines in the sequence. In addition it has a [2-(2-
amino ethoxy)-ethoxyl] acetic acid spacer located at the N-terminal between the peptide 
and the fluorophore. 
The synthesis of the fluorescein-labelled tracer (Figure 9) was performed using 
Aminomethyl-ChemMatrix resin as solid support functionalized with Fmoc-Rink-Linker, 
which, not only reduces the resin functionalization, but also provides a C-terminal amide 
after the peptide cleavage from the resin.  
The peptide elongation was carried out by automated microwave assisted technology 
following the Fmoc/tBu strategy and using TBTU and DIEA as coupling reagent system. 
After completing the linear peptide assembly by microwave, the intermediate 9 was 
characterized through the analysis of a crude sample, obtained from the cleavage of a little 
portion of resin with a proper cleavage cocktail. The RP-HPLC and MALDI-TOF analysis 
show the good outcome of the reaction. Subsequently, the coupling with the spacer was 
performed manually by SPPS using HBTU-DIEA, yielding the product 10.  
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Figure 9. Structure of FP fluorescein-labelled tracer.  
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The next synthetic step, related to the removal of the trityl (S-Trt) protecting groups on the 
cysteines and their subsequent oxidation to form a disulfide bond, was the subject of an 
intensive investigation, with the aim to indentify an efficient methodology to perform the 
reaction on solid phase instead of in solution as previously done.  
Typically, the cyclization of linear peptides on the solid support, where pseudodilution is 
achieved, presents an important benefit for the intramolecular disulfide bond formation.
38,39
 
Solid phase disulfide bridge formation has the advantage that it favors the intramolecular 
reactions, avoiding the intermolecular one. Moreover, on-resin oxidations can be carried 
out in small solvent volumes that can be easily removed together with the excess oxidizing 
agent by filtration. Several protocols have been developed for on-resin disulfide bond 
formation and include the use of hazardous oxidizing agents like thallium and mercury 
complexes, or iodine-mediated methods.
40,41
 Furthermore, the common on-resin oxidation 
methods provide reduced by-product formation, especially when sensitive residues as Trp 
and Met are present in the peptide sequence.
42
  
Since Kamber et al.
43
 discovered that in peptides where thiols are protected by 
acetamidomethyl (Acm) groups, iodine offered the potential to carry out removal and 
simultaneous oxidative disulphide bond formation in one-single step, several disulphide-
bonded peptides have been synthesized using this strategy.
44
 Unfortunately, side reactions 
are often associated with this procedure including, for example, iodination of some 
sensitive residues such as Tyr, Met, and Trp. To limit these undesired side reactions, the 
excess of iodine should be quenched or adsorbed after completion of the disulfide reaction 
by addition of sodium bisulfate or thiosulfate, ascorbic acid, powdered zinc dust, activated 
charcoal, or by dilution with water followed by extraction with carbon tetrachloride. 
Starting from the several reported methodologies, we have focussed on the study of the I2-
mediated disulfide bonds on solid phase. Several trials have been performed changing the 
equivalents of iodine and the time of the treatment. The best reaction conditions were 
identified in two treatments of 15 minutes with 5 equivalents of I2 in DMF followed by a 
quench (3x1 min) with a saturated solution of sodium bisulfate in DMF to eliminate the 
iodine and to prevent the iodination of the methionine. Under these conditions the cleavage 
of the Trt-cysteine protecting groups and the cyclization happen in only a single reaction 
step leading to the product 11 in almost quantitative yield. It is important to notice the 
difficulty to monitor the reaction evolution by RP-HLPC due to the similar retention times 
of the oxidized and the reduced form independently on the elution gradient used. In the 
same way, MALDI-TOF analysis was not providing clear statement of the reaction due to 
the detected isotopic cluster which complicates the spectra interpretation. Only by HR-
ESMS it was possible to clarify the course of the reaction. 
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Scheme 1. Synthetic scheme of the FP fluorescein-label tracer. 
The fluorescent moiety has been introduced by the coupling with the 5(6) 
carboxyfluorescein performed using PyBOP-HOAt-DIEA/3:3:6, overnight. 
The cleavage of the peptide from the resin and the complete removal of side-chain 
protecting groups were accomplished by treatment with TFA solution containing water and 
TIS as scavengers (TFA-TIS-H2O/95:3:3, 2h). The solvent was removed in vacuo and the 
peptide 12 was precipitated with TBME, dissolved in a mixture of acetonitrile-water (1:1) 
and lyophilized. 
The crude was purified by RP-HPLC at semi-preparative scale providing the final product 
12 in 11% overall yield and with a purity higher than 98% (Figure 10). The pure product 
was fully characterized by RP-HPLC, HR-ESMS, MALDI-TOF and amino acids analysis. 
 
Figure 10: HPLC and MALDI-TOF traces of the FP fluorescein-labelled tracer 12. HPLC were recorded using a 30-60% 
B gradient in 8 min (A = 0.045% TFA in H2O and B = 0.036% TFA in ACN). 
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2.7.2. FP: validation experimental conditions 
The fluorescein-labelled tracer has been used to perform a preliminary FP assay with the 
aim to set up the experimental conditions and to evaluate the behavior of the tracer during 
these experiments. 
A direct binding assay was initially performed with the fluorescein-labelled tracer 12 and 
VEGF, obtaining a Kd values of the tracer in accordance with those reported in literature 
(Table 9).
37
  
Peptide  Sequence 
Literature 
Kd (nM) 
Experimental 
Kd (nM) 
12 Cf-X-CDIHVMWEWECFERL-NH2 140 ± 40 146 ± 32 
Table 9. Direct binding FP assay of fluorescein-labelled tracer 12. X = [2-(2-amino-ethoxy)-ethoxy]-acetic acid. 
Based on the Kd value determined in direct binding FP experiments described above, we 
established a competition FP assay in which a well-known peptidic VEGF inhibitor 
(v107)
45
 can be screened for its ability to displace the tracer 12 from VEGF.  
Affinity of competitor for VEGF was quantified as an equilibrium dissociation constant (Ki 
value), which was calculated from the inhibition curve.
46
  
The unlabeled peptide 107 was able to compete with tracer 12 for binding to VEGF; with a 
Ki value of 0.4 ± 0.03 M.  
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Figure 11. v107 competition assay graph. V107 sequence: H-GGNECDIARMWEWECFERL-NH2. 
The same experimental conditions will be used to screen the cyclic hexapeptides of the 
library and to evaluate their interaction with the protein. This assay is a complementary 
approach to the NMR studies to measure the interaction of the cyclic hexapeptides to the 
VEGF. Moreover, this method can also provide information about the interaction site 
exploiting the competition with the tracer which is known to interact with VEGF in a 
region recognized by its receptor. 
2.7.3. A Fluorine-labelled tracer 
In spite of the NMR spectroscopy has gained increasing importance for the identification of 
compounds that bind to macromolecules, screening of chemical libraries using traditional 
spectroscopic methods produces complex 
1
H-NMR spectra and requires labelled protein 
samples.  
The 
19
F-NMR spectroscopy represents an alternative simple methodology for the screening 
of ligands that bind to proteins, which also provides qualitative information about the 
relative binding strengths and the presence of multiple binding sites. 
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19
F nucleus has lately attracted much attention in the screening field for various reasons. 
First and most important is its high sensitivity; this is due to 
19F’s high gyromagnetic 
constant (γF ~ 0.94 γH) but also to its 100% natural abundance. Moreover, fluorine displays 
a wide chemical shift range, which makes it unlikely for overlapping to occur. Other useful 
properties include its high sensitivity towards binding events; this often induces important 
changes to fluorine chemical shift and line width due to fluorine’s large CSA (Chemical 
Shift Anisotropy). Given the remarkable relaxation properties above, binding detection can 
often be performed simply by acquiring 1D spectra in with and without the target protein. 
Nonetheless, a more general approach to discriminate between fluorine containing ligands 
among non-binders consists on the determination on transversal relaxation rates (T2), either 
by direct measurement of linewidth or by using T2 filters.
47,48
 
Obviously such experiments are limited to some extent, as they require the presence of 
fluorine atoms in the assayed compounds. This element, however, is rather common in 
commercial drugs and often, medicinal chemists enhance metabolic stability or modulate 
compound lipophilicity by incorporating such element. On the other hand, fluorine is 
seldom found in natural sources or solvents; for these reasons it has been proposed as an 
alternative to avoid background resonances arising from the protein or the annoying solvent 
signals, which often have deleterious consequences for the performance of ligand based 
experiments.  
In the field of 
19
F spectroscopy, recently FAXS (fluorine chemical shift anisotropy and 
exchange for screening) has been reported as a ligand-based binding competition screening 
experiment
49-51
 that utilizes a weak affinity spy molecule containing a CF3 or CF moiety 
and 
19
F as the nucleus of detection. The FAXS approach has some distinct advantages. The 
absence of overlap allows the screening of large chemical mixtures and the automated 
spectra analysis. The large CSA of fluorine results in a large difference in line width for the 
spy molecule in the free and bound states, especially at the high magnetic fields currently 
used. This phenomenon, combined with the large exchange contribution, allows for the 
selection of a weak-affinity spy molecule, thus resulting in both a lower binding affinity 
threshold for the identified NMR hits and protein consumption. 
We have focused on this technique as an alternative (or parallel) method to FP for 
screening the cyclic peptides of our library, in order to confirm if the candidate peptides 
interact with the VEGF in its site of recognition with the VEGFR. A fluorine version of the 
FP tracer has been synthesized using the same methodology previously described for the 
FP tracer 12. The coupling with a fluorine moiety instead of with the carboxyfluorescein 
was performed in the last step, just before the resin cleavage. This tracer will be used as 
spy molecule in the ligand-based binding competition screening experiment based on 
19
F as 
the nucleus of detection.  
After the synthesis of the linear peptide 11, the fluorine moiety has been introduced by the 
coupling with the 4,4,4-Trifluoro-3-(trifluoromethyl)butanoic acid performed using 
PyBOP-HOAt-DIEA/20:60:60, in DMF for 1.5 hours. 
 
Chapter 2 
 
 
172 
Fmoc-O2O-CDIHVMWEWECFERL NH
O
vii)  Piperidine 20% in DMF
viii) (CF3)2CHCH2COOH, PyBOP, HOAt, DIEA
ix) TFA-H2O-TIS/95:3:3
11 13
CF3-O2O-CDIHVMWEWECFERL
CF3
OCF3
F3C
 
Scheme 2. The last step of the synthesis of fluorine-labelled tracer. 
The cleavage of the peptide from the resin and the complete removal of side-chain 
protecting groups were accomplished by treatment with TFA solution containing water and 
TIS as scavengers (TFA-TIS-H2O/95:3:3, 2h). The crude was purify by RP-HPLC at semi-
preparative scale providing the product 13 in 8% overall yield and with a purity higher than 
98% (Figure 12). The pure product was fully characterized by RP-HPLC, RP-HPLC-MS, 
MALDI-TOF and amino acids analysis. 
             
Figure 12. HPLC and MALDI-TOF traces of the fluorine-labelled tracer 13. HPLC was recorded using a 30-60% B 
gradient in 8 min (A = 0.045% TFA in H2O and B = 0.036% TFA in ACN). 
2.8. EGF target protein 
One of the target protein proposed at the beginning of this project was the Epidermal Grow 
Factor (EGF) which is widely involved in tumorigenesis and in the glioma progression.  
In order to explore the EGF binding ability of the cyclohexapeptides two main approaches 
were evaluated.  
The first one is based on the NMR observation of 
15
N-labelled EGF and the use of 
chemical shift perturbation experiments. As previously described for the VEGF, this 
approach allows screening over a wide range of affinities (mM-nM). In addition to identify 
positive binders, this method allows a quantitative characterization of the interactions and 
the direct identification of the binding site within the protein, but requires the expression of 
15
N-labelled EGF in E. coli. Despite the structure of free EGF has been solved by NMR 
using recombinant protein,
52
 the EGF expression represent a non-trivial problem. Indeed, 
while the EGF expression was successfully obtained, although with low yield, the further 
work to produce the 
15
N-labelled version, proved particularly challenging and it is currently 
in progress.  
As the expression of 
15
N-labelled EGF was a limiting factor, some alternative binding 
assays have been evaluated. For example it is possible to use the competition fluorescence 
polarization assay employing the experimental conditions validated for the VEGF. In such 
a case, it is necessary to find a fluorescent tracer EGF-ligand that could be displaced by the 
candidate inhibitors. Nowadays, only Suramin has been described as inhibitor of EGF-
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EGFR interaction.
52
 Suramin is a symmetric polysulfonate compound that uses half of the 
molecule to interact with the C-terminal region of EGF. Suramin alone is poorly 
fluorescent and it has not any functional group susceptible of being conjugated with a 
suitable fluorescent moiety but can give a fluorescent signal according to hydrophobic 
media and to the target molecule which can induce a conformational change resulting in a 
fluorescence enhancement.
53
 Unfortunately this does not happen when Suramin interacts 
with EGF, so Suramin can not be used as EGF-fluorescent tracer.  
The second approach is based on the thermodynamic characterization of the EGF-ligand 
binding, by isothermal titration calorimetry (ITC) which is perhaps the most rigorous 
method for the characterization of protein-ligand interactions. In this method, the 
interactions are detected by the intrinsic heat change. From ITC measurements it is possible 
to determine the thermodynamic parameters such as binding enthalpy (H), stoichiometry, 
entropy (S) and association constant (K) of the binding process. ITC experiments cover an 
optimum range of dissociation constants from 100 M to 10 nM; however, modification of 
experimental design using competition methods can be used to extend this range.  
Independently on the type of chosen assay, it is necessary to synthesize the EGF 
considering the low amount of protein that can be produced by EGF expression and the 
high cost of the commercially available one. 
2.8.1. Attempt to EGF synthesis  
The human EGF is 6045-Da protein with 53 amino acid residues, three intramolecular 
disulphide bridges and a large number of trifunctional amino acids bonds, thus represents a 
considerable challenge to the peptide chemist. Few procedures are reported for this 
synthesis which was performed both by assembly of shorter peptide building blocks
54
 or by 
a stepwise manner.
55
 
During this project the EGF was synthesized by SPPS in association with the microwaves 
assisted technology. Aminomethyl ChemMatrix resin was chosen as solid support which 
was functionalized with an AB linker (3-(4-Hydroxymethylphenoxy) propionic acid) in 
order to reduce the resin functionalization (0.4 mmol) and to obtain a carboxylic function 
as C-terminal. After the incorporation of the first amino acid by manual coupling (5eq AA/ 
5eq DIPCDI/ 0.5 eq DMAP; DCM, 0.5 h x 2) the peptide chain elongation was performed 
by microwaves assisted synthesis using TBTU/DIEA as coupling reagent in association 
with the Fmoc/tBu chemistry.  
The synthesis progression was monitored at different stages, and up to 35 amino acids it 
was possible to identify the product by MS-HPLC and MALDI-TOF analysis; nevertheless 
at the end of the synthesis the crude characterization does not provide any evidences of the 
desired product and giving a very complex HPLC chromatogram. The complexity of the 
spectrum could be related to possible deletions of amino acids due to a low efficiency of 
the attempted synthetic methodology, or to the formation of multiple disulfide bonds 
between the cysteines in the sequence. Although the peptide has not been subjected to 
oxidative conditions, it is possible that the six cysteines in the sequence have formed intra 
and/or inter disulfide bonds leading to a complex mixture of products.  
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In order to confirm this hypothesis and to simplify the crude, the product was reduced 
using a large excess of DTT (100 eq 5mg/ml, r.t. 30 min), then it was purified by sephadex: 
NAP-5 (cut off= 5000 Da). The HPLC after the reduction is significantly simplified and its 
comparison with the HPLC of the expressed and commercial EGF revealed some common 
peaks. In any case the MALDI-TOF and MS-HPLC analysis do not identify the mass 
corresponding to the product. 
A new synthesis has been attempted slightly changing the synthetic methodology, by 
setting a double coupling as default after the first 15 amino acids in order to push the 
reaction. In this case the product was detected by MALDI-TOF and MS-HPLC up to 40 
amino acids, but at the end of the synthesis (53 AA) the product was not identified also 
after the reductive treatment with DTT. 
The products obtained from the two attempted synthesis and the commercial EGF, were 
subjected to a gel electrophoresis analysis using a polyacrilamide gel. The results reveled 
that the synthetic products have a smaller size compared to the commercial protein. In 
addition, by comparison of the two synthetic products it was noticed that the second 
attempt has provided a peptide with a higher molecular weight than the first one showing 
that the large excess of reagents used in the double coupling has pushed the reaction but, 
however, was not enough to obtain the final product.  
In conclusion, despite the microwaves assisted heating technology is, in general, an 
efficient method for the synthesis of peptide with different lengths and amino acids 
compositions, in this case the synthesis were failed. These results suggest that the stepwise 
synthetic approach is not probably the best method to produce this protein. Thus, further 
investigations will be performed to identify an alternative approach to obtain the protein, 
for example will be evaluated to synthesize EGF exploiting the native chemical ligation or 
by fragment condensation. 
2.9. In vitro assays for biological activity evaluation: preliminary results 
The candidates cyclo-4a and cyclo-4b (labeled with the BBB shuttle and the unconjugated 
ones) were also tested in a viability cell assay at the group of Prof. Seoane in the Vall 
d'Hebron Institut d'Oncologia of Barcelona (VHIO). The preliminary data showed that one 
of the compounds active in the VEGF binding assay (cyclo-4b) showed a remarkable 
activity when compared to the control compound (Cetuximab) at work dose of 66 nM. The 
epimer compound (cyclo-4a), which only differs in the chirality of one carbon, was 
significantly less active. Moreover, the results showed the loss of activity when the 
compounds are linked to the BBB shuttle indicating that they are in the silent mode when 
circulating and that a hydrolysable specific linker is required to release the compound when 
reaching the brain tissue. 
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Figure 14. Results of viability assay measured by WST-1 reagent upon 24 h treatment with Cetuximab/Cancertech 
compounds. 
2.10. Conclusion  
A library of cyclic haxapeptides to search for anti-EGF and anti-VEGF binders was 
designed and synthesized. The design of the peptide drugs has been rationalized to obtain 
symmetric cyclic hexapeptides: cyclo-(DPro-XY-DPro-XY) synthetically accessible with 
drug-like properties as protease resistant and metabolically stable (e.g. by the insertion of 
unnatural amino acids). Moreover, the design aims the access to rigid structures to increase 
the binding activities and to obtain a fixed peptidic backbone structure which makes easier 
the exploration of different amino acid side chains.  
In the first stage, the methodology has been explored to identify a synthetic procedure to 
easily access to the cyclic peptides with high yields and purities. The key points of the 
optimized synthetic procedure are represented by the use of a 2-Chlorotrityl resin as a 
polymeric support which allows to obtain the side-chain protected linear precursor and to 
exploit all the advantages of solid-phase chemistry. The introduction of D-prolines has the 
double effect to promote the peptide cyclization (being -turn elements) and to increase the 
metabolic resistance of the final products (as non natural amino acids). DPPA/NaHCO3 
were chosen as the best reagents to perform the cyclization in solution. 
A library of cyclic compounds were produced by using a representative base of amino 
acids for X and Y positions: Trp, Glu, Ile, Ser and Arg and for each combination, one 
epimer was synthesized.  
Different NMR studies have been performed to characterize the structure of the cyclic 
peptides defining that they contain a rigid structure with a common motive of two -turns 
type II’. 
The cyclo hexapeptides were tested by NMR for binding interaction against the vascular 
endothelial growth factor (VEGF) 
13
CMet-labelled. Despite several tested compounds 
produce alteration in the chemical shift of the protein, mainly two peptides (cyclo-4a, 
cyclo-4b) showed binding interaction in the active binding site, so they could be promising 
drug candidate. 
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In order to confirm the NMR results, the same system was evaluated by using fluorescent 
polarization (FP). Since the problems encountered in the fluorescent signal acquisition 
during the first trial with a BODIPY-labelled ligand, a new fluorescein-labelled ligand was 
synthesized. 
The synthesis was developed optimizing the previously established procedure to form the 
disulfide bond, in which the oxidation was carried out in solution using ammonium 
hydroxide and required five days. With our optimized method, the reaction was performed 
on solid-phase with only 30 minutes with iodine, allowing the synthesis of the tracer fully 
on solid phase. 
The tracer was used to validate the PF experimental conditions that will be employed to 
screen the cyclic compounds of the library. 
In order to test the peptide library against the epidermal growth factor, the EGF synthesis 
by microwaves assisted technology was attempted. Despite the failure of the two trials, the 
results have provided important information about the synthetic approach to use, discarding 
the stepwise as method of choice. In addition, during this step, it was performed a complete 
characterization of the commercial EGF, which will be a useful reference during the further 
attempts that will be performed in order to obtain the EGF both synthetically and by 
expression.  
Two cyclic hexapeptides were evaluated by PAMPA assay which models the passive 
transport at the BBB and both of them showed passive diffusion ability. Whereas the BBB 
transport evaluation in a cell based model displayed that these two candidates conjugated 
with the BBB shuttle were able to cross the BBB by using the active transport via 
transferrin receptor, resulting in a more selective transport.  
Based on the viability cell assay results which show that the two candidates are biological 
active but when they are linked to the BBB-shuttle become inactive. A hydrolysable link 
between the cyclopeptide and the BBB-shuttle will be evaluated in order to release the 
active compound when it reaches the brain tissue keeping its activity. 
Based on the structural features of the two compounds identified as the best candidates of 
this first cyclic hexapeptide library, it will be possible to plan properly the modifications to 
optimize their interaction with the target protein. Thus a new set of cyclopeptides could be 
developed, maintaining the same set of amino acids but, for instance, changing the 
stereochemistry or shifting the residues along the peptide chain, to explore their influence 
on the structural and conformational properties of the cyclohexapeptides and the 
consequent effect on the binding with the target. 
A different approach could be to introduce and additional level of restriction in the 
structure through a bicyclic formation or to expand the size of the ring, either by including 
a third pair of pXY to obtain cyclic nonapeptides, or by including a Z amino acid into the 
motive pXYZ to obtain cyclic octapeptides. 
The hits compounds identified during this first part of the project, could be also validated 
and characterized in better detail with other throughput methods, either using the same 
NMR techniques but with different experimental design or using additional techniques, to 
acquire a wider set of thermodynamic, kinetic and structural data to investigate the 
compound properties. 
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An alternative approach could be to develop a new sub-set of cyclopeptides in silico and to 
test them against the target proteins by using computational tools such as docking. The 
obtained results will provide important information related with the possible activity of 
these potential therapeutic agents against the tested targets and the most promising 
candidates will be synthesized so as to be validated. 
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3.1. Linear peptides 
3.1.1. Synthesis  
All the linear peptides were synthesized by SPPS using the Fmoc/tBu strategy and 2-
chlorotrityl (Cl-Trt) resin (f=1.60 mmol/g) in accordance to the experimental procedures 
reported in the section 6.5 of the Chapter 6. Syntheses were performed at a 200-µmol scale. 
Solid-phase peptide elongations was done manually in polypropylene syringes, using 
PyBOP, HOAt and DIEA as coupling reagents. Solvents and soluble reagents were 
removed by suction. Washings between synthetic steps were done with DMF (5 x 30 s) and 
DCM (5 x 30 s). During couplings the mixture was left to react with intermittent manual 
stirring and the good outcome of each coupling was verified by ninhydrin, chloranil or p-
nitrophenyl ester test, depending on the type of amine which should be detected. After the 
removal of the last Fmoc group by treatment with 20% of piperidine in DMF, the cleavage 
of the peptide from the resin was accomplished by treatment with a solution of 2% TFA in 
DCM (5x 1 min). Crude products were analyzed by RP-HPLC, MS-HPLC and MALDI-
TOF. The initial resin loading was determined by UV spectroscopy as reported in the 
section 6.5.6. 
The overall yield of each linear peptide synthesis was estimated by Fmoc UV detection 
related to the last cleavage step, whereas the purity of the crudes was determined through 
analytical HPLC analysis. HPLC chromatograms were recorded on a Waters Alliance 2695 
separation module using a Sunfire C18 column flow 1mL/min, solvents H2O (0.045% TFA) 
and ACN (0.036% TFA). The gradient (G) is expressed as % of ACN in H2O (peak 
detected at =220 nm).  
3.1.2. Characterization 
H-Trp(Boc)-Pro-Arg(Pbf)-Trp(Boc)-Pro-Arg(Pbf)-OH (1a) 
Initial loading: 0.53 mmol/g 
HPLC: tR (min, G0100 ACN in 8 min) = 7.27  
MS-HPLC calcd for: C80H108N14O17S2, expected: 1600.75, found: 1601.50 [M+H]
+
 
MALDI-TOF, [M+H]
+
: 1601 Da 
Yield: 82 % 
Purity: 83 % 
H-Trp-Pro-Arg-Trp-Pro-Arg-OH (1a’) 
Initial loading: 0.53 mmol/g 
Cleavage cocktail: TFA/TA/H2O/TIS/EDT - 81.5:5:5:1:5 (3 h) 
HPLC: tR (min, G0100 ACN in 8 min) = 4.45  
MS-HPLC calcd for: C44H60N14O7, expected: 896.48, found: 897.50 [M+H]
+
 
MALDI-TOF, [M+H]
+
: 897.64 Da 
Yield: 86 % 
Purity: 80 % 
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H-D-Trp(Boc)-Pro-Arg(Pbf)-D-Trp(Boc)-Pro-Arg(Pbf)-OH (1b) 
Initial loading: 0.56 mmol/g  
HPLC: tR (min, G0100 ACN in 8 min) = 7.86  
MS-HPLC calcd for: C80H108N14O17S2, expected: 1600.75, found: 1601.50 [M+H]
+
 
MALDI-TOF, [M+H]
+
: 1601 Da 
Yield: 70 % 
Purity: 94 % 
H-D-Trp-Pro-Arg-D-Trp-Pro-Arg-OH (1b’) 
Initial loading: 0.56 mmol/g 
Cleavage cocktail: TFA/TA/H2O/TIS/EDT - 81.5:5:5:1:5 (3 h) 
HPLC: tR (min, G0100 ACN in 8 min) = 4.54  
MS-HPLC calcd for: C44H60N14O7, expected: 896.48, found: 897.70 [M+H]
+
 
MALDI-TOF, [M+H]
+
: 897.53 Da 
Yield: 90 % 
Purity: 70 % 
H-Trp(Boc)-D-Pro-Arg(Pbf)-Trp(Boc)-D-Pro-Arg(Pbf)-OH (1c) 
Initial loading: 0.71 mmol/g 
HPLC: tR (min, G0100 ACN in 8 min) = 7.73  
MS-HPLC calcd for: C80H108N14O17S2, expected: 1600.75, found: 1602 [M+H]
+
 
MALDI-TOF, [M+H]
+
: 1601.63 Da 
Yield: 75 % 
Purity: 83 % 
H-Trp(Boc)-Pro-D-Arg(Pbf)-Trp(Boc)-Pro-D-Arg(Pbf)-OH (1d)  
Initial loading: 0.50 mmol/g 
HPLC: tR (min, G30100 ACN in 8 min) = 6.70  
MS-HPLC calcd for: C80H108N14O17S2, expected: 1600.75, found: 1601.9 [M+H]
+
 
MALDI-TOF, [M+H]
+
: 1601.71 Da 
Yield: 70 % 
Purity: 92 % 
H-Arg(Pbf)-Pro-Trp(Boc)-Arg(Pbf)-Pro-Trp(Boc)-OH (2a) 
Initial loading: 0.60 mmol/g 
HPLC: tR (min, G30100 ACN in 8 min) = 6.55  
MS-HPLC calcd for: C80H108N14O17S2, expected: 1600.75, found: 1602 [M+H]
+
 
MALDI-TOF, [M+H]
+
: 1601.91 Da 
Yield: 77 % 
Purity: 88 % 
H-Arg-Pro-Trp-Arg-Pro-Trp-OH (2a’) 
Initial loading: 0.60 mmol/g 
Cleavage cocktail: TFA/TA/H2O/TIS/EDT - 81.5:5:5:1:5 (3 h) 
HPLC: tR (min, G0100 ACN in 8 min) = 4.63  
Peptides synthesis and characterization  
 
 
184 
MS-HPLC calcd for: C44H60N14O7, expected: 896.48, found: 897.50 [M+H]
+
 
MALDI-TOF, [M+H]
+
: 897.53 Da 
Yield: 90 % 
Purity: 83 % 
H-D-Arg(Pbf)-Pro-Trp(Boc)-D-Arg(Pbf)-Pro-Trp(Boc)-OH (2b) 
Initial loading: 0.55 mmol/g 
HPLC: tR (min, G30100 ACN in 8 min) = 7.50  
MS-HPLC calcd for: C80H108N14O17S2, expected: 1600.75, found: 1602.0 [M+H]
+
 
MALDI-TOF, [M+H]
+
: 1602.08 Da 
Yield: 91 % 
Purity: 90 % 
H-D-Arg-Pro-Trp-Arg-D-Pro-Trp-OH (2b’)  
Initial loading: 0.55 mmol/g 
Cleavage cocktail: TFA/TA/H2O/TIS/EDT - 81.5:5:5:1:5 (3 h) 
HPLC: tR (min, G0100 ACN in 8 min) = 4.89 
MS-HPLC calcd for: C44H60N14O7, expected: 896.48, found: 897.01 [M+H]
+
 
MALDI-TOF, [M+H]
+
: 897.47 Da 
Yield: 85 % 
Purity: 70 % 
H-Arg(Pbf)-D-Pro-Trp(Boc)-Arg(Pbf)-D-Pro-Trp(Boc)-OH (2c) 
Initial loading: 0.43 mmol/g 
HPLC: tR (min, G0100 ACN in 8 min) = 8.25  
MS-HPLC calcd for: C80H108N14O17S2, expected: 1600.75, found: 1601.81 [M+H]
+
 
MALDI-TOF, [M+H]
+
: 1602.11 Da 
Yield: 75 % 
Purity: 90 % 
H-Arg(Pbf)-Pro-D-Trp(Boc)-Arg(Pbf)-Pro-D-Trp(Boc)-OH (2d)  
Initial loading: 0.50 mmol/g 
HPLC: tR (min, G0100 ACN in 8 min) = 8.18 
MS-HPLC calcd for: C80H108N14O17S2, expected: 1600.75, found: 1602 [M+H]
+
 
MALDI-TOF, [M+H]
+
: 1601.71 Da 
Yield: 89 % 
Purity: 73% 
H-Ser(tBu)-D-Pro-Trp(Boc)-Ser(tBu)-D-Pro-Trp(Boc)-OH (3a) 
Initial loading: 0.73 mmol/g 
HPLC: tR (min, G0100 ACN in 8 min) = 7.13  
MS-HPLC calcd for: C56H78N8O13, expected: 1070.57, found: 1071.63 [M+H]
+
 
MALDI-TOF, [M+H]
+
: 1071.71 Da 
Yield: 86 % 
Purity: 91 % 
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H-Ser(tBu)-D-Pro-Trp(Boc)-Ser(tBu)-D-Pro-D-Trp(Boc)-OH (3a’) 
Initial loading: 0.83 mmol/g 
HPLC: tR (min, G0100 ACN in 8 min) = 7.46  
MS-HPLC calcd for: C56H78N8O13, expected: 1070.57, found: 1071.57 [M+H]
+
. 
MALDI-TOF, [M+H]
+
: 1071.90 Da 
Yield: 80 % 
Purity: 90 % 
H-Glu(OtBu)-D-Pro-Trp(Boc)-Glu(OtBu)-D-Pro-Trp(Boc)-OH (4a) 
Initial loading: 0.71 mmol/g 
HPLC: tR (min, G0100 ACN in 8 min) = 7.81 
MS-HPLC calcd for: C60H82N8O15, expected: 1154.59, found: 1155.59 [M+H]
+
 
MALDI-TOF, [M+H]
+
: 1155.71 Da 
Yield: 89 % 
Purity: 85 % 
H-Glu(OtBu)-D-Pro-Trp(Boc)-Glu(OtBu)-D-Pro-D-Trp(Boc)-OH (4b) 
Initial loading: 0.81 mmol/g 
HPLC: tR (min, G0100 ACN in 8 min) = 7.77 
MS-HPLC calcd for: C60H82N8O15, expected: 1154.59, found: 1155.52 [M+H]
+
 
MALDI-TOF, [M+H]
+
: 1155.90 Da 
Yield: 85 % 
Purity: 83 % 
H-Ile-D-Pro-Trp(Boc)-Ile-D-Pro-Trp(Boc)-OH (5a) 
Initial loading: 0.70 mmol/g 
HPLC: tR (min, G0100 ACN in 8 min) = 7.17 
MS-HPLC calcd for: C54H74N8O11, expected: 1010.55, found: 1011.5 [M+H]
+
 
MALDI-TOF, [M+H]
+
: 1011.56 Da 
Yield: 84 % 
Purity: 95 % 
H-Ile-D-Pro-Trp(Boc)-Ile-D-Pro-D-Trp(Boc)-OH (5b) 
Initial loading: 0.72 mmol/g 
HPLC: tR (min, G0100 ACN in 8 min) = 7.55 
MS-HPLC calcd for: C54H74N8O11, expected: 1010.55, found: 1011.5 [M+H]
+
 
MALDI-TOF, [M+H]
+
: 1011.56 Da 
Yield: 78 % 
Purity: 97 % 
H-Ser(tBu)-D-Pro-Glu(OtBu)-Ser(tBu)-D-Pro-Glu(OtBu)-OH (6a) 
Initial loading: 0.90 mmol/g 
HPLC: tR (min, G0100 ACN in 8 min) = 5.82 
MS-HPLC calcd for: C42H72N6O13, expected: 868.52, found: 869.44 [M+H]
+
 
MALDI-TOF, [M+H]
+
: 869.56 Da 
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Yield: 88 % 
Purity: 80 % 
H-Ser(tBu)-D-Pro-Glu(OtBu)-Ser(tBu)-D-Pro-D-Glu(OtBu)-OH (6b) 
Initial loading: 0.85 mmol/g 
HPLC: tR (min, G0100 ACN in 8 min) = 5.58 
MS-HPLC calcd for: C42H72N6O13, expected: 868.52, found: 869.50 [M+H]
+
 
MALDI-TOF, [M+H]
+
: 869.55 Da 
Yield: 80 % 
Purity: 80 % 
H-Ser(tBu)-D-Pro-Ile-Ser(tBu)-D-Pro-Ile-OH (7a) 
Initial loading: 0.73 mmol/g 
HPLC: tR (min, G0100 ACN in 8 min) = 5.88 
MS-HPLC calcd for: C36H64N6O9, expected: 724.47, found: 725.30 [M+H]
+
 
MALDI-TOF, [M+H]
+
: 725.51 Da 
Yield: 80 % 
Purity: 94 % 
H-Glu(OtBu)-D-Pro-Ile-Glu(OtBu)-D-Pro-Ile-OH (8a) 
Initial loading: 0.90 mmol/g 
HPLC: tR (min, G0100 ACN in 8 min) = 5.82 
MS-HPLC calcd for: C40H68N6O11, expected: 808.49, found: 809.34 [M+H]
+
 
MALDI-TOF, [M+H]
+
: 809.54 Da 
Yield: 77 % 
Purity: 95 % 
3.2. Cyclic peptides 
3.2.1. Synthesis  
The head-to-tail peptide cyclizations were performed according to the protocol G described 
in the section 6.7 of the chapter 6 General methods and procedures. The linear peptides 
were dissolved in DMF (5 mM solution) and to the solution were added NaHCO3 (8 eq) 
and DPPA (2 eq). The reaction was left to proceed at r.t. under stirring and monitored by 
analytical HPLC. NaHCO3 was removed by filtration and the solvent was evaporated under 
reduced pressure. 
Complete deprotection of the peptide was performed by acidolytic treatment with a 
TFA/TIS/H2O solution or TFA/phenol/H2O/TA/EDT for Arg containing peptides. The 
reaction was carried out at r.t. for 1 hour on orbital shaker. For the cleavage of Arg 
containing peptides the reaction time was increased to 3 h. The crude was precipitated 
through addition of cold tert-butyl methyl ether. The suspension was centrifuged at 4000 
rpm and 4ºC for 10 min. The ether fraction was discarded and the process repeated up to 3 
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times. The peptide residue was dried under a N2 flow stream, dissolved in a mixture of 
H2O/ACN (1:1) and lyophilized. 
The cyclopeptides were purified by automated flash chromatography using IscoCombi flash 
equipment or by HPLC at semi-preparative scale. Purifications were run using ReadySep 
C18 column (or C18 Sunfire column for the semi-Prep-HPLC) and a 30 min linear 
gradients of ACN in H2O which were optimized for each sample. Peaks of interest were 
analyzed by analytical HPLC, combined and lyophilized. 
The final products were analyzed and fully characterized by MALDI-TOF, HR-ESMS and 
amino acids analysis. Purity was checked by analytical HPLC. The yield of each 
cyclopeptide was determined by amino acid analysis.  
3.2.2. Characterization 
&D-Trp-Pro-Arg-D-Trp-Pro-Arg& (cyclo-1b) 
Cleavage cocktail: TFA/TA/H2O/TIS/EDT - 81.5:5:5:1:5 (3 h) 
Purification by automated flash chromatography with RediSep C18 (0:20 to 20:25 
H2O/ACN + 0.1% TFA, gradient over 30 min). (20 mg, 75%). Purity: 95%  
HPLC: tR (min, G1060 ACN in 8 min) = 2.978 
HR-ESMS calcd for: C44H58N14O6, expected: 879.47365, found: 879.4759 (m/z) 
&Trp-D-Pro-Arg-Trp-D-Pro-Arg& (cyclo-1c)  
Cleavage cocktail: TFA/TA/H2O/TIS/EDT - 81.5:5:5:1:5 (3 h) 
Purification by automated flash chromatography with RediSep C18 (0:20 to 20:25 
H2O/ACN + 0.1% TFA, gradient over 30 min) (60 mg, 80%). Purity: 95%  
HPLC: tR (min, G2070 ACN in 8 min) = 2.99  
HR-ESMS calcd for: C44H58N14O6, expected: 879.47365, found: 879.47546 (m/z) 
&Trp-Pro-D-Arg-Trp-Pro-D-Arg& (cyclo-1d) 
Cleavage cocktail: TFA/TA/H2O/TIS/EDT - 81.5:5:5:1:5 (3 h) 
Purification by automated flash chromatography with RediSep C18 (0:20 to 20:25 
H2O/ACN + 0.1% TFA, gradient over 30 min) (10 mg, 20%). Purity: 95 % 
HPLC: tR (min, G0100 ACN in 8 min) = 4.12  
HR-ESMS calcd for: C44H58N14O6, expected: 879.47365, found: 879.47449 (m/z)
 
&D-Arg-Pro-Trp-D-Arg-Pro-Trp& (cyclo-2b)  
Cleavage cocktail: TFA/TA/H2O/TIS/EDT - 81.5:5:5:1:5 (3 h) 
Purification by automated flash chromatography with RediSep C18 (0:20 to 20:25 
H2O/ACN + 0.1% TFA, gradient over 30 min). (30 mg, 84%). Purity: 97 %  
HPLC: tR (min, G1060 ACN in 8 min) = 4.75  
HR-ESMS calcd for: C44H58N14O6, expected: 879.47365, found: 879.47377 (m/z) 
&Arg-D-Pro-Trp-Arg-D-Pro-Trp& (cyclo-2c)  
Cleavage cocktail: TFA/TA/H2O/TIS/EDT - 81.5:5:5:1:5 (3 h) 
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Purification by automated flash chromatography with RediSep C18 (0:20 to 20:25 
H2O/ACN + 0.1% TFA, gradient over 30 min). (60 mg, 80%). Purity: 95 % 
HPLC: tR (min, G0100 ACN in 8 min) = 4.34 
HR-ESMS calcd for: C44H58N14O6, expected: 879.47365, found: 879.47429 (m/z)
 
&Arg-Pro-D-Trp-Arg-Pro-D-Trp& (cyclo-2d)  
Cleavage cocktail: TFA/TA/H2O/TIS/EDT - 81.5:5:5:1:5 (3 h) 
Purification by automated flash chromatography with RediSep C18 (0:20 to 20:25 
H2O/ACN + 0.1% TFA, gradient over 30 min). (30 mg, 30%). Purity: 95 % 
HPLC: tR (min, G0100 ACN in 8 min) = 4.60 
HR-ESMS calcd for: C44H58N14O6, expected: 879.47365, found: 879.47481 (m/z) 
&Ser-D-Pro-Trp-Ser-D-Pro-Trp& (cyclo-3a)  
Cleavage cocktail: TFA/H2O/TIS - 95:2.5:2.5 (1 h) 
Purification by automated flash chromatography with RediSep C18 (0:20 to 20:50 
H2O/ACN + 0.1% TFA, gradient over 30 min). (33 mg, 70%). Purity: 98 %  
HPLC: tR (min, G0100 ACN in 8 min) = 5,47   
HR-ESMS calcd for: C38H44N8O8, expected: 741.33549, found: 741.33646 (m/z) 
&Ser-D-Pro-Trp-Ser-D-Pro-D-Trp& (cyclo-3b) 
Cleavage cocktail: TFA/H2O/TIS - 95:2.5:2.5 (1 h) 
Purification by automated flash chromatography with RediSep C18 (0:20 to 20:50 
H2O/ACN + 0.1% TFA, gradient over 30 min) (27 mg, 60%). Purity: 98 %  
HPLC: tR (min, G0100 ACN in 8 min) = 5,59   
HR-ESMS calcd for: C38H44N8O8, expected: 741.33549, found: 741.33646 (m/z) 
&Trp-D-Pro-Glu-Trp-D-Pro-Glu& (cyclo-4a) 
Cleavage cocktail: TFA/H2O/TIS - 95:2.5:2.5 (1 h) 
Purification by automated flash chromatography with RediSep C18 (0:30 to 30:80 
H2O/ACN + 0.1% TFA, gradient over 30 min). (67 mg, 50%). Purity: 97 %  
HPLC: tR (min, G30100 ACN in 8 min) = 3.44   
HR-ESMS calcd for: C42H48N8O10, expected: 825.35662, found: 825.35695 (m/z) 
&Trp-D-Pro-Glu-Trp-D-Pro-D-Glu& (cyclo-4b) 
Cleavage cocktail: TFA/H2O/TIS - 95:2.5:2.5 (1 h) 
Purification by automated flash chromatography with RediSep C18 (0:30 to 30:50 
H2O/ACN + 0.1% TFA, gradient over 30 min). (95 mg, 60%). Purity: 95 %  
HPLC: tR (min, G30100 ACN in 8 min) = 3.67   
HR-ESMS calcd for: C42H48N8O10, expected: 825.35662, found: 825.35545 (m/z) 
&Ile-D-Pro-Trp-Ile-D-Pro-Trp& (cyclo-5a)  
Cleavage cocktail: TFA/H2O/TIS- 95:2.5:2.5 (1 h) 
Purification by automated flash chromatography with RediSep C18 (0:30 to 30:80 
H2O/ACN + 0.1% TFA, gradient over 30 min). (59 mg, 75%). Purity: 95 % 
Chapter 3 
 
 
189 
HPLC: tR (min, G30100 ACN in 8 min) = 6.04   
HR-ESMS calcd for: C44H56N8O6, expected: 793.43956, found: 793.44013 (m/z)
 
&Ile-D-Pro-Trp-Ile-D-Pro-D-Trp& (cyclo-5b)  
Cleavage cocktail: TFA/H2O/TIS - 95:2.5:2.5 (1 h) 
Purification by automated flash chromatography with RediSep C18 (0:40 to 40:70 
H2O/ACN + 0.1% TFA, gradient over 30 min). (53 mg, 68%). Purity: 96 % 
HPLC: tR (min, G30100 ACN in 8 min) = 6.04   
HR-ESMS calcd for: C44H56N8O6, expected: 793.43956, found: 793.43955 (m/z)
 
&Ser-D-Pro-Glu-Ser-D-Pro-Glu& (cyclo-6a)  
Cleavage cocktail: TFA/H2O/TIS - 95:2.5:2.5 (1 h) 
Purification by HPLC-semi-preparative (SunFirePrep C18, 0:50 H2O/ACN + 0.1% TFA, 
linear gradient over 30 min). (35 mg, 15%). Purity: 95 % 
HPLC: tR (min, G050 ACN in 8 min) = 4.61  
HR-ESMS calcd for: C26H38N6O12, expected: 627.26205, found: 627.26162 (m/z)
 
&Ser-D-Pro-Glu-Ser-D-Pro-D-Glu& (cyclo-6b)  
Cleavage cocktail: TFA/H2O/TIS - 95:2.5:2.5 (1 h) 
Purification by HPLC-semi-preparative (SunFirePrep C18, 0:50 H2O/ACN + 0.1% TFA, 
linear gradient over 30 min). (80 mg, 41%). Purity: 95 %  
HPLC: tR (min, G050 ACN in 8 min) = 4.50  
HR-ESMS calcd for: C26H38N6O12, expected: 627.26205, found: 627.26186 (m/z)
 
&Ser-D-Pro-Ile-Ser-D-Pro-Ile& (cyclo-7a)  
Cleavage cocktail: TFA/H2O/TIS - 95:2.5:2.5 (1 h) 
Purification by automated flash chromatography with RediSep C18 (0:10 to 10:30 
H2O/ACN + 0.1% TFA, gradient over 30 min). (57 mg, 50%). Purity: 98 % 
HPLC: tR (min, G2070 ACN in 8 min) = 3.62  
HR-ESMS calcd for: C28H46N6O8, expected: 595.34499, found: 595.34503 (m/z) 
&Glu-D-Pro-Ile-Glu-D-Pro-Ile (cyclo-8a)  
Cleavage cocktail: TFA/H2O/TIS - 95:2.5:2.5 (1 h) 
Purification by automated flash chromatography with RediSep C18 (0:10 to 10:40 
H2O/ACN + 0.1% TFA, gradient over 30 min). (104 mg, 70%). Purity: 95%  
HPLC: tR (min, G0100 ACN in 8 min) = 5.11 
HR-ESMS calcd for: C32H50N6O10, expected: 595.34499, found: 595.34503 (m/z)
 
3.3. Synthesis of fluorine and carboxyfluorescein labelled peptides (12-13) 
Linear peptide sequence: H-CDIHVMWEWECFERL-NH2 (9) 
The synthesis was performed at 100 mol scale. Aminomethyl ChemMatrix resin (300 mg, 
f=0.58 mmol/g) was functionalized with the AB linker by treatment with Fmoc-Rink 
Linker (64.75 mg, 3 eq), TBTU (38.53 mg, 3 eq) and DIEA (42 l, 6 eq) in DMF. The 
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coupling was performed manually and the reaction was left to proceed 1 h, then the solvent 
was removed by filtration and the peptide washed with DMF (5x1 min) and DCM (5x1 
min). The capping was performed adding Ac2O (113 l, 10 eq) and DIEA (209 l. 10 eq) in 
DMF and stirring manually for 15 min. The resin was transferred into the microwaves 
reactor and the peptide chain elongation was performed by microwaves assisted heating 
technology, according to the conditions described in the section 6.5.13. TBTU/DIEA were 
used for the amino acid coupling reactions and piperidine 20% in DMF for the Fmoc 
deprotection. A double coupling was set as default for each coupling. 
At the end of the linear peptide synthesis a small amount of resin was subjected to 
deprotection by treatment with TFA/TIS/H2O-94:3:3 cleavage cocktail solution (3 h). The 
identity of the product was confirmed by MALDI-TOF and the quality of the reaction was 
checked by analytical HPLC. 
Initial loading: 0.33 mmol/g 
HPLC: tR (min, G0100 ACN in 8 min) = 4.73  
MALDI-TOF calcd for: C90H127N23O23S3, expected: 1993.86, found: 1995.2570 [M+H]
+ 
O2O-CDIHVMWEWECFERL-NH2 (10) 
Fmoc-8-amino-3,6-dioxaoctanoic acid (115.5 mg, 3 eq) and HBTU (96,33 mg, 3 eq) were 
sequentially added to the peptide-resin 9 in DMF, followed by DIEA (140 l, 6 eq). The 
mixture was allowed to react with intermittent manual stirring for 1 h. The solvent was 
removed by filtration, and the resin was washed with DMF (5 x 1 min) and DCM (5 x 1 
min). Finally the Fmoc group was removed by treatment with piperidine 20% in DMF. A 
small amount of resin was subjected to deprotection by treatment with a cleavage cocktail 
solution (TFA/TIS/H2O-94:3:3, 3 h). The identity of the product was confirmed by 
MALDI-TOF and the quality of the reaction was checked by analytical HPLC. 
HPLC: tR (min, G0100 ACN in 8 min) = 4.76  
HR-MS calcd for: C96H138N24O26S3, expected: 2138.94, found: 2141.60 [M+H]
+ 
MALDI-TOF: [M+H]
+
: 2141.29  
O2O-C(&)-DIHVMWEWEC(&)-FERL-NH2 (11) 
To the peptide-resin 10 in DCM, I2 (19 mg, 5 eq) was added. The reaction was left with 
intermittent manual stirring for 15 min. The solvent was removed and the treatment was 
repeated again. The peptide resin was washed with DMF (5x1 min), a saturated solution of 
NaHSO4 (5x1 min) and CHCl3 (5x1 min). A small amount of resin was subjected to 
deprotection by treatment with a cleavage cocktail solution (TFA/TIS/H2O-94:3:3, 3 h) and 
the accomplishment of the reaction was monitored by HS-ESMS and MALDI-TOF 
analysis. 
HPLC: tR (min, G0100 ACN in 8 min) = 4.77  
HR-ESMS calcd for: C96H136N24O26S3, expected: 2136.92, found: 2136.9223 (m/z)
 
MALDI-TOF, [M+H]
+
: 2139.03 Da 
Cf-O2O-C(&)-DIHVMWEWEC(&)-FERL-NH2 (12) 
Chapter 3 
 
 
191 
A mixture of 5(6)-carboxyfluorescein (15.67 mg, 3 eq), PyBOP (23.4 mg, 3 eq) and HOAt 
(6.12 mg, 3 eq) was dissolved in the minimum volume of DMF and pre-activated by adding 
DIEA (15.67 l, 6 eq). After 1 min the mixture was added to the peptide-resin 11. The 
mixture was allowed to react overnight. The solvent was removed by filtration and the resin 
was washed with DMF (5x1 min) and DCM (5x1 min). The treatment with the cocktail 
cleavage solution TFA/TIS/H2O-94:3:3 (3 h) provided the peptide complete deprotection 
and cleavage from the resin. The purification by HPLC-semi-preparative (SunFirePrep 
C18, 30:60 H2O/ACN + 0.1% TFA, linear gradient over 25 min) yielded the product 12 as 
white solid. (10 mg, 11 %). Purity: 95%. 
HPLC: tR (min, G3060 ACN in 8 min) = 3.92 
MS-HPLC calcd for: C117H146N24O32S3, expected: 2494.97, found: 1249 [(M+2H)/2]
+
, 
833.22 [(M+H)/3]
+
 
MALDI-TOF, [M+H]
+
: 2496.36 Da 
CF3-O2O-C(&)-DIHVMWEWEC(&)-FERL-NH2 (13) 
A mixture of 4,4,4-Trifluoro-3-(trifluoromethyl)butanoic acid (83 l, 20 eq), PyBOP (312 
mg, 20 eq) and HOAt (245 mg, 60 eq), was dissolved in the minimum volume of DMF and 
pre-activated by adding DIEA (313 l, 60 eq). After 1 min the mixture was added to the 
peptide-resin 11. The mixture was allowed to react with intermittent manual stirring 1.5 h. 
The solvent was removed by filtration and the resin was washed with DMF (5x1 min) and 
DCM (5x1 min). The peptide complete deprotection and cleavage from the resin was 
accomplished by acidolytic treatment with the cocktail cleavage solution TFA/TIS/H2O-
94:3:3 (3 h). The purification by HPLC-semi-preparative (SunFirePrep C18, 30:60 
H2O/ACN + 0.1% TFA, linear gradient over 25 min) yielded the product 13 as white solid. 
(9 mg, 8 %). Purity: 98% 
HPLC: tR (min, G3060 ACN in 8 min) = 3.92 
MS-calcd for: C101H138F6N24O27S3, expected: 2328.92, found: MALDI-TOF, [M+H]
+
: 
2330.0076 Da 
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